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Chapter 1
General introduction and outline of the thesis
The unprepared mind cannot see the outstretched hand of opportunity. 
(Alexander Fleming)
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introDUction
An invasive fungal disease (IFD) is a life-threatening infection that is almost exclusively 
diagnosed in the immunocompromised host. IFD can be divided into moulds (hyphae 
forming fungi) and yeasts (strings of connected budding cells forming pseudohyphae). 
While the most common yeast infection in human is caused by candida species, the 
most common invasive mould infection is caused by Aspergillus species and called inva-
sive aspergillosis (IA). Patients with haematological malignancies who are treated with 
intensive chemotherapy and haematopoietic stem cell transplant recipients are most 
prone to develop IA. Incidence rates of IA vary substantially and depend on host and 
environmental factors but also the modalities of stem cell transplantation as well as the 
use of antifungal prophylaxis. The patients at highest risk are patients with a newly di-
agnosed acute myeloid leukaemia (AML) undergoing remission induction chemotherapy 
and allogeneic stem cell transplant recipients who need systemic immunosuppressive 
therapy for graft-versus-host disease. Without prophylaxis the incidence of IA in these 
populations can be as high as 10-20% (1-3). IA does not only lead to a higher overall 
mortality and morbidity but also to higher medical costs (4). The case fatality rate of 
IA is estimated to lie between 20-38% 6 to 12 weeks after diagnosis (5). Therefore, 
optimizing the management of IA is key in order to reduce the burden of this devastat-
ing complication in the immunocompromised host.
For more than 15 years voriconazole, a drug of the triazole class, has been the 
recommended treatment for this life-threatening infection after a pivotal randomized 
trial showed an improved survival with voriconazole compared with amphotericin B 
deoxycholate. However, also with voriconazole the overall 6-week mortality is still un-
acceptably high at 25-30% (6). Another strategy in the management of IA is prevention 
with antifungal prophylaxis. The European Conference on Infections in Leukaemia-5 
guideline recommends antimould prophylaxis when the incidence of mould infections 
is high (7). Firm criteria for what constitutes “high risk” are lacking but it has been 
proposed that subpopulations with >8-10% fall into this category. Unfortunately reliable 
data on the exact local prevalence of mould infections are often lacking (3).
A troublesome emerging problem in patients with IA is the increasing incidence of 
triazole-resistant A. fumigatus. Although limited by numbers, case series have dem-
onstrated that the overall mortality of patients infected with triazole-resistant A. 
fumigatus becomes very high (50-88%) (8, 9). Remarkably, from a global perspective 
the highest prevalence of triazole resistance has been documented in the Netherlands. 
It increased from 0% before the year 2000 to 5.3% in 2009, and further increased to 
15% in 2018 (8, 10). More recently, triazole resistance was observed in 5% of IA cases 
in Belgium as well and in 2017 researchers from the Erasme hospital in Brussels even 
reported a prevalence of 13% (11, 12). Different azole-resistant IA cases have been 
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described globally but resistance rates vary substantially between geographic regions 
and between hospitals (13).
This thesis focuses on risk factors for and the diagnosis of invasive aspergillosis. Ad-
ditionally, the management of azole-resistant aspergillosis is addressed.
aZole-resistant asPerGillosis: oUtcome anD treatment
IA is mostly, although not exclusively, caused by Aspergillus fumigatus. As previously 
mentioned, azole-resistant A. fumigatus strains are an emerging global problem and 
complicate the management of this infection enormously (13). Azole-resistance 
is mostly caused by a mutation in the Cyp51A gene that encodes for the lanosterol 
14α-demethylase, the target enzyme for azoles. Two mutation combinations in this 
Cyp51A gene, TR34/L98H and TR46/T289A/Y121F, account for more than 80% of the 
mutations conferring resistance in the Netherlands (14, 15). These mutations are as-
sumed to have an environmental origin caused by agricultural use of azole fungicides 
(16-18). Case series indicate that IA caused by azole-resistant Aspergillus is associated 
with very high mortality rates of 50-88% (8, 9). Until now, case series have included 
very few patients and preclude a reliable estimation of the impact of azole-resistance 
on mortality. Furthermore, studies in which the outcome of patients infected with 
a triazole-susceptible or a triazole-resistant A. fumigatus is compared are lacking. 
Therefore, a 5-year retrospective cohort study (2011-2015) was performed to com-
pare the mortality between patients diagnosed with a voriconazole-susceptible and a 
voriconazole-resistant IA. chapter 3 describes the results of this study.
Detection of azole-resistant aspergillosis is challenging. First, a positive fungal cul-
ture is required to allow for the use of conventional phenotypic resistance testing. 
However, in the vast majority of IA cases no positive culture can be retrieved. Second, 
phenotypic susceptible testing according to internationally agreed methods is almost 
exclusively done in mycology reference labs and is thus time-consuming. Recently, the 
clinical validity and relevance of PCR-based susceptibility testing was demonstrated 
using a commercially available multiplex qPCR: i.e. the AsperGenius© qPCR. Besides 
detecting the presence of Aspergillus DNA, this qPCR allows to detect the two most fre-
quent resistance-associated mutations (TR34/L98H and TR46/T289A/Y121F). Chong and 
colleagues evaluated the diagnostic performance of this qPCR in 201 patients showing 
a sensitivity and specificity of 89% and 89% compared with galactomannan and culture 
results as the gold standard. In addition, this study showed that response to voricon-
azole therapy was poor, when it was given to patients infected with an azole-resistant 
A. fumigatus strain (9). There are still several open questions to be answered following 
these studies. First, how the daily use of this qPCR impacts the management and thus 
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outcome of patients that are suspected of having an IA remains to be demonstrated. In 
particular, it remains to be seen what the outcome is of patients in which this qPCR is 
used to guide antifungal therapy. Does the immediate switch from a triazole to another 
antifungal drug as soon as resistance is documented by PCR reduces the overall mortal-
ity compared to the high mortality described above?
To get a reliable picture of the fungal infection management landscape in the Neth-
erlands and in particular in the context of increasing triazole-resistance, a meeting 
was organized with haematologists, infectious disease physicians and microbiologists 
from all academic university hospitals in The Netherlands. A survey questioned the 
prophylactic, diagnostic and therapeutic strategies regarding IFD in all academic cen-
tres. The results were processed and during a consensus meeting the protocol for a 
prospective multicentre study was developed and implemented as the AZOle Resistance 
MANagement study (AZORMAN) (NCT03121235). The process and rationale of this study 
are described in chapter 2. In this study, a standard diagnostic and therapeutic protocol 
for IA was agreed upon to be used for patients with an underlying haematological dis-
ease who present with a new pulmonary infiltrate and for whom the treating physician 
decides to order a diagnostic bronchoscopy. The primary objectives of the study are: 
(1) To improve the outcome of patients infected with azole-resistant A. fumigatus by 
facilitating the early detection of RAMs and with this, earlier initiation of the most 
appropriate therapy and (2) To monitor the prevalence of IA due to A. fumigatus strains 
carrying the TR34/L98H and TR46/T289A/Y121F RAMs in the Netherlands, in particular 
in culture-negative patients. Indeed, previous studies have based prevalence estimates 
on culture positive cases of IA only and this may lead to a biased estimate of the 
prevalence.
This multicentre prospective study currently running in 11 haematology centres in the 
Netherlands and Belgium started in 2017 and as of October 2019 recruited more than 
2/3 of the projected 280 patients. In chapter 9 preliminary results from the AZORMAN 
study are presented.
A report of an international consensus meeting on the management of infections 
caused by azole-resistant Aspergillus fumigatus was published in 2015. The experts 
recommended a switch from voriconazole to liposomal-amphotericin B in confirmed 
azole-resistant aspergillosis (19). Guidelines advocate that the duration of antifungal 
treatment should depend on clinical response, degree of immunosuppression and re-
sponse on imaging (20). However, liposomal-amphotericin B can only be administered 
intravenously and has obvious toxicity limitations (kidney failure, electrolyte distur-
bances). Therefore, the treatment of azole-resistant IA is logistically challenging and 
costly as most of the patients will stay hospitalized for the daily intravenous administra-
tion of liposomal-amphotericin B as there are no validated oral step-down treatment 
options for patients with azole-resistant IA. In the AZORMAN-study (see chapter 2 and 
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9) two options are suggested as possible step-down therapy for azole-resistant aspergil-
losis. These are liposomal-amphotericin B given intravenously thrice weekly rather than 
daily at a dose of 5mg/kg or a treatment with posaconazole tablets while targeting 
high serum trough levels 3-5mg/L. The latter strategy can only be considered when 
the minimum inhibitory concentration (MIC) of posaconazole of the azole-resistant A. 
fumigatus strain is below 2mg/L. Furthermore, these options should only be consid-
ered for patients showing clinical and radiological improvement with daily treatment 
with liposomal-amphotericin B. In chapter 4, we describe the rationale for the use of 
high-dose posaconazole (HD POS) targeting high serum trough levels and describe our 
experience with this strategy regarding safety and efficacy. The long terminal half-life 
of LAmB suggests that intermittent dosing could be effective, making the application 
of outpatient antifungal therapy (OPAT) possible. In chapter 5, together with col-
leagues from Leiden and Leuven, we describe our experience with intermittently dosed 
liposomal-amphotericin B in the outpatient setting for the treatment of invasive fungal 
infections.
The most devastating form of IA is haematogenic dissemination of this fungus to the 
brain. Brain infections with Aspergillus have a very high mortality and survivors are 
left with at least some neurological deficit (21). Although the chances of survival have 
improved since voriconazole became available, azole-resistant A. fumigatus strains 
now turn back the clock to the amphotericin B era. Few cases of central nervous system 
(CNS) aspergillosis caused by azole-resistant Aspergillus fumigatus have been reported, 
but almost always with a fatal outcome (19). Most patients were treated with combina-
tion antifungal therapy. Given the dismal prognosis of cerebral infections with azole-
resistant A. fumigatus and the lack of antifungals with activity against azole-resistant 
A. fumigatus that adequately penetrate the brain we describe our experience with the 
use of intraventricular liposomal-amphotericin B (L-AmB) on top of systemic antifungal 
therapy in 3 patients in chapter 6.
DiaGnosis of inVasiVe asPerGillosis
The strength of a diagnosis of IA is currently reported according to the revised defini-
tions of the European Organization for Research and Treatment of Cancer/Mycosis Study 
Group (EORTC/MSG) (22). IA is categorized into proven, probable and possible IFD. A 
proven diagnosis requires histopathologic evidence of fungal invasion. A diagnosis of 
probable IA is based on the presence of a combination of host factors, clinical features 
and a positive mycology test. A diagnosis of possible IA is made in the presence of host 
factors and clinical features but in the absence of mycological criteria (23). To fulfil 
mycological criteria a direct test or indirect test has to be present. Direct tests are 
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the detection of fungal elements or culture positive for Aspergillus species. Indirect 
tests are the presence of antigen or cell-wall constituents like galactomannan antigen 
(GM) or beta-D-glucan (24). Despite the fact that PCR for the detection of Aspergillus 
in human specimens exists for almost three decades, the technique was not included 
in the EORTC/MSG consensus definitions for diagnosing IFD because of the lack of 
standardisation (25). A good step towards standardization is the use of a commercially 
available PCR like the aforementioned AsperGenius© qPCR. Although this test was ret-
rospectively validated (9, 26), large prospective studies investigating its real-life added 
value and validity by using the PCR in different laboratories are lacking. The interim 
results of a first prospective and ongoing study are described in chapter 9. Above, we 
described the troublesome emergence of azole-resistant IA. Yet, mixed infections with 
azole-susceptible and azole-resistant strains of A. fumigatus have been described in 
the past by demonstrating the presence of two different A. fumigatus strains with two 
different susceptibility profiles with the use of conventional culture based methods 
(27). However, many if not the majority of cases of IA that physicians are confronted 
with are culture-negative. In chapter 8, we describe three patients infected with an 
azole-susceptible and azole-resistant A. fumigatus and in whom, for the first time, the 
mixed infection was demonstrated by cyp51A PCR amplicon melting curve analysis using 
the AsperGenius© assay.
Galactomannan antigen detection and detection of Aspergillus DNA are labour in-
tensive diagnostic tests with turnaround time of at least 24h to 72h as they are mostly 
performed in batches with 96 well plates. A bed-side point of care test is lacking but 
also a rapid and easy to perform test that can be used in small microbiology labs is lack-
ing as well. A newly CE-marked later flow device (LFD) may be such a test. It consists 
of a self-contained immunochromatographic assay using a mouse monoclonal antibody 
(JF5) for the detection of an extracellular glycoprotein released by Aspergillus during 
active growth (28). In the study described in chapter 7 and performed in collaboration 
with the University Hospitals Leuven and coordinated by dr. T. Mercier, we evaluate this 
test on bronchoalveolar lavage fluid (BALf) collected from adult haematology patients 
from 4 centres in The Netherlands and Belgium.
inflUenZa-associateD asPerGillosis
For almost a century, influenza has been known to set up for bacterial superinfections, 
but recently patients with severe influenza admitted to ICU were also reported to 
develop invasive pulmonary aspergillosis (29, 30). As these reports were almost exclu-
sively single centre-based and limited to a single influenza season, several important 
questions regarding the epidemiology of influenza-associated invasive aspergillosis 
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(IAA) remain unanswered. Therefore, we aimed to measure the incidence of invasive 
pulmonary aspergillosis over several seasons in patients with influenza pneumonia in 
the intensive care unit (ICU) and to assess whether influenza was an independent risk 
factor for invasive pulmonary aspergillosis. The results are presented in chapter 10.1. 
Furthermore, we evaluated if the higher mortality of patients with influenza-associated 
aspergillosis in the ICU can be attributed to the Aspergillus superinfection in se or if it 
is just a marker of overall disease severity. Therefore, we also performed a mortality 
analysis on our influenza cohort of 432 patients admitted to the ICU with influenza (see 
chapter 10.2).
aZole-ecHinocanDin combination tHeraPY for inVasiVe 
asPerGillosis
As previously mentioned, triazoles like voriconazole or isavuconazole are the recom-
mended treatment options for IA (6, 20, 31). Still, mortality remains unacceptably high 
at 25-30%. Azoles block the synthesis of ergosterol, a part of the fungal membrane 
while antifungals from the echinocandin class block the synthesis of Beta-D glucan, a 
component of the cell. Both drugs may work synergistically as suggested in vitro studies 
and neutropenic animal models (32, 33). These observations led to the performance of 
a clinical trial comparing the efficacy of voriconazole with or without anidulafungin, an 
echinocandin, in a population with haematological malignancy (34). In this trial 6-week 
mortality was 30% lower in the group treated with combination antifungal therapy 
(19.3%) versus monotherapy (27.5%) but was not statistically significant (p=0.09%). This 
is the reason why combination therapy has not been adopted by current guidelines. A 
second clinical trial is needed to confirm these promising finding. In 2019, following 
a study proposal by dr. B. Rijnders and Prof. dr. J. Maertens submitted to BeNeFit a 
grant was awarded to implement such a clinical trial in 25 haematology centres in the 
Netherlands and Belgium. BeNeFit is a new collaboration between Belgium (KCE) and 
the Netherlands (ZonMW) in order to support large pragmatic intervention trials. The 
writing of the study protocol was initiated and coordinated by dr. B. Rijnders and drs. 
A. Schauwvlieghe and can be found in chapter 11.
sUmmarY
Several studies were performed to investigate the incidence, mortality, risk factors 
and diagnostics of IA. chapter 3 focusses on mortality of azole-resistant IA. chapter 
2 describes the design and rationale of the AZORMAN study. Preliminary results from 
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this study are presented in chapter 9. chapter 4 and 5 describe different step-down 
treatment options for patients infected with an azole-resistant A. fumigatus strain 
when treated successfully with daily liposomal-amphotericin B. chapter 6 describes 
how azole-resistant Aspergillus CNS infections may be managed. chapter 7 shows the 
performance of a novel CE-marked point-of-care test: a lateral flow device. chapter 
8 presents how azole-susceptible and azole-resistant Aspergillus co-infection can be 
diagnosed using Aspergillus qPCR test. The incidence and other characteristics of in-
fluenza-associated aspergillosis can be found in chapter 10. Future work is the subject 
of chapter 11: i. e. the protocol of the DUET study (azole-echinocandin combination 
therapy for IA). We conclude with a general discussion in chapter 12.
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Education never ends, Watson. It is a series of lessons, with the greatest for the last. 
(Arthur C Doyle)
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sUmmarY
background
Patients with haematological malignancies are at risk for invasive fungal diseases (IFD). 
A survey was conducted in all Dutch academic haematology centres on their current 
diagnostic, prophylactic and therapeutic approach towards IFD in the context of azole 
resistance.
methods
In all 8 centres, a haematologist and microbiologist filled in the questionnaire that 
focused on different subgroups of haematology patients.
results
Fungal prophylaxis during neutropenia was directed against Candida and consisted of 
fluconazole and/or amphotericin B suspension. Mould-active prophylaxis was given to 
acute myeloid leukaemia patients during chemotherapy in two of eight centres. All 
centres used azole prophylaxis in a subset of patients with graft-versus-host disease. A 
uniform approach towards the diagnosis and treatment of IFD and in particular azole-
resistant Aspergillus fumigatus was lacking. In 2017, all centres agreed to implement 
a uniform diagnostic and treatment algorithm regarding invasive aspergillosis with a 
central role for comprehensive diagnostics and PCR-based detection of azole resistance. 
This study (DB-MSG 002) will re-evaluate this algorithm when 280 patients have been 
treated.
Discussion
A heterogeneous approach towards antifungal prophylaxis, diagnosis and treatment was 
apparent in the Netherlands. Facing triazole-resistance, consensus was reached on the 
implementation of a uniform diagnostic approach in all eight centres.
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introDUction
Invasive fungal disease (IFD) occur in 5 to 40% of patients with haematological malig-
nancies. Approximately 95% of the IFD are caused by Aspergillus and Candida species.
[1] IFD is associated with a very significant morbidity and mortality that is explained by 
the difficulties in diagnosing IFD rapidly.[1] In addition, the presence of an IFD leads to 
a delay in subsequent anti-leukemic therapy, and therefore also indirectly affects the 
outcome of the patient.[2]
Antifungal prophylaxis prevent IFD during acute myeloid leukaemia (AML) therapy 
or during graft-versus-host disease (GVHD). These benefits have to be weighed against 
risks of drug toxicity, interactions, selection of resistance and costs. Different opinions 
on the preferred antifungal strategy in these patients exist and the approach varies 
considerably from institution to institution.
Over the last 10 years resistance of A. fumigatus against triazoles, has become a 
significant problem in the Netherlands but has recently also been reported in other 
countries.[3-5] Triazole-resistance can develop through long-term azole therapy in 
patients with chronic pulmonary aspergillosis. However, the selection of tri-azole re-
sistance in the environment by the use of azole fungicides is far more important. This 
in agreement with the observation that the majority of triazole-resistant A. fumigatus 
strains contain the environmental TR34/L98H or the TR46/Y121F/T289A mutation pat-
tern in their Cyp51A gene.[6] This gene encodes for the target enzyme of triazoles.[7] 
Infections with a triazole-resistant A. fumigatus result in a high mortality and the best 
diagnostic and treatment approach is uncertain.[5, 8] We conducted a survey on fungal 
diagnostics, antifungal prophylaxis and treatment in all Dutch academic haematology 
centres. The survey facilitated the development of a consensus approach towards the 
management of invasive aspergillosis (IA) in a context of rising azole resistance.
materials and methods
A questionnaire was sent to a haematologist and a microbiologist with special interest 
in supportive care and medical mycology respectively and both parties were asked to 
answer as a team for their centre. The questionnaire focused on (1) primary prophylaxis 
during AML chemotherapy, during allogeneic hematopoietic stem cell transplantation 
(allo-HSCT) and at the time of GVHD. (2) How was screened for IFD and which diagnostic 
tests were performed. (3) The current antifungal treatment for different clinical sce-
narios. The results were processed and during a consensus meeting the protocol for the 
AzoRMan-study was developed and implemented.
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resUlts
Prophylaxis (table 1)
Prophylaxis directed against Candida
Fluconazole is given during neutropenia of >10 days in 4/8 centres at very different dos-
ages and amphotericin B oral suspension was used in 2. One centre also uses amphoteri-
cin B lozenge. One centre starts fluconazole when surveillance cultures grow Candida. 
If surveillance cultures show Candida species resistant to fluconazole, some centres 
switch to amphotericin B suspension and one centre adds amphotericin B suspension to 
fluconazole. Finally, one centre stops fluconazole and no other prophylaxis is initiated.
Mould-active prophylaxis
Only one centre applies mould-active prophylaxis (itraconazole) during chemotherapy 
induced neutropenia of >10 days and during myeloablative allo-HSCT. Therapeutic drug 
monitoring of itraconazole is performed and when no effective plasma concentrations 
are reached, a switch to voriconazole is made. In another centre nebulized liposomal 
amphotericin B (L-AmB) at 15mg QD, twice weekly is used for this purpose. All centres 
start mould-active prophylaxis when corticosteroids are given for GVHD but the drugs 
of choice differ (table 1).
antifungal agent Dosage number of centres
Candida prophylaxis 
during longstanding 
chemotherapy-
induced neutropenia
Fluconazole
50mg
/24h
1
200mg 2
400mg 1
Amphotericin B suspension
500mg/6h 2
200mg/12h 1
Fluconazole when surveillance 
cultures grow Candida
1
anti-mould 
prophylaxis in 
aml/mDs/allotx 
during longstanding 
chemotherapy-
induced neutropenia
Itraconazole suspension
Start with 200 mg bid, dose 
increased based on TDM results
1
L-AmB aerosols 15mg twice weekly 1
None 6
allotx with 
GVHD treated 
with systemic 
corticosteroids
Itraconazole
Start with 200 mg bid, dose 
increased based on TDM results
1
2,5mg/kg/12h 1
Voriconazole 200mg/12h 1
Posaconazole 300mg/24h tablets 5
table 1: Prophylactic strategies used against Candida and Aspergillus.
AlloTx=Allogeneic stem cell transplantation; AML=Acute Myeloid Leukaemia; GVHD= Graft-versus-
Host disease; MDS=Myelodysplastic syndrome; TDM=Therapeutic Drug Monitoring. L-AmB=liposomal 
amphotericin-B.
28 Chapter 2
Diagnosis
Diagnostic procedures (table 2)
A chest CT is routinely performed in all centres after three to five days of neutropenic fe-
ver without an infectious focus despite antibiotic therapy. When the chest CT scan shows 
pulmonary infiltrates a broncho-alveolar lavage (BAL) with galactomannan (GM) detection 
and fungal culture is performed in all centres (if clinically feasible). Twice weekly serum 
GM monitoring as a screening tool is performed in one centre only. Two centres perform 
an Aspergillus DNA PCR on BAL routinely; in one centre this is done only when BAL GM is 
positive or when an EORTC compatible radiological finding is suggestive of an IFD.
Susceptibility testing (table 3)
Different Aspergillus susceptibility testing methods are used: VIPcheckTM or Etest fol-
lowed by confirmation with testing according to the European Committee on Antibiotic 
Susceptibility Testing (EUCAST) method when resistance is suspected based on the 
screening assay. The EUCAST method is operational in the mycology reference labora-
tory (RefLab). Resistance screening is done in all but one centre with a 4-well plate 
(VIPcheckTM) in which three of the four wells contain agar supplemented with an azole 
(voriconazole, itraconazole and posaconazole) and the fourth functions as a growth 
control. The other centre uses the Etest (bioMérieux) for resistance screening. Simul-
taneously to the screening test, four centres send the Aspergillus strain directly to the 
RefLab for MIC testing. PCR testing for the presence of TR34 and TR46 directly on cultured 
A. fumigatus colonies is performed on-site in four centres to speed up resistance detec-
tion. A PCR-based resistance assay is performed directly on BAL in 3 centres. For this 
purpose, a commercially available qPCR (AsperGenius®) or an in-house PCR is used. One 
centre sends BAL samples to the RefLab for PCR testing.
Diagnostic procedure Possibilities nr of centres
screening with serum Gm (twice weekly) during prolonged 
neutropenia
Yes 1
No 7
chest ct-scan when 3-5 days neutropenic fUo despite broad-
spectrum antibiotic treatment
Yes 8
No 0
Bronchoscopy with BAL (when no evident cause for infiltrative 
lesions on imaging)
Yes 8
No 0
GM measurement on BAL fluid sample, if BAL sampling is performed
Yes 8
No 0
Aspergillus species PCR on BAL fluid
Yes, always 2
Yes, if GM is positive 1
No 5
table 2: Diagnostic strategies used in patients at risk for or suspected of having an IFD.
BAL=Bronchoalveolar lavage; GM=Galactomannan; FUO=Fever of unknown origin. IFD=Invasive 
Fungal Diseases
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treatment (table 4)
Suspected invasive fungal infection:
All centres use voriconazole as the initial treatment for patients in a respiratory stable 
condition suspected of having an IFD while waiting for the microbiological tests. One 
centre frequently uses posaconazole as well and another centre with a high local azole 
resistance prevalence prefers L-AmB if the patient is very ill. The feasibility of BAL fluid 
sampling is the decisive factor in another centre to guide therapy and voriconazole is 
given if a BAL is obtained and therefore, the detection of azole resistance becomes 
more likely. If BAL is not feasible, this centre gives L-AmB as antifungal.
Proven or probable IA:
Voriconazole is the treatment of choice for all centres when a BAL-GM assay is positive 
in a respiratory stable patient and the lesions on chest CT are not widespread, fungal 
culture remains negative and no susceptibility PCR is performed or the test was not 
successful. In the same clinical situation with a patient in respiratory distress or with 
extensive pulmonary infiltrates, five centres would still start voriconazole. Two centres 
would start L-AmB and one centre posaconazole.
susceptibility assay Possibilities nr of centers
Aspergillus species: screening for 
azole resistance with ViPtmcheck-
testing
Yes 7
No
1
Sends Aspergillus strain 
directly to RefLab
Phenotypic azole resistance 
testing (eUcast) of cultured 
Aspergillus strains
Directly sent to RefLab for EUCAST testing 4
Send to RefLab only if VIP screening is 
positive
2
Send to RefLab only if E-test is positive 1
EUCAST testing on site=RefLab 1
testing for ram on cultured 
Aspergillus strains
Yes, in-house 4
Yes, not in-house 1
No 3
testing for ram (CYP51A) directly 
on BAL fluid
Yes 2
No 4
On indication (if BAL culture is negative and 
patient is not doing clinically well)
1
Sends BAL sample to the RefLab 1
table 3: Diagnostic tests done on BAL fluid samples.
EUCAST=The European Committee on Antimicrobial Susceptibility Testing; GM=Galactomannan; 
VIPTM testing=resistance assay (explanation: see text); RAM=Resistance associated mutations 
(TR34/L98H, TR53, and TR46/Y121F/T289A); RefLab=National mycology reference laboratory in 
Nijmegen (The Netherlands). BAL=Broncho-alveolar lavage.
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Proven or probable IA and documented voriconazole resistance
If voriconazole resistance is demonstrated with one of the phenotypic susceptibility 
tests or by a resistance PCR, all centres give L-AmB.
therapeutic drug monitoring
Voriconazole
Two centres do not perform therapeutic drug monitoring (TDM). Two centres do TDM 
when toxicity or treatment failure is suspected. The other centres routinely perform 
TDM.
Posaconazole
Three centres always perform TDM and two centres do not. The other three centres 
perform TDM on indication only.
Triazole resistance data
In 2016 A. fumigatus isolates from 784 clinical patients were screened for triazole 
resistance using a four-wells agar plate (VIPcheckTM). Isolates that grew on the triazole-
Presentation clinical condition treatment options nr of centers
chest ct: suspected ifD but 
microbiological results pending
Respiratory and clinically stable Voriconazole 8
Respiratory and clinically instable
Voriconazole 6
L-AmB 1
+BAL possible Voriconazole
1
+BAL impossible L-AmB
bal Gm pos, culture/Pcr neg
Respiratory and clinically stable Voriconazole 8
Critically ill
Voriconazole 5
L-AmB 2
Posaconazole 1
resistance detected by culture 
or Pcr
Respiratory and clinically stable/
instable
L-AmB 8
tDm voriconazole
No 2
Sometimes* 2
Always 4
tDm posaconazole
No 2
Sometimes* 3
Always 3
table 4: Treatment of invasive aspergillosis
BAL=Bronchoalveolar lavage; Resp=Respiratory; L-AmB=liposomal amphotericin-B; IFD=Invasive 
Fungal Diseases; PCR=Polymerase Chain Reaction; GM=Galactomannan; TDM=Therapeutic Drug 
Monitoring; +BAL possible/impossible: BAL sampling was possible/impossible; *Sometimes=when 
toxicity or therapeutic failure is suspected
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containing agar have a high probability of resistance and were sent to the Reflab for 
phenotypic and genotypic characterization. 101 isolates (12.9%) were triazole-resistant, 
which was higher than 2014 (7.2%) and 2015 (10.7%). In individual centres, resistance 
ranged from 9.5% to 20.5%.[6] Recently, a nationwide Dutch cohort study reported data 
from 144 patients with influenza pneumonia admitted to all eight University Inten-
sive Care Units. 23 patients (16%) were diagnosed with influenza-associated invasive 
aspergillosis and triazole resistance was reported in 29% of those with a positive A. 
fumigatus culture.[9]The clinical relevance of triazole resistance was also described 
in another recent study in which a multiplex real-time PCR test (AsperGenius© assay) 
was performed on BAL samples from 201 patients. This qPCR allows the simultaneous 
detection of Aspergillus species and identification of the most common mutations in 
the A. fumigatus Cyp51A conferring resistance by using melting curve analysis. In 11 of 
the 68 patients in which the resistance PCR could be successfully performed, the TR34/
L98H or TR46/T289A/Y121F resistance pattern was documented. More importantly, the 
detection of resistance correlated with voriconazole treatment failure.[8]
DiscUssion
Prophylaxis directed at candida
The European Conference on Infections in Leukaemia (ECIL) 5 guidelines on antifungal 
prophylaxis recommends fluconazole (400mg q24h) when the mould infections are rare 
and a mould-directed diagnostic approach is in place (B-I).[10] The latter is the case 
in all centres that were surveyed but the dose of fluconazole varies among centres and 
is generally lower than was used in most randomized trials (400mg q24h).[11-15] Some 
studies suggest that lower doses may suffice.[16] Three centres use oral amphotericin B 
as primary prophylaxis and in others oral amphotericin B is given on top of fluconazole 
if surveillance cultures remain positive. In a pooled analysis of oral fluconazole versus 
amphotericin B no significant advantage of either of the two drugs was observed. Data 
on the efficacy of prophylactic amphotericin B are scarce.[17] According to the EBMT, 
fluconazole is the drug of choice for the prophylaxis of invasive candidiasis before 
engraftment in allo-HSCT recipients, and may be started at the beginning or after the 
end of the conditioning regimen (A-I).[18]
mould-active prophylaxis
The advantage of primary mould-active prophylaxis with posaconazole was shown in 
two randomized trials.[13, 14] The Dutch guideline on antifungal management as well 
as the ECIL-5 guideline recommends posaconazole for primary prophylaxis (A-I) when 
the incidence of mould infections is high.[10, 19] Firm criteria for what constitutes 
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`high risk` are lacking but it has been proposed that subpopulations with >8-10% fall 
into this category. Unfortunately, reliable data on the local prevalence of mould infec-
tions are often lacking.[20] One centre administers aerosolized L-AmB twice weekly for 
the prevention of IFD in AML patients undergoing intensive chemotherapy. Its efficacy 
and cost-effectiveness have been demonstrated in a single-centre randomized placebo-
controlled trial and an observational study.[21, 22] One centre uses itraconazole as 
antifungal prophylaxis. A major concern of itraconazole is its poor gastrointestinal tol-
erance and CYP3A4 inhibitory properties. Both the ECIL-5 and the IDSA guidelines give 
moderate recommendations against its use.[10, 23] All centres use a diagnostic protocol 
that includes a lung CT after three to five days of fever despite antibiotic therapy and 
proceed to BAL sampling when infiltrates are documented. Indeed, a survival benefit of 
azole prophylaxis compared with a diagnostic-driven approach has not been convinc-
ingly shown and so both continue to be reasonable strategies.
mould-active prophylaxis in GVHD
Antifungal prophylaxis has been established as standard of care after allo-HSCT with 
grade II or higher GVHD, but issues concerning drug-drug interactions and factors com-
promising bioavailability have to be considered. Ullman et al. performed a randomized 
trial in which fluconazole and posaconazole oral solution were compared as fungal 
prophylaxis in patients with GVHD. Posaconazole prevented IA and resulted in lower 
numbers of deaths related to IFD although the overall mortality did not differ.[14] All 
centres administer azole prophylaxis (4 posaconazole, 2 voriconazole, 2 itraconazole) 
to patients with GVHD of grade II or higher in accordance with ECIL-5 recommendations 
in which an A-I recommendation is given for posaconazole and a B-I to itraconazole and 
voriconazole.[10]
Diagnosis of ia
Pulmonary imaging with high-resolution CT (HRCT) was shown to accelerate and 
improve the diagnosis of IA.[23] The IDSA guideline advocates imaging with chest CT 
when a patient is suspected to have IA. IDSA guidelines also encourage BAL since signs, 
symptoms or imaging by itself are often aspecific. All centres use HRCT and BAL as the 
standard diagnostic procedure. Serum GM monitoring has a moderate sensitivity of ±70% 
but is insensitive in non-neutropenic patients and the specificity has varied between 
studies.[23, 24] Only one centre routinely monitors serum GM in patients with pro-
longed neutropenia. All centres measure BAL-GM and Aspergillus DNA PCR is performed 
in 3 centres on BAL fluid samples). The clinical implementation of PCR-based diagnosis 
was debated, though not recommended for routine clinical practice in the 2016 IDSA 
guidelines as few assays have been standardized and well validated.[23]
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susceptibility testing
Azole resistance was rare in The Netherlands before the year 2000 but its prevalence 
has continued to increase since then.[25] It is currently based on a limited number of 
resistance-associated mutations (RAMs) in the cyp51A-gene (TR34/L98H, TR53, and TR46/
Y121F/T289A) and is most likely caused by the environmental use of azole fungicides.
[7, 26, 27] The TR34/L98H and TR46/Y121F/T289A accounted for 83% of resistance muta-
tions in 2016.[6] IDSA guidelines do not recommend standard susceptibility testing but 
these guidelines cannot be applied to The Netherlands.[23, 28] Case series indicate 
that IA caused by azole-resistant Aspergillus, is associated with a very high mortality.
[5, 8] The diagnostic tools used for the detection of azole resistance vary from centre 
to centre. Most perform agar-based screening assays for resistance (VIPcheckTM testing). 
Phenotypic azole resistance testing according to the EUCAST method is performed by 
the National mycology reference laboratory only (RefLab). Four centres directly send 
Aspergillus strains to the RefLab and three await the result of the screening assay.
Only very recently, the clinical validity and relevance of PCR-based susceptibility 
testing on BAL was demonstrated and may explain the limited uptake of resistance 
detection by PCR at the time of the survey. The AsperGenius® qPCR is a multiplex PCR 
and can detect the presence of Aspergillus DNA and in addition detect the 2 mutations 
described above. [8, 29] In a recent study the diagnostic performance was evaluated on 
BAL-samples in 201 patients.[8, 29] The Aspergillus BAL qPCR, had a sensitivity of 89% 
and a specificity of 89% and was able to detect A. fumigatus that carried resistance-
associated mutations (RAM) in the majority of patients, even in culture-negative BAL. 
Furthermore, this study showed that response to voriconazole therapy, when given to 
patients infected with a resistant A. fumigatus was poor.[8]
treatment
The ECIL-6 guideline attributes an A-I recommendation to both voriconazole and isavu-
conazole for the treatment of IA [30]. Unfortunately, in 2016 surveillance data showed 
that triazole resistance was present in 101 of 784 (12.9%) patients with a positive A. 
fumigatus culture.[6] These data are based on clinical isolates and it is uncertain what 
fraction of these patients met EORTC/MSG criteria. However, the clinical relevance 
of azole resistance in patients with an invasive Aspergillus infection was described in 
a recent multicenter study and small case series have reported a very high mortality 
in patients infected with a voriconazole resistant A. fumigatus that received initial 
therapy with voriconazole.[5, 8] The management of IA in The Netherlands in the 
context of a progressively rising incidence of IA caused by azole-resistant A. fumigatus 
strains is challenging because evidence-based data on the most appropriate manage-
ment of this emerging clinical problem are lacking. At the time of the survey, all centres 
start voriconazole when the patient is respiratory and clinically stable while awaiting 
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culture and/or resistance PCR results. In a clinically unstable patient, five centres still 
start voriconazole, one centre starts posaconazole and another centre starts L-AmB. 
The feasibility to perform a BAL (and thus cultures) is the decisive factor for one centre. 
In 2015 an international consensus paper on the management of IA caused by azole-
resistant Aspergillus isolates advised L-AmB or echinocandin-voriconazole combination 
as treatment of choice in regions with environmental triazole resistance rates of Asper-
gillus exceeding 10%.[25]
TDM was systematically used in four centres for voriconazole, on indication or not at 
all in two centres each. Although some studies suggest a relation between voriconazole 
serum levels and the incidence of adverse events, randomized clinical trials that con-
vincingly show the value of TDM are still lacking.[31]
Off-guideline management (as compared with the Dutch guideline on fungal infec-
tions) was observed in some of the centres.[19] One common reason for a delay in 
policy change after new convincing evidence was published and incorporated in guide-
lines is the absence of a dedicated haematologist with special interest in infectious 
diseases and supportive haematological care who critically assesses the local practice 
on a regular basis. We asked the centres for the reasons of their off-guideline policies 
and the following answers were given: The continued use of itraconazole instead of 
posaconazole as anti-mould prophylaxis in 2 centres was driven by the higher costs 
of other azoles. Both centres recently moved to voriconazole after it became avail-
able as a generic drug. One centre preferred voriconazole over posaconazole and this 
was driven by the unpredictable absorption of the oral solution and the lack of an 
intravenous formulation of posaconazole when it first came on the market. Another 
centre used nebulised liposomal amphotericin-B as anti-mould prophylaxis and did this 
based on locally generated evidence that supports its (cost-)effectivity.[21, 22] Finally, 
the continued use of oral amphotericin-B solution as anti-yeast prophylaxis (on top of 
fluconazole) was driven by the fact that it is a harmless intervention (as no systemic 
toxicity occurs with a non-absorbed drug) and because with this policy, the incidence 
of candidemia had been very low with this policy for more than 15 years. Therefore, 
these centres were reluctant to change a safe policy that seems to be very efficacious.
Protocol (figure 1)
Following this survey, a consensus meeting was organised with representatives of all 
8 centres and led to the development of a standardized diagnostic and therapeutic 
protocol on the management of IFD in haematology patients. This protocol was devel-
oped in collaboration with the recently established Dutch-Belgian Mycosis Study Group 
(DB-MSG) and was implemented in all academic haematology centres in 2017 with the 
goal to gather evidence on the optimal approach towards IFD in the context of azole 
resistance (The Azole Resistance MANagement Study (AzoRMan) or DB-MSG 002 study, 
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NCT03121235). The study aims to demonstrate that the use of resistance testing by 
PCR on BAL fluid from haematology patients with suspected IA will lead to an improved 
outcome by detecting resistance earlier and changing triazole therapy to L-AmB as soon 
as resistance is detected. Indeed, the majority of cases of IA remain culture negative 
and therefore, the use of resistance testing by PCR is considered crucial.[8, 32] The 
AzoRMan-study is schematically depicted in figure 1 and further information available 
at www.clinicaltrials.gov. In brief, treatment is based on the documentation of azole 
susceptibility or resistance and step-down treatment options for patients treated for 
documented or presumed azole resistance are given.
figure 1: Treatment protocol for Azole-resistance Management-study.
MIC, Minimal Inhibitory concentration; IV, Intravenously. *Posaconazole HD can only be considered 
as treatment option when the MIC (EUCAST) ≤1 g/dL. HRCT, High Resolution CT scan; PCR, poly-
merase chain reaction; PO, by mouth; BAL, Broncho-alveolar lavage
Treatment with L-AmB is advised when azole-resistance is documented or when no 
susceptibility data are available and the local azole-resistance rate is >10%. This is sup-
ported by the fact that the A. fumigatus strains with the environmental TR34/L98H or the 
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TR46/Y121F/T289A mutation pattern circulating in the Netherlands remain susceptible 
to L-AmB.[33] The activity of L-AmB was also confirmed in vivo in immunocompetent 
and immunosuppressive murine models of IA.[34] This approach may be less appropriate 
in different settings in which resistance mechanisms other than the environmental TR34/
L98H or the TR46/Y121F/T289A mutation patterns are predominant.[35]
If a treatment response is observed during therapy with L-AmB 3mg/kg/day, a switch 
to L-AmB 5 mg/kg/day three times a week or to oral posaconazole (when the posacon-
azole MIC is below 2mg/L) is made with a posaconazole target trough serum level of 3 to 
4 mg/L. The logical behind the posaconazole strategy is the observation that Aspergil-
lus strains carrying RAMs often have a posaconazole minimum inhibitory concentrations 
(MIC) that is <2mg/L.[36] The efficacy of posaconazole at high serum levels was demon-
strated in a pharmacodynamic study in mice with invasive azole-resistant aspergillosis 
by Mavridou et al.[37] This study showed that posaconazole retains activity against an 
A. fumigatus strain that carried the TR34/L98H mutation with a posaconazole MIC of 0.5 
mg/L as long as serum drug levels are sufficiently high. No human data on the use of this 
treatment strategy have been published. However, in a phase 3 pharmacokinetics and 
safety study for posaconazole tablets the average serum concentration of posaconazole 
in quartile 4 of the 186 patients that received posaconazole tablets at 300mg per day 
was 2.3-9.5 mg/L. It was not associated with a specific safety signal and therefore, 
a serum level between 3 and 4 mg/L is a realistic target.[38] Posaconazole with high 
serum trough levels is the only oral step-down treatment option for patients with azole-
resistant IA. Although clinical evidence remains anecdotal, preclinical animal studies 
and experience in veterinary medicine provides proof op principle in its efficacy.[37, 39]
conclUsion
This survey shows the heterogeneous landscape in the prevention, diagnosis and treat-
ment of IA in The Netherlands. In the context of the rapidly increasing prevalence of 
azole resistance, the AzorMan study was implemented to evaluate a uniform diagnostic 
and therapeutic approach.
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abstract
background
Triazole resistance is an increasing problem in invasive aspergillosis (IA). Small case 
series show mortality rates of 50%-100% in patients infected with a triazole-resistant 
Aspergillus fumigatus, but a direct comparison with triazole-susceptible IA is lacking.
methods
A 5-year retrospective cohort study (2011-2015) was conducted to compare mortality 
in patients with voriconazole-susceptible and voriconazole-resistant IA. A. fumigatus 
culture-positive patients in three University Medical Centers were investigated to 
identify patients with proven, probable and putative IA. Clinical characteristics, day-
42 and day-90 mortality, triazole resistance profiles and antifungal treatments were 
investigated.
results
Of 196 patients with IA, 37 (19%) harbored a voriconazole-resistant infection. Hema-
tological malignancy was the underlying disease in 103 (53%) patients, and 154 (79%) 
patients were started on voriconazole. Compared with voriconazole-susceptible cases, 
voriconazole resistance was associated with an increase in overall mortality of 21% 
on day-42 (49% versus 28%, p=0.017) and 25% on day-90 (62% versus 37%, p=0.0038) 
corresponding with a hazard ratio of 1·4 (day-42 95%CI 0.8 to 2.5; p=0.272). In non-
ICU patients a 19% lower survival rate was observed in voriconazole-resistant cases at 
day-42 (p=0.045). The mortality in patients receiving appropriate initial voriconazole 
therapy was 24% compared with 47% in those receiving inappropriate therapy (p=0.016), 
despite switching to appropriate antifungal therapy after a median of 10 days.
conclusions
Voriconazole resistance was associated with an excess overall mortality of 21% at day-42 
and 25% at day-90 in patients with IA. A delay in the initiation of appropriate antifungal 
therapy was associated with increased overall mortality.
Triazoles are the mainstay of therapy for invasive aspergillosis (IA) and have led to a 
substantial improvement in overall survival. However, triazole resistance has become 
a concern for the management of infections caused by Aspergillus fumigatus. Through 
culture-based surveillance studies the number of countries that report azole resistance 
continues to increase, although resistance frequencies vary considerably between dif-
ferent geographic regions [1]. Resistance rates as high as 29% have been observed in 
specific patient populations, such as critically-ill patients [2]. Variations in resistance 
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frequencies may reflect true geographical differences or might be due to other vari-
ables, including study design, patient populations and laboratory practices [3,4].
Triazole resistance may develop through therapy of individual patients with Aspergil-
lus disease primarily occurring in patients with chronic pulmonary aspergillosis [5]. More 
important, triazole resistance may develop in the environment following exposure to 
azole fungicides [6]. Patients inhale A. fumigatus spores resistant to medical triazoles, 
which may evolve into triazole-resistant IA. The environmental route is characterized 
by an apparent lack of patient risk factors as the majority of patients who present 
with triazole-resistant IA have not been previously treated with medical triazoles [7]. 
The optimal management of patients suspected of IA in regions with environmental 
resistance remains unclear, and an expert panel recommend considering moving away 
from triazole monotherapy when regional resistance frequencies exceed 10% [8]. This 
10% threshold has been the subject of debate given the toxicity, costs, lack of oral 
formulations and of comparative clinical trials of non-triazole antifungals like liposo-
mal amphotericin B (L-AmB) and echinocandins or antifungal combination therapies. 
Animal experiments consistently show that the efficacy of triazoles in infection with 
A. fumigatus with elevated triazole MICs is reduced compared with wild-type infection 
[9,10]. This has been shown for itraconazole, voriconazole, posaconazole and isavuco-
nazole. Furthermore, several small case series reported mortality rates of 50%-100% in 
patients with triazole-resistant IA [11]. These rates are higher than those reported in 
recent clinical trials, where mortality rates in triazole-treated aspergillosis patients 
were below 30%, but selection bias may partially explain the very high mortality and 
therefore, the exact impact of triazole resistance remains to be defined as direct 
comparisons between triazole-susceptible and triazole-resistant infection are lacking 
[7,12]. To investigate the characteristics and outcome of voriconazole-susceptible IA 
and voriconazole-resistant IA, we conducted a retrospective, multicentre study in a 
large cohort of A. fumigatus culture-positive patients.
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study design
A retrospective cohort study was performed in three tertiary care University Medical 
Centers in the Netherlands: Radboud University Medical Center in Nijmegen, Leiden 
University Medical Center in Leiden and Erasmus University Medical Center in Rotter-
dam.
General management of ia
Diagnostic work-up in patients suspected of invasive pulmonary mould disease, typically 
included chest CT and, if possible, bronchoscopy and bronchoalveolar lavage (BAL). In 
patients with acute myeloid leukemia, myelodysplastic syndrome, and hematopoietic 
stem cell transplant recipients a diagnostic driven strategy was used including moni-
toring of serum galactomannan (GM) during neutropenia or in febrile patients. Chest 
CT was performed in patients with positive serum GM, in those with persistent fever 
despite three to five days of broad-spectrum antibacterial therapy, and in patients with 
progressive respiratory failure. If CT confirmed the presence of pulmonary infiltrates, 
a BAL was performed for fungal culture and GM measurement. Voriconazole was the 
first choice treatment option for patients with IA. During the study period no hospital 
treatment guidelines were available for documented voriconazole-resistant IA, but 
when resistance was documented or suspected in critically-ill patients, treatment was 
changed to either triazole and echinocandin combination therapy or L-AmB.
Data collection
The microbiology database was searched for positive A. fumigatus cultures of patients 
admitted between January 2011 and December 2015. In order to select patients with 
IA the clinical records of culture-positive patients needed to meet three conditions: (i) 
antifungal therapy was started within one month before or after a positive culture, (ii) 
the patient had received at least two days of antifungal therapy, and (iii) the patient 
could be classified as probable or proven IA according to EORTC/MSG definitions or 
putative or proven according to AspICU criteria for the subgroup of patients admitted 
to the ICU [13,14].
Patient characteristics included age, gender, underlying diseases, ward/ICU admis-
sion, and antifungal prophylaxis or therapy. ICU admission was defined as initiation of 
antifungal therapy in the ICU and stay in the ICU for at least two consecutive days. 
In addition, patients who were admitted to the ICU during their hospitalization were 
analyzed separately in a cox regression model. Furthermore, the appropriateness of 
initial antifungal therapy was assessed for patients treated with voriconazole. Anti-
fungal therapy was considered appropriate if voriconazole was started in patients with 
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voriconazole-susceptible disease and inappropriate in those with voriconazole-resistant 
IA. Switch to appropriate antifungal therapy and time to switch were determined.
The study was reviewed by the Institutional Review Boards, which confirmed that 
the study did not fall under the Dutch law on research on human subjects. Data were 
processed after encoding and in accordance with the Dutch Personal Data protection 
act.
mycology
Fungal cultures were routinely performed if a patient underwent bronchoscopy with 
BAL and if ordered for other respiratory specimens. A. fumigatus was identified by 
macroscopic and microscopic morphology and growth at 48°C. A. fumigatus isolates 
were routinely screened for the presence of triazole resistance using an agar-dilution 
method (VIPcheckTM, Nijmegen, the Netherlands) [15]. The method relies on agar-
wells supplemented with itraconazole, voriconazole and posaconazole and a growth 
control. Fungal growth on any triazole-containing well was considered indicative of 
resistance and these isolates were sent to Radboud University Medical Center for MIC-
testing according to the EUCAST reference method [16]. Infection was considered to 
be voriconazole-resistant if one or more cultured A. fumigatus isolates exhibited a 
voriconazole MIC above the clinical breakpoint of 2 mg/l. If a patient had more isolates 
cultured within one month of initiation of antifungal therapy, the most resistant isolate 
was used to classify the patient. In addition, the presence of a resistance mutation in 
cyp51A was determined by Cyp51A-gene sequencing, which is specific for A. fumigatus 
sensu strictu, excluding sibling species from the A. fumigatus species complex [17,18].
Data analysis
The primary endpoints were day-42 and day-90 mortality in voriconazole-resistant IA 
compared with voriconazole-susceptible IA cases. Day zero was set at day of initiation 
of antifungal therapy. Other factors with possible impact on survival were also inves-
tigated including choice of first-line antifungal therapy, ICU-admission, Acute Physiol-
ogy And Chronic Health Evaluation II (Apache II) score, and appropriateness of initial 
antifungal therapy.
statistical analysis
Statistical analysis on the relation of voriconazole resistance and mortality was per-
formed in SAS® 9.4 and SPSS® 24 with survival analysis (Kaplan-Meier) and the log-rank 
method. Confidence intervals were calculated with the Kaplan-Meier method. Possible 
confounders, i.e. ICU admission, underlying hematological disease and center, were 
analyzed for each comparison with Cox regression survival analysis, Kaplan-Meier sur-
vival (Log rank) and Fisher exact. Other differences were compared with Fisher exact.
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Demographics
In the five-year period 2,266 patients with a positive A. fumigatus culture in the three 
centers were eligible for the study. Overall, 196 (8.6%) patients met our case definition, 
i.e. received antifungal therapy within 30 days of a positive culture, received at least 
two days of antifungal therapy and could be classified according to the EORTC/MSG or 
AspICU criteria (Figure 1). A proven infection was documented in 43 (22%) patients, a 
putative diagnosis in 36 (18%) patients and a probable diagnosis in 117 (60%) patients 
(Table 1). Hematological malignancy was the most frequent underlying disease diag-
nosed in 103 of 196 (53%) patients. Eighty-five (43%) patients were admitted to the 
ICU during hospital admission, while 59 (30%) patients first received antifungal therapy 
in the ICU. Voriconazole was the initial therapy in 154 (79%) patients. Further details 
regarding the demography for individual centers and the total patient population are 
shown in Table 1.
Voriconazole susceptibility
Voriconazole resistance was observed in 37 of 196 (19%) patients, but the resistance 
frequency varied between 10% and 31% in individual centers (Table 1). Voriconazole-
figure 1: Inclusion of patients with positive A. fumigatus cultures from lower respiratory tract 
or sterile specimens between January 2011 and December 2015. 2,266 patients had one or more 
positive cultures, and 196 patients could be classified according to the definitions of AspICU and 
EORTC/MSG. IA, invasive aspergillosis; †, mortality.
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Parameter✚ Center 1
(60 cases)
Center 2
(59 cases)
Center 3
(77 cases)
Total
(196 cases)
Patient Male / Female 34 / 26 36 / 23 45 / 32 115 / 81
Median age 64 (3 – 79) 61 (4 – 80) 61 (2 – 83) 62 (2-83)
Hematological malignancy 23 (38%) 34 (58%) 46 (60%) 103 (53%)
Autoimmune disease 12 (20%) 6 (10%) 6 (8%) 24 (12%)
Solid organ transplant 8 (13%) 5 (8%) 11 (14%) 24 (12%)
Structural lung disease 5 (8%) 6 (3%) 3 (4%) 14 (7%)
Solid tumor 3 (5%) - 3 (4%) 6 (3%)
Congenital immune disorder 4 (7%) - - 4 (2%)
Other 4 (7%) 8 (4%) 2 (3%) 14 (7%)
None 1 (2%) - 6 (8%) 7 (4%)
ICU-admission 20 (33%) 23 (39%) 16 (21%) 59 (30%)
APACHE II-score 21 25 21 22
IA Putative 15 (25%) 14 (24%) 7 (9%) 36 (18%)
Probable 24 (40%) 39 (66%) 54 (70%) 117 (60%)
Proven 21 (35%) 6 (10%) 16 (21%) 43 (22%)
Voriconazole-susceptible 54 (90%) 41 (69%) 64 (83%) 159 (81%)
Voriconazole-resistant 6 (10%) 18 (31%) 13 (17%) 37 (19%)
ICU Voriconazole-susceptible 18 (90%) 17 (74%) 10 (63%) 45 (76%)
Voriconazole-resistant 2 (10%) 6 (26%) 6 (37%) 14 (24%)
non-ICU Voriconazole-susceptible 36 (90%) 24 (67%) 54 (89%) 114 (83%)
Voriconazole-resistant 4 (10%) 12 (33%) 7 (11%) 23 (17%)
Management Triazole prophylaxis - 16 (27%) 4 (5%) 20 (10%)
Voriconazole 42 (70%) 45 (76%) 67 (87%) 154 (79%)
Itraconazole 1 (2%) - - 1 (0.5%)
Posaconazole 1 (2%) - 2 (3%) 3 (2%)
L-AmB 13 (22%) 13 (22%) 1 (1%) 27 (14%)
Echinocandin - - 1 (1%) 1 (0.5%)
VCZ+L-AmB - - 4 (5%) 4 (2%)
VCZ+Ecand 3 (5%) 1 (2%) 1 (1%) 5 (3%)
VCZ+intrathecal caspofungin/L-AmB - - 1 (1%) 1 (0.5%)
Inappropriate therapy / appropriate therapy 3 / 57 15 / 44 12 / 65 30 /196
Outcome 42-day mortality 13 (22%) 26 (65%) 23 (30%) 62 (32%)
90-day mortality 23 (38%) 29 (85%) 29 (38%) 81 (42%)
42-day mortality ICU 11 (55%) 18 (78%) 7 (44%) 36 (61%)
90-day mortality ICU 13 (65%) 20 (87%) 7 (44%) 40 (68%)
42-day mortality non-ICU 2 (3%) 8 (14%) 15 (19%) 25 (18%)
90-day mortality non-ICU 10 (17%) 9 (15%) 22 (29%) 41 (30%)
table 1: Demographics, invasive aspergillosis classification, voriconazole susceptibility, manage-
ment and outcome of 196 patients with culture-positive invasive aspergillosis.
✚L-AmB, liposomal-amphotericin B; VCZ, voriconazole.
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resistant IA was diagnosed in 14 of 59 (24%) ICU patients and in 23 of 137 (17%) non-ICU 
patients. Voriconazole resistance corresponded with resistance to isavuconazole for 
all 14 patients where isavuconazole susceptibility was determined (Table 2). In 30 of 
37 (81%) patients the A. fumigatus isolate showed a pan-triazole resistant phenotype, 
while in seven patients the susceptibility to itraconazole, voriconazole and posacon-
azole varied. Analysis of triazole-resistant A. fumigatus isolates showed resistance 
mutations that are associated with the environmental route of resistance selection in 
32 of 37 (87%) patients; TR34/L98H in 18 patients and TR46/Y121F/T289A in 13 patients 
(Table 2). In five voriconazole-resistant isolates no mutations were found in the Cyp51A-
gene, suggesting that other uncharacterized resistance mutations might be present. In 
seven patients (19%) a mixed infection was diagnosed; this consisted of an infection 
with a triazole-resistant and susceptible A. fumigatus in six patients (S/R), while in one 
patient isolates with two different resistance mutations were recovered (R/R; Table 2). 
All cultured A. fumigatus isolates were susceptible to amphotericin B.
mortality
The overall mortality in the 195 patients with IA was 62 (32%) at day-42 and 81 (42%) at 
day-90 (Table 1). One patient was discharged to a hospice on day-25 but the exact day 
of death was not known, therefore his survival was censored at 25 days. Comparing the 
patients infected with voriconazole-susceptible and voriconazole-resistant A. fumiga-
tus, a 21% higher overall mortality was observed in patients infected with a resistant 
isolate; 44 of 158 (28%; 95%CI 21% to 35%) patients with voriconazole-susceptible infec-
tion had died at day-42 versus 18 of 37 (49%; 95%CI 34% to 66%; log-rank test, p=0.017) 
of those with voriconazole-resistant IA. At day-90 the absolute difference in mortality 
had increased to 25% (58 of 158; 37%; 95%CI 30% to 45% and 23 of 37; 62%; 95%CI 47% 
to 77%, respectively; log-rank test, p=0.0038; Figure 2A). As expected, the cumulative 
survival rates were much lower for 59 patients who first received antifungal therapy in 
the ICU; mortality was 26 of 45 (58%) for patients with voriconazole-susceptible IA and 
10 of 14 (71%) for those with voriconazole-resistant IA at day-42 (log-rank test, p=0.37; 
Figure 2B). For 136 patients who first received antifungal therapy on the ward (non-ICU 
group) a 19% lower survival rate was observed for patients with voriconazole-resistant 
IA, compared with voriconazole-susceptible infection, with a mortality rate of 8 of 
23 (35%) and 19 of 113 (16%) at day-42, respectively (log-rank test, p=0.045; Figure 
2C). The mortality for 18 patients infected with TR34/L98H was not different from 13 
patients with TR46/Y121F/T289A infection (supplementary Figure S1).
At the discretion of the treating physician, 27 of 196 (14%) patients received initial 
antifungal therapy with L-AmB. Eight of these 27 patients were infected with voricon-
azole-resistant A. fumigatus. The survival at day-42 of L-AmB treated patients was 55% 
compared with 71% for voriconazole-treated patients (log-rank test, p=0.04; Figure 3). 
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figure 2a
Group / Day 0 42 90
VCZ-S 159 114 (72%; CI 65% - 79%) 100 (63%; CI 55% - 70%)
VCZ-R 37 19 (51%; CI 34% - 66%) 14 (38%; CI 23% - 53%)
P-value log rank test 0.017 0.0038
figure 2: Cumulative survival of patients with voriconazole-susceptible and voriconazole-resistant 
IA. A. Cumulative survival of all patients with IA. B. Cumulative survival of patients that started 
antifungal therapy at the ICU. C. Cumulative survival in non-ICU patients with IA. Blue lines rep-
resent patients with IA due to voriconazole-susceptible A. fumigatus (VCZ-S); Red lines represent 
patients with IA due to voriconazole-resistant A. fumigatus (VCZ-R). One patient was discharged 
to a hospice after 25 days and his survival was therefore censored at day-25.
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figure 2b
Group / Day 0 42 90
VCZ-S 45 19 (42%; CI 28% - 56%) 15 (33%; CI 20% - 47%)
VCZ-R 14 4 (29%; CI 9% - 52%) 4 (29%; CI 9% - 52%)
P-value log rank test 0.37 0.57
figure 2: Cumulative survival of patients with voriconazole-susceptible and voriconazole-resistant 
IA. A. Cumulative survival of all patients with IA. B. Cumulative survival of patients that started 
antifungal therapy at the ICU. C. Cumulative survival in non-ICU patients with IA. Blue lines rep-
resent patients with IA due to voriconazole-susceptible A. fumigatus (VCZ-S); Red lines represent 
patients with IA due to voriconazole-resistant A. fumigatus (VCZ-R). One patient was discharged 
to a hospice after 25 days and his survival was therefore censored at day-25.
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figure 2c
Group / Day 0 42 90
VCZ-S 114 95 (84%; CI 76% - 90%) 85 (75%; CI 66% - 82%)
VCZ-R 23 15 (65%; CI 42% - 81%) 10 (43%; CI 23% - 62%)
P-value log rank test 0.045 0.002
figure 2: Cumulative survival of patients with voriconazole-susceptible and voriconazole-resistant 
IA. A. Cumulative survival of all patients with IA. B. Cumulative survival of patients that started 
antifungal therapy at the ICU. C. Cumulative survival in non-ICU patients with IA. Blue lines rep-
resent patients with IA due to voriconazole-susceptible A. fumigatus (VCZ-S); Red lines represent 
patients with IA due to voriconazole-resistant A. fumigatus (VCZ-R). One patient was discharged 
to a hospice after 25 days and his survival was therefore censored at day-25.
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However, the proportion of ICU-patients in the L-AmB-treated group was significantly 
higher compared with voriconazole-treated patients (13 of 27 (48%) versus 43 of 154 
(28%); Fisher exact test, p=0.04), indicating that confounding by indication at least 
partly explained this difference.
The mortality of patients receiving appropriate and inappropriate therapy was 
compared for 154 patients with initial voriconazole therapy. Thirty patients (81%) with 
voriconazole-resistant IA initially received voriconazole therapy and were classified to 
have received inappropriate antifungal therapy (Table 2). Therapy was switched to 
appropriate therapy in 18 patients after a median of 10 days (range 1 to 39 days). Inap-
propriate voriconazole therapy corresponded with reduced survival at day-42 compared 
with appropriate therapy (76% and 53%, respectively; log-rank test, p=0.016; Figure 4). 
Six patients presented with mixed infection (Table 2).
Group / Day 0 42 90
VCZ 154 110 (71%; CI 64% - 78%) 95 (62%; CI 54% - 69%)
L-AmB 27 14 (55%; CI 35% - 72%) 11 (43%; CI 24% - 61%)
P-value log rank test 0.04 0.025
figure 3: Cumulative survival of L-AmB-treated IA patients compared with voriconazole-treated 
patients. Red line represents patients with IA who were treated with voriconazole (VCZ); Blue line 
represents patients with IA who were treated with liposomal amphotericin B (L-AmB). One patient 
was discharged to a hospice after 25 days and his survival was therefore censored at day-25.
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cox regression analysis
ICU admission, underlying hematological disease, and center were analyzed as pos-
sible confounders for mortality. ICU admission contributed significantly to mortality, 
whereas the presence of hematological disease had no effect (see Supplementary Table 
1). Comparison of the centers indicated that the resistance frequency was significantly 
higher in centre 2 in comparison with centers 1 and 3 (p=0.009). The hazard ratio at 
day-42 for patients who started voriconazole therapy on the ICU was 7.7 (95%CI 3.9 to 
15.3; p<0·001), while a hazard ratio of 1.4 was found for voriconazole resistance (95%CI 
0.8 to 2.4; p=0·272; Table S1). In patients where voriconazole therapy was initiated 
on the ward, voriconazole resistance frequency was higher in patients who required 
ICU-admission compared to those who completed treatment on the ward (8 of 16 (50%) 
compared with 15 of 111 (14%) patients, respectively; p=0.044).
Group / Day 0 42 90
Appropriate 124 94 (76%; CI 67% - 82%) 83 (67%; CI 58% - 74%)
Inappropriate 30 16 (53%; CI 34% - 69%) 12 (40%; CI 23% - 57%)
P-value log rank test 0.016 0.0049
figure 4: Cumulative survival of patients that initially received voriconazole therapy; patients re-
ceiving appropriate initial voriconazole therapy were compared with those receiving inappropriate 
therapy. Blue line represents patients with IA who received appropriate initial voriconazole ther-
apy; red line represents patients with IA who received inappropriate initial voriconazole therapy.
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DiscUssion
Our retrospective cohort study showed a higher mortality in patients with voriconazole-
resistant IA compared with voriconazole-susceptible IA. In a setting of primary therapy 
with voriconazole, the absolute difference in day-42 and day-90 mortality ranged be-
tween 21% and 33%, respectively for the overall patient group and for non-ICU patients. 
These observations are in line with results from in-vivo models of resistant infection 
and case series [7,9,10,12,19]. However, these case series included a small number of 
IA patients and were therefore prone to selection or publication bias. In the subset of 
patients admitted to the ICU, no significant difference in survival between voriconazole-
resistant and voriconazole-susceptible IA was found. However, the smaller sample size 
of this subgroup as well as the high mortality of 67% in voriconazole-susceptible IA 
patients in the ICU makes this analysis severely underpowered.
L-AmB is considered alternative treatment for IA but a randomized comparison with 
voriconazole has never been performed and therefore, its efficacy relative to voricon-
azole remains unclear [24]. In our study the survival of L-AmB treated patients was not 
better than voriconazole-treated patients with IA. However, patients that received L-
AmB were more often admitted to the ICU compared with patients on voriconazole and 
therefore had an a priori higher probability of dying. Although the very small number of 
patients in this subanalysis makes any definite conclusions premature, this may indicate 
that in critically-ill patients and those with advanced IA the clinical deterioration could 
not be reversed by polyene-based therapy. Indeed, pre-clinical studies showed that 
L-AmB, even at a dose of 10 mg/kg, was ineffective when treatment was delayed until 
48 hours post-infection [25], underscoring the need for early intervention. Treatment 
delay was also found to be associated with poorer outcome of IA in clinical studies 
[26], which is supported by our observation of lower survival when the initial antifungal 
therapy was inappropriate.
Voriconazole resistance was dominated by mutations associated with environmental 
resistance selection, accounting for 87% of resistance mutations [7,11,12]. The majority 
of isolates were pan-azole resistant and there was 100% cross-resistance between vori-
conazole and isavuconazole. There are no known risk factors that can help to identify 
patients at high risk for triazole-resistant IA, and in our study all cases of inappropriate 
antifungal therapy were due to voriconazole therapy in voriconazole-resistant IA.
Our study has several limitations, including its retrospective design. Many factors may 
impact on the outcome of IA and some of these could act as confounder as they may not 
be well balanced between voriconazole-susceptible and voriconazole-resistant patient 
groups. We identified possible confounders in our cohort. As expected ICU-admission 
was associated with significant higher mortality. However, when ICU-patients were 
excluded, mortality in voriconazole-resistant IA remained significantly higher compared 
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with voriconazole-susceptible IA. Furthermore, patients with voriconazole-resistant 
IA were more likely to require ICU-admission, suggesting that initial therapy was not 
successful. Cox regression analysis indicated that the hazard of death due voriconazole-
resistance was 1.4 times higher than in voriconazole-susceptible infection.
Our study relied on aspergillus culture as this enabled reliable resistance screening 
and in-vitro susceptibility testing. Agar-based resistance screening through VIPcheckTM 
was found to be highly sensitive and specific to identify resistant A. fumigatus colonies 
in cultures, and unlike PCR-based resistance detection, allows detection of a broad 
range of resistance mutations, including uncharacterized mechanisms [15]. However, 
sensitivity of culture is low and thus our cohort represents a small subset of IA cases 
and may not be directly translatable to culture negative cases of IA. However, a recent 
study that used PCR cyp51A resistance testing directly on BAL of hematology patients 
with IA showed a 31% difference in overall mortality, similar to what we observed [19].
As 79% of patients received initial therapy with voriconazole, our study represents 
an escalation strategy, i.e. initial voriconazole and escalation when resistance is docu-
mented. An escalation strategy is recommended by the IDSA, where MIC-testing is advo-
cated in patients suspected of resistance or failing to primary antifungal therapy [24]. 
In our study a higher mortality was observed if patients with voriconazole-resistant IA 
started on voriconazole despite intensive resistance screening. Treatment was switched 
after a median of 10 days, which did not prevent poor clinical outcome. A management 
strategy based on less intensive resistance testing, such as recommended by the IDSA, 
might result in excess mortality in those patients with voriconazole-resistant IA. Direct 
detection of resistance mutations by molecular techniques in BAL-fluid may reduce the 
time to resistance detection, and PCR-based strategic studies are currently ongoing.
As appropriate initial antifungal therapy was found to be critical, upfront combi-
nation antifungal therapy may be required to increase the probability of survival of 
patients at risk for IA in geographic regions with high resistance rates. Combination 
therapy includes voriconazole or isavuconazole combined with an echinocandin or L-
AmB, but clinical evidence supporting these treatment options is lacking. However, the 
10% threshold recommended by an expert panel was met in our centers, and the Dutch 
treatment guideline has now been revised recommending routine triazole resistance 
testing and combination therapy for patients suspected of IA, at least until the presence 
of resistance has been ruled out [27]. In most countries resistance rates are lower than 
reported in the Netherlands, which does not justify a de-escalation strategy [1,28].
Our findings underscore the need for rapid resistance tests and antifungal drugs based 
on new targets. As azole fungicide use appears to be an important driver for resistance 
in A. fumigatus and new resistance mutations continue to emerge in the environment 
[29], strategies need to be developed aimed at overcoming resistance selection in the 
environment. However, antimicrobial resistance (AMR) action plans and ‘One-Health’ 
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research are generally restricted to bacterial resistance [30]. Governments, medical 
research councils and public health organizations are called to action to prioritize 
fungal research and help to overcome the problem of triazole resistance.
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There is nothing more deceptive than an obvious fact. (Arthur C Doyle)
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abstract
background
Oral follow-up therapy is problematic in moulds with reduced azole-susceptibility, 
such as azole-resistant A. fumigatus infection. Currently only intravenous liposomal 
amphotericin B (L-AmB) is advocated by guidelines for the treatment of azole-resistant 
aspergillosis infections. Preclinical research indicates that high-dose posaconazole 
(HD-POS) might be a feasible option provided that high drug exposure (i.e. POS serum 
through levels >3 mg/L) can be achieved and is safe.
objectives
To describe our experience with the use of oral HD-POS as a treatment strategies for 
patients infected with pathogens with a POS MIC close to the clinical breakpoint.
Patients/methods
We review evidence supporting the use of HD-POS and describe our experience on safety 
and efficacy in 16 patients. In addition, we describe the adverse events (AE) observed 
in 25 patients with POS concentrations at the higher end of the population distribution 
during treatment with the licensed dose.
results
Sixteen patients were treated intentionally with HD-POS for voriconazole-resistant 
invasive aspergillosis (7/16), mucormycosis (4/16), salvage therapy for IA (4/16) and IA 
at a sanctuary site (spondylodiscitis) in 1. Grade 3-4 AEs were observed in 6 and all of 
them were considered at least possibly related. Grade 3-4 AEs were observed in 5 of the 
25 patients with spontaneous high POS serum through levels considered at least possibly 
related using Naranjo scale.
conclusions
HD-POS is a treatment option if strict monitoring for both exposure and for AE is pos-
sible.
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introDUction
Invasive aspergillosis (IA) in patients with haematological malignancies is associated 
with a mortality of 20-30%. (1, 2) Triazole resistance is increasingly reported in different 
countries through culture-based surveillance studies, (3) and is associated with a much 
higher mortality of 50-88%. (4, 5) In 2015, a consensus meeting on the management 
of azole-resistant IA was organized (6) and liposomal-amphotericin B (L-AmB) was 
advocated as the preferred therapy but has obvious toxicity limitations and can only be 
administered intravenously. Treatment of IA has to be continued for a minimum of 6–12 
weeks but occasionally much longer. (7) Other treatment options are therefore urgently 
needed. Phase II studies on new antifungals are just about to start and subsequent 
phase III studies typically take 3 or 4 years to complete. Therefore, these drugs will 
not provide a short term solution. Targeting high-exposure posaconazole (POS) may be 
a potential oral step-down treatment option for azole-resistant IA and other difficult-
to-treat mould infections.
POS is approved in patients with haematological malignancies both for prophylaxis 
and treatment of refractory IA or when intolerance to first-line agents occurs. (8, 9) 
The agent is available as oral suspension, a delayed-release tablet and an intravenous 
formulation. Oral absorption of POS oral suspension is affected by food and gastric pH. 
In contrast, POS-tablets contains the active drug mixed with a pH-sensitive polymer 
(10) and this polymer releases the drug in the intestines, causing three-fold increased 
exposures compared to POS oral suspension. (11)
Therapeutic drug monitoring (TDM) has been widely implemented to assess thera-
peutic efficacy of POS oral suspension but its usefulness is in a state of flux following 
the introduction of the new POS formulations specifically in the setting of prophylaxis. 
(12-14) Current guidelines recommend a Ctrough concentration of ≥0.7 mg/L for pro-
phylaxis and >1.0 mg/L for primary and >1.25 mg/L for salvage therapy, (15) although 
these concentrations were determined independent of the susceptibility of the infect-
ing pathogen. (13)
These targets have been derived for susceptible pathogens and are not valid for 
pathogens with attenuated susceptibilities. A different approach is needed to optimize 
treatment in case of reduced susceptibility.
Preclinical research indicates that high-dose posaconazole (HD-POS) might be a 
feasible option provided that high drug exposure (i.e. POS serum through levels >3 
mg/L) can be achieved and is safe. Hence, we argued that oral high-dose treatment 
strategies might be feasible to treat pathogens with relatively low MICs/MICs just above 
the clinical breakpoint (low-resistant). Human data on the treatment of pathogens with 
reduced susceptibility as well as safety of POS Ctrough concentrations of >3 mg/L are 
sparse.
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Here, we review the evidence supporting the use of HD-POS and describe our experi-
ence on safety and efficacy in 16 patients. In addition, we describe the adverse events 
(AE) observed in 25 patients with POS concentrations at the higher end of the popula-
tion distribution during treatment with the licensed dose.
Patients / methods
We set out to explore safety of HD-POS and retrospectively collected clinical and 
laboratory data of patients from 2 Dutch academic medical centres (Erasmus University 
Medical Centre, Rotterdam and Radboud University Medical Centre, Nijmegen) in which 
POS Ctrough concentrations >3 mg/L had been documented in two different popula-
tions. All patients were in care by one of the authors of this paper. Data were extracted 
and reviewed by J.B. and A.S. Group 1 consisted of patients intentionally treated with 
HD-POS targeting POS Ctrough concentrations >3 mg/L and Group 2 were patients that 
reached POS Ctrough concentrations >3 mg/L with the licensed dose. We focused on AEs 
(related or unrelated to POS) described in the patient files and laboratory data. Data 
from these patients were reviewed for toxicities according to the Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.03. An AE was defined as unfavourable 
or unintended sign or symptom while the patient was treated with POS, whether or 
not the sign or symptom was related to POS. The Naranjo scale was used to determine 
for the assessment of causality of potential AE with POS. This is a questionnaire for 
determining a potential likelihood that an adverse drug reaction is actually linked to a 
drug. Probability is assigned using a scoring system with the following possible results: 
definite, probable, possible of doubtful. (16) Medians and 25th to 75th inter-quartile 
ranges were used for statistic descriptions. This type of research does not fall under 
the Dutch law of research on human subjects. However, to safeguard the privacy of the 
patients, the data were stored anonymously after data extraction.
resUlts
Group 1
Sixteen patients were treated intentionally with HD-POS for voriconazole-resistant IA 
(7/16), mucormycosis (4/16), salvage therapy for IA (4/16) and IA at a sanctuary site 
(spondylodiscitis) in 1. The median POS dose given was 600 (IQR 400,750) mg daily when 
the POS Ctrough concentrations of >3 mg/L was reached after a median of 8 (IQR 6,40) 
days. Ten patients had significantly higher Ctrough concentration (above 4 mg/L) and 6 
patients had Ctrough concentrations between 3.0 and 4.0 mg/L and on average patients 
had these concentrations for a median 76 days (IQR 20,162). Thirteen patients received 
POS-tablet, 1 patient posaconazole-oral suspension (POS-OS) and 2 patients a combina-
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tion of formulations. AEs are described in table 1. Grade 3-4 AEs were observed in 6 
patients and all of them were considered at least possibly related using Naranjo scale. 
In 3 out of16 patients the treatment was stopped following an AE: arterial hypertension 
(grade 2), QTc prolongation, cardiac troponin T increased and left ventricular failure 
(grade 3) and leukocytopenia (grade 4).
Efficacy
Of the 7 patients with azole-resistant IA treated with HD-POS, 4 survived while 3 died 
from their underlying disease but unrelated to the IA. In 2 patients HD-POS was used 
as salvage therapy. One patient with IA caused by A. terreus was treated with HD-POS 
because serum galactomannan levels increased under conventional dosage which is a 
predictor of poor outcome (table 3). All patients with mucormycosis survived.
Group 2
This group consisted of 25 patients. The median POS Ctrough concentration was 4.3 
mg/L (IQR 3.5-6.0). 19, 5 and 1 patient received POS-tablet, POS-OS and the IV for-
mulation respectively. Posaconazole was given to 18 and 7 patients for prophylaxis and 
treatment, respectively. All observed AEs are described in table 2. The most frequently 
adverse event Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Diarrhoea 1
Nausea 1
Vomiting 3
Increased hepatic enzymes 4 1 1(3) 2(5|7)
Cardiac troponin T increased 1(6)
Electrocardiogram QTc corrected interval prolonged 1 1 1(6)
Leukopenia 1(4)
Hypokalaemia 3 3
Hyperkalaemia 1
Headache 1
Delirium 1 1(2)
Alopecia 1
Hypertension 2
Heart failure 1(5)
Rash 1
table 1: Adverse events of 16 patients receiving intentionally HD-POS graded accordingly to the 
Common Terminology Criteria for Adverse Events (version 4.03). Digits refer to the number of 
patients in whom these AEs have been documented. Prolongation in the QTc interval was assessed 
by comparing electrocardiograms obtained at baseline and during HD-POS treatment, if available.
(*) Naranjo adverse drug reaction probability scale: >9: definite, 5 to 8: probable, 1-4: possible. -3 
to 0: doubtful.
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observed AE were hypokalaemia in 8 patients and neurological in 6 patients (headache, 
convulsions). Grade 3-4 AEs were observed in 5 and all of them were considered at least 
possibly related using Naranjo scale. In 8 of the 25 patients the dosage was reduced. 
Follow-up Ctrough concentrations were between 1.1 and 4.3 mg/L after dosage reduc-
tion.
DiscUssion
Little is known about the toxicity of patients attaining high POS Ctrough of >3 mg/L. 
The upper boundary level of average POS serum concentrations of 3.75 mg/L is set by 
the European Medicines Agency based on experience with the POS-OS and preclini-
cal toxicology findings (17). In this study, we reviewed the safety and tolerability of 
HD-POS. In both group 1 and group 2, three patients were seen with a combination of 
hypertension and hypokalaemia that required antihypertensive therapy and potassium 
supplementation. The most striking case was a child treated with POS, L-AmB and mica-
fungin for a proven aspergillosis following surgical removal of Aspergillus lesions in the 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
adverse event
Diarrhoea 4
Nausea 4
Vomiting 2
Increased hepatic enzymes 2 3 1(4)
Electrocardiogram QT corrected interval prolonged 2 1
GGT increased 1
Anorexia 5 1
Hyponatremia 2 1(1)
Hypokalaemia 7 1
Headache 5
Seizure 1
Alopecia 2
Hypertension 2 1(7) 1(4)
Hypotension 1(#)(7)
Rash 3
table 2: Adverse events of 25 patients receiving POS with high spontaneous concentration graded 
accordingly to the Common Terminology Criteria for Adverse Events(version 4.03). Digits refer to 
the number of patients in whom these AEs have been documented. (*)These grade 3 or 4 AE were 
considered at least possible related to POS.(#) Refractory shock, rapidly fatal. Distributive shock 
most likely according to treating physician.(*) Naranjo adverse drug reaction probability scale: >9: 
definite, 5 to 8: probable, 1-4: possible. -3 to 0: doubtful.
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spleen, left lung and right kidney. This patient developed several hypertensive crises 
and developed hypokalaemia for which oral supplementation was needed. 8 months 
after POS treatment, the patient died due to a vasopressor refractory shock. During 
these hypertensive crises, aldosterone could not be measured (<50 pmol/L) and renine 
was within normal range. In retrospect, POS may have caused the hypertension, and 
hypokalaemia. Recently, a case of POS induced heart failure, hypertension and hypo-
kalaemia was described with low renin and aldosterone levels. The inhibition of the 
enzyme 11-beta-hydroxysteroid dehydrogenase 2 is suggested as the potential mecha-
nism causing apparent mineralocorticoid excess. (18-20) This enzyme is homeostatic 
regulator and damps mineralocorticoid activity by converting cortisol to cortisone.
The AE of HD-POS observed in this study are in line with previous reports of AE due to 
POS. A phase III study assessing PK and safety of POS-tablet demonstrated that nausea 
and diarrhoea were the most common treatment-related AEs leading to POS discon-
tinuation in 2% and 1%, respectively. (21) Only 9 patients (10%) in this study attained 
an average Ctrough concentration between 2.5 and 3.75 mg/L and six patients (3%) 
reached Ctrough concentrations ≥3.75 mg/L. No increase of AEs in patients with higher 
POS serum concentrations was observed but the study was not powered to detect such a 
relation. Very recently, PK and safety results from a phase 3 study of IV POS in patients 
at risk for invasive fungal disease were published. Six percent of the patients had a 
steady-state concentration between >2.5 and ≤3.65 mg/L without signs of toxicity. (22) 
In a retrospective analysis of 64 patients receiving POS-tablet as prophylaxis, median 
POS steady state concentrations of 1.67 mg/L (0.52-3.83 mg/L) were documented. 
In 21% of the patients a QTc prolongation was observed and the median steady state 
concentration was 2.04 mg/L. (23) In a single-centre study, 343 courses of POS prophy-
laxis (IV or tablet) were assessed for safety and effectiveness. 20% of these patients 
developed liver injury, mostly hyperbilirubinemia but this is often multifactorial. More 
importantly, grade 3-4 elevations in hepatic enzymes were only observed in 2% of the 
patients without pre-existing liver injury with mostly spontaneous resolution despite 
treatment continuation. (24) Thus, in the current literature, information about the 
toxicity of high POS serum concentrations is limited but no increase in the number of 
AEs was observed in patients with higher than average serum concentrations.
azole-resistant ia
The large majority of azole-resistant A. fumigatus isolates harbour TR34/L98H or TR46/
Y121F/T289A mutations in the cyp51A gene, (25, 26) encoding the cytochrome p450 
sterol 14α-demethylase, the target of azoles. A. fumigatus isolates carrying resistance 
associated mutations have high minimal inhibitory concentrations (MICs) for itracon-
azole and/or voriconazole as well as isavuconazole. (27) The MIC of POS often remains 
close to the susceptible population (i.e. MIC ≤0.5 to 1 mg/L). (28) MIC levels of POS 
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>0.25 mg/L are considered resistant according to the EUCAST breakpoint, but this is 
based on population susceptibility and on concentrations achieved with the POS-OS at 
licensed dose. Indeed, drug exposure with POS-OS will marginally cover the A. fumigatus 
wild-type population, let alone low-level POS-resistant isolates. Higher exposures can 
be achieved with the newer formulations. (13) The pharmacodynamic-pharmacokinetic 
(PK-PD) relationships of POS have been studied in vivo. A murine model of IA indicated 
that low-level POS-resistant isolates can be treated when the POS exposure is increased. 
Two in vivo studies demonstrated that POS retains efficacy against A. fumigatus isolates 
with POS-MIC of 0.5 mg/L as long as POS exposure is sufficiently high. (29, 30) Based 
on these experiments, the required POS exposure (area-under-the concentration time 
curve (AUC)) in patients can be calculated for isolates with an increased MIC. The 
probability of target attainment for treatment of IA using standard dosing of POS-tablet 
is estimated to be ~80 % for isolates with POS-MIC of 0.25 mg/L and >90% for isolates 
with a POS-MIC of 0.125 mg/L. (28) The probability of target attainment for a POS-MIC 
of 0.5 mg/L was 24% and for a POS-MIC ≥ 0.5 mg/L it was 0%.
As determination of the AUC requires multiple sampling moments, and this AUC is 
linear correlated to Ctrough concentrations, quite often the Ctrough concentrations are 
used in daily practice as surrogate markers. (13, 28) Monte Carlo simulations estimated 
that the POS Ctrough concentrations needed to be 1.44-1.55 mg/L for isolates with a 
POS-MIC of 0.25 mg/L and 3.09-3.33 mg/L for isolates with a POS-MIC of 0.5 mg/L. (28)
As the aforementioned in vivo experiments indicated that A. fumigatus with a POS-
MIC of 0.5 mg/L can be treated with elevated POS dosing, we hypothesized that target-
ing high exposure with HD-POS is an oral step-down treatment option for azole-resistant 
IA. Although clinical evidence supporting HD-POS has not been described, preclinical 
animal studies and experience in veterinary medicine provided proof-of-principle for 
its efficiency. (28, 29)
mucormycosis
Limited in vivo models are available that assess POS for the treatment of mucormycosis. 
A neutropenic mouse model indicated similar pharmacodynamics for mucormycosis 
compared to A. fumigatus infections. An AUC/MIC of 87 was needed to treat Rhizopus 
oryzae infection, which was comparable to the target needed for IA (AUC/MIC of 76). 
(31) Efficacy of POS showed a dose-response relationship in another in vivo model of 
experimental mucormycosis in which a dose of 100mg/kg/day showed significant reduc-
tion of mortality of Lichtheimia corymbifera infection. (32) Similar dose-response rela-
tionships were seen for Mucor species and R. oryzae. (33, 34) Compared to A. fumigatus 
isolates, the MICs of Mucorales are often higher with a geometric mean CLSI MIC of 0.39 
mg/L (35) and an epidemiological cut-off value of 1 mg/L for L. corymbifera, R. oryzae, 
and R. microspores and 4 mg/L for M. circinelloides (Figure 1). (36) Furthermore, the 
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figure 1: Posaconazole MIC distributions of most common Mucorales species: Rhizopus oryzae, 
Mucor circinelloides, Rhizopus microspores and Lichtheimia corymbifera
MICs were extracted from Espinel-Ingroff et al. (36) MICs were determined according to the CLSI 
method for susceptibility testing of molds (M38-A2).
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EUCAST MICs for Mucorales are higher than CLSI MICs for most species. (37) Taken into 
account the similar target AUC/MIC for Mucorales as A. fumigatus, but higher MICs for 
Mucorales isolates compared to A. fumigatus, it seems reasonable to pursue higher than 
normal POS serum concentrations for the treatment of mucormycosis as long as this is 
not associated with toxicity. (13)
POS-OS has been used as salvage therapy for mucormycosis with a success rate of 
approximately 60-80%. (38) A recently published matched-paired analysis assessed the 
clinical effectiveness and safety of POS tablets and intravenous formulation in compari-
son with amphotericin B as first-line treatment and with POS-OS as salvage treatment 
for invasive mucormycosis. POS tablets and intravenous formulation were effective in 
terms of treatment response and associated mortality. However, these observations 
should be interpreted with caution given the small sample size in this study (43). Clini-
cal data on PK/PD are lacking due to limited susceptibility data from clinical studies. 
(38)
Dosing and tDm
The pharmacokinetics of posaconazole tablets are best described by a one-compartment 
pharmacokinetic model with sequential zero-order and first-order absorption and a 
first-order disposition from the central compartment. Recently, several covariates were 
identified influencing bioavailability (like disease state, body weight, formulation), 
adsorption rate (food status) and clearance (dosing regimen) of POS tablets. Only body 
weight was considered clinically relevant. (39) Knowledge on the PK of POS helps to 
identify the optimal dose when targeting high exposure. Subsequently, an infrastructure 
is needed where one can quickly assess drug concentrations to deploy an adaptive 
approach in terms of dosing. With the new formulations of POS a loading dose is given, 
which enables early assessment, typically by day 3, of POS concentrations. Follow-up 
samples are measured again before the 5th dose of every changed dosage.
The pharmacokinetics described above translate into an expected doubling of the 
Ctrough concentration when the dose of POS-tablet or IV formulation is doubled. For 
example, when the Cthrough concentration is 1.5 mg/L, increasing the dose from 300 
mg once daily to 300mg twice daily can be expected to lead to a serum concentration 
of 3 mg/L. For safety reasons, we advise to increase the dose with no more than 200 
mg per step.
inhibitory potential of HD-Pos
POS is a strong CYP3A4 inhibitor and the clinician should therefore also remain vigilant 
for drug interactions. In our case series, we had two patients with significant interac-
tions. Toxicity of HD-POS in combination with vincristine was seen in a child with ALL, 
resulting in hepatotoxicity, convulsions and hypertension which might be attributed to 
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the inhibition of CYP3A4 as well as P-gp resulting in increased levels of vincristine. (40) 
Another allogeneic stem cell transplant patient developed IA despite prophylaxis with 
voriconazole. Treatment with L-AmB was started but switched to HD-POS for progres-
sive renal impairment. POS Ctrough concentration was 5.2 mg/L. After the patient was 
treated with panobinostat, a histone deacetylase (HDAC) inhibitor, grade 4 leukopenia 
developed. After 4 weeks of persisting grade 4 leukopenia, POS treatment was stopped 
as presumed culprit and leukopenia improved. This interaction could have been pre-
dicted based on the interaction of panobinostat with ketoconazole where panobinostat 
maximum serum concentrations were increased by an average of 1.6-fold. (41)
safety monitoring for HD-Pos
We propose that the following safety measures are taken if HD-POS is used as a treat-
ment strategy. At least the following laboratory tests should be performed twice weekly 
during the first 2 weeks and as long as the POS dosage is being increased: electrolytes, 
renal clearance, haemoglobin, leukocyte differentiation, thrombocytes and liver 
enzymes. Posaconazole, may cause QT prolongation. Therefore, an ECG should be re-
corded before the start of HD-POS as well as during treatment. If no lab abnormalities 
possibly related to POS are observed the monitoring interval can be increased.
In conclusion, registration of new antifungals with efficacy against azole-resistant 
A. fumigatus is expected to take several more years. Therefore, targeting high serum 
concentrations of POS using the tablet or IV formulation is, in our point of view, a 
possible step-down option in patients with azole-resistant IA as long as the POS-MIC is 
<1 mg/L and for patients treated for mucormycosis with L-AmB. It should only be used 
when close monitoring for AE is implemented as described above in conjunction with 
TDM and when the benefits are likely to outweigh the risks.
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abstract
background
Triazole resistant A. fumigatus has been documented in many parts of the world. In 
the Netherlands, incidence is now above 10% and results in the need for long-term 
parenteral therapy with liposomal amphotericin B (LAmB). The long terminal half-life 
of LAmB suggests that intermittent dosing could be effective, making the application of 
outpatient antifungal therapy (OPAT) possible. Here, we report our experience with the 
use of OPAT for Invasive Fungal Infections (IFI).
methods
All adult patients treated with LAmB with a 2 or 3 times weekly administration via the 
outpatient departments in four academic tertiary care centres in the Netherlands and 
Belgium since January 2010 were included in our analysis. Patient characteristics were 
collected, as well as information about diagnostics, therapy dose and duration, toxicity, 
treatment history and outcome of the IFI.
results
In total, 18 patients were included. The most frequently used regimen (67%) was 5mg/
kg 3 times weekly. A partial response to the daily treatment prior to discharge was 
confirmed by CT-scan in 17 (94%) of patients. A favourable outcome was achieved in 13 
(72%) patients. Decrease in renal function occurred in 10 (56%) cases but was reversible 
in all and was treatment limiting in 1 patient only. 100-day mortality and 1-year mortal-
ity after initiation of OPAT were 0% and 6%, respectively.
conclusions
In a selected population, and after confirmation of initial response to treatment, our 
data support the use of OPAT with LAmB for treatment of IFI in an intermittent dosing 
regimen.
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bacKGroUnD
Invasive Fungal Infections (IFI) are often life-threatening and occur predominantly in 
immunocompromised patients. After surviving the initial phase of infection, prolonged 
treatment with an antifungal agent is often necessary to ensure complete resolution (1, 
2). Unfortunately, the different antifungal drugs in the current medical armamentarium 
all have shortcomings when used for a prolonged period of time (3). For invasive asper-
gillosis (IA) voriconazole became the first-choice treatment after an improved survival 
was documented over conventional amphotericin B (cAmB). Furthermore, voriconazole 
has a favourable adverse event profile compared to conventional formulations of am-
photericin B and it is rarely associated with renal toxicity (4, 5). Nonetheless, no direct 
comparison between voriconazole and the more well-tolerated liposomal amphotericin 
B (LAmB) has been made. In recent years, increasing rates of triazole resistant Aspergil-
lus fumigatus in particular in Europe but also in other continents have become a major 
concern (6-10). This has led to a renewed incentive to reconsider therapeutic strategies 
using LAmB (11, 12). For many IFI caused by non-Aspergillus fungi, e.g. Mucorales spp., 
LAmB already is the preferred first-line treatment (13, 14). Therefore, treatment with 
LAmB is increasingly indicated and sometimes even the last resort in the management 
of invasive fungal disease.
LAmB is solely administered in an intravenous formulation. Both safety concerns and 
logistical reasons prevent dismission from the hospital during intravenous treatment; 
however, often the treatment duration is long and exceeds the period of necessity of 
hospitalisation for clinical reasons (1, 2). The practical limitations of daily intravenous 
treatment are evident. Reduction of duration of hospital stay would be favourable when 
considering both patient quality of life as well as economic costs. Furthermore, contin-
ued daily intravenous administration will lead to high cumulative dosages, associated 
with a higher rate of adverse events. As an alternative, we have started to apply Out-
patient Antifungal Therapy (OPAT) with LAmB. OPAT has been implemented successfully 
in the past with various antibiotics. In bacterial infections, increasing antimicrobial 
resistance rates have made prolonged intravenous treatment with reserve antibiotics 
necessary. For example, the increasing rate of Methicillin Resistant Staphylococcus 
aureus has been an important reason to apply prolonged OPAT with vancomycin (15-17). 
With LAmB, outpatient use has recently been implemented in a prophylactic setting 
(18).
Two recent reviews of the pharmacokinetic properties of LAmB strengthen the hy-
pothesis that LAmB can effectively be applied as OPAT (19, 20). LAmB has a relatively 
short elimination half-life of 7 hours shortly after initiation of therapy, which increases 
to over 100 hours after prolonged use. This phenomenon is attributed to accumulation 
in tissues and slow redistribution (21, 22). When these pharmacokinetic properties of 
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LAmB are taken into account, (23-25), it can be expected that a therapeutic concentra-
tion can be attained is a less frequent dosing scheme. Moreover, it may be possible 
to (partially) avoid nephrotoxicity if the total dose of LAmB is spread over multiple 
days (25, 26). Nephrotoxicity however remains an important caveat in the application 
of OPAT with LAmB, as mentioned in pharmacological review papers and in previous 
experimental experience (19, 20, 22, 27).
For those in need of prolonged antifungal treatment, step-down therapy to intermit-
tent dosing in the context of outpatient treatment could offer similar efficacy with the 
potential of improved safety. An intermittent dosing strategy is occasionally applied in 
several hospitals in the Netherlands and Belgium. In this study, we are introducing the 
concept of treatment of IFI with intermittent LAmB dosing as OPAT.
metHoDs
study setting and patient population
A multi-centre retrospective cohort study was conducted within the Netherlands and 
Belgium. Hospitals that participate in the Dutch-Belgian Mycoses study group (DB-MSG) 
(28), a consortium committed to the clinical research of IFI, were sent an inquiry about 
their experience in the application of OPAT with LAmB in the past 10 years. Of the 
11 medical centers that participate in the DB-MSG, four responded that they had ap-
plied OPAT with LAmB in recent years. OPAT was applied at the home of the patient or 
within the hospital outpatient department. All adult patients treated with LAmB with 
a less frequently than daily administration via the outpatient departments of Leiden 
University Medical Center, Erasmus MC Rotterdam, Radboud University Medical Center 
Nijmegen, and the University Hospitals Leuven since January 2012 were included. These 
centres are all tertiary care university hospitals and engaged in extensive solid organ 
and hematopoietic stem cell transplantation programs.
Study protocols and definitions
No uniform protocols for the start of intermittent therapy with LAmB were present. 
Typically for Aspergillus disease, a 3 mg/kg dose was started. For Mucor species a 
typical dose was between 5-10 mg/kg. The choice to start treating with intermittent 
therapy with LAmB was made according to the clinical judgement of the treating 
physician usually based on imaging and clinical course. Patients that were started on 
OPAT with LAmB were closely monitored for the occurrence of nephrotoxicity and most 
patients received the drugs in the outpatient department of the hospital. In the first 
month, all patients had at least a weekly monitoring of electrolyte and kidney function. 
In the subsequent weeks, monitoring occurred at least once every two weeks.
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Nephrotoxicity was defined as a >1.5 times increase of baseline serum creatinine 
levels resulting in an eGFR of less than 40 ml/min/1.73 m2 during treatment or as 
electrolyte disorders suspected to be the result of renal damage and requiring cessation 
of treatment with LAmB at the discretion of the treating physician. Resolution of IFI 
was defined as clinically observed absence of complaints that are likely to be caused 
by IFI in combination with findings concordant with resolution of IFI on high-resolution 
CT-scan and the absence of the need to restart antifungal therapy within 6 months.
Data collection
At the participating sites, lists of patients that received LAmB as an outpatient were 
provided by the hospital pharmacy. Based on these lists, the electronic medical records 
were examined to ensure eligibility for inclusion in our study. The only inclusion crite-
rion was at least 2 weeks of intermittent treatment outside of the hospital with LAmB 
for an invasive fungal infection meeting the diagnostic criteria of the revised (2008) 
EORTC/MSG definitions for invasive fungal disease (29).
After retrieval of all relevant information, the data of all participants was pseud-
onymized. Patient characteristics including age, diagnosis of immunocompromising 
disease, diagnosis of IFI, comorbidity and immune status were collected, as well as 
information about performed diagnostics, dosage of therapy, duration of therapy, treat-
ment history, switch of antifungal therapy, renal function and outcome of the IFI. The 
latter three variables were considered the primary study outcomes to assess the safety 
and efficacy of this strategy. IFI were classified according to the 2008 revised European 
Organisation for Research and Treatment of Cancer – Mycoses Study Group criteria for 
the classification of IFI (29).
analyses
Descriptive statistics of clinical variables of patients were calculated using the com-
plete dataset. Kaplan Meier curves of survival during OPAT with LAmB were constructed. 
The analyses were performed using STATA v 16 (Statacorp, College Station, Texas, USA).
ethics
The study was reviewed by the institutional review board of the LUMC Leiden in the 
Netherlands, which confirmed that the study did not fall under the Dutch law on 
research on human subjects. The institutional review board from UZ/KU Leuven in 
Belgium approved the study. Data were processed after pseudonymization by the local 
investigators and in accordance with Personal Data Protection Acts of the respective 
countries.
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resUlts
Between January 1st 2010 and September 1st 2018, a total of 18 adult patients received 
LAmB as an outpatient in a dosing frequency of two or three times a week. Triazole 
resistance, demonstrated by either PCR or culture, has been the most common reason 
(in 10 cases) to choose treatment with LAmB instead of voriconazole in the patients with 
Invasive Aspergillosis. Of all patients, nine (50%) were male and median age was 60 years. 
Fourteen patients (78%) had a haematological malignancy as underlying predisposing 
disease. Other underlying diseases were Chronic obstructive Pulmonary Disease (COPD), 
Sickle Cell disease and Chronic Granulomatous Disease (CGD). Suspected causative agents 
of IFI were Aspergillus spp. (12 patients), Mucorales spp. (3 patients), Fusarium spp. 
(2 patients) and a combination of both Aspergillus and Mucor (1 patient). Table 1 sum-
marizes the descriptive characteristics of the study cohort. A response to treatment prior 
to discharge and start of OPAT with LAmB was confirmed by CT-scan in 17 patients. For the 
remaining patient, clinical improvement had been the reason to proceed with OPAT. Pa-
tients switched from daily treatment as an inpatient to intermittent OPAT with LAmB after 
a median of 56 days (range 14-193 days). Median dosage of liposomal amphotericin B was 3 
mg/kg, administered three times each week. Some patients switched drug dosage and/or 
frequency as detailed in the legend. None of the patients received combination therapy. 
Resolution of infection was finally achieved in 13 patients. The remaining patients were 
readmitted to the hospital, switched to another antifungal, died or were lost to follow-up.
Nephrotoxicity during OPAT occurred in 10 cases, of which in only one case treatment 
needed to be switched to another antifungal agent (posaconazole, after establishing 
intermediate sensitivity).
All patients in our dataset had normalised renal functions after decreasing of dosage 
or cessation of LAmB therapy. Severe hypokalaemia (less than 2.5 mmol/litre) was not 
observed during treatment with LAmB in an intermittent scheme. No intravenous or oral 
substitution of potassium was has been applied.
For the remaining cases, the treating physician opted for a dose reduction (four cases) 
or, after establishing a sufficient treatment response, for the cessation of antifungal 
therapy (five cases). The 100-day mortality and 1-year mortality were 0 and 1 patients 
out of 18 respectively. All-cause mortality until the end of follow-up was 39% but was 
related to the underlying immunocompromising disease. In all cases treated for invasive 
aspergillosis, the reason to treat with LAmB was triazole resistance (demonstrated in 
10 patients, presumed in 3 patients). Readmission to the hospital was necessary due 
to factors related to the infection (3 patients) or to LAmB-related nephrotoxicity (1 
patient). Figure 1a shows the survival rates of all patients in a Kaplan Meier analysis 
since start of OPAT. Figure 1b shows the time until resolution of infection. Figure 1c 
shows the time until nephrotoxicity occurred during intermittent treatment.
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total number of patients 18
Patient characteristics
Sex, male (%) 9 (50)
Age, median (range) 60 (18-78)
Underlying predisposing disease, number of pts. (%)
ALL 6 (33)
AML/MDS-RAEB2 4 (22)
CLL 3 (17)
COPD 2 (11)
Aplastic Anemia 1 (6)
CGD 1 (6)
Sickle Cell Disease 1 (6)
Prior allogeneic HSCT for any underlying disease 8 (44)
invasive fungal infection, number of pts. (%)*
Aspergillosis 13 (72)
Mucormycosis 3 (17)
Fusariosis 2 (11)
Cryptococcosis 1 (6)
reason to treat invasive aspergillosis with lamb,
Number of patients (% of patients with IA)
Triazole resistance identified with culture or PCR 10 (77)
Resistance presumed because IA occurred despite adequate prophylaxis with a triazole 2 (15)
Resistance presumed because IA showed progression despite adequate treatment with a triazole 1 (8)
treatment
Dosage in mg/kg and frequency in times/week†, number of patients treated with the regimen at any point
2 mg/kg 3 times/week 1
3 mg/kg 2 times/week 1
3 mg/kg 3 times/week 12
5 mg/kg 3 times/week 2
6 mg/kg 3 times/week 5
10 mg/kg 2 times/week 2
Response to treatment confirmed by CT before start of intermittent therapy, number of pts (%) 17 (94)
Number of days between date of diagnosis and start of intermittent therapy, median number of 
days (range)
56 (14-193)
nephrotoxicity^, number of patients (%)
Occurrence of nephrotoxicity at some point during intermittent LAmB treatment
Of which
10 (56)
- resulting in switch to other antifungal agent 1 (10)
-  resulting in cessation of antifungal treatment (because of concurrent sufficient clinical and 
radiological response to treatment)
4 (40)
- resulting in dose or frequency reduction~ 5 (50)
table 1: Patient characteristics
Legend: On next page
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Legend: LAmB denotes liposomal amphotericin B, ALL Acute Lymphoid Leukaemia, AML Acute 
Myeloid Leukaemia, MDS-RAEB2 Myelodysplastic Syndrome with Refractory Anaemia with Excess 
Blasts-2, CLL Chronic Lymphatic Leukaemia, HSCT hematopoietic stem cell transplantation, CT 
Computed tomography, COPD Chronic Obstructive Pulmonary Disease, PCR Polymerase Chain Re-
action, CGD chronic granulomatous disease, IA invasive Aspergillosis. * Numbers add up to more 
than 100% due to one patient suffering from an infection caused by both Mucor and Aspergillus. 
^Nephrotoxicity defined as either serious electrolyte disturbances necessitating treatment cessa-
tion at the discretion of the treating clinician or at least 50% increase of creatinine levels resulting 
in a eGFR of less than 40 ml/min. †Numbers add up to more than 100% because of 5 patients with 
dose alterations during the study period. ~ Dose reductions were as follows: 2 patients treated 
with 6 mg/kg 3 times weekly and 1 patient treated with 5 mg/kg 3 times/week were switched to 3 
mg/kg 3 times weekly. Of 2 patients treated with 3mg/kg 3 times/week, one was switched to 3mg/
kg 2 times/week and 1 patient was switched to 2mg/kg 3 times/week. Kidney function normalised 
in all 5 patients. ‡ Resolution of infection defined as clinically observed absence of complaints that 
are likely to be caused by Invasive Fungal Infection in combination with clinically irrelevant or 
absent abnormalities concordant with Invasive Fungal Infection on High-resolution CT-scan.
figure 1a: Overall survival from start of intermittent treatment
Legend: OPAT denotes outpatient antifungal therapy, LAmB liposomal amphotericin B. Censored 
cases were lost to follow up.
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figure 1b: Time to resolution of IFI after start of intermittent therapy.
Legend: IFI denotes invasive fungal infection, OPAT denotes outpatient antifungal therapy, LAmB 
liposomal amphotericin B. Censored cases stopped intermittent treatment before resolution of in-
fection. Resolution of IFI was defined as clinically observed absence of complaints that are likely to 
be caused by IFI in combination with findings concordant with resolution of IFI on High-resolution 
CT-scan.
figure 1c: Occurrence of nephrotoxicity from start of intermittent treatment
Legend: OPAT denotes outpatient antifungal therapy, LAmB liposomal amphotericin B. Censored 
cases stopped intermittent treatment before nephrotoxicity occurred. Nephrotoxicity was defined 
as a >1.5 times increase of baseline serum creatinine levels resulting in an eGFR of less than 40 
ml/min/1.73 m2 during treatment or as electrolyte disorders suspected to be the result of renal 
damage and requiring cessation of treatment with LAmB at the discretion of the treating clinician.
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DiscUssion
This study shows that the use of OPAT with LAmB in a 2 or 3 times weekly dosing scheme 
results in high rates of therapy response in a selected patient population and after 
confirmation of an initial response to daily IV therapy with LAmB. However, safety issues 
did arise, resulting in mostly reversible nephrotoxicity and in some cases infection or 
therapy-related readmission to the hospital.
The majority of patients in this study needed prolonged use of LAmB for the treat-
ment of triazole resistant A. fumigatus infections. After the first reports of voriconazole 
resistant A. fumigatus appeared in 2009 from the Netherlands (30), triazole resistance 
has now extensively been reported in many regions all over the world (7, 11). Although 
the prevalence is low in some regions, the rates have been steadily increasing in others 
(7, 31). The high rates of triazole resistance also impact decision making in patients 
for whom susceptibility testing is not possible. In many cases, the clinician may fear 
presence of resistance in case of worsening of clinical or diagnostic parameters after 
treatment with a triazole even with negative or absent resistance tests. Because of 
difficulty in establishing triazole-resistance or sensitivity, the clinical suspicion of resis-
tance is becoming an important reason to abstain from further treatment with triazoles 
and opting for LAmB instead. Fortunately, more possibilities to detect resistance have 
become available. The impact of resistance testing of invasive aspergillosis using PCR 
is expected to more effectively guide the clinician in the optimal choice of therapy 
(32) and is being evaluated in a prospective multicentre study in the Netherlands and 
Belgium (NCT03121235).
renal toxicity
Since the introduction of (conventional) amphotericin B as treatment of fungal infec-
tions, nephrotoxicity has been a major concern. Nevertheless, nephrotoxicity has 
significantly decreased after the introduction of the liposomal formulation of ampho-
tericin B (33-36). In particular, patients that need prolonged therapy and are exposed to 
outcome n=18
Median number of days of follow-up, median (range) 741 (145-2543)
All-cause mortality at end of follow-up, number of pts (%) 7 (39)
100 day mortality after start of OPAT, number of pts (%) 0 (0)
1 year mortality after start of OPAT number of pts (%) 1 (6)
Resolution of infection‡, number of pts (%) 13 (72)
table 2: Outcomes
Legend: ‡ Resolution of infection defined as clinically observed absence of complaints that are 
likely to be caused by Invasive Fungal Infection in combination with clinically irrelevant or absent 
abnormalities concordant with Invasive Fungal Infection on High-resolution CT-scan.
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high doses over a prolonged period of time are vulnerable for the development of renal 
adverse events. A decrease in dosage could also be beneficial in mitigating the drug-
related renal toxicity. However, nephrotoxicity occurring at the end of the anticipated 
therapy period has been a reason to stop antifungal treatment prematurely and instead 
evaluate the natural course of the disease. Importantly, the associated nephrotoxicity 
was reversible in the majority of cases after cessation of therapy or dose alteration. 
The occurrence and time course of nephrotoxicity did differ from literature describing 
patients with daily dosing (37-39). Additionally, some experience in the assessment of 
the safety of the use of LAmB in an outpatient setting is previously described by Malani 
et al in 2005 (27). The authors of this study also found high rates of nephrotoxicity; the 
results are nonetheless not directly comparable due to their inclusion of application of 
non-lipid formulations of amphotericin B. The mentioned literature reports generally 
lower rates of reversibility of nephrotoxicity and shorter duration until occurrence 
of nephrotoxicity. However, a recent study also reports a high rate of reversibility 
of nephrotoxicity after use of LAmB (40). Possibly, our data supports the theory that 
nephrotoxicity occurs later and has a higher probability to be reversible when applying 
LAmB in an intermittent dosing schedule.
Application of OPAT strategies are slowly expanding within the field of infectious 
diseases and are being implemented in regular practice. Similar to LAmB, intravenous 
vancomycin therapy is also associated with renal toxicity but has nonetheless been 
successfully implemented in an OPAT programme for many years now (16, 17). Despite 
early reluctance, the expected logistic and toxicity-related disadvantages (41, 42) are 
outweighed by the advantages of a decrease in hospital stay with similar therapeutic 
effectiveness thanks to the implementation of monitoring of toxicity and therapeutic 
drug monitoring (15, 17, 43).
study strengths and limitations.
Despite a nation-wide inquiry, only a small subset of adult patients treated for IFI have 
been identified. The means by which these patients have been selected to undergo 
OPAT is inherently biased, i.e. the decision of the clinician to apply this therapeutic 
strategy has been dependent on many factors, both known and unknown. Since no 
guideline refers to or advises OPAT with LAmB, and due to lack of supportive literature, 
physicians may only have elected this approach in specific situations. Additionally, lack 
of existing intra- or extramural infrastructure to apply OPAT could be a limiting factor. 
Due to this selection, presumably patients with a relatively favourable prognosis with 
regard to the IFI were included in our study. Also, the heterogeneity of both the patient 
population and the different dosings that have been used make it difficult to draw any 
hard conclusions about efficacy and tolerability. As it is impossible to adjust for all of 
these factors, the results of our study cannot be directly compared with other cohorts 
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of patients with IFI. However, the baseline variables that have been presented, summa-
rize the most important characteristics, possibly contributing to identifying potentially 
eligible patients for this treatment strategy. Only patients with an initial response to 
therapy with LAmB showing no or only mild prior adverse events related to LAmB use 
were subjected to this strategy. Hence, the involved physicians balanced the risks of 
inadequate treatment of invasive fungal disease against the advantages of treatment 
in the outpatient setting. For future adaptation of this strategy, it is important for the 
clinician to weigh these factors before deciding on applying OPAT with LAmB.
sUmmarY anD conclUsions
After documentation of an initial treatment response and in a selected patient group, 
intermittent therapy with LAmB in the outpatient setting appeared to be a valuable 
treatment option for IFI. Frequent monitoring of renal function and potassium levels, 
for example once every week, is strongly recommended for early recognition of nephro-
toxicity, as it can also occur during prolonged OPAT. This treatment strategy is expected 
to provide advantages in costs, decrease of hospital-associated infections and patient’s 
quality of life. Further research will be necessary to expand upon the possibilities that 
this treatment strategy offers. The identification of eligible patient populations that 
would most benefit from this strategy as well as further study of the toxicity concerns 
in this setting, are warrented.
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abstract
objectives
In the pre-azole era, central nervous system (CNS) infections with Aspergillus had a 
dismal outcome. Survival improved with voriconazole but CNS infections caused by 
azole-resistant A. fumigatus is precluding its use. Intravenous liposomal-amphotericin 
B (L-AmB) is the preferred treatment option for azole-resistant CNS infections but has 
suboptimal brain concentrations.
methods
We describe three patients with biopsy proven CNS aspergillosis where intraventricular 
L-AmB is added to systemic therapy. 2 patients with azole-resistant and 1 patient with 
azole-susceptible CNS aspergillosis were treated with intraventricular L-AmB at a dose 
of 1mg weekly.
results
We describe 3 patients successfully treated with a combination of intravenous and in-
traventricular L-AmB. All three patients survived but one patient has serious headache, 
most likely not related to this treatment.
conclusions
Intraventricular L-AmB may have a role in the treatment of therapy-refractory CNS 
aspergillosis when added to systemic therapy.
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introDUction
Few cases of central nervous system (CNS) aspergillosis caused by azole-resistant 
Aspergillus fumigatus (ARAF) have been reported, and almost always with a fatal 
outcome [1]. Most patients were treated with combination antifungal therapy. Cerebral 
infections caused by ARAF have almost always a dismal prognosis. Unfortunately, there 
a no antifungals available that have activity against ARAF and adequately penetrate 
the brain. Therefore, we added intraventricular liposomal-amphotericin B (L-AmB) to 
systemic therapy in 3 patients. In this paper, we describe these patients and our clinical 
experience. All patients provided informed consent.
case Presentation
case 1
An 18-year-old woman with common acute lymphatic leukaemia (ALL) receiving re-
mission induction chemotherapy was diagnosed with a probable invasive pulmonary 
aspergillosis (IPA). Combination therapy with intravenous (IV) voriconazole and L-AmB 
(3mg/kg QD) was started. Serum galactomannan was positive (Optical Density (OD) 2.8) 
and sputum grew an ARAF with the CYP51A TR34/L98H mutation. Eight days on therapy, 
a paresis of the right arm and leg and a right facial nerve paralysis were observed. 
Brain MRI showed multiple lesions (figure 1A) and a brain biopsy demonstrated hyphae 
compatible with Aspergillus (figure 1C). L-AmB dose was increased to 10 mg/kg and 
voriconazole (8mg/kg BID) was replaced by posaconazole and dosed at 300mg BID to 
achieve serum trough concentrations >3mg/L with the hope of achieving therapeutic 
brain tissue levels. Posaconazole trough concentrations of 5.2 and 6.0 mg/L were 
documented. Follow-up MRI 15 days after the initiation of therapy showed increased 
perilesional oedema. During the following 5 months the patient was treated with oral 
posaconazole 300 mg BID with IV L-AmB daily at 5mg/kg. Six months after diagnosis 
posaconazole was stopped as cerebral lesions and perilesional oedema had decreased 
and the arm and leg paresis and facial nerve palsy had improved. Chemotherapy was 
reinitiated and another 3 months later L-AmB was discontinued. At that time the lesions 
on brain MRI had decreased in size but not disappeared completely. Unfortunately, six 
months later the patient was admitted for an epileptic seizure. MRI showed increase 
in size and oedema around 1 of the 7 lesions. Combination treatment with L-AmB IV 
(5mg/kg QD) and posaconazole (300mg BID) was reinitiated and was now combined with 
intraventricular weekly administration of L-AmB (1mg/week). The patient could be 
discharged with outpatient therapy with L-AmB IV, posaconazole orally and once weekly 
intraventricular L-AmB using an Ommaya reservoir that was placed for this purpose. The 
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intraventricular L-AmB therapy was well-tolerated and continued for 4 months. The MRI 
remained essentially unchanged in these 4 months at that time, the patient was able 
to walk and cycle independently but has unilateral hand motor dysfunction as the only 
sequela.
case 2
A 13-year-old patient with iron overload due to multiple transfusions for beta-thal-
assaemia was diagnosed with a probable invasive pulmonary and multifocal cerebral 
aspergillosis 8 months after allogeneic stem cell transplantation (figure 1B). An ARAF 
was cultured from BAL fluid. Galactomannan in CSF was positive (OD 1.3). Voriconazole 
(8mg/kg BID IV) and L-AmB (6 mg/kg) were started. Ten days later an epileptic seizure 
occurred. MRI showed increasing size of the brain lesions and again an ARAF grew from 
a brain biopsy (table 1). An Ommaya reservoir was placed for the intraventricular 
administration of L-AmB as well as caspofungin (for details on dosing see table 1). Also 
intravenous caspofungin (70mg QD) and flucytosine 25mg/kg QID mg) were initiated. 
With this intervention, the patient improved and lesions decreased in size. Weekly in-
traventricular administration of L-AmB was continued for 10 weeks and intraventricular 
caspofungin for 6 months. Systemic therapy with flucytosine, L-AmB and caspofungin 
was discontinued after 2, 6 and 6 months respectively. No further improvement of the 
remaining brain lesions was observed after 6 months.
Several years later the patient developed disabling headache. On imaging the skull 
and dura mater diameter had thickened significantly. A dura biopsy did not lead to a 
conclusive diagnosis. At last follow-up 9 years post-allogeneic transplant the complains 
of severe headaches had disappeared but spasticity, occasional epileptic seizures and 
frontal lobe syndrome have led to severe disability.
case 3
A 15-year-old girl with common ALL developed aphasia 23 days after chemotherapy 
initiation. MRI showed 1 lesion in the left frontal and 1 in the temporal lobe. A chest 
CT showed nodular lesions. BAL sampling was performed. Galactomannan (OD 4.5) was 
positive and voriconazole-susceptible A. fumigatus was cultured (voriconazole MIC 
0.5mg/L). Treatment with voriconazole (4mg/kg) and L-AmB (5 mg/kg) was initiated 
and L-AmB stopped on day 16 when voriconazole drug levels were therapeutic. Despite 
voriconazole serum levels between 3 and 12 mg/L, a follow-up MRI 3 weeks into therapy 
showed that lesions had increased in size. Intravenous L-AmB was reinitiated and weekly 
intraventricular administration of L-AmB 1 mg was started via a Rickham reservoir while 
voriconazole was continued as well. Follow-up brain MRI’s and lung CT at 1 and 2 months 
into this therapy showed decreasing size of the brain lesions and no increasing lung 
lesions. A lung biopsy confirmed an invasive aspergillosis infection. Eventually, without 
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factors Patient 1 Patient 2 Patient 3
sex, age F, 18 F, 16 F, 15
Underlying disease ALL Thalassemia, allogeneic 
SCT
ALL
Classification IPA 
(eortc/msG)
Biopsy proven Biopsy proven Biopsy proven (brain and 
Lung)
culture positive sample Sputum, brain biopsy BAL, brain biopsy BAL
MIC Voriconazole 8 16 0.5
MIC Posaconazole 2 0.5 0.063
MIC Itraconazole >16 16 0.25
MIC Isavuconazole 0.5
Gm value blood 1.3 0.9 0.4
Gm value csf 0.5 1.30 0.5
Gm value bal 2.8 0.36 4.5
biopsy brain Positive Positive Positive
treatment regimen (day 
after diagnosis)
1.  Voriconazole + L-AmB 
IV (3 mg/kg) (d0-d5)
1.  L-Amb IV + 
voriconazole (6 mg/kg) 
(d0-d10)
1.  Voriconazole + L-AmB 
IV (d0-d10)
2.  Posaconazole + L-AmB 
IV (10mg/kg) (d5-d26)
2.  L-AmB IV + Caspofungin 
IV (d10-d13)
2.  Voriconazole (d11-d20)
3.  Posaconazole + L-AmB 
IV (3mg/kg) + IT 
L-AmB* (d26-d191)
3.  L-AmB IV + Caspofungin 
IV/IT✚ (d13-d24)
3.  Voriconazole + L-AmB 
3mg/kg IV/ weekly IT 
(d21-d109)
4.  L-AmB 5 mg/kg 3x/
week (d191-d251)
4.  L-AmB IV and IT* + 
Caspofungin IV and IT✚ 
(d24-d32)
4.  Voriconazole 
(d110-d149)
5.  Treatment re-
initiation L-AmB IV + IT 
*(d386-d515)
5.  L-AmB IV and IT* + 
Caspofungin IV and 
IT✚ + Flucytosin IV 
(d32-d97)
5.  Voriconazole + L-AmB 
3mg/kg IV/ weekly IT* 
(d149-d176)
6.  L-AmB IV + Caspofungin 
IV and IT✚ + Flucytosin 
IV (d97-d201)
6.  Isavuconazole + L-AmB 
3mg/kg IV and weekly 
IT (d176-d227)
7.  Isavuconazole + L-AmB 
weekly IT* (d228-d348)
8. Isavuconazole (d349-
XXX)
table 1: Clinical and epidemiological characteristics of patients with cerebral azole-resistant in-
vasive aspergillosis
Abbreviations: BAL=bronchoalveolar lavage, CSF=cerebrospinal fluid, F=Female, IPA=invasive pul-
monary aspergillosis, EORTC/MSG= European Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious 
Diseases Mycoses Study Group [EORTC/MSG] host factor, F=Female, IPA=invasive pulmonary as-
pergillosis, IT=intrathecal/intraventricular, IV=intravenous, L-AmB=Liposomal Amphotericin B, 
MIC=minimal inhibitory concentration. *Intraventricular/intrathecal L-AmB was given at a dose of 
1mg weekly ✚Caspofungin IT 1 mg QD for 2 weeks1mg 3x/week for 1 month and 3x/week 0.5 mg 
thereafter
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a change in therapy all infections sites improved, as well as the neurological disabilities 
of the patient. After 3 months of combination therapy, a step-down to voriconazole 
monotherapy was made. During the following 6 weeks voriconazole levels were subop-
timal (range 0.3-2.6mg/L) and unfortunately, 6 weeks later dysarthria developed and an 
MRI showed that lesions had increased in size. A brain biopsy confirmed the Aspergillus 
infection of the brain. IV and intraventricular L-AmB was reinitiated. IV administration 
of L-AmB was stopped after two months but intraventricular continued for 8 months 
while voriconazole was switched to isavuconazole for liver enzyme elevations. Eventu-
ally follow-up imaging of lungs and brain showed a good response to therapy. Patient 
is doing well and has been successfully treated for ALL. During ALL therapy, patient is 
receiving isavuconazole as secondary antifungal prophylaxis.
DiscUssion
We describe 2 cases of ARAF and 1 case with azole-susceptible CNS aspergillosis treated 
with intraventricular L-AmB. Brain infections with Aspergillus have a high mortality and 
survivors are left with at least some neurological deficit [2]. Although voriconazole im-
proved the chances of survival, ARAF now turns back the clock to the amphotericin-B era.
Over the last 10 years, azole-resistance has become an important emerging problem 
and is associated with a very high mortality [3-6]. When voriconazole resistance is 
documented in a patient infected with a cerebral Aspergillus infection, treatment be-
comes very difficult. Indeed, few other systemic antifungal agents have been shown to 
penetrate the brain. Furthermore, the therapeutic effect of new drugs is still unknown 
[7, 8]. Pharmacokinetic and pharmacodynamic animal data suggest that compared 
with other formulations of amphotericin-B, L-AmB results in the highest brain tissue 
concentrations of amphotericin-B and it was effective as therapy in a mouse model of 
candida encephalitis [9]. Therefore, it is regarded as the preferred second-line therapy 
for cerebral fungal infections but should, at least initially, be dosed at 5 to 10 mg/kg to 
achieve therapeutic brain tissue concentrations quickly [1, 10]. For azole-resistant CNS 
infection, L-AmB can be combined with a second drug but itraconazole, posaconazole 
and echinocandins do not lead to adequate drug concentrations in CSF or brain tissue 
with standard dosing regimens [1]. Furthermore, it seems that combination therapy 
does not lead to synergistic treatment effect in vitro against azole-resistant A. fumiga-
tus isolates [11]. To improve the CSF and brain penetration higher systemic exposure 
may be aimed for to subsequently reach higher CSF and brain concentrations that can 
exert a pharmacological effect even in the setting where pathogen susceptibility is re-
duced. Furthermore, a damaged blood-brain barrier, which is the case in patients with 
an angio-invasive Aspergillus infection will likely improve the penetration of selected 
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drugs. With this in mind, we combined posaconazole with L-AmB in the first case [12]. 
Ultimately, we decided to administer L-AmB directly into the cerebrospinal fluid space 
as well. The administration was well tolerated with no subjective side effects. Contrary 
to the first and third case, we observed long-term complications in the second case. 
We argue that these side effects are probably the result of chronic inflammation and 
scarring during and after the infection rather than L-AmB or caspofungin mediated tox-
icity although we cannot exclude with certainty that local combination of drug therapy 
contributed to these side effects.
Current guidelines do not recommend the use of intraventricular administration 
of antifungals due to the risk of important adverse events (e.g. chemical meningitis, 
seizures) [13]. Historically, intrathecal/intraventricular administration of conventional 
AmB deoxycholate has been and is still being used to treat patients with coccidioidal 
meningitis. The side effects of intrathecal/intraventricular administration of AmB de-
oxycholate make it difficult to use and only low doses of typically 0.1 mg are used after 
which the dose is slowly increased up to 1.0 mg [14]. The reported side effects of AmB 
deoxycholate, led us to opt for intraventricular L-AmB instead. Based on a theoretical 
total CSF volume of approximately 100-150 mL in our patients, the administration of 
1mg of L-AmB would result in a peak CSF concentration of L-AmB of 10 microgram/mL-
which is comparable to the peak plasma concentrations after systemic administration 
by Groll et al [9]. Distribution kinetics as well as clearance mechanism were unknown 
so we had no knowledge on possible accumulation, hence we started with a presumed 
safe dose. In case 1 we tried to measure L-AmB in retrospect on left-over CSF fluid but 
no L-AmB could be detected (limit of detection 0.5 mg/L). In hindsight we argue that 
the clearance of L-AmB is much more rapid than initially expected. This is explained 
by the fact that 500 ml of CSF is produced and reabsorbed each day and helps clearing 
L-AmB. Both the dose and frequency of once weekly intraventricular administration of 
1 mg L-AmB might thus be suboptimal and a higher dose as well as a more frequent 
administration may be preferred for future patients. Intrathecal/intraventricular L-
AmB at a higher dose (10mg per administration) for seven consecutive days was shown 
to be well tolerated in 18 patients with cryptococcal meningitis [15]. Although the 
exact role of intrathecal/intraventricular L-AmB remains to be defined in patients with 
an Aspergillus infection of the CNS, we propose to initiate intrathecal/intraventricular 
L-AmB as soon as voriconazole resistance is documented at a dose of 5mg and prefer-
ably twice weekly. If available, L-AmB CSF concentration monitoring may guide dosing 
after the first dose.
Finally, whether local therapy needs to be given in conjunction with systemic therapy 
is unknown. The benefit of combination therapy may be a more favourable ratio of 
plasma/brain concentrations and perhaps a longer detainment of adequate CSF/brain 
concentrations.
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Case series like ours have several limitations. In particular, all 3 patients received 
systemic treatment as well. Therefore, the exact contribution of the intraventricular 
L-AmB administration cannot be defined. However, it is very unlikely that prospective 
clinical studies will ever be performed to find the best possible treatment option for 
very rare infections like CNS aspergillosis. Therefore, treatment should be based on in 
vitro and animal data and eventually the experience described in case reports and case 
series can be helpful as well.
In conclusion, 3 patients with a CNS infection with A. fumigatus were treated with 
combination antifungal therapy that included intraventricular L-AmB. All 3 survived but 
one patient was left with severe sequalae.
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abstract
background
Invasive pulmonary aspergillosis (IPA) is a potentially lethal infection in patients with 
hematological diseases or following allogeneic stem cell transplantation. Early diagno-
sis is essential as delayed treatment results in increased mortality. Recently, a lateral 
flow device (LFD) for the diagnosis of IPA was CE-marked and commercialized by OLM 
Diagnostics.
methods
We retrospectively analyzed bronchoalveolar lavage fluid (BALf) collected from adult 
hematology patients from 4 centers in the Netherlands and Belgium. Galactomannan 
was retested in all samples. All samples were applied to an LFD and read out visually by 
two independent researchers, blinded to the diagnosis of the patient. All samples were 
also read out using a digital reader.
results
We included 11 patients with proven IPA, 68 patients with probable IPA, 44 patients 
with possible IPA, and 124 patients with no signs of IPA (‘controls’). In cases of proven 
IPA versus controls, sensitivity and specificity were 0.82 and 0.86 (visual readout), and 
0.82 and 0.96 (digital readout), respectively. When comparing patients with proven 
and probable IPA as cases versus controls, sensitivity and specificity were 0.71 and 0.86 
respectively. When excluding serum and BALf galactomannan as mycological criteria 
from the 2008 EORTC/MSG consensus definitions, the LFD was less specific than galac-
tomannan when comparing proven and probable IPA to controls (0.86 vs 0.96, p=0.005), 
but had similar sensitivity (0.76 vs 0.85, p=0.18).
conclusions
In this large study of the CE-marked LFD in BALf from hematology patients, the LFD had 
a good performance for the diagnosis of IPA.
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bacKGroUnD
Invasive pulmonary aspergillosis (IPA) remains a significant infectious complication in 
patients with hematological diseases or following allogeneic hematopoietic stem cell 
transplantation (HSCT)(1). Delayed initiation of Aspergillus-specific therapy increases 
overall mortality, making early diagnosis essential(2). The diagnostic tools currently 
used in clinical practice consist of fungal culture, direct microscopy (preferably using 
optical brighteners), and detection of galactomannan (GM), (1-3)-β-D-glucan (BDG), 
and/or Aspergillus DNA by PCR(3). However, these tools have several limitations in 
terms of both sensitivity, turnaround time and practicability. The sensitivities of direct 
tests such as fungal culture or microscopy of samples taken from the site of infection 
[e.g. bronchoalveolar lavage fluid (BALf)] are as low as 20% to 50%(3). Indirect tests, 
which detect cell wall antigens produced by Aspergillus, such as GM on serum or BALf 
and BDG in serum, show better sensitivities compared to direct tests(4, 5), but require 
large numbers of samples to be cost-efficient, as these assays run on 96-well plates. 
Even when performed in-house, these tests are often run in batches, once or twice 
weekly, which increases the turnaround time and further delays diagnosis.
More recently, an Aspergillus-specific lateral flow device (LFD) has been developed, 
consisting of a self-contained immuno-chromatographic assay using a mouse monoclonal 
antibody (JF5) for the detection of an extracellular glycoprotein released by Aspergillus 
during active growth(6) (Figure 1). Because of the single-test design and the minimal 
sample preparation required, this assay could provide a solution to some of the above-
mentioned issues. In addition, preliminary evaluation has shown a sensitivity of 73% and 
specificity of 90% when applied to BALf(7).
However, except for one recent letter (8), all previously published studies with the LFD 
have used a prototype device. The current CE-marked LFD (AspLFD, OLM Diagnostics, 
Newcastle Upon Tyne, United Kingdom) differs in several aspects from this prototype, 
including the immunoglobulin G subclass of the antibody as well as the chromogen; this 
could impact the diagnostic characteristics of this test. A small retrospective compara-
tive study (including 9 BALf samples) between the prototype device and the currently 
available assay showed only fair agreement between both assays (Cohen’s kappa 0.43)
(9). Although their sensitivities were fairly similar - though lowest in the hematology 
patients at 68% - the novel assay proved to be more specific(9). Of note, samples were 
stored frozen between testing with the old and new device, which could partly explain 
this difference.
The aim of this study was to assess the performance of the recently CE-approved 
LFD in a large multicenter cohort of hematology patients wo underwent diagnostic 
bronchoscopy with BALf sampling.
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figure 1: Lateral flow devices, showing from 
left to right a negative result, followed by in-
creasing test line intensity. The control line is 
visible at the top, while the test line appears 
below the control line.
materials anD metHoDs
This retrospective study comprised 247 BALf samples from 247 hemato-oncology pa-
tients from 2 academic centers in the Netherlands (Erasmus University Medical Center, 
Rotterdam, and Radboud University Medical Center, Nijmegen) and 2 centers in Belgium 
(University Hospitals Leuven, Leuven, and AZ St Jan Bruges, Bruges), collected between 
2010 and 2018. Informed consent was waived due to the retrospective nature of this 
study on stored BALf samples previously collected as part of routine clinical care. The 
study had no impact on patient management. The LFD was provided by OLM Diagnostics. 
OLM Diagnostics had no role in the design of this study, its execution, analysis, interpre-
tation of the data, or decision to publish.
Patient selection criteria included (i) age ≥ 18 years; (ii) having an underlying hema-
tological disease or following HSCT; (iii) at least 500 microliter of BALf sample available 
for analysis stored at ≤ -20°C; (iv) a chest CT scan performed within 7 days of BALf 
sampling, and (v) access to the full clinical data set. All four participating centers had 
an integrated care pathway for immunocompromised patients in place, using a standard-
ized protocol: after 72-120 hours of persistent fever unresponsive to broad-spectrum 
antibiotics, a computed tomography (CT) scan of the chest was performed. Abnormal 
CT findings were followed by a bronchoscopy and the collection of BALf for extensive 
microbiologic (including GM detection) and microscopic analysis. Mold-active antifungal 
prophylaxis was given per institutional policy. We targeted a case:control ratio of 1:2 
to reflect the estimated 30% incidence of IPA in hematology patients referred for bron-
choscopy in our centers. The following clinical data were collected: demographic data, 
underlying disease, host factors, serum BDG (±3 days before or after BALf sampling; 
if available), GM in BALf and serum (±3 days before or after BALf sampling) as deter-
mined by the local laboratory, fungal culture results, other microbiological findings, 
microscopy (with the use of optical brighteners), histopathology (including autopsy) 
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results, use of mold-active antifungals >24h before bronchoscopy, use of mold-active 
prophylaxis, absolute neutrophil count, and chest CT scan and bronchoscopy findings. 
Survival through 12-weeks after initiation of Aspergillus-specific therapy was recorded, 
as well as time to last follow-up.
Case definitions
Patients were classified independently by two physicians as having proven IPA, probable 
IPA or possible invasive fungal disease in accordance with the revised European Orga-
nization for Research and Treatment of Cancer Invasive Fungal Infections Cooperative 
Group (EORTC)/Mycoses Study Group of the National Institute of Allergy and Infectious 
Diseases (MSG) consensus definitions(10). A primary analysis only considered patients 
with proven IPA as true cases. A secondary analysis also included patients with probable 
IPA as true cases. Patients considered as not having IPA (‘controls’) were patients not 
fulfilling any of the EORTC/MSG clinical and mycological criteria, patients with features 
suggestive of IPA on pulmonary imaging but with BALf GM optical density index (ODI) 
<1.0 (see below) and a documented alternative diagnosis (e.g. bacterial) not receiving 
mold-active therapy, and patients not receiving any specific anti-mold therapy at all 
who survived for more than 6 months after bronchoscopy.
study procedures
Repeated GM and LFD testing were performed on all 247 BALf samples at the Belgian Na-
tional Reference Centre for Mycosis in accordance with the manufacturer’s instructions.
Galactomannan enzyme immunoassay: BALf GM detection was performed using the 
Plateliaä Aspergillus enzyme immunoassay (Bio-Rad, Marnes-la-Coquette, France). All 
samples were retested in parallel with the LFD to correct for the long-term storage 
at ≤ -20°C. The GM ODI measured at the local lab was used for classification; the GM 
ODI tested at the central lab after storage was used for all other analyses. Sample 
pretreatment and addition of conjugate was performed manually, while incubation, 
washing, addition of chromogen and stopping solutions, and readout was performed 
automatically by a BEP-III analyzer (Siemens Healthcare, Erlangen, Germany). Although 
there is no universally agreed upon threshold for BALf GM positivity, we defined an ODI 
of ≥1.0 as positive, in line with a recent meta-analysis(11) and with the most recent 
EORTC/MSG consensus recommendations(12).
Aspergillus lateral-flow device: Briefly, BALf samples were defrosted at room 
temperature and vortexed. Seventy microliters of BALf were added to the release 
port on the LFD (AspLFD, OLM Diagnostics, Newcastle Upon Tyne, United Kingdom) 
and incubated at room temperature for 15 minutes. Hemorrhagic samples or viscous 
samples due to large amounts of mucus underwent pretreatment in accordance with 
the manufacturer’s instructions, consisting of heating at 100°C for 3 minutes after 
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adding 300 microliter of EDTA-containing buffer to 150 microliter of BALf, followed by 
centrifugation at 14,000 g for 5 minutes. Seventy microliters of the supernatant were 
then applied to the LFD. The LFD was removed from its protective package immediately 
before applying the sample. Appearance of the control line in the result window showed 
that the test had run correctly. The appearance of the Aspergillus-specific test line was 
determined after exactly 15 min, with results being recorded as positive if the test line 
was present. In the absence of a test line, the result was recorded as negative. Each 
LFD was independently assessed by two evaluators who were otherwise blinded to the 
final diagnosis (TM and EG). Immediately after reading, the readouts were compared 
between the 2 evaluators and discordant results were resolved by consensus. During 
the set-up of this experiment, we noticed a delayed appearance of a test line after 
more than 15 minutes in some samples that were negative at the 15-minute mark. We 
therefore performed a second visual readout of all 247 samples between 30 minutes 
and 1 hour after applying the sample to the LFD. In addition, we investigated the added 
value of an objective readout method and quantification of results using a digital LFD 
reader (aLF Reader, QIAGEN Lake Constance, Stockach, Germany). Peak positions were 
determined using negative and positive controls included in the LFD kit.
statistical analysis
To calculate sensitivity and specificity with a maximum 95% confidence interval (CI) of 
10% width at 80% power, we relied on data previously published by Heldt et al(7), and 
calculated appropriate sample sizes using the method described by Buderer et al(13). 
Based on a pooled sensitivity of 73%, a pooled specificity of 90%, and an expected preva-
lence of 30% in hematology patients undergoing diagnostic bronchoscopy, we estimated 
a required total of at least 228 patients.
A 2-sided p-value of ≤0.05 was considered statistically significant. The diagnostic 
characteristics of the LFD were compared to those of GM using McNemar’s chi-squared, 
since GM and the LFD are paired observations. Cox regression was used to determine 
the relation between the LFD result and outcome, controlling for age, gender, HSCT, 
neutropenia, and prednisone-equivalent dose of ≥ 0.3 mg/kg/day for >21 days.
True positives were defined as patients with proven IPA according to the EORTC/MSG 
definitions, and true negatives as patients without any evidence of IPA. These strict 
criteria were used because probable and (to an even greater extent) possible catego-
ries (as defined by consensus) are not definitive diagnoses but an assessment of the 
likelihood of having invasive fungal disease. However, for comparison with previously 
published findings, our secondary analysis also considered EORTC/MSG defined probable 
cases as true positives. The EORTC/MSG definitions were used both with and without 
BALf and serum GM test results included. Indeed, as the GM assay itself is an accepted 
microbiologic criterion in these definitions, a comparison of the diagnostic performance 
124 Chapter 7
of the LFD and GM without the removal of GM from the definition leads to incorporation 
bias. The negative predictive value (NPV), positive predictive value (PPV), sensitivity, 
and specificity with likelihood ratios (LRs) and their 95% CI’s were calculated.
Cohen’s kappa coefficient (with 95% CI) was calculated to measure the agreement 
between the LFD results (consensus of visual or digital readout) and GM ODI results, 
between the visual readings of the 2 evaluators, and between visual and digital read-
out. According to the classification by Landis and Koch, kappa values of >0.8 represent 
an almost perfect agreement. The effect of long-term storage on GM ODI values was 
evaluated using the paired Mann–Whitney U test.
Statistical analysis was performed using R v3.5.1 (R Foundation for Statistical Com-
puting, Vienna, Austria).
resUlts
Key characteristics of the 247 patients included in this study are shown in Table 1. 
Eleven patients had proven IPA, 68 had probable IPA, 44 had possible invasive fungal 
disease, and 124 patients had no IPA, as defined by the EORTC/MSG definitions. As-
pergillus species were cultured from 30 (12.1%) BALfs, and 75 (30.4%) had a GM ODI ≥ 
1.0. Empiric antifungal therapy was started in 21.5% of cases of proven and probable 
IPA. Retesting of BALf GM at the reference lab was not significantly different from 
the originally reported value (median GM ODI at time of sampling 0.20 [interquartile 
range 0.10 - 1.65], versus 0.20 after thawing [interquartile range 0.10 - 1.45], p=0.37). 
Contingency tables for all subgroups are provided in Supplement 1.
Proven iPa versus controls
The diagnostic performance of BALf GM and the LFD for 11 proven IPA cases versus 
124 controls is shown in Table 2. Youden’s index was used to determine the optimal 
optical intensity (OI) cutoff to discriminate between cases of proven IPA and controls. 
The diagnostic performance of digital readout in this subgroup, using an OI cutoff of 
33.15mV (resulting in an area under the curve [AUC] of 0.921), is shown in Table 2. 
There was excellent agreement between the independent visual readouts of the 2 
evaluators (disagreement on 6% of samples, Cohen’s kappa 0.86, 95% CI 0.79 – 0.93), 
and substantial agreement between visual and digital readout (Cohen’s kappa 0.65, 95% 
CI 0.48 – 0.83), resulting in a significantly improved positive predictive value due to a 
lower number of false positives using digital readout. Sensitivity of visual readout of the 
LFD was identical to GM (ODI cutoff ≥ 1.0) in this small subgroup of proven IPA (0.82 vs 
0.82, p=1.00), but specificity was lower (0.86 vs 0.96, p=0.005). Diagnostic performance 
of digital readout was identical to that of GM (ODI cutoff ≥ 1.0) in this subgroup.
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n 247
center (%)
Belgium 1 40 (16.2)
Belgium 2 134 (54.3)
The Netherlands 1 33 (13.4)
The Netherlands 2 40 (16.2)
age, years (median [iQr]) 63 [52, 71]
male gender (%) 148 (59.9)
mould-active prophylaxis (%) 17 (6.9)
Disease (%)
Acute myeloid leukemia 75 (30.4)
Allogeneic SCT 68 (27.5)
Lymphoma 58 (23.5)
Multiple myeloma 14 (5.7)
Acute lymphatic leukemia 10 (4.0)
Myelodysplastic syndrome 8 (3.2)
Autologous SCT 7 (2.8)
Other 7 (2.8)
neutropenia (%) 118 (47.8)
Use of high-dose corticoids (%) 85 (34.4)
t-cell suppression (%) 125 (50.6)
Severe inborn immune deficit (%) 1 (0.4)
serum Gm oDi (median [iQr]) 0.10 [0.07, 0.20]
Serum GM not performed (n [%]) 34 (13.8)
Aspergillus species (%)
A. fumigatus 25 (10.1)
A. flavus 3 (1.2)
A. fumigatus + A. terreus 1 (0.4)
A. versicolor 1 (0.4)
Negative 217 (87.9)
Serum β-D-glucan, pg/mL (median [IQR]) 0.00 [0.00, 123.61]
absolute neutrophil count, /mm³ (median [iQr]) 140.00 [0.00, 3200.00]
table 1: Patient characteristics. SCT = stem cell transplantation, IQR = interquartile range, GM ODI 
= galactomannan optical density index
Proven or probable iPa versus controls
To allow for a comparison with previous reports on the prototype version of the LFD(14–
16) and with other diagnostic tests for IPA, we assessed the diagnostic performance 
in patients with EORTC/MSG defined proven and probable IPA taken together as cases 
(n=79) versus controls (n=124), using different cutoffs (≥ 1.0 or ≥ 0.5) for BALf GM 
positivity (Table 3). Youden’s index was calculated again for each BALf GM cutoff. The 
sensitivity and specificity of visual readout of the LFD were significantly lower than 
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lfD
(visual readout)
lfD
(digital readout)
Gm oDi
≥ 1.0
Gm oDi
≥ 0.5
sensitivity (95% ci) 0.82 (0.48, 0.98) 0.82 (0.48, 0.98) 0.82 (0.48, 0.98) 0.82 (0.48, 0.98)
Specificity (95% CI) 0.86 (0.79, 0.92) 0.96 (0.91, 0.99) 0.96 (0.91, 0.99) 0.93 (0.87, 0.97)
Positive predictive value (95% ci) 0.35 (0.17, 0.56) 0.64 (0.35, 0.87) 0.64 (0.35, 0.87) 0.50 (0.26, 0.74)
negative predictive value (95% ci) 0.98 (0.94, 1.00) 0.98 (0.94, 1.00) 0.98 (0.94, 1.00) 0.98 (0.94, 1.00)
Positive likelihood ratio (95% ci) 5.97 (3.54, 10.06) 20.29 (8.23, 50.04) 20.29 (8.23, 50.04) 11.27 (5.66, 22.43)
negative likelihood ratio (95% ci) 0.21 (0.06, 0.74) 0.19 (0.05, 0.66) 0.19 (0.05, 0.66) 0.20 (0.06, 0.69)
table 2: Diagnostic performance in cases of proven invasive pulmonary aspergillosis versus con-
trols. CI = confidence interval. GM ODI = galactomannan optical density index. LFD = lateral flow 
device.
figure 2: Receiver operating characteristic (ROC) curves of the lateral flow devices in different 
subgroups of invasive pulmonary aspergillosis (IPA). (a) Proven IPA vs controls. (b) Proven or prob-
able IPA vs controls, galactomannan (GM) positive ≥ 1.0. (c) Proven or probable IPA vs controls, GM 
positive ≥ 0.5. (d) Proven or probable IPA vs controls, GM excluded as mycological criterion.
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those of BALf GM (≥ 1.0) in this subgroup (sensitivity 0.71 vs 0.82, p=0.020; specificity 
0.86 vs 0.96, p=0.005). Compared to visual readout of the LFD, serum GM had a sig-
nificantly lower sensitivity (0.37 vs 0.73, p<0.001) and higher specificity (1.00 vs 0.86, 
p<0.001). BDG was only measured in 9 patients, and could therefore not be compared 
to the LFD. The receiver operating characteristic (ROC) curves for each subgroup are 
shown in Figure 2. The agreement between BALf GM and the LFD was substantial, with 
a Cohen’s kappa of 0.61 (95% CI 0.51 – 0.72) for visual readout, and a kappa of 0.63 (95% 
CI 0.53 – 0.74) for digital readout (cut-off 16.62mV).
Of course, as GM is used as one of the mycological criteria in the EORTC/MSG criteria, 
this leads to a bias towards GM. Therefore, we omitted BALf and serum GM from the 
mycological criteria to allow for a direct comparison of the diagnostic characteristics 
of GM and the LFD. Specificity remained significantly higher for BALf GM (0.86 vs 0.96, 
p=0.005), with a trend towards a higher sensitivity for BALf GM (0.76 vs 0.85, p=0.18). 
However, 8 (18.1%) out of the 44 cases of possible invasive fungal disease had a posi-
tive LFD by visual readout, all with low OI (median OI of the positive LFDs 19.06mV, 
interquartile range 14.36mV – 26.11mV).
We found an exponential correlation between the GM ODI and the OI of the LFD as 
measured by the digital reader (Figure 3). The correlation between both was moderate 
with an adjusted R² of 0.52. Based on the results from this plot, we further identified 
2 distinct subgroups, with a breakpoint around a GM ODI of 4.0. Indeed, LFD sensitivity 
was significantly lower in cases with BALf GM < 4.0 (0.47 vs 0.75, p=0.014) while speci-
ficity was similar (0.86 vs 0.88, p=0.909). Furthermore, in cases with a positive fungal 
culture, the GM ODI was significantly higher (median 6.2 vs 2.75, p=0.046) and there 
was a trend towards higher OI’s of the LFD (median 113.62mV vs 33.87mV, p=0.054). 
The qualitative result of the LFD was not significantly different in culture positive cases 
(77.8% positive vs 67.3%, p=0.477). As only 17 patients (6.9%) were receiving mold-
active prophylaxis, this subgroup was too small to assess the effect of prophylaxis on 
diagnostic performance. However, in the subgroup that received empiric antifungal 
therapy prior to BALf sampling, the sensitivity was significantly lower (0.47 vs 0.77, 
p=0.32) while specificity was similar (1.00 vs 0.85, p=0.610).
When reading out the LFD between 30 minutes and 1 hour after applying the sample, 
7.9% of the initial negative results had become positive, increasing the sensitivity to 
0.80 (95% CI 0.69 – 0.88) and decreasing the specificity to 0.79 (95% CI 0.71 – 0.86). 
In multivariate Cox-regression, the LFD was not a significant predictor of mortality in 
cases of proven or probable IPA, either when used as a binary variable (p=0.492) or as a 
continuous variable (p=0.982).
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DiscUssion
We present the largest multicenter trial of a newly CE-approved LFD for the diagnosis 
of IPA in hematology patients to date, including a total of 247 patients from 4 hospitals 
in Belgium and the Netherlands, 79 of whom had proven or probable IPA according to 
consensus definitions. The primary analysis was restricted to the performance of the 
BALf LFD using only EORTC/MSG proven cases as true positives and cases with no IPA 
as true negatives. Unfortunately, proven IPA is a rare condition; many patients are 
thrombocytopenic or in need of supplemental oxygen and are typically not eligible 
for invasive procedures. In addition, such an analysis introduces disease progression 
bias, especially when relying on autopsy data. Nevertheless, in this well-documented 
subgroup, the recently released LFD showed a good diagnostic performance: sensitivity 
was identical to BALf GM (≥ 1.0), although specificity was significantly lower when read 
visually. The excellent negative predictive value of 98% in proven IPA could allow clini-
cians to convincingly withhold mold-active antifungal therapy in at-risk patients with 
unexplained CT findings. However, generalizing this high NPV to all patient populations 
should be done cautiously as it is greatly influenced by the prevalence of IPA (Figure 
4). Our results are well in line with previously reported studies on the LFD prototype 
assay(17). Importantly, a digital readout of the LFD greatly increased the performance 
of the assay in terms of specificity, positive predictive value and positive likelihood 
ratio, making it identical in performance to GM (Table 2).
Given the rarity of proven cases of IPA, the EORTC/MSG consensus definitions are of-
ten used as a diagnostic reference standard. However, these definitions were basically 
figure 3: Jitterplot of the galactomannan optical density index vs the intensity of the lateral flow 
device for all included patients. (a) Overview of all measurements. (b) Zoomed in detail of mea-
surements with galactomannan optical density index ≤ 4.0.
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developed for clinical and epidemiological research and not for the accurate evaluation 
of diagnostic tests. Indeed, these criteria are subject to misclassification as well as 
to incorporation bias (e.g. BALf GM is one of the microbiological criteria for assigning 
probable disease). Nevertheless, this method of evaluation is still frequently used. 
We decided to compare the performance of the LFD to the definitions as published 
and to the definitions with exclusion of GM as a mycological criterion, and found the 
diagnostic performance of the LFD to be similar to previously published results of the 
prototype device in hematology patients with proven or probable IPA(7) (sensitivity 0.71 
vs 0.67, p=0.744, and specificity 0.86 vs 0.91, p=0.36). This contrasts with the results of 
a comparative study of 14 cases of proven and probable IPA where samples were tested 
using both the prototype and CE-marked LFD, which found an increased specificity 
for the CE-marked LFD(9). Furthermore, we noticed delayed positive reactions with 
appearance of a test line after 30 to 60 minutes in some cases, which resulted in an 
increased sensitivity but a decrease in specificity when compared to the consensus 
reference. A similar effect was seen in a small study of 9 hematology patients with 
proven or probable IPA(8). This could possibly be explained by non-specific reactions, as 
the rate of conversion to a positive line is similar in cases and in controls (8.9% and 7.3% 
respectively). We therefore do not recommend delayed readout.
Interestingly, our study found a significantly lower sensitivity of the LFD in patients 
with a GM ODI of < 4.0. We clearly demonstrated an exponential relation between the 
intensity of the LFD test line and the GM ODI. Visual readout of the LFD was reliable with 
good inter-evaluator agreement, which was confirmed objectively by digital readout.
figure 4: Negative predictive value (NPV) and positive predictive value (PPV) as a function of 
prevalence of the tested population, in cases of proven invasive pulmonary aspergillosis (IPA) vs 
controls (a) and in cases of proven and probable IPA vs controls. The red line marks the estimated 
prevalence used in our study (30%).
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The quantitative and qualitative results of the LFD on BALf were not predictive of 
outcome in multivariate Cox regression. This is not unexpected, as similar results were 
seen with GM testing on BALf(18). This is likely the result of differences in BALf sam-
pling techniques, which are not standardized between physicians and can even differ 
between procedures by the same physician. This can result in differences in sampling 
volume, leading to dilution. Furthermore, peripheral lesions and lesions in the upper 
lobes can be more difficult to reach.
The large sample size of our study allows for an estimation of the performance of the 
LFD with narrow confidence intervals. Furthermore, the use of independent and blinded 
observers and the use of a digital reader ensure a high methodological standard for our 
study. However, this study also has several limitations. The retrospective design implies 
an artificial prevalence of the disease, thereby influencing the predictive values. We 
tried to overcome this by selecting cases and controls in a rate similar to what is seen in 
our centers. However, in settings where IPA is more (or less) frequent, these values will 
differ. Furthermore, the storage conditions of the samples at ≤ -20°C could theoreti-
cally influence the diagnostic performance of the test. We tried to remove this bias by 
retesting of GM in parallel with the LFD, which did not show any significant degradation 
over time. However, though similar in chemical structure, it is not guaranteed that the 
mannoprotein antigen detected by the LFD is equally stable as GM detected by the 
Platelia enzyme immunoassay.
In conclusion, the CE-marked BALf LFD appears to have a good diagnostic perfor-
mance for diagnosing IPA in hematology patients, with an even better performance 
for excluding IPA. The LFD can be used as a point-of-care test, unless the sample is 
hemorrhagic or heavily contaminated with mucus, in which case a pretreatment in the 
lab is required. This test could be used as a first-line diagnostic tool in the bronchoscopy 
suite, given its short turnaround time and economic advantage over GM testing in low-
volume settings. However, in view of its low positive predictive value, the LFD is no 
substitute for additional diagnostic testing (GM, BDG, PCR) to definitively confirm or 
exclude the diagnosis of IPA.
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abstract
introduction
The AsperGenius® assay is a multiplex real-time polymerase chain reaction (qPCR) test 
that allows for simultaneous detection of Aspergillus species and identification of the 
most common mutations in the A. fumigatus cyp51A gene conferring resistance (TR34/
L98H and TR46/Y121F/T289A) by using melting curve analysis. Mixed infections with 
azole-resistant and susceptible A. fumigatus have rarely been described.
methods
The AsperGenius® multiplex real-time PCR assay (PathoNostics, Maastricht, the Neth-
erlands) was used on bronchoscopic alveolar lavage (BAL) samples of 91 consecutive 
patients with a suspected invasive Aspergillus infection at the Erasmus MC University 
Medical Center, Rotterdam.
results
In 3 cases the AsperGenius® assay indicated the simultaneous presence of wild-type 
and mutant genes (2 patients with TR34/L98H mutation and 1 patient with TR46/T289A/
Y121F mutation) and therefore mixed infections with azole-susceptible and resistant 
isolates. In one of the three cases, the mixed infection was confirmed by phenotypic 
antifungal testing of multiple A. fumigatus colonies.
conclusion
The use of a dedicated A. fumigatus cyp51A resistance PCR allowed for the detection of 
mixed infections with azole-resistant and susceptible Aspergillus strains. These mixed 
infections may remain undiagnosed with conventional phenotypic susceptibility testing.
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introDUction
Invasive aspergillosis(IA) is the most frequent pulmonary mould infection in severely 
immunosuppressed hosts. The introduction of voriconazole has significantly decreased 
the mortality of IA.1 However, azole-resistance in Aspergillus fumigatus is increasingly 
reported2, 3 and its prevalence ranges from 0.6% to 27.8% across studies.4, 5 The reported 
mortality of IA caused by azole-resistant strains is very high and varies between 50 and 
88%.2, 6 There are several screening assays for azole-resistance available (VIPTM check, 
E-test) but fungal broth microdilution susceptibility testing is the standard diagnostic 
technique. However, cultures often remain negative. Recently, a CE-IVD certified multi-
plex qPCR was developed(AsperGenius®). It does not only demonstrate the presence of 
Aspergillus, but also the presence of certain cyp51A mutations that confer resistance of 
A. fumigatus to azoles. Cyp51A encodes the cytochrome p450 sterol 14α-demethylase, 
the target of azoles. There are two main mutation patterns in the cyp51A gene that 
cause azole resistance: TR34/L98H and TR46/Y121F/T289A.7
In theory, mixed infections with azole-susceptible and azole-resistant A. fumigatus 
may occur as well but will only be detected if phenotypic testing of multiple colonies is 
done, a non-standard practice.8 Here, we describe three cases, in which a co-infection 
was demonstrated using cyp51A molecular analysis on BAL.
metHoDs
The methodology of the AsperGenius® assay (PathoNostics, Maastricht, the Netherlands) 
has been described elsewhere.6, 9, 10 At Erasmus MC, the AsperGenius® qPCR, a fungal 
culture (followed by phenotypic resistance testing if positive) and galactomannan(GM) 
testing is routinely performed on BAL when IA is suspected.
resUlts
Between December 2014 and February 2017 the AsperGenius assay was performed on 
BAL samples with a positive GM assay of 91 patients suspected of having IA. In 79%(72/91) 
of the patients, DNA of A. fumigatus or Aspergillus species was demonstrated. In 45 of 
the 72 patients, the resistance PCR was successful and could therefore differentiate 
between wild-type(WT) and the presence of resistance associated mutations(RAMs). 
TR34/L98H mutations were detected in eight cases and Y121F/T289A mutations were 
detected in three cases. Interestingly, in three additional cases, the AsperGenius assay 
showed the presence of both WT and resistant A. fumigatus isolates. So overall, RAMs 
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were detected in as much as 14 of the 45(31%) patients in which the resistance PCR 
provided a result.
case 1
A routine chest CT-scan of a 50-year-old lung transplant recipient showed peri-
bronchovascular consolidations. A BAL was performed, GM was positive (OD 4.0) and 
A. fumigatus was cultured. The only colony that had grown was susceptible to all 
antifungals tested(EUCAST). Voriconazole was initiated and therapeutic drug levels 
were documented.11 Two weeks later he was admitted to the ICU for respiratory insuf-
ficiency and antibiotic therapy was initiated. Again, BAL sampling was performed (GM 
0.5 OD, fungal culture negative) and a Parainfluenza virus type 1 PCR was positive. The 
AsperGenius® PCR on the BAL showed two melting peaks in the supernatant fraction of 
the BAL. One peak was located at the melting temperature of WT A. fumigatus and the 
other at the melting temperature of the L98H mutated A. fumigatus(figure 1a). The 
patient died 24 days after initiation of voriconazole. The results of the resistance PCR 
only became available after the patient had died. Retrospectively, the AsperGenius® 
assay was also performed on residual BAL fluid from the first BAL sample that had been 
collected. A. fumigatus WT-DNA was isolated from both the supernatant and pellet frac-
tion but the resistance PCR also showed a double peak for the L98H probe melting curve 
analysis(figure 1b). Therefore, the mutated as well as the WT A. fumigatus had been 
present previously but only WT had been detected by conventional phenotypic analysis.
case 2
A 60-year-old woman received corticosteroids for 5 months for pyoderma gangrenosum 
and was admitted for respiratory failure. Ceftriaxone and ciprofloxacin were started. 
The next day mechanical ventilation was needed. Chest CT-scan showed several spheri-
cal consolidations. Oseltamivir and antifungal treatment(voriconazole and caspofungin) 
were added empirically. A BAL showed a GM of 5.6 OD and A. fumigatus was cultured. 
Liver toxicity led to a switch from voriconazole to liposomal-amphotericin-B(L-AMB). 
The phenotypic resistance test(EUCAST) of the Aspergillus strains cultured from BAL fluid 
showed that 5 of the 6 A. fumigatus colony forming units (cfus) had a minimal inhibi-
tory concentration(MIC) of 0.25mg/L for itraconazole, voriconazole, and posaconazole, 
while the MIC of the sixth cfu was >8mg/L for itraconazole, 4mg/L for voriconazole and 
0.5mg/L for posaconazole. The qPCR of the BAL sample confirmed the presence of A. 
fumigatus and the resistance PCR showed melting curves specific for mutant(T289A/
Y121F) and WT-DNA(figure 2a/b) indicating a mixed infection. Patient died of progres-
sive multiple organ failure 10 days after the start of L-AMB.
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figure 1: (a) Case 1 melting curves using the L98H mutation probe. Two melting peaks were 
detected for the supernatant fraction. One peak was specific for wild-type DNA (marked by an 
arrow), the other peak was specific for L98H mutant DNA (marked by a star). A specific melting 
peak was detected for the pellet extract (marked by a X), and corresponds to the mutant positive 
control, indicating L98H mutant DNA. (b) Case 1 melting curves using the L98H mutation probe on 
leftover BAL: A double peak for wild-type (marked by an arrow) as well as mutant (marked by a X) 
is present in the supernatant fraction indicating that low concentrations of A. fumigatus mutant 
L98H DNA were present in the supernatant of the BAL.
case 3
A seven-year-old patient, recently diagnosed with AML, was admitted for dyspnoea. 
A chest CT-scan showed multiple nodular lesions. A BAL was performed and GM was 
positive(OD 3.9). Combination therapy was initiated with L-AMB and voriconazole and 
therapeutic voriconazole drug levels were documented. The BAL culture showed one 
cfu of A. fumigatus susceptible to all antifungals tested(EUCAST). AsperGenius® qPCR 
confirmed the presence of A. fumigatus DNA and the resistance PCR showed both L98H 
mutant DNA and WT-DNA(figure 3). Voriconazole was discontinued after two weeks and 
L-AMB was continued for 12 weeks. A new CT-scan, performed a month after L-AmB dis-
continuation, showed that the lesions had increased in size. Pathology of a CT-directed 
biopsy of one of the lesions showed only chronic interstitial inflammation and cultures 
remained negative. Unfortunately, the patient suddenly died 13 months later.
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figure 3: L98H mutation analysis for case 3. Two melting peaks were detected for the supernatant 
fraction. One peak was specific for wild-type DNA (marked by an arrow), the other peak was spe-
cific for L98H mutant DNA (marked by a X).
figure 2: Case 2 mutation analysis. (a) T289A mutation analysis and (b) Y121F mutation analysis: 
Multiple specific melting peaks were detected for all extracts (pellet and supernatant), which 
were mutant (marked by a X) and wild-type (marked by an arrow) indicating the presence of wild-
type and mutant DNA. The green melting curve is indicating the positive control representing the 
mutant marker. 
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DiscUssion
We describe three patients with an IA infection in which WT as well as mutant cyp51A 
DNA from A. fumigatus was detected. In one patient, the mixed infection was confirmed 
by phenotypic resistance testing of multiple A. fumigatus colonies. To the best of our 
knowledge, this is the first report in which co-infection of azole-resistant and suscep-
tible A. fumigatus was detected by a molecular assay.
A. fumigatus mixed-infections are rarely recognized. A recent paper described 3 
cases of culture confirmed A. fumigatus mixed infection of susceptible and resistant 
isolates.8 However, the majority of BAL samples from patients with IA are culture nega-
tive. As such, the presence of azole resistance may remain undetected.6, 12, 13 In 2 of 
our 3 cases BAL cultures showed growth of A. fumigatus but phenotypic testing failed 
to show resistance in 2 of the 3 cases. As growth of only 1 colony of A. fumigatus was 
present in case 1 and 3, only this colony could be tested phenotypically which might 
explain the discrepancy between the resistance PCR and the culture results. Thus, 
performing a resistance PCR directly on BAL may yield additional information and may 
avoid the reporting of very major errors(i.e. sensitive result when resistant A fumigatus 
is present).
Treatment with voriconazole is associated with a high risk of treatment failure and 
mortality in patients with azole-resistant A. fumigatus.2, 6 Non-culture based methods 
of resistance testing therefore have the advantage that appropriate antifungal therapy 
can be initiated immediately and hopefully reduce the risk of treatment failure.2, 6 A. 
fumigatus is genetically diverse and multiple genotypically different isolates can be 
obtained from multiple BAL samples of one patient.14 Recently, a case report described 
the presence of different Aspergillus genotypes in different body compartments.15 Mixed 
cultures of A. fumigatus strains are present in environmental and clinical samples.8, 16 
One of the isolates can be dominant and can disseminate, causing disease. The pres-
ence of different isolates with different susceptibility profiles complicates the diagnosis 
and management of IA.8, 14
These observations show that even if an azole-susceptible Aspergillus isolate is 
cultured, the patient can still harbour an azole-resistant isolate in regions where TR34/
L98H and TR46/Y121F/T289A environmental strains are endemic. As described in case 1, 
two BAL samples were performed. The first BAL sample was performed before and the 
second BAL two weeks after azole treatment was initiated. The first BAL sample grew 
A. fumigatus susceptible to voriconazole. The second BAL was culture negative but the 
PCR analysis showed a mixed infection with TR34/L98H mutated and WT A. fumigatus. 
In retrospect, mixed infection could also be demonstrated on the first BAL sample. 
We therefore suggest that in regions where azole-resistance has been described, at 
least 5 and preferably all distinct A. fumigatus colonies are phenotypically tested for 
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the presence of azole-resistance and if possible the BAL sample itself is tested for the 
presence of known cyp51A mutations that confer resistance to azoles. Importantly, 
it should be noted that the AsperGenius® detects only the 2 most common mutations 
found in azole-resistant and A. fumigatus isolates with other mutations or non-cyp51A 
mutations will remain undetected. Therefore, the assay should be used in addition to 
conventional susceptibility testing. Furthermore, in vitro simulations showed that a 
ratio of mutant:WT below 1:5 will also remain undetected.
In conclusion, the AsperGenius® assay can detect mixed infections with azole-resistant 
and azole-susceptible A. fumigatus isolates enabling on-time and targeted therapy. 
Importantly, it can detect mixed infections when conventional fungal cultures are nega-
tive.
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abstract
introduction
Invasive aspergillosis (IA) is the most common mould infection in patients with acute 
leukaemia or graft-versus-host-disease. A relatively low attributable mortality is ob-
served when IA is diagnosed early and treatment with an azole initiated promptly. How-
ever, azole resistance in Aspergillus fumigatus is increasingly reported in Europe and is 
associated with a higher mortality. Unfortunately, phenotypic susceptibility testing of 
moulds is time-consuming, not widely available and most importantly fungal cultures 
remain negative in the majority of the patients with IA. AsperGenius® is a multiplex 
real-time polymerase chain reaction (PCR) assay that allows for a simultaneous detec-
tion of Aspergillus species and identification of the most common mutations in the A. 
fumigatus CYP51A gene conferring resistance. The use of this PCR has the potential to 
diagnose azole resistance more frequently and faster and should therefore facilitate 
the initiation of appropriate therapy at an earlier point in time. A fast diagnosis and 
correct treatment of azole-resistant aspergillosis should lead to an improved outcome.
methods
All Dutch academic haematology units agreed on a consensus IA management protocol. 
In this protocol, the AsperGenius® PCR is used directly on broncho-alveolar lavage fluid 
(BALf) to accelerate the diagnosis of azole-resistance and change antifungal treatment 
accordingly if resistance is detected. This management protocol was used in the Azole 
Resistance Management Study (AzoRMan), a prospective multicentre observational 
study in immunocompromised adult haematological patients, with pulmonary lesion(s) 
on chest CT scan that are undergoing a diagnostic bronchoscopy to confirm or rule 
out IA. The objective of this study is to evaluate the impact of the AsperGenius® PCR 
on the outcome of patients infected with an azole-resistant A. fumigatus. The study 
also makes prospective monitoring possible of the prevalence of the 2 most common 
resistance-associated mutations (RAMs) in the A. fumigatus CYP51A gene and in particu-
lar in culture-negative cases of IA.
results
As of December 2019, 212 patients have been included from 9 centres. Galactomannan 
was positive (1.0 or higher) on BALf in 46/190 patients (24%) with available GM result. 
The AsperGenius® species and fumigatus PCR was positive in 40% and 29% of the patients 
respectively. In patients with a positive or negative galactomannan on BALf, the Asper-
gillus species PCR was successful in 78% and 28% of patients, respectively. RAMs were 
documented in 4 patients (8.5%) of a total 47 patients in whom the resistance PCR was 
successful.
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conclusion
The majority of patients with a haematological disease that undergo BALf sampling to 
confirm or rule out an IA, do not have this infection. In the 47 patients in whom the 
resistance PCR was successful, the prevalence of CYP51A gene mutations was 8.5%. 
Given the fact that in only 47 of the 195 with available AsperGenius® PCR result, the 
resistance PCR was successful, the sample size of the study population needs to be 
increased substantially in order to answer the primary research question.
AzoRMan-study: interim analysis 153
9
introDUction
Invasive aspergillosis (IA) is the most common mould infection in immunocompromised 
haematological patients. A relatively low mortality is observed when diagnosis is made 
early and treatment with voriconazole or isavuconazole, the first choice of treatment, is 
initiated promptly (1, 2). However, azole-resistance in Aspergillus fumigatus is increas-
ingly reported in Europe (3) and is mostly caused by resistance associated mutations 
(RAMs) in the cyp51A gene, encoding for the target enzyme of azoles 14alpha-methylase. 
Fungal susceptibility testing is difficult, time consuming and not widely available. Fur-
thermore, cultures remain negative in the majority of patients with IA. AsperGenius®, 
is a CE certified multiplex real-time polymerase chain reaction (PCR) assay that allows 
for a simultaneous detection of Aspergillus species and identification of the most com-
mon mutations in the A. fumigatus CYP51A gene conferring resistance to itraconazole, 
voriconazole and posaconazole (4). The use of this PCR results in faster diagnosis of 
azole-resistance and thus the initiation of appropriate therapy at an earlier point in 
time. Furthermore, the advantage of this PCR is that it can detect azole-resistance in 
culture-positive but also culture-negative broncho-alveolar lavage samples. Recently, 
it has been shown that azole-resistance is associated with an increase in mortality of 
21% compared to azole-susceptible IA cases 42 days after the start of antifungal treat-
ment. Mortality of azole-resistant IA is as high as 62% three months after diagnosis (5). 
Unfortunately, from a global perspective the highest incidence of IA has been observed 
in The Netherlands and therefore, strategies to tackle the impact of azole resistance on 
outcome are urgently needed. After extensive discussions and a face-to-face meeting 
with representatives of all university medical centres in the Netherlands as described 
in chapter 2, a consensus diagnostic and therapeutic protocol was agreed upon (6). In 
this protocol, the AsperGenius® PCR is part of the diagnostic protocol and antifungal 
treatment is changed if resistance is detected (see figure 1). The value of this protocol 
will be evaluated in the study described below that we call the Azole Resistance Man-
agement (AzoRMan) study. The study has two main objectives. The first objective is to 
improve the outcome of patients infected with an azole-resistant A. fumigatus by the 
early detection of resistant associated mutations and with this the early initiation of 
the most appropriate therapy (liposomal-amphotericin B) (7). The second objective is 
to monitor the prevalence in the Netherlands of invasive aspergillosis due to strains car-
rying the TR34/L98H or the TR46/T289A/Y121F CYP51a resistance associated mutations 
using PCR in particular in culture-negative cases of IA.
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study design
This is a prospective multicentre observational study performed in 9 centres in The 
Netherlands and 2 centres in Belgium. The study population consists of patients with 
an underlying haematological disease (AML, allogeneic stem cell transplant etc.) aged 
18 years and older. These patients are eligible for the study if they are presenting with 
a new pulmonary infiltrate on chest CT-scan that may be caused by an invasive fungal 
infection and are planned to undergo or have just undergone a bronchoscopic alveolar 
lavage (BAL). The treating physician is planning to start voriconazole or isavuconazole 
or posaconazole after the BAL has been sampled (or after the galactomannan (GM) and 
PCR result become available) or has already started voriconazole or isavuconazole or 
posaconazole before BAL sampling.
asperGenius® Pcr
The Dutch centres send BAL sample of at least 1 ml, preferably 2 ml to Erasmus Uni-
versity Medical Centre where the AsperGenius® PCR is done routinely following the 
manufacturer’s instructions (Pathonostics, Maastricht, The Netherlands) (4, 8, 9). As 
already mentioned, when performed on BALf the AsperGenius® PCR allows for the rapid 
detection of Aspergillus DNA and the absence or presence of the 2 most prevalent 
azole resistance-associated mutations (TR34/L98H or the TR46/T289A/Y121F in CYP51a). 
The use of this PCR will therefore decrease the time to detection of azole-resistance 
compared with the time consuming phenotypic resistance testing. Furthermore, at 
least 50% of IA cases are culture-negative and in these patients phenotypic testing is 
not possible.
Treatment protocol (figure 1)
Haematological patients undergo BAL sampling as per standard of care. The diagnostic 
and treatment protocol that was implemented in the study centres is described in figure 
1. In brief, if azole-resistance is detected with PCR or standard phenotypic susceptibility 
testing, the treating physician will switch from the triazole to liposomal-amphotericin 
B 3mg/kg IV. In case of treatment limiting toxicity of liposomal-amphotericin B, the 
use of an echinocandin in combination with posaconazole is suggested aiming at serum 
Ctrough levels of 3-4mg/L. The rationale and feasibility of posaconazole high-dose has 
been described elsewhere (chapter 4). Step-down therapy from liposomal-amphotericin 
B is allowed to oral therapy with posaconazole after at least 2 weeks of liposomal-
amphotericin B therapy and after a documented clinical and/or radiological response. 
In this step-down strategy, posaconazole serum Ctrough levels of 3-4mg/L are aimed 
for. Importantly, step-down to posaconazole will not be done if an A. fumigatus strain 
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with a MIC of >0.5 microgram/ml is cultured. As an alternative to posaconazole step-
down, IV liposomal-amphotericin B 5mg/kg thrice weekly can be given as well following 
our experience with Outpatient Parenteral Antifungal Therapy (OPAT) with liposomal-
amphotericin B as described in chapter 5.
figure 1: Treatment protocol for Azole Resistance Management (AzoRMan)-study.
MIC=Minimal Inhibitory concentration; IV=Intravenously. *Posaconazole HD can only be con-
sidered as treatment option when the MIC (EUCAST) ≤ 1g/dL. HRCT= High Resolution CT scan, 
PCR=polymerase chain reaction, PO=by mouth, BAL= broncho-alveolar lavage.
Primary and secondary endpoints
The primary endpoint of the study is the proportion of patients with azole-resistance 
IA that have treatment failure and this will be compared with a fixed 75% treatment 
failure incidence (as described in the retrospective AsperGenius® PCR validation study 
(8)). The secondary endpoints of this study are prevalence of azole-resistance docu-
mented by fungal culture and resistance PCR and the proportion of patients included 
in this study that have died 6 weeks after the start of appropriate antifungal therapy. 
156 Chapter 9
The latter will be compared with a fixed 50% overall mortality in the same way as the 
primary endpoint analysis is done.
sample size calculation
The use of real-time detection of azole-resistance allows for a proactive change in 
therapy from the first line voriconazole therapy to other agents as soon as resistance is 
detected. In patients that start a non-azole therapy right from the start, the antifungal 
therapy can be changed to voriconazole as soon as the absence of RAM is documented. 
The goal is to demonstrate that this approach reduces the incidence of antifungal 
treatment failure. Based on previous research, we can assume that treatment failure 
is seen in 75% if the PCR is not performed and therefore voriconazole is continued 
in patients with RAMs (8). We assume that treatment failure will be reduced to 35% 
when the antifungal therapy is changed to liposomal-amphotericin B in the presence of 
RAMs. Using these percentages, we will need 15 patients with detected RAMs that are 
switched to non-azole therapy (e.g. liposomal-amphotericin B) or in which liposomal-
amphotericin B is continued (if it was given as the primary therapy) to show with a 
statistical power of 90% that this approach leads to a decrease in treatment failures to a 
number significantly less than 75%. With an estimated prevalence of CYP51a resistance 
of 7.5%, this means that 200 patients are needed in which the CYP51a PCR is successfully 
performed. As we can expect that the AsperGenius® resistance PCR will be successful 
in 75-80% of the samples that are tested, this means that we need galactomannan 
positive BAL samples from 280 patients. The study will end when at least 15 patients 
with CYP51a mutations have been found. Sample size calculation was done with http://
powerandsamplesize.com/Calculators/Test-1-Proportion/1-Sample-Equality with 0.75 
and 0.35 as parameters and 90% power.
resUlts
The results presented here are preliminary. Some data are still missing because not 
all centres have completed the electronic case report form (eCRF) for all the included 
patients yet.
baseline characteristics
As of December 2019, 212 patients have been included in the study. The median age 
of the patients in the study is 64 years and the majority is male (table 1). The most 
frequent underlying haematological malignancy is acute myeloid leukaemia (60%), fol-
lowed by myelodysplastic syndrome (17%) and acute lymphoblastic leukaemia (6%). 45 
patients had received an allogeneic stem cell transplant.
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baseline characteristics results Data missing
median age (iQr) 64 (55,69) 20
male sex (iQr) 86 (67%) 83
bmi (kg/m2) (iQr) 24 (22,28) 84
allogeneic stem cell transplant recipient 45 (35%) 85
autologous stem cell recipient 6 (5%)
Underlying haematological disease 128 84
AML 77 (60%)
MDS 22 (17%)
ALL 7 (6%)
CML 6 (5%)
NHL 5 (4%)
Other 11 (9%)
table 1: Baseline characteristics.
Abbreviations: IQR: Interquartile range; BMI=Body Mass Index, AML=acute myeloid leukemia; 
MDS=myelodysplastic syndrome; ALL=acute lymphoblastic leukaemia, CL=chronic myeloid leuke-
mia; NHL=non-Hodgkin lymphoma.
Performance diagnostics
The results of galactomannan (GM) were available for 190 patients. If a GM test result 
with an optical density ≥1.0 is considered positive, 46 (24%) patients had a positive 
BAL GM with a median optical density of 5.0 IQR (3.0 and 5.9). In 11 patients (8.5%), a 
positive culture for Aspergillus species was present of a total of the 130 patients with 
available information on culture results (n=10 A. Fumigatus, n=1 A. Terreus). Results of 
the AsperGenius® PCR were available for 195 patients in this interim analysis. The Asper-
Genius® species PCR was positive in 77 of 195 (40%) patients. The Aspergillus Fumigatus 
PCR is only performed when the species PCR is positive. A positive fumigatus PCR was 
observed in 57 patients (29%). Of these 57 patients, the resistance PCRs that detected 
the TR34 and the TR46 mutation pattern were successful in 47 (82%) and 45 (79%) pa-
tients, respectively. In 4 patients, a resistance-associated mutation (RAM) was identified 
(3 TR34 and 1 TR46). Thus, in the patients in whom the resistance PCR was successfully 
performed, the prevalence of RAMs was 4 of 47 or 8.5% (95% C.I. 0.005-0.165). The As-
perGenius® PCR was performed in 138 patients with a negative BAL GM (optical density 
<1). In this subpopulation, a positive AsperGenius® species and A. Fumigatus PCR was 
documented in 38 (28%) and 26 (19%) patients respectively. The opposite (a positive GM 
in a patient with a negative AsperGenius® species PCR) was observed in 7 patients only. 
In patients with a positive GM, 78% (36/43) and 67% (31/43) had a positive Aspergillus 
species and fumigatus PCR; respectively. In 3 patients with positive GM, data are missing 
on the result of the AsperGenius® PCR. The CYP51A resistance PCR was successfully 
performed in 29 of the 31 patients with a positive A. fumigatus PCR. An Aspergillus 
Fumigatus with a RAM was documented in 1 patient with a negative GM on BAL.
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Galactomannan
<0.5 0.5-0.9 >1
bal Galactomanan 129 15 46
Aspergillus species positive 32 6 36
Aspergillus species negative 88 7 7
A. fumigatus positive 20 6 31
A. fumigatus negative/nP 101 7 12
A. Terreus positive 1 0 1
tr34/l98H and tr46/t289a/Y121f Wt 10 4 26
tr34/l98H and tr46/t289a/Y121f not successful 6 1 2
tr34/l98H Wt and tr46/t289a/Y121f not successful 2 1 0
tr34/l98H not successful and tr46/t289a/Y121f Wt 1 0 0
tr34/l98H resistant and tr46/t289a/Y121f Wt 1 0 2
tr34/l98H Wt and tr46/t289a/Y121f resistant 0 0 1
table 2: Microbiological results of diagnostic tests performed.
Abbreviations: GM=galactomannan, BAL=bronchoscopic alveolar lavage, NP= not performed, 
WT=Wild-type
outcome
Not all patients started antifungal therapy. Of those who started therapy and of which 
we have information on antifungal therapy (n=98), as expected the majority (80%) of 
the patients started with azole monotherapy: 68 patients with voriconazole, 9 with 
posaconazole and 1 patient with isavuconazole. 14 patients (14%) started with com-
bination antifungal therapy although this should not have been the case according to 
the study protocol: 7 patients with voriconazole and anidulafungin, 5 patients with 
voriconazole and liposomal-amphotericin B and 2 patients with posaconazole combined 
with anidulafungin. 3 patients started with echinocandin monotherapy: 2 and 1 with 
anidulafungin and caspofungin, respectively. Centres have been informed again that pa-
tients in which combination therapy is (planned to be) initiated should not be included. 
In 36 patients, antifungal therapy was changed 72 hours or later after start of the first 
antifungal drug. Antifungal therapy was changed by adding or switching to another 
antifungal drug. 42 patients (20%) died within 12 weeks after BAL sampling of a total of 
101 patients with available data on the 12-week outcome.
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age 
(years)
sex Disease bal Gm cult mic per antifungal Died
VOR ITRA POS ISA
66 M AML 1.6 + 16 1 0.25 16 No
52 F AlloTx/HL 0.3 + 2 2 0.25 8 No
55 M AlloTx/FL 4.8 + 8 4 1 8 Yes
48 M AML 5.6 - Yes
table 3: Data on all azole-resistant cases.
Abbreviations: M=Male; F=female; BAL=broncho-alveolar lavage, Cult= Culture; MIC= minimal inhib-
itory concentration; Vor= Voriconazole; ITRA=itraconazole, POS=posaconazole; ISA=isavuconazole.
DiscUssion
As shown in chapter 5, azole-resistance is associated with a 25% higher overall mortal-
ity three months after the start of antifungal therapy and the initiation of initially 
inappropriate antifungal therapy is associated with reduced survival (5). Unfortunately, 
from a global perspective the azole-resistance prevalence is probably the highest 
in The Netherlands (3, 5). The AsperGenius® PCR is a CE certified and commercially 
available multiplex real-time PCR that can demonstrate Aspergillus DNA and is able to 
simultaneously detect the presence of the most frequently described CYP51a mutations 
that confer resistance of A. fumigatus to itraconazole, voriconazole and posaconazole 
(4). Obviously, the advantage of this PCR is that it can detect azole-resistance in 
culture-positive but also culture-negative BAL samples. Therefore, it can help with 
the detection of azole resistance at an earlier time point in the course of the disease. 
The clinicians that are treating these patients face a devil’s dilemma. Because cultures 
of most patients with IA remain negative (11), the first hint for the clinician that the 
Aspergillus strain infecting the patient might be azole-resistant will be at the time of 
clinical failure of azole therapy. However, the mortality of patients in which a switch 
to another antifungal therapy is made at the time of clinical treatment failure is very 
high. Therefore, one may consider initiating therapy with an antifungal of another class 
than the triazoles (e.g. liposomal-amphotericin B or an echinocandin) or with combina-
tion therapy right from the start. However, this comes with toxicity and these other 
antifungals can only be given intravenously. To evaluate if the use of PCR can help the 
clinician, a meeting was organized with representatives of all Dutch university hospitals 
and resulted in the AzoRMan-treatment protocol of this study (figure 1). This protocol 
was subsequently implemented in the academic haematology treatment centres in 
The Netherlands (chapter 2) (6). During the course of the study other non-academic 
centres in the Netherlands (Meander MC) and centres in Belgium (AZ Sint-Jan Brugge 
and University Hospitals Leuven) joined the study. Indeed, azole-resistance proved to 
be an important emerging problem in Belgium as well (12, 13).
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To the best of our knowledge, the AzoRMan-study is the largest prospective study 
evaluating the value of real-time PCR diagnosis of azole-resistance. This study evalu-
ates if PCR based therapy will help with the timely initiation of the most appropriate 
antifungal therapy in order to improve the outcome of azole-resistant IA. In this study 
patients with an underlying haematological malignancy are included when BAL sampling 
is ordered by the clinician to confirm or exclude the presence of an invasive fungal 
infection in the patient. Given the fact that the data described above are an interim 
analysis, the results should be considered preliminary and should be interpreted with 
this in mind. GM or PCR was positive in 24% and 40% of the patients, respectively. 
Therefore, no evidence of IA was present in the majority of the included patients. 
On GM positive BALf samples, the resistance PCR could be successfully performed in 
29 of 43 patients. In the 47 patients in which the resistance PCR was successful, the 
prevalence of RAMs was lower than expected at 8.5%. However, confidence intervals are 
wide so no definite conclusions can be drawn at this time. Also, with only 4 patients in 
whom a RAM was detected, no conclusions can be drawn on the impact of the PCR on 
patient outcome. Only 11 of the 130 patients (8%) were culture positive (9 of 35 (26%) 
of the GM positive patients). This underlines the importance of molecular methods to 
detect azole-resistance. The low rate of culture positive cases is not unexpected as it is 
in line with many other studies (11). However, only 1 of the 4 patients in whom azole-
resistant IA was documented was culture negative. Remarkably, two of these patients 
had a co-infection with Mucorales and this is in line with a study by Pelzer et al. (14). 
In this single-centre study by Pelzer et al. the performance of the AsperGenius® was 
evaluated in 100 allogeneic stem cell recipients with pulmonary infiltrates undergoing 
BAL sampling (14). According to the EORTC/MSG criteria (15), 23 patients had probable 
IA, even though 11 patients had received azole prophylaxis. RAMs were documented 
in three patients (2 cases with TR34/L98H and 1 case with TR46/Y121F/T289A). All 
three cases were culture-positive and resistance was confirmed by classic phenotypic 
susceptibility testing. Remarkably, all three patients with azole-resistant IA were co-
infected with Mucorales. Aspergillus PCR showed a sensitivity of 65% but combined with 
GM sensitivity and specificity was 96% and 100%, respectively.
An update of the Dutch guideline on the treatment of invasive fungal infections was 
published in December 2017 and tries to incorporate the fact that the prevalence of 
azole-resistance in the Netherlands was higher than 10% for several consecutive years 
as well as the observation that the initiation of inappropriate therapy leads to a statisti-
cally as well as clinically important increase in the overall mortality. (5,16). This Dutch 
guideline now recommends combination antifungal therapy (azole and echocandin or 
azole and liposomal-amphotericin B) as one of the treatment options for patients sus-
pected of having IA at least until resistance has been ruled out by culture or molecular 
diagnostic methods. Treating all patients with non-azole antifungals like liposomal-
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amphotericin B is associated with significantly more toxicity, is more expensive and 
can only be given intravenously. The latter is very cumbersome because treatment in 
immunocompromised haematology patients often needs to be given for months. With 
the results of this interim analysis, one may argue if combination antifungal therapy is 
actually necessary because resistance was observed in fewer than 10% of the patients in 
whom the resistance PCR was successfully performed. Furthermore, in the large major-
ity of the patients in our study galactomannan and PCR were negative and therefore, 
IA was virtually excluded in the majority of patients. This means that starting combina-
tion therapy in all these patients would lead to a substantial overuse of non-azole 
antifungals as azole resistance could be documented in only 2% of them. Therefore, 
we recommend that, in general, antifungal therapy should not be initiated in patients 
who are planned to undergo bronchoscopy and BAL unless a very typical radiology is 
seen on high-resolution CT of the lungs or at the time when the GM (and/or PCR) turns 
out to be positive. If antifungal therapy is initiated preceding the bronchoscopy, the 
interim analysis of the AzoRMan study supports the alternative approach to patients 
with a suspected invasive aspergillosis mentioned in the Dutch guideline. This approach 
consists of starting azole monotherapy while waiting for prompt antifungal resistance 
testing by PCR and culture and adapting therapy according to the test results (17).
About one in four patients with a negative BAL GM, have a positive Aspergillus species 
PCR in this study. Due to lack of standardization, PCR was not yet included in the 
EORTC/MSG criteria of 2008 and it is not clear which patients with a positive PCR but a 
negative GM should be treated. In particular in those patients with atypical pulmonary 
infiltrates this is a difficult clinical decision to be made. In the 2019 update of the 
EORTC/MSG criteria, PCR has been included in the probable IA definition (18). Both 
tests are complementary but will not replace one another.
Unfortunately, this interim analysis also shows that the sample size of the AzoRMan 
study should be increased substantially if the primary endpoint of the study is to be 
answered. The estimated prevalence of resistance seems correct but in the sample size 
calculation we assumed that the resistance PCR would be successful in 75% of samples 
and that a higher proportion of the included patients would suffer from IA. Taking the 
results of the interim analysis into account, the sample size should be at least doubled 
to 600 patients.
conclUsion
The majority of the patients with a haematological disease that undergo BALf sampling 
to confirm or rule out an IA, do not have this infection. In the 47 patients in whom the 
resistance PCR was successful, the prevalence of CYP51A gene mutations was 8.5%. 
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Given the fact that in only 47 of the 212 patients included so far, the resistance PCR 
led to an interpretable result, the sample size of the study population needs to be 
increased substantially in order to answer the primary research question.
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abstract
background
Invasive pulmonary aspergillosis (IPA) typically occurs in an immunocompromised host. 
For almost a century, influenza has been known to set up for bacterial superinfec-
tions, but recently patients with severe influenza were also reported to develop IPA. 
We conducted a retrospective multicentre cohort study to measure the incidence of IPA 
over several seasons in ICU patients with influenza pneumonia and to evaluate whether 
influenza was an independent risk factor for IPA.
methods
Data were collected from patients admitted to 7 ICUs with severe influenza during 
seven influenza seasons. To determine if influenza was independently associated 
with IPA, a subgroup of non-immunocompromised influenza-positive patients (cases) 
were compared with influenza-negative patients (controls) admitted to the ICU with 
community-acquired pneumonia (CAP) using logistic regression analyses.
findings
Of the 432 patients admitted to the ICU with influenza, IPA was diagnosed in 19% 
(83/432) a median of 3 days after ICU admission. The incidence was comparable for 
influenza A and B. The incidence in the 117 immunocompromised influenza patients was 
as high as 32% (38/117), while 14% (45/315) of the non-immunocompromised influenza 
patients developed IPA. In contrast, only 5% (16/315) of the non-immunocompromised 
influenza-negative controls developed IPA (p<0·0001). The 90-day mortality in influenza 
patients with and without IPA was 51% and 28%, respectively (p<0·0001). In the retro-
spective cohort study, influenza was found to be independently associated with IPA (aOR 
5·2, 95% CI 2·6-10·3, p<0·0001), besides a higher APACHE II score, male sex and use of 
corticosteroids.
interpretation
Influenza was identified as an independent risk factor for IPA and associated with a high 
mortality. Future studies should evaluate whether a faster diagnosis and/or antifungal 
prophylaxis could improve outcome of influenza-associated aspergillosis.
funding
None
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researcH in context
evidence before this study
We searched PubMed for articles published between January 1963 and October 2017, 
using the search terms “influenza” and “aspergillus” or “aspergillosis”. This search 
yielded case series which described invasive pulmonary aspergillosis (IPA) in patients 
admitted to the ICU with influenza. Yet, a systematic evaluation of the risk of IPA in a 
large population of ICU patients with influenza over several consecutive influenza sea-
sons was missing. Also, it remained to be demonstrated if influenza was independently 
associated with aspergillosis.
added value of this study
This study is, to our knowledge, the largest study ever performed on the risk for IPA 
in this patient population with 432 ICU patients with influenza included. It is also the 
first to evaluate this complication over several consecutive seasons in a large number 
of ICUs. Furthermore, by comparing non-immunocompromised influenza-positive and 
influenza-negative patients, we aimed to show that influenza was an independent risk 
factor for IPA. The following conclusions could be drawn: First, the incidence of IPA 
was >10% in each of the 7 seasons and was almost equal in influenza A and influenza B 
patients. Therefore, once a patient with influenza needs intensive care support, the 
risk for IPA does not depend on the influenza season and influenza subtype. Second, 
the overall incidence of aspergillosis was 19% and was as high as 32% in the subgroup 
of patients who were also immunocompromised at the time of their influenza infec-
tion. The overall mortality in the patients with IPA was very substantial at 51%. Last 
but not least, we compared 315 non-immunocompromised (i.e. no EORTC/MSG host 
factor) influenza-positive patients with an equal number of non-immunocompromised 
influenza-negative patients with severe community-acquired pneumonia (CAP) for the 
occurrence of IPA. We showed that influenza was independently associated with IPA 
(aOR 5·2, 95% CI 2·6-10·3, p<0·0001).
implications of all the available evidence
The independent association between influenza and IPA and the high mortality calls for 
increased awareness and a more aggressive diagnostic approach. Future studies should 
evaluate if prophylaxis is useful.
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introDUction
Invasive pulmonary aspergillosis (IPA) typically occurs in a severely immunocompro-
mised host and isolation of Aspergillus species in the immunocompetent host is mostly 
considered colonization.1,2 The six-week mortality of IPA is 20-30%3,4 but is much higher 
in critically-ill patients.4,5 Influenza is a common viral respiratory tract infection. In a 
subset of patients with influenza, intensive care admission is needed. This may be due 
to bacterial superinfection1,6,7 but also influenza in itself can cause severe acute respi-
ratory distress syndrome (ARDS),which is associated with a mortality of 14% to 41%.8,9
Influenza-associated aspergillosis was occasionally described decades ago and several 
small case series were reported recently.1,9,10 65% of the reported cases did not have 
classic host factors for IPA as defined by the European Organization for Research and 
Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National 
Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG).1,11 These 
EORTC/MSG criteria are used to classify patients with a fungal infection into proven, 
probable or possible aspergillosis but are not applicable to the ICU setting. For the 
ICU setting, an algorithm (AspICU algorithm) was described by Blot and colleagues to 
distinguish IPA from Aspergillus colonization in critically-ill patients.12
In 2012, Wauters and colleagues reported an incidence of 23% of proven or probable 
IPA in 44 H1N1 influenza patients in two consecutive influenza seasons (2009-2011). 
Remarkably, 44% of the IPA cases lacked any of the classical EORTC/MSG host factors.9 
Recently, a Dutch study described 23 (16%) cases of IPA among 144 patients admitted to 
the ICU with influenza during the 2015-16 H1N1 influenza season.13 These observations 
suggest that influenza infection requiring ICU admission is a risk factor for IPA and that 
the incorporation of influenza as a host factor in the current diagnostic criteria may be 
appropriate. However, it remains unclear if influenza is independently associated with 
the occurrence of IPA and if the risk varies from season to season. This study aims to 
describe the epidemiology and outcome of IPA in ICU patients over seven consecutive 
influenza seasons and to evaluate whether influenza is independently associated with 
IPA.
metHoDs
study design and data collection
We performed a retrospective cohort study in seven tertiary care ICUs (2 in Belgium 
and 5 in The Netherlands). The search strategy for influenza-positive patients admit-
ted to the ICU during influenza seasons 2009-2016 consisted of reviewing all patients 
with a positive influenza polymerase chain reaction (PCR) in the registry of the local 
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microbiology department and matching these with ICU admissions. We selected a group 
of patients admitted to the ICU with severe community-acquired pneumonia (CAP) and 
with a documented negative influenza PCR test as the comparison group because these 
patients are equally admitted to the ICU from outside the hospital with respiratory 
insufficiency due to pneumonia as well (figure 1). A list of patients with a negative 
influenza PCR was retrieved from the microbiology departments and these patients 
were matched for ICU admission. All patients were evaluated whether an infiltrate was 
present on chest imaging, antibiotic therapy was initiated and if a diagnosis of CAP 
was made at ICU admission. The patient files were also reviewed to exclude that an 
influenza infection was diagnosed elsewhere and to confirm that the pneumonia was not 
hospital acquired. Figure 1 describes the inclusion process in detail. The study protocol 
was approved by the institutional review board (IRB) of both Belgian sites and by the 
IRB of the initiating Dutch centre (Erasmus University Medical Centre, Rotterdam) for 
the 5 Dutch sites.
Study population (figure 1)
Patients were ≥18 years, admitted to the ICU for >24 hours with acute respiratory 
failure, had pulmonary infiltrates on imaging and a confirmed influenza infection based 
on a positive airway PCR test. A subgroup of the influenza-positive cohort (cases) was 
compared with an influenza-negative comparison group (control group) for the oc-
currence of IPA. Cases were the subgroup of influenza-positive patients that did not 
have an EORTC/MSG host factor (table S1, appendix p3), already posing them at risk 
for IPA. Controls were patients admitted to the ICU for severe CAP with a negative 
influenza PCR. Like the cases, controls were EORTC/MSG host factor negative. Exclusion 
criteria for all patients were respiratory failure not being the primary reason for ICU 
admission and a history of IPA. Please note that the terms cases and controls do not 
point towards a case-control study design from a methodological point of view. They 
describe two patient groups where cases should be interpreted as “influenza-positive 
non-immunocompromised patients with respiratory insufficiency” and controls as 
“influenza-negative non-immunocompromised patients with CAP”.
Definition of Invasive Pulmonary Aspergillosis (IPA)
The definition of IPA is modified from the AspICU algorithm and is based on the presence 
of clinical, radiological and mycological criteria in all IPA cases.12 Details on the defini-
tions can be found in table 1.
This modified IPA definition does not require an EORTC defined host factor because 
otherwise patients with influenza but without an EORTC host factor could never fulfil 
the IPA definition as long as influenza is not part of the EORTC host factor definition. 
To be on the conservative side, we excluded all patients in whom the only mycological 
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figure 1: Overview of inclusion process and IPA cases with corresponding mortality: (a) inclusion 
process influenza patients and cases; (b) inclusion process control group.
Abbreviations: CAP= Community acquired pneumonia; EORTC/MSG= European Organization for Re-
search and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National 
Institute of Allergy and Infectious Diseases Mycoses Study Group; ICU= intensive care unit; IPA= 
Invsasive pulmonary aspergillosis; RT-PCR= real-time polymerase chain reaction
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figure 1: Overview of inclusion process and IPA cases with corresponding mortality: (a) inclusion 
process influenza patients and cases; (b) inclusion process control group.
Abbreviations: CAP= Community acquired pneumonia; EORTC/MSG= European Organization for Re-
search and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National 
Institute of Allergy and Infectious Diseases Mycoses Study Group; ICU= intensive care unit; IPA= 
Invsasive pulmonary aspergillosis; RT-PCR= real-time polymerase chain reaction
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evidence for IPA was a lower positive respiratory tract culture (sputum, bronchial as-
pirate) for Aspergillus species but who had a negative or unavailable broncho-alveolar 
lavage (BAL) culture and galactomannan test. These patients were defined as colonized 
and were excluded from the final analysis.14 Every influenza patient was reviewed and 
consensus was achieved (NP,RV,AS,LV,JW,BR) to ascertain whether the modified IPA 
definition was met.
moDifieD iPa Definition: The definition of IPA is modified from the AspICU algorithm and is based on the 
presence of clinical, radiological and mycological criteria in all IPA-cases.
clinical criteria: one of the following signs/symptoms has to be present:
• fever refractory to at least 3 days of appropriate antibiotic therapy
• recrudescent fever after a period of defeverescence of at least 48 hours while still on antibiotics and 
without other apparent cause
• Dyspnea
• Hemoptysis
• Pleural friction rub/chest pain
• Worsening respiratory insufficiency in spite of appropriate antibiotic therapy and ventilatory support
raDioloGical criteria: any infiltrate on pulmonary imaging by portable chest X-ray or CT-scan of the 
lungs.
This radiological definition is different from the EORTC defined radiological criteria (e.g. halo sign or air-
crescent sign) because these EORTC criteria apply to patients with prolonged neutropenia but are of little 
use for ICU patients.
mYcoloGical criteria: ≥1 of the following has to be present
• Histopathology or direct microscopic evidence of dichotomous septate hyphae with positive culture 
for Aspergillus from tissue
• a positive Aspergillus culture from a broncho-alveolar lavage (bal)
• A galactomannan optical index on BAL of ≥1
• A galactomannan optical index on serum of ≥ 0.5.
table 1: Modified IPA definition
The Platelia Aspergillus test was used for galactomannan detection in all centers (Bio-Rad Labora-
tories, Marnes-la-Coquette, France). Aspergillus species were identified by their culture charac-
teristics and microscopic morphology.
statistical analYsis
In univariable analysis, categorical variables were compared by Fisher’s exact test and 
Chi-square test, and continuous variables with t-test or Mann-Whitney U test where 
appropriate. On the entire population of the influenza-positive cohort, a multivariable 
analysis was done by binary logistic regression to detect independent risk factors for 
the development of IPA in influenza patients. The dependent variable was the pres-
ence of IPA and independent variables were those previously described as a possible 
risk factor for IPA in the ICU or associated with IPA in the univariable analysis.4,15 The 
estimate of association was expressed as adjusted odds ratio (aOR) with corresponding 
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95% confidence interval (CI). Multiple imputations were performed to handle missing 
data, using 20 imputations and 1000 iterations following the Markov-Chain Monte Carlo 
methods, and the pooled results are presented (Table S4, appendix p5). In addition, 
a binary logistic regression analysis with multiple imputations was performed on the 
entire cohort of cases and controls to determine if influenza was independently associ-
ated with IPA. Data were analysed with SPSS Version 24 (Armonk, NY:IBM corp). No cor-
rection for multiple testing was performed for the univariable analyses and a two-tailed 
significance level of 0·05 was used. These p-values should therefore be interpreted with 
this limitation in mind. A statistician from the department of Biostatistics of Erasmus 
University Medical Center (ERA) supervised the analysis.
role of funding source
This study was part as part of our routine work. No funding was provided. The cor-
responding author had full access to all of the data and the final responsibility to submit 
for publication.
resUlts
Inclusion/exclusion process (figure 1)
Between 01/2009 and 06/2016, 541 influenza-positive patients were admitted to 7 ICUs. 
84 patients were excluded for the following reasons: respiratory insufficiency was not 
the reason for ICU admission (n=67), medical history of IPA (n=9) or insufficient clinical 
data (n=8). Another 25 patients were excluded because they met the criteria for Asper-
gillus colonization. In total, 432 patients with influenza were included in the influenza 
cohort. 315 of them were EORTC/MSG host factor negative and were defined as cases. 
The search strategy for the comparison group with severe CAP patients resulted in the 
selection of 315 patients (figure 1).
Influenza patient characteristics (table 2)
Patient characteristics are summarized in table 2. Mean age was 59 years and 56% 
(240/432) were male. Influenza A and B was found in 82% (355/432) and 18% (77/432), 
respectively. 79% (338/432) of the patients received a neuraminidase inhibitor. 27% 
(117/432) were EORTC/MSG host factor positive. The mean APACHE II score was 22 
SD±8. 75% (326/432) of the patients required intubation for mechanical ventilation for 
a median duration of 11 [IQR 5,21] days. 52 patients received extracorporeal membrane 
oxygenation (ECMO). The overall ICU mortality in the influenza-positive patients was 
25% (107/432).
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Influenza cohort
(n = 432)
iPa
(n = 83)
no iPa
(n=349) p
baseline factors
Age (years) 59 ± 15 60 ± 12 59 ± 16 0·35
Sex (men), n (%) 240 (56) 56 (67) 184 (53) 0·015*
APACHE II score on admission 22 ± 8 25 ± 9 22 ± 7 0·005*
BMI >30 kg/m2, n (%) 93/410 (23) 17/83 (20) 76/327 (23) 0·59
Diabetes, n (%) 88 (20) 10 (12) 78 (22) 0·036*
Liver cirrhosis 25 (6) 5 (6) 20 (6) 1·0
Chronic kidney disease 71 (16) 16 (19) 55 (16) 0·44
KnoWn risK factors
EORTC host factor, n (%) 117 (27) 38 (46) 79 (23) <0·0001*
Haematological malignancy, n (%) 66 (15) 22 (27) 44 (13) 0·002*
Solid organ transplant, n (%) 32 (7) 11 (13) 21 (6) 0·024*
Solid organ malignancy, n (%) 21 (5) 4 (5) 17 (5) 1·0
Neutropenia, n (%) 22 (5%) 11 (13) 11 (3) 0·001*
COPD, n (%) 79 (18) 13 (16) 66 (19) 0·49
stUDieD risK factors
CS 28 days before ICU, n (%)a 145/426 (34) 46/82 (56) 99/344 (29) <0·0001*
Median dose CS 28days before ICUadm (IQR) 0·14 (0·06;0·28) 0·22 (0·10;0·33) 0·10(0·06;0·24) 0·003*
Smoking in the past year 114/332 (34) 26/61 (43) 88/271 (32) 0·13
icU Data
Mechanical ventilation, n (%) 326 (75) 75 (90) 251 (72) 0·0004*
Mechanical ventilation days (IQR) 11 (5,21) 14 (9,31) 9 (4,17) 0·001*
NO/HFOV, n (%) 42 (10) 13 (16) 29 (8) 0·04*
ECMO or ECCOR, n (%) 52 (12) 16 (19) 36 (10) 0·024*
Vasopressors, n (%) 287/423 (67) 67/82 (81) 220/341 (65) 0·002*
RRT, n (%) 100/423 (24) 35/83 (42) 65/340 (19) <0·0001*
Median days of ICU stay [IQR] 11 [6,23] 19 [12,38] 9 [5,20] <0·0001*
oUtcome Data
ICU mortality, n (%) 107 (25) 37 (45) 70 (20) <0·0001*
Hospital mortality, n (%) 133 (31) 41 (49) 92 (26) <0·0001*
90 days mortality after ICU admission, n (%) 141 (33) 42 (51) 99 (28) 0·0001*
inflUenZa
Influenza A, n (%) 355 (82) 71 (86) 284 (81) 0·37
Influenza B, n (%) 77 (18) 12 (14) 65 (19) 0·37
Influenza treatment, n (%) 338/428 (79) 70/83 (84) 268/345 (78) 0·25
DiaGnostics
BAL sampling performed, n (%) 233 (54) 81 (98) 152 (44) <0·0001*
BAL culture positive, n (%) 50/80 (62·5)
BAL Galactomannan performed, n(%) 137 (32) 76 (92) 61 (17) <0·0001*
BAL Galactomannan positive, n (%) 67/76 (88)
Serum GM serum performed, n (%) 47 (11) 31/83 (37) 16 (5) <0·0001*
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IPA characteristics in patients with Influenza (table 3)
83 (19%) of the severe influenza patients admitted to the ICU fulfilled the IPA definition. 
The proportion of patients with IPA among the influenza cases varied per centre (6% to 
26%, table S2, appendix p3). IPA was diagnosed at a median of 3 (IQR 0,7) days after 
ICU admission. A. fumigatus was almost exclusively cultured when identification to 
the species level was available. Susceptibility data were available in 17 patients and 4 
voriconazole-resistant strains were documented. While the number of patients admit-
ted to the ICU with influenza varied substantially from year to year, the prevalence of 
IPA was >10% in all calendar years (figure S4, see appendix p5). IPA was found in 20% 
(71/355) and 16% (12/77) from the patients with influenza A and influenza B pneumonia, 
respectively. No clear association could be demonstrated between the prevalence of IPA 
and the influenza subtypes that circulated in the respective calendar years (table S6, 
appendix p6).
In 98% of the IPA cases (81/83) a BAL was done, yielding a positive Aspergillus culture 
in 50 (60%) and a positive galactomannan test (optical density (OD) ≥1·0) in 67 (88%) of 
the 76 patients of whom the BAL was not only cultured but also tested for the presence 
of galactomannan (table 3). Serum galactomannan test was done in 31/83 (37%) of the 
IPA cases and was positive (i.e.≥0·5) in 65% (20/31). 21 of the 83 patients (25%) with 
IPA were previously healthy and 7 (33%) of them died. Given the fact that by definition 
patients with influenza who are not immunocompromised do not fulfil the EORTC/MSG 
host factor definition, only 36 of 83 (43%) had a proven (n=16) or probable (n=20) IPA 
according to the EORTC/MSG classification.11 According to the AspICU algorithm, specifi-
cally designed for ICU patients, 48 patients (58%) were diagnosed with IPA while 30 were 
not classifiable as they had a positive galactomannan test on BAL but a negative lower 
respiratory tract culture which is the entry criterion in the AspICU algorithm.12 92% of 
the IPA cases (76/83) received mould-active antifungal therapy. In these patients, no 
difference in the number of days from influenza diagnosis to antifungal therapy initia-
tion was observed between survivors and non-survivors 90 days after ICU admission (4 
[IQR 1,10] versus 5 [IQR 1,7] days, p=0·64).
table 2: Overview of the characteristics of influenza-positive cohort
APACHE= acute physiology and chronic evaluation score, BAL= broncho-alveolar lavage, BMI= body 
mass index, COPD= chronic obstructive pulmonary disease, CS= corticosteroids, ECMO= extracor-
poreal membrane oxygenation, EORTC= European Organization for Research and Treatment of 
Cancer/Invasive Fungal Infections Cooperative Group, GM= galactomannan; ICU= intensive care 
unit, IPA= invasive pulmonary aspergillosis, IQR= interquartile range, NO/HFOV= nitric oxide/high-
frequency oscillation ventilation, RRT= renal replacement therapy, SD= standard deviation.
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IPA characteristics in patients with Influenza
BAL culture positive, n (%) 50/80 (62·5)
BAL Galactomannan positive, n (%) 67/76 (88)
Serum Galactomannan positive, n (%) 20/31 (65)
EORTC/MSG criteria
• Proven, n (%) 16 (19)
• Probable, n (%) 20 (24)
• Not classifiable, n (%) 47 (57)
AspICU criteria
• Proven, n (%) 16 (19)
• Putative, n (%) 32 (39)
• colonizer, n (%) 5 (6)
• Not classifiable, n (%) 30 (36)
Initial Treatment:
• Voriconazole, n (%) 61 (73)
• echinocandine, n (%) 2 (2)
• combination (triazole + echinocandine), n (%) 9 (11)
• liposomal-amfotericine b, n (%) 4 (5)
• no treatment, n (%) 7 (8)
table 3: IPA characteristics in patients with Influenza
BAL= broncho-alveolar lavage, EORTC/MSG= European Organization for Research and Treatment 
of Cancer/Invasive Fungal Infections Cooperative Group, IPA= invasive pulmonary aspergillosis.
Comparison of influenza patients with and without IPA (Table 2)
ICU mortality in the IPA cases was higher than in patients without IPA (37/83 or 45% 
versus 70/349 or 20%, p<0·0001) and the ICU stay was longer (19 days [IQR 12,38] versus 
9 days [IQR 5,20], p<0·0001). The mortality 90 days after ICU admission was 51% (42/83) 
in patients with IPA and 28% (99/349) in those without IPA (p<0·0001).
Patients with IPA required mechanical ventilation more often (90% (75/83) versus 72% 
(251/349), p=0·0004) and for a longer period (+5 days; p=0·001).
Independent risk factors for the occurrence of IPA on the pooled data of all influenza-
positive patients (regardless of the presence or absence of EORTC/MSG host factor) 
are presented in figure 2a. A list of all variables used in the multivariate analyses can 
be found in the appendix (table S4, appendix p5). Corticosteroid (CS) therapy in the 
4 weeks before ICU admission was independently associated with IPA (aOR 1·59, 95% 
CI 1·30 to 1·99;p<0·0001) per 0·1mg/kg/day prednisone equivalent). Finally, male sex 
(aOR 1·84, 95% CI 1·05 to 3·22;p=0·034) and a higher admission APACHE II were associ-
ated with IPA as well (aOR 1·05,95% CI 1·01 to 1·09;p=0·007 per 1·0 point APACHE II 
increase).
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figure 2: Forest plots of risk factors for the development of IPA
The solid lines represent the 95% confidence intervals (CIs). There has been corrected for centre as 
well but this is not depicted here as no significant differences were found. (a) Analysis of risk fac-
tors for patients with influenza in the ICU to develop IPA. (b) Overview of case-control comparison. 
Factors independently associated with the development of IPA are highlighted in red.
Abbreviations: APACHE= acute physiology and chronic evaluation score; BMI= body mass index; CI= 
confidence interval; COPD= chronic obstructive pulmonary disease.
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all eortc
neg patients
(n=630)
Influenza +
cases
(n=315)
Influenza -
controls
(n=315)
p
baseline cHaracteristics
Age (years) 59 ± 17 58 ± 16 60 ± 17 0·15
Sex (men), n (%) 371 (59) 169 (54) 202 (64) 0·008*
APACHE II admission 23 ± 8 22 ± 8 23 ± 8 0·29
BMI (kg/m2), median (IQR)
Missing, n
25 (22,29)
21
27 (23,30)
18
24 (22,28)
3
<0·0001*
Diabetes, n (%) 114 (19) 63 (20) 51 (16) 0·21
Liver cirrhosis, n (%) 44 (7) 18 (6) 26 (8) 0·21
Chronic Kidney Diseasex,n (%) 69 (11) 31 (10) 38 (12) 0·37
COPD, n (%) 123 (20) 68 (22) 55 (17) 0·19
corticosteroiDs
CS 28 days before ICU, n (%) 99/619 (16) 57/304 (19) 42/315 (13) 0·005
Median dose CS 28days before ICUadm 
(IQR) when receiving CS
·078 [·054, ·176] ·070 [·054, ·171] ·080 [·053, ·179] 0·79
Missing, n 22 10 12
icU Parameters
Mechanical ventilation, n (%) 475 (75) 246 (78) 229 (73) 0·12
Median ventilation days, days [IQR]
Missing, n
9 [4, 18]
35
11 [5, 21]
26
4 [4, 14]
9
0·002*
NO/HFOV, n (%) 64 (10) 37 (12) 27 (9) 0·17
ECMO or ECCOR, n (%) 65 (10) 45 (14) 20 (6) 0·04*
ECMO days, median [IQR] 10 [6, 20] 11 [8, 21] 9 [5, 18] 0·44
Vasopressors, n (%) 415 (66) 216 (69) 199 (63) 0·17
Renal replacement therapy, n(%) 103 (16) 61/307 (20) 42 (13) 0·03*
oUtcome Data
ICU mortality, n (%) 125 (20) 58 (18) 67 (21) 0·37
Hospital mortality, n (%) 164 (26) 76 (24) 88 (28) 0·28
Mortality< 90 days after ICU admission 177 (28) 78 (25) 99 (31) 0·70
Median ICU stay, days [IQR]
Missing
11 [6, 21]
19
11 [6, 23]
15
10 [6, 18]
4
0·15
IPA, n (%) 61 (10) 45 (14) 16 (5) <0·0001*
DiaGnostics
BAL sampling, n (%) 318 (50) 145 (46) 173 (55) 0·026*
BAL Galactomannan performed, n(%) 187 (30) 81 (26) 106 (34) 0·029*
iPa aspicU classification
IPA-proven, n (% of IPA cases) 8 (13) 6 (13) 2 (13)
IPA-putative, n (% of IPA cases) 32 (52) 27 (60) 5 (31)
IPA-colonizer, n (% of IPA cases) 4 (7) 3 (7) 1 (6)
IPA non classifiable, n (% of IPA cases) 17 (28) 9 (20) 8 (50)
table 4: Overview of characteristics of the cases and controls
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Comparison of influenza-positive cases and influenza-negative CAP 
controls (Table 4 and association analysis figure 2b)
315 of the influenza patients had no underlying EORTC/MSG risk factor and were de-
fined as cases and 45 (14%) of them were diagnosed with IPA. In comparison, 16 of the 
315 CAP controls (5%) were diagnosed with IPA. Baseline characteristics of the cases 
and controls are summarized in table 4. BAL sampling and galactomannan measure-
ment on BAL was more frequently performed in CAP controls (BAL in 55% (173/315), 
galactomannan in 34% (106/315)) than in influenza-positive cases (46% (145/315) and 
26%(81/315)). To evaluate if in the pooled patient population of influenza cases and 
CAP controls, influenza was associated with IPA, a binary logistic regression analysis 
was performed. This analysis confirmed the independent association between influenza 
and IPA (aOR 5·19 95% CI, 2·63 to 10·26; p<0·0001) (figure 2b). A list of all variables 
used in the multivariate analyses can be found in the appendix (table S5, appendix p5). 
In the case-control analyses, other independent risk factors for IPA were male sex and 
receipt of corticosteroids in the 4 weeks preceding ICU admission at a dose below the 
corticosteroid dose that is included in the EORTC/MSG host factor definition (figure 2b).
DiscUssion
To the best of our knowledge, this study is the largest ever performed on the incidence, 
risk factors and outcome of IPA in ICU patients with influenza. Furthermore, the data 
provide evidence that influenza infection is an independent risk factor for IPA. Indeed, 
in a total of 630 non-immunocompromised patients admitted to the ICU with CAP of 
which 50% were infected with influenza, the presence of influenza increased the risk 
of IPA from 5 to 14%. Furthermore, the ICU mortality in the IPA cases was 45% and even 
in previously healthy individuals the mortality was 33%. This is in accordance with the 
47% mortality described in earlier case series1 but somewhat lower than described in 
recent cohorts.13,16 Of note, 85 patients of this cohort had been included in previous 
studies.9,13 In the subgroup with an EORTC/MSG host factor, the IPA incidence was as 
high as 32% and 61% of them had died 90 days after ICU admission. As the diagnosis of 
APACHE= acute physiology and chronic evaluation score, AspICU: algorithm for invasive aspergil-
losis in ICU as described by Blot and colleagues12, BAL= broncho-alveolar lavage, BMI= body mass 
index, COPD= chronic obstructive pulmonary disease, CS= corticosteroids, ECCOR= extracorporeal 
CO2 removal, ECMO= extracorporeal membrane oxygenation, adm= admission, EORTC= European 
Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, 
ICU= intensive care unit, IPA= invasive pulmonary aspergillosis, IQR=Interquartile range, NO/HFOV= 
nitric oxide/high-frequency oscillation ventilation, RRT= renal replacement therapy, SD= standard 
deviation. X=Glomerular filtration rate < 60mg /1.73m2
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IPA is challenging, a systematic approach towards the diagnosis of IPA in ICU patients 
with influenza may result in an even higher incidence of IPA and should be the focus of 
future prospective studies.
The reported overall incidence of IPA in critically ill patients varies widely from <1 to 
6·9%15,17,18 and corresponds with the 5% incidence in our CAP control group.9,13,19 A recent 
study of 2901 ICU patients with influenza showed the presence of a co-infection in 17% 
and Aspergillus spp. in 7% of these patients with a co-infection.20 The lower incidence 
in this study could be explained by a different diagnostic approach (e.g. no use of BAL 
galactomannan measurement), a lower overall awareness as well as the fact that only 
co-infections diagnosed within two days of hospital admission were registered.
As influenza is not considered a host factor for IPA, only part of our patients with IPA 
fulfilled one of the diagnostic criteria for IPA as defined by the EORTC/MSG or AspICU 
algorithm.11,12 In addition, influenza patients with IPA mostly have non-specific radi-
ology and classic radiological features only occur in 5% of critically-ill patients with 
IPA.1,12,14,21,22 Autopsy series indicated that strict interpretation of the host factors for 
invasive fungal disease contributes to missed diagnosis of IPA.5,23 Therefore, we clas-
sified our patients using a modified IPA definition in which no specific host factor was 
required. However, stringent mycological criteria were used, compatible with the case 
definition of EORTC/MSG, AspICU and van de Veerdonk and colleagues.11-13 Of course, 
the same classification was used for the control group. Furthermore, to avoid an over-
estimation of the incidence of IPA, we excluded all 25 patients with only a positive 
figure 3: Bronchoscopy and histopathology of a representative case of influenza-associated As-
pergillus tracheobronchitis.
A.  Bronchoscopic examination reveals diffusedly inflamed mucosal tissue, with multiple whitish 
nodules, dispersed from trachea into main bronchial structures. Some nodules show central 
necrosis.
B.  Haematoxylin-Eosin staining of biopsied specimen from trachea at 50x magnification, showing 
focal ulceration with submucosal necrosis and squamous metaplasia.
C.  Haematoxylin-Eosin staining of biopsied specimen at 100x magnification, revealing invasion of 
submucosa by fungal hyphae, type Aspergillus, and dense infiltration with neutrophils.
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respiratory tract (i.e. sputum or tracheal aspirate) but a negative or unavailable BAL 
culture as the only microbiological evidence for IPA.
The optical density (OD) cut-off above which a galactomannan test in BAL should 
be considered positive is a matter of debate. The sensitivity of BAL galactomannan 
measurement was 88% when applying an OD≥0·5 on biopsy proven IPA cases in the ICU.24 
However, in a recent observational study the value of BAL galactomannan testing in the 
ICU was questioned because the specificity compared with a positive BAL culture was 
low at 38% and 62% with a galactomannan OD cut-off of ≥1·0 and 3.0 respectively.25 
However, given the limited sensitivity of BAL culture for the diagnosis of IPA, the use of 
a positive culture as the gold standard makes the interpretation of their results difficult. 
In our case definition we used a galactomannan OD cut-off of ≥1·0. Yet, when an OD≥3·0 
would be applied only 8 (10%) of the 83 IPA-influenza cases would have been classified 
differently. In addition, the median galactomannan OD of all influenza-IPA cases was as 
high as 5·8 IQR [2·8-6·7]. Furthermore, when we reviewed all 15 patients with proven 
IPA that also underwent BAL galactomannan testing, in 14 of these 15 patients with 
biopsy proven IPA, the BAL GM optical density was >1.0. Also, 6 patients without IPA 
had a galactomannan BAL measurement with a value <1.0 and were autopsied. In none 
of them, an IA was found at autopsy. Therefore, the specificity of galactomannan in 
BAL with a cut-off threshold of 1.0 in our study seems to be excellent. Remarkably, 
the observation that 17 of the 28 patients (61%) with a positive BAL galactomannan 
test, also had a positive serum GM was unexpected as in non-neutropenic haematology 
patients the sensitivity of serum galactomannan is low. This suggests that angio-invasion 
is often present in influenza patients with IPA.
We could not confirm the previous observation that a delayed initiation of anti-
fungal therapy was associated with a fatal outcome.13 A particularly high awareness 
was present in one of the participating centres as this centre already published on 
influenza-associated IPA in 2012. In this centre, BAL sampling was performed in 102 
of 149 influenza patients. 26% of the patients in this centre fulfilled the IPA diagnosis 
with an ICU mortality of 38% compared to an ICU mortality of influenza-associated 
aspergillosis in all other centres of 50%. This suggests that increased awareness may 
improve outcome.
Azole resistance is an emerging problem and has been particularly reported in The 
Netherlands with a prevalence of 13% in 2016.26 As azole resistance testing has only 
recently become a standard procedure in ICU, data on azole resistance were available 
for 17 patients only and resistance was documented in 4 of them.
Why patients with influenza are at risk for IPA is not yet clear.27,28 Respiratory epi-
thelium damage and mucociliary clearance dysfunction may facilitate the invasion of 
Aspergillus (figure 3).7,9,29 Moreover, influenza-induced ARDS and hypoxia may cause 
immune-paralysis.30-32 Almost all cases to date have been associated with the pandemic 
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influenza A H1N1 infection but influenza B may trigger an Aspergillus superinfection as 
well.13,33 This observation was confirmed in this study as an almost equal proportion of 
both influenza A and influenza B patients developed IPA. We were unable to look at the 
influenza subtype as a possible risk factor for IPA as subtyping was only available in a 
small number of patients. However, no association could be found between the of IPA 
and the influenza subtypes that circulated in the respective calendar years. Further-
more, the fact that the of IPA was >10% in all calendar years suggests that the severity 
of illness rather than influenza subtype is more important. Whether our observation is 
specific for influenza or if it may also apply to pneumonia patients admitted to the ICU 
with a respiratory virus other than influenza remains to be seen. The observation that 
the use of CS prior to the ICU admission was independently associated with IPA is in ac-
cordance with a Cochrane review showing an association between CS use and increased 
influenza mortality. On the other hand, CS use before ICU admission could be a marker 
of the severity of the influenza infection, making it a possible confounder by indication. 
However, the available evidence on the value of CS in patients with influenza argues 
against its use as long as data from a prospective randomized clinical trial are lacking.34
Given the high incidence of IPA we observed, antifungal prophylaxis might be a valid 
approach. Whether antifungal prophylaxis will be superior to a standardized diagnostic 
approach combined with prompt initiation of antifungal therapy as soon as IPA is diag-
nosed remains to be demonstrated.
limitations
First, given the retrospective design of this study, confounding cannot be ruled out 
and a standardized diagnostic approach towards IPA was lacking. However, the time 
needed to collect a similar amount of data prospectively clearly argues for the added 
value of this retrospective study. Also, as we did not correct for multiple testing, all 
univariate p-values should be interpreted with this in mind. Second, as only 60% of the 
patients with IPA had a positive BAL culture, the diagnosis of IPA was based on a positive 
galactomannan BAL test in a substantial number of patients. Given the observation that 
BAL sampling was performed in 98% of the influenza patients diagnosed with IPA but 
only in 44% of the patients not diagnosed with IPA we cannot exclude that the actual 
incidence of IPA may be even higher. We have no reasons to believe that compared 
with the influenza patients, a risk of underdiagnosis of IPA in the influenza-negative 
controls was present. Actually, BAL galactomannan sampling was more often performed 
in our control group. Third, one may argue that in a subset of the patients the IPA will 
have developed before ICU admission and may have resulted in clinical deterioration 
and ultimately ICU admission. However, this does not change the conclusion that in 
patients with influenza that need ICU support, IPA is highly prevalent and associated 
with a high mortality. Another limitation is that all but 1 of the 7 centres were tertiary 
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care academic ICUs. Therefore, extrapolation to small primary care ICUs should be 
done with caution. However, the incidence of IPA in the single primary care ICU of 
this study was comparable at 15%. The use of ECMO support was somewhat higher in 
the influenza-positive cases (14%) than in the influenza-negative CAP controls (6%) and 
therefore one may argue that ECMO may be a confounder in the analysis. However, 
only 4 of 83 IPA infections in our study were diagnosed with IPA >72h after the start of 
ECMO support. Also, in a recent study on fungal infections in 2129 patients on ECMO 
the incidence of Aspergillus superinfections was similar to the general intensive care 
population. Importantly, this study confirmed that in the subgroup of influenza patients 
on ECMO, the incidence of IPA was 14%.35 A final limitation is the choice of our com-
parison group. By choosing severe CAP patients as controls we can only conclude that 
compared with influenza-negative patients with CAP, the presence of influenza is a 
risk factor for IPA. Several other patient groups could have been chosen as controls as 
well (e.g. non-infectious ARDS) but we preferred a control group that was comparable 
to the influenza cases as much as possible. Therefore, we considered patients with 
CAP the most appropriate controls as, like influenza patients, they present with acute 
respiratory failure and are admitted to the ICU from the community.
conclUsion
In ICU patients with influenza, the incidence of IPA was high as was the mortality. 
Influenza was independently associated with IPA. An aggressive diagnostic approach 
should be pursued and the value of antifungal prophylaxis studied.
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eDitorial
For almost a century, superinfections with S. pneumoniae and S. aureus have been 
a well-known complication of seasonal influenza. More recently, invasive pulmonary 
aspergillosis (IPA) was described as another important complication. Influenza associ-
ated invasive pulmonary aspergillosis (IAPA) has so far been predominantly described 
in critically ill patients admitted to the ICU with influenza pneumonia [1-3]. Following 
a number of single-center case series of IAPA, the Dutch-Belgian Mycoses Study Group 
(DB-MSG) evaluated its incidence in the largest cohort study of patients admitted to 
the ICU with influenza so far. In this study, 19% of the 432 patients admitted to the ICU 
during seven consecutive influenza seasons were diagnosed with IAPA. Furthermore, the 
study also demonstrated that in patients admitted to the ICU with community-acquired 
pneumonia, the detection of influenza was strongly associated with a subsequent diag-
nosis of invasive pulmonary aspergillosis and half of the patients diagnosed with IAPA 
died in the ICU [1].
In this issue of Clinical Infectious Diseases, a single-center retrospective cohort study 
performed over five consecutive influenza seasons at a large tertiary care center in 
Alberta, Canada reports on the incidence of IPA in 111 patients admitted to the ICU for 
respiratory failure caused by an influenza infection. These data are a welcome addition 
to the data currently available in the literature. In contrast with the incidence of IAPA 
of 12 to 28% described in Europe and Asia so far, Schwartz et al diagnosed an IAPA in 
only 8 of 111(7.2%) patients. Before we start wondering about how it is possible that 
the incidence of IAPA in Canada may be lower than in Europe or Asia, it is important 
to put this incidence of 7% into perspective. Indeed, apart from patients undergoing 
remission induction chemotherapy for acute myeloid leukemia, patients with severe 
graft-versus-host disease and perhaps also lung transplant patients, no other patient 
population has an incidence of IA as high as 7%.
Histopathological evidence of the presence of Aspergillus species from a sterile 
body site remains the gold standard of IPA diagnosis. However, sampling lung tissue 
in an ICU patient is clearly not without risk and actually rarely performed. Sputum or 
tracheal aspirate cultures are a low-cost and easy to perform diagnostic test but the 
sensitivity when used to diagnose IPA in ICU patients does not exceed 50% [4]. Several 
non-culture-based assays are now available to demonstrate the presence of Aspergillus 
in blood or airway samples and testing for the presence of galactomannan (GM), a cell 
wall component of Aspergillus, is the most-validated of these non-culture based tests. 
Because most studies that evaluated GM for the diagnosis of IA in ICU patients included 
few patients with a proven infection, doubts remain regarding the value of GM testing 
in ICU patients. However, in a prospective study that was conducted in the setting of 
a very high autopsy rate a substantial number of proven infections were included. In 
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this unique study, testing for the presence of GM on broncho-alveolar lavage (BAL) fluid 
had a sensitivity 88% and specificity of 87%. One of the most striking observations in 
this study was that GM testing on BAL identified 11 of a total of 26 (autopsy) proven IPA 
cases. Without GM testing these cases would have been missed if fungal cultures had 
been used only. As expected, GM testing on serum performed substantially poorer[5, 
6]. In the study by Schwartz and colleagues, clinicians tested for the presence of GM on 
BAL in as few as 16 of the 111 patients. It is therefore very likely that the incidence of 
7% would have been higher if GM had been tested on BAL in all patients.
However, a true difference in incidence of IAPA across continents may well be the 
case and several hypotheses can be postulated here. Differences in the incidence of 
invasive aspergillosis have been linked to single nucleotide polymorphisms in several 
genes of the innate immune system. Single nucleotide polymorphisms (SNPs) in the 
Pentraxin 3 (PTX3) gene decrease antifungal clearance and phagocytosis by neutrophils 
and therefore increase the susceptibility to invasive mold infections. These PTX3 SNPs 
have been linked to an increased fungal infection risk in each of the 3 patient groups at 
highest risk for invasive mould infections: solid organ transplant recipients, allogeneic 
stem cell transplant recipients and patients with acute leukemia [7-9]. Future studies 
should look at the role of PTX3 in IAPA.
Apart from genetic factors, environmental factors are likely to play a role as well, 
as IAPA is often diagnosed in the first days after and even on the day of ICU admission. 
This suggests that the infection is caused by Aspergillus spores inhaled by the patient 
preceding hospital admission. Therefore, it is likely that differences in Aspergillus spore 
counts in the air (e.g. rural rather than urban, dry versus wet climate) will influence 
the risk of IAPA. Apart from diagnostic and genetic factors, the way health-care is orga-
nized locally may also influence the incidence of IAPA across countries and continents. 
Indeed, so far data on IAPA come almost entirely from tertiary care ICU centers. But 
even within these tertiary care ICU populations, the specific patient referral policy is 
likely to influence the IAPA risk. For instance, if extra-corporal membrane oxygenation 
is only performed at the sites included in a specific study, the patients admitted at 
these ICUs will often be referred from first care hospitals after conventional ventilatory 
support has been shown to be insufficient. These differences in ventilatory failure may 
not be reflected in APACHE scores. Also, patients admitted to the ICU in tertiary care 
centers may more often have specific underlying disease in which tertiary care hospitals 
are more often specialized (e.g. vasculitis, solid organ transplantation, autoimmune 
diseases). Finally, we have more speculative explanations for the observed differences 
in IAPA. Differences in influenza vaccination policies will influence the uptake of influ-
enza vaccination and could change the severity of illness of an influenza infection in 
the population under study. Even more speculative is that the reported higher incidence 
of IAPA in recent years might be the caused by the widespread use of neuraminidase 
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inhibitors in patients infected with influenza. Fundamental research indicates that 
neuraminidase seems to play a role in the host immunity against Aspergillus species 
and blocking neuraminidase could increase the risk for Aspergillus superinfection [10]. 
Finally, the reported incidences of IAPA in ICU patients may only reflect the tip of 
iceberg. Some patients in the study by Schwartz et al. survived without treatment while 
others died despite best antifungal therapy. It might be that Aspergillus superinfection 
is quite common during influenza but only clinically relevant in patients admitted to 
the ICU.
But what is the clinical relevance of IAPA? Is it just an innocent bystander or is it truly 
one of the steps on the path from influenza infection to the death of these patients 
in the ICU? Half of the patients with IAPA in the cohort study from Dr. Schwartz et al. 
died. This is in line with the reported mortality of IAPA cases in the DB-MSG study. To try 
to answer the question whether the significantly higher mortality observed in patients 
with IAPA can be attributed to the Aspergillus superinfection or if it is just a marker of 
overall disease severity, we performed a mortality analysis on the DB-MSG study cohort. 
Remember, in this study 432 patients admitted to the ICU with influenza were included 
of whom 117 were immunocompromised according to the European Organization for 
Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and 
the National Institute of Allergy and Infectious Diseases Mycoses Study Group EORTC/
MSG criteria [11]. 83 of the 432 patients (19%) were diagnosed with IAPA, and the 90-day 
mortality was 51%, which was substantially higher than the mortality in the 349 patients 
without IAPA (28%, P<0.001). A Kaplan Meier survival curve was made for patients with 
and without IAPA (figure 1A) and a cox regression analysis was performed to determine 
whether IAPA, as a time-dependent covariate, was independently associated with 90-
day mortality, using the independent covariates as depicted in figure 1B [12]. In the 
immunocompromised subgroup, one third of patients (38 (32%)) developed IAPA and 71% 
died. The cox regression analysis showed that the emergence of IAPA was independently 
associated with 90-day mortality (adjusted Hazard Ratio (aHR) 1.944, 95% CI 1.307-
.2·891, p=0.001, figure 1B) as were age (aHR 1.032, 95% CI 1.018-1·046), APACHE II (aHR 
1.046, 95% CI 1.023-1.069), diabetes (aHR 1.599, 95% CI 1.092-2.342), being immu-
nocompromised according to EORTC/MSG criteria (excluding corticosteroid use) (aHR 
1.670, 95% CI 1.146-2.434) and corticosteroid therapy before ICU admission (aHR 1.118, 
95% CI 1.035-1.207 per 0.1 mg/kg/day prednisone equivalent). These results strongly 
suggest that IAPA is independently associated with mortality in patients admitted to the 
ICU with influenza. Although, we acknowledge that observational data can never prove 
a causal relationship with 100% certainty, the association of IAPA and mortality was 
independent of confounders like severity of illness and being immunocompromised at 
ICU admission. This finding, again, confirms the relevance of diagnosing IAPA in the ICU. 
In accordance with recent literature, corticosteroids exposition before ICU admission 
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in patients with severe influenza significantly impacted mortality as well, and strongly 
suggests that caution is needed regarding the use of adjuvant corticosteroid therapy for 
patients with severe pneumonia during the influenza season [13, 14].
Many outstanding questions remain to be resolved. To answer these questions, the 
quality of future research on IAPA needs to be improved further. For this we will need a 
consensus definition of IAPA to be used in future studies. Therefore, a group of experts 
in the field of invasive fungal infections and intensive care medicine met to discuss 
and eventually formulate a workable set of definitions. We expect these to become 
publicly available as early as 2020. Future studies should try to find risk factors for 
IAPA, other than those already found (i.e. being immunocompromised and a higher 
figure 1a: Kaplan Meier 90-day survival 
function of the influenza cohort.
IAPA= Influenza-associated aspergillosis. 
ICU=Intensive Care Unit.
figure 1b: Forest plot Cox regression analysis
IAPA=Influenza-associated aspergillosis. CS=Corticosteroids. CS therapy before ICU=CS therapy in 
the 4 weeks preceding ICU admission Immunocompromised=patients with a host factor as defined 
by the EORTC/MSG criteria[12].
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APACHE II score). This will allow for stratification of patients included in studies on the 
prevention of IAPA (e.g. with systemic or inhaled antifungal prophylaxis). It will also 
help the clinician when a decision needs to be made upon the invasiveness of diagnostic 
procedures to be done. Indeed, in a patient at very high risk for IAPA, a more invasive 
diagnostic strategy is justified. Once the diagnosis is made, the optimal therapy of IAPA 
needs to be found. Until new data arise, it is logical to treat these patients according to 
guidelines on the treatment of invasive aspergillosis. However, patients with Aspergillus 
tracheobronchitis may need to be treated differently. Also, it may well be that at least 
a subset of patients with IAPA can be treated for just a few weeks rather than a typical 
duration of at least 6 weeks and often many months in patients with a probable invasive 
aspergillosis according to the EORTC/MSG definition. Finally, we think that a better 
understanding of the underlying immunological mechanism and pathogenesis of IAPA 
is clearly needed because this may eventually lead to targeted prevention or therapy.
In conclusion, IAPA is a frequent and potentially lethal complication of influenza 
in critically-ill patients. While its incidence may vary between geographical regions 
and centers, also small primary care ICU’s will see these patients if the awareness 
among physicians is in place. Data like the study by Schwartz et al. demonstrate that in 
patients with influenza admitted to the ICU with respiratory insufficiency a diagnostic 
bronchoscopy should be done to look for tracheobronchitis with biopsy of visible le-
sions if possible but also to sample BAL fluid. If the patient is not yet intubated, a 
very experienced bronchoscopist is often still able to perform a “mini-BAL” in just a 
few minutes while the patient is receiving high-flow nasal oxygen therapy. GM testing 
should be done on serum and preferentially also on BAL fluid. At ICU admission, a fungal 
culture on sputum or tracheal aspirates should be done. If IAPA is excluded on admission 
but progressive radiological and or clinical deterioration is observed during or after ICU 
admission, a repeated radiological and/or bronchoscopic evaluation is needed to rule 
out IAPA (again).
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Chapter 11
Azole-echinocandin combination therapy for invasive 
aspergillosis. A randomized pragmatic superiority 
trial (DUET)
My mama always said, life is like a box of chocolates. 
You never know what you’re gonna get. (Forrest Gump)
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list of abbreViations anD releVant Definitions
ABR ABR form, General Assessment and Registration form, is the application form that is 
required for submission to the accredited Ethics Committee (In Dutch, ABR = Algemene 
Beoordeling en Registratie)
A. fumigatus
A. species
AE
AML
Aspergillus fumigatus
Aspergillus species
Adverse Event
Acute Myeloid Leukemia
AR
BAL
Adverse Reaction
Bronchoscopic Alveolar Lavage
BID Twice daily
CA Competent Authority
CCMO 
CRF
CT
Central Committee on Research Involving Human Subjects; in Dutch: Centrale Commissie 
Mensgebonden Onderzoek
Case Report Form
Cycle Treshold
CV Curriculum Vitae
D Day
DSMB Data Safety Monitoring Board
DDI
EORTC
EORTC/MSG 
 
ESCMID
Drug-drug interaction
European Organisation for Research and Treatment of Cancer
European Organization for Research and Treatment of Cancer/Invasive Fungal Infections 
Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses 
Study Group
European Society of Clinical Microbiology and Infectious Diseases
EU European Union
EudraCT European drug regulatory affairs Clinical Trials
GCP
GVHD
HSCT
IA
Good Clinical Practice
Graft Versus Host Disease
Hematopoietic stem cell transplantation
Invasive Aspergillosis
IB Investigator’s Brochure
IC
ICH 
iMTA
IRB
IV
Informed Consent
International Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use
institute for Medical Technology Assessment
Institutional review board
Intravenous
IMP Investigational Medicinal Product
IMPD Investigational Medicinal Product Dossier
METC Medical research ethics committee (MREC); in Dutch: medisch ethische toetsing 
commissie (METC)
MITT
MSG
PCR
Modified intention to treat
Mycoses Study Group
Polymerase Chain Reaction
PO
QALY
Per os (oral intake)
Quality-adjusted life year
RAMS
RT
Azole reistance associated mutations
Resistance
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(S)AE (Serious) Adverse Event
SOC
SOT
SPC
Standard of care
Solid Organ Transplant
Summary of Product Characteristics
Sponsor The sponsor is the party that commissions the organization or performance of the 
research, for example a pharmaceutical company, academic hospital, scientific 
organisation or investigator. A party that provides funding for a study but does not 
commission it is not regarded as the sponsor but referred to as a subsidizing party.
SUSAR
SWAB
Suspected Unexpected Serious Adverse Reaction
Stichting Werkgroep Antibioticabeleid (in Dutch)
TR Tandem Repeat
Wbp Personal Data Protection Act (in Dutch: Wet Bescherming Persoonsgevens)
WMO Medical Research Involving Human Subjects Act (in Dutch: Wet Medisch-wetenschappelijk 
Onderzoek met Mensen
sUmmarY
rationale
Patients with underlying haematological malignancies or immunocompromised for vari-
ous other reasons, are prone to fungal infections. Invasive aspergillosis (IA) is a com-
mon complication during remission inducing chemotherapy for acute leukemia or other 
hematological malignancies, as well as those who have undergone allogeneic hemato-
poietic stem cell transplantation (HSCT) or solid organ transplantation (SOT). For more 
than 15 years voriconazole, a drug of the triazole class, has been the recommended 
treatment for this life-threatening infection after a pivotal randomized trial showed 
an improved survival with voriconazole compared with amphotericin B deoxycholate. 
However, also with voriconazole the overall 6-week mortality is still unacceptably high 
at 25-30% (Herbrecht et al., 20021). Therefore, a randomized controlled trial assed the 
efficacy of voriconazole with or without anidulafungin for the treatment of IA in haema-
tology patients to prove that combination therapy can improve outcome.2 Among the 
277 patients with IA in this study, the 6-week mortality with combination therapy was 
30% lower (19.3%) than with monotherapy (27.5%), p=0.087. In a post-hoc analysis of 
the 222 patients with radiographic abnormalities and a positive galactomannan antigen 
test, a statistically significant difference in mortality was observed (p=0.037). Though, 
this study did not result in conclusive evidence in favor of combination therapy, it is a 
credible study which adds to the already existing in vitro and animal studies in support 
of echinocandin triazole combination therapy for IA and thus paves the way for a second 
larger and pragmatic clinical trial. Another important and new consideration about the 
management of IA is the upcoming of infections with triazole-resistant A.fumigatus. 
This is increasingly becoming a worldwide problem and leads to longer hospital stay, 
higher costs and is associated with a very high mortality. It is very likely that the exces-
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sive use of antifungals of the triazole class in agriculture has formed the basis of this 
problem. Since 2018 the Dutch Working Party on Antibiotic therapy (SWAB) guideline on 
the management of invasive fungal infections therefore recommends upfront combina-
tion therapy (azole plus echinocandins or liposomal-amfotericine B) until resistance can 
be excluded as one of the treatment options for IA.
Given the evidence in favor of voriconazole-echinocandin combination therapy as 
well as the increasing incidence of voriconazole-resistant A. fumigatus in Belgium and 
the Netherlands, a large clinical study on the value of combination therapy is urgently 
needed.
objectives
Primary objective
1.  Evaluate if the survival in patients with a triazole susceptible IA can be improved 
when the initial therapy consists of triazole and echinocandin combination therapy 
instead of triazole monotherapy. This objective is captured in the primary endpoint 
as well as secondary endpoints 1 to 6)
Secondary objectives
1.  Evaluate if a triazole/echinocandin combination therapy improves the overall qual-
ity of life and if it is a cost-effective intervention (these objectives are captured in 
secondary endpoint 11 and 12)
2.  Evaluate the outcome of patients in which a triazole-resistant A. fumigatus is de-
tected in relation to the initial antifungal therapy they had received (i.e. triazole 
monotherapy or combination therapy). This objective translates into secondary 
endpoint 7 an 8.
3.  Evaluate the outcome of patients in which resistance testing is unsuccessful in func-
tion of the antifungal therapy they received. This translates into secondary endpoint 
10.
4.  Evaluate if the baseline serum galactomannan value and the serum galactomannan 
kinetics are predictive of overall 6-week survival. This translates into secondary 
endpoint 3 and 9.
study design and intervention: The study is designed as a large pragmatic clinical trial 
to facilitate enrolment as much as possible. In particular, we want to leave the choice 
of the triazole (voriconazole or isavuconazole or posaconazole IV or oral) to the treating 
physician. This will not only lead to less patients being excluded but also allow the 
clinician to switch from one drug to another (within the same class) in case of treat-
ment limiting toxicity. With the unbiased endpoint of overall survival, we consider a 
pragmatic approach that allows for easy recruitment of a sufficient number of patients 
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more important than the use of one specific drug within a class or the use of a placebo. 
Combination therapy will be discontinued after 28 days in all patients in which triazole 
susceptibility has been documented but when a treatment response is observed before 
day 28, the echinocandin can be discontinued as from day 7.
study population
Immunocompromised patients who fulfill the EORTC/MSG host factor and mycological 
criteria of invasive aspergillosis ICU patients with influenza who fulfill a definition of IA 
specific for this population
Primary endpoint
Primary endpoint
Overall survival 42 days after the start of antifungal therapy in the MITT population
Secondary endpoints
1. Overall aspergillus attributable mortality 12 weeks after the start of antifungal 
therapy.
2. Overall survival 12 weeks after the start of antifungal therapy in the MITT popula-
tion
3. Overall survival 6 weeks after the start of therapy in the subgroup of patients in the 
MITT population with a positive serum galactomannan test at baseline.
4. Overall survival 6 weeks after the start of therapy in the subgroup of non-ICU pa-
tients who fulfill the EORTC/MSG probable or proven definition (MITT population).
5. Overall survival 6 weeks after the start of therapy in the subgroup of non-ICU pa-
tients with an underlying haematological disease (MITT population)
6. Overall survival 6 weeks after the start of therapy in the subgroup of non-ICU pa-
tients without an underlying haematological disease (MITT population)
7. Overall survival 6 weeks after the start of therapy in patients that started with 
triazole monotherapy and in which triazole resistance is detected during follow-up 
(MITT population)
8. Overall survival 6 weeks after the start of therapy in patients that started with 
triazole-anidulafungin combination therapy and in which triazole resistance is de-
tected during follow-up (MITT population)
9. In the subgroup of patients with a positive serum galactomannan; Kinetics of serum 
galactomannan levels with combination versus monotherapy
10. Outcome of patients in which resistance testing was unsuccessful
11. Time to hospital discharge (in the MITT subgroup of patients admitted to the hospital 
at baseline)
12. Cost-effectivity of azole-anidulafungin combination therapy
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Nature and extent of the burden and risks associated with participation, benefit 
and group relatedness: The safety of this combination therapy has previously been 
demonstrated in a large randomization clinical trial (Marr et al., 2015).2 As a result of 
the underlying disease as well as the chemotherapy, serious adverse events are very 
frequently observed in this patient population (e.g. bleeding, life threatening infec-
tions, death due to progression of the underlying disease). The study will comprise of 4 
study visits and as most patients will be hospitalized at the start of therapy few of these 
will be additional hospital visits on top of the standard of care.
this video presentation describes the study in more detail as well
https://www.youtube.com/watch?v=Knq58Zar4hY
1. introDUction anD rationale
Invasive aspergillosis (IA) is a common complication during remission inducing chemo-
therapy for acute leukemia as well as in those who have undergone allogeneic hemato-
poietic stem cell transplantation (HSCT) or solid organ transplantation (SOT). For more 
than 15 years voriconazole, a drug of the triazole class, has been the recommended 
treatment for this life-threatening infection after a pivotal randomized trial showed 
an improved survival with voriconazole compared with amphotericin B deoxycholate. 
However, also with voriconazole the overall 6-week mortality is still unacceptably high 
at 25-30% (Herbrecht et al., 20021). Voriconazole blocks the synthesis of ergosterol, a 
part of the fungal membrane, while antifungals from the echinocandin class block the 
synthesis of β-(1,3)-D glucan, a component of the cell wall. Both drugs may therefore 
work synergistically as suggested by in vitro studies, neutropenic animal models of 
IA and case series (Philip et al., 20053; Petraitis et al., 20034). This synergistic effect 
was the hypothesis of a randomized trial that assessed the efficacy of voriconazole 
with or without anidulafungin for the treatment of IA in haematology patients (Marr 
et al., 20122). Among the 277 patients with IA in this study, the 6-week mortality with 
combination therapy was 30% lower (19.3%) than with monotherapy (27.5%), p=0.087. 
In a post-hoc analysis of the 222 patients with radiographic abnormalities and a posi-
tive galactomannan antigen test, a statistically significant difference in mortality was 
observed (p=0.037). These results were clearly promising and although we agree that 
in real-life in haematology patients a diagnosis of IA is indeed very often based on the 
combination of a positive galactomannan and pulmonary abnormalities, formal conclu-
sions on the value of combination therapy cannot be based on a post-hoc analysis from 
a single clinical trial. This is the reason why, despite the 30% relative reduction in 
mortality that was observed, combination therapy has not been included as preferred 
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first choice therapy for all patients with IA in the 2017 ESCMID guideline nor in the 
2017 Dutch SWAB guideline. Therefore, a second clinical trial is needed to confirm this 
finding.
Another important reason to study upfront combination therapy for patients with IA in 
the Netherlands and Belgium is the increasing incidence of triazole-resistant A. fumiga-
tus. Indeed, from a global perspective the highest prevalence of triazole resistance has 
been documented in the Netherlands. It increased from 0% before the year 2000 to 5.3% 
in 2009, and further increased to 15% in 2017. Unfortunately, more recently triazole 
resistance was observed in 5% of IA cases in Belgium as well and in 2017 researchers 
from the Erasme hospital in Brussels even reported a prevalence of 13% (Vermeulen et 
al., 20155; Montesinos et al., 20176). It has also clearly been demonstrated that the 
overall mortality becomes very high (50-88%) when patients infected with a triazole-
resistant A. fumigatus initially receive inappropriate voriconazole therapy and therapy 
is only changed at a time when it has become clinically obvious that the IA is progressing 
(Lestrade et al., 20187, van der Linden et al., 20158; Chong et al., 20159). These impor-
tant observations recently led to a change in the treatment recommendations of the 
2017 Dutch SWAB guideline on fungal infections. In the absence of any evidence from 
prospective studies on the treatment of IA in regions with a high prevalence of azole 
resistance, this guideline recommends 2 possible strategies. The first is upfront combi-
nation therapy (triazole combined with an echinocandin or liposomal amphotericin B) 
until resistance can be excluded. The second option, which should only be considered 
in non-critically ill patients and in centers that are able to perform real-time PCR as 
well as cultured based resistance testing on BAL samples, is to start with voriconazole 
monotherapy while waiting for the resistance test (Kullberg et al., 201810). Unfortu-
nately, resistance testing will not lead to an interpretable result in approximately 35% 
of the patients with IA. Indeed, fungal cultures remain negative in the majority of 
the patients with IA and PCR testing for CYP51 resistance associated mutations is not 
always successful either. For this subgroup of patients, the SWAB guideline recommends 
switching from triazole monotherapy to combination therapy as soon as it becomes 
clear that no resistance result will become available. The latter recommendation has 
been criticized when it relates to patients that are not very sick and have an infection 
that is limited to the lungs and that is not widespread. Indeed, some clinicians argue 
that close monitoring for treatment progression is a valid option as well because the 
poor outcome of azole resistant IA has not (yet) been convincingly demonstrated for 
culture negative cases.
The goals of this study are therefore 3-fold.
First, the main study and the primary endpoint will evaluate if the overall mortality 
can be decreased with initial azole-echinocandin combination therapy compared with 
triazole monotherapy in patients with IA and documented voriconazole susceptibility.
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Second, the study design described below will also allow to study several other sub-
populations; Indeed, the outcome of the following subgroups will be evaluated as well; 
a. Patients starting azole monotherapy but who switch to directed therapy when it has 
become clear that the infection is caused by an azole resistant A. fumigatus. b. patients 
in which eventually no resistance data become available in relation to the treatment 
they received.
Third, we want to evaluate what the outcome is of patients that turn out to be 
infected with a triazole resistant A. fumigatus who started with a triazole-echinocandin 
combination therapy.
Please note that a 20-minute presentation with illustrated slides has been put to-
gether in order to explain the background and the design of the study. This presentation 
is available via this URL: https://www.youtube.com/watch?v=Knq58Zar4hY and may 
help to understand the design and logistics of the study as an introduction to the full 
protocol
2. obJectiVes
Primary objective
1.  Evaluate if the survival in patients with a triazole susceptible IA can be improved 
when the initial therapy consists of triazole and echinocandin combination therapy 
instead of triazole monotherapy. This objective is captured in the primary endpoint 
as well as secondary endpoints 1 to 6)
secondary objectives
1.  Evaluate if a triazole/echinocandin combination therapy improves the overall qual-
ity of life and if it is a cost-effective intervention (these objectives are captured in 
secondary endpoint 11 and 12)
2.  Evaluate the outcome of patients in which a triazole-resistant A. fumigatus is de-
tected in relation to the initial antifungal therapy they had received (i.e. triazole 
monotherapy or combination therapy). This objective translates into secondary 
endpoint 7 an 8.
3.  Evaluate the outcome of patients in which resistance testing is unsuccessful in func-
tion of the antifungal therapy they received. This translates into secondary endpoint 
10.
4.  Evaluate if the baseline serum galactomannan value and the serum galactomannan 
kinetics are predictive of overall 6-week survival. This translates into secondary 
endpoint 3 and 9.
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3. stUDY DesiGn
A non-blinded phase 3 multicenter randomized pragmatic clinical trial.
Intervention: Add anidulafungin IV to the standard of care therapy that consists of a 
triazole (voriconazole or isavuconazole or posaconazole).
In both the intervention and control group, the triazole will be given for at least 
6 weeks. In the intervention group the echinocandin will be discontinued after 28 
days but when a treatment response is observed and the patients can be discharged 
from the hospital, the echinocandin can be discontinued from day 7 onwards accord-
ing to the choice of the treating physician. Figure 1 illustrates the study design and 
the patient flow in the study. The youtube presentation https://www.youtube.com/
watch?v=Knq58Zar4hY also clearly explains this flowdiagram.
4. stUDY PoPUlation
4.1. Population (base)
The study population will consist of patients age 18 or older that fulfill the host-factor 
definition of the EORTC/MSG11 in combination with any pulmonary infiltrate and a 
positive fungal culture from a bronchoalveolar lavage or positive serum (optical density 
≥0.5) or BAL galactomannan (optical density ≥1.0). This not only includes patients 
with proven or probable IA but also patients with a pulmonary infiltrate that does not 
comply with the EORTC radiological criteria (halo, nodule, cavitary lesion). We consider 
the inclusion of this latter patient population important as well because not only the 
mortality of these patients is comparable to patients with an EORTC/MSG probable IA 
but clinicians also uniformly treat these patients in the same way as they treat patients 
with probable IA (Nucci et al., 201012).
The host-factor definition of the EORTC/MSG implies that not only patients with an 
underlying haematological disease can be included but any patients that is sufficiently 
immunocompromised to fulfil the host-factor definition. Furthermore, ICU patients with 
a predicted mortality not exceeding 50% and admitted with influenza and respiratory 
insufficiency can be included as well as this has recently been described as an important 
risk factor for IA by Schauwvlieghe et al13.
4.2. inclusion criteria
Patients should fulfill the following inclusion criteria:
1. 18 years or older
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2. Have started or will start voriconazole or isavuconazole (or posaconazole if vori-
conazole or isavuconazole cannot be given as per treating physician’s decision) as 
antifungal therapy on the baseline visit.
3. For all patients: presence of one of the EORTC/MSG host factors as defined in ap-
pendix 1 or being admitted to the ICU with influenza
4. For non-ICU patients or ICU patients without influenza: Meet the EORTC/MSG clini-
cal criterium (appendix 1)
5. For non-ICU patients or ICU patients without influenza: Meet the mycological crite-
rium (appendix 1) or fulfil inclusion criterium 7
6. For ICU patients with influenza we consider an isolated positive sputum culture for 
Aspergillus spp. insufficient as a mycological criterium. Therefore, in these patients 
only one of the following mycological criteria are acceptable; Serum galactomannan 
ä0.5, BAL galactomannan ä1.0 or Aspergillus spp. cultured in BAL fluid.
7. Please note that patients with AML receiving chemotherapy or patients with ALL 
receiving or having received corticosteroid therapy within the last 4 weeks in the 
context of their pre-phase, induction, consolidation, intensification or interphase 
treatment as well as patients receiving systemic immunosuppressive therapy for 
GVHD can be included before the mycological criterium is fulfilled on condition 
that they fulfill the EORTC/MSG lung CT radiology criteria (halo sign, well-described 
nodule, cavity as described in appendix 1) at the time of inclusion and as long as the 
mycological test results are expected to become available within 96 and no later 
than 7 days after inclusion. If these test results turn out to be negative, the patient 
will be withdrawn from the study and further treatment is at physician’s discretion.
4.3. exclusion criteria
1. Known history of allergy, hypersensitivity or serious reaction to azole or echinocan-
din antifungals;
2. Patients with chronic invasive aspergillosis or a chronic non-invasive aspergillus 
infection (e.g. aspergilloma) defined as the clinical or radiological sign of infection 
being present for >28 days.
3. Receipt of itraconazole, voriconazole, posaconazole or isavuconazole as prophylaxis 
for at least 7 days in the 14 days preceding the date of the first radiological signs 
of the Aspergillus infection. Patients in which the most recent serum level of the 
triazole given as prophylaxis was subtherapeutic can be included (*).
4. Receipt of echinocandin prophylaxis for >96 hours in the preceding 7 days
5. Receipt of systemic antifungal treatment with an echinocandin or an azole for the 
current episode of invasive aspergillosis for a duration of > 96 hours.
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6. For patients in the Netherlands only: Diagnostic testing to exclude azole resistance 
will not be possible (sputum cultures are negative and BAL sampling will not be 
performed)
7. ICU patients only: Patients with a sequential organ failure assessment (SOFA) score 
>11 at the time of screening for the study are excluded. If randomization is done >24 
hours after screening the calculation should be repeated before the patient can be 
randomized (appendix 3)
8. ICU patients only: Patients in which weaning from the ventilator or ECMO system is 
deemed unlikely due to irreversible lung damage
9. Patients with any condition which, in the opinion of the investigator, could affect 
patient safety, preclude evaluation of response (e.g. because survival beyond 6 
weeks is unlikely due to the underlying disease status)
10. Patient previously included in this study
(*) Subtherapeutic levels are defined as itraconazole (parent compound only) <0.5 mg/L 
or posaconazole <0.7mg/L or voriconazole <1.0mg/L or isavuconazole <1.0mg/L
5. treatment of sUbJects
5.1. investigational product/treatment
Anidulafungin
Detailed information on anidulafungin, the investigational product used in this study 
can be found in the SPC. A short summary is given here. The information currently 
available on combination therapy with a triazole and an echinocandin for the treatment 
of IA is described below (6.2).
Mechanism of action
Anidulafungin is a semi-synthetic echinocandin, a lipopeptide synthesised from a fer-
mentation product of Aspergillus nidulans. Anidulafungin selectively inhibits 1,3-β-D 
glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in 
inhibition of the formation of 1,3-beta-D-glucan, an essential component of the fungal 
cell wall. Anidulafungin has shown fungicidal activity against Candida species and activ-
ity against regions of active cell growth of the hyphae of Aspergillus fumigatus.
Chemical Name
Anidulafungin has the chemical name 1-[(4R,5R)-4,5- Dihydroxy-N2- [[4”-(pentyloxy)
[1,1’:4’,1”-terphenyl]- 4- yl]carbonyl]- Lornithine]echinocandin B.
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Name of medicinal product
ECALTA 100 mg powder for concentrate for solution for infusion
Method of administration
For intravenous use only.
ECALTA should be reconstituted with water for injections to a concentration of 3.33 
mg/mL and subsequently diluted to a concentration of 0.77 mg/mL.
Dosage & duration
Adult patients receive a loading dose on day-1 of 200mg IV, followed by 100 mg daily 
thereafter.
Anidulafungin will be given for at least 7 days but no longer than 28 days. Please 
note that this refers to the MITT primary endpoint population. In patients in which 
triazole resistance is demonstrated or in which the results of the resistance test are 
inconclusive, the treatment duration of combination therapy can be much longer. These 
patients are not included in the MITT primary endpoint population.
Intervention
Treatment with a triazole (voriconazole or isavuconazole or posaconazole) + anidula-
fungin IV. The triazole is administered for at least 6 weeks while anidulafungin is given 
for at least 7 and a maximum of 28 days.
Comparator
Treatment with a triazole (voriconazole or isavuconazole or posaconazole) for at least 
6 weeks.
In both groups, the route of administration is according to the choice of the treating 
physician as well as the decision to perform or not perform therapeutic drug monitoring 
of the triazole drug.
5.2. Use of co-intervention (if applicable)
Not applicable
5.3. resistance testing
At the end of 2017, the Dutch SWAB guideline on the treatment of invasive fungal 
infections was updated. To take the increasing incidence of triazole resistance in the 
Netherlands into account, this guideline describes 2 preferred treatment strategies for 
patients with invasive aspergillosis. One strategy is to start with combination therapy 
(azole in combination with echinocandin or azole with liposomal amphotericin-B) until 
resistance test results become available. This is an option for critically ill patients or in 
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a setting where real-time resistance testing is not readily available. In a setting where 
real-time and state-of-the-art resistance testing is available, treatment with triazole 
monotherapy is recommended as an alternative strategy.
To allow for the treatment with triazole monotherapy in the Dutch patient population 
of this study, resistance testing will be done in all patients included in the Netherlands 
at the study site or at Erasmus MC if not part of the standard local diagnostic work-up. 
Furthermore, all Belgian sites in which triazole resistance testing is not the current 
standard of care, will be given the opportunity to send BAL samples to a central lab 
in Belgium (UZ Leuven or AZ Sint-Jan in Brugge) for real-time resistance testing free 
of charge. All participating centers will also receive the lab tools to perform in-house 
phenotypic resistance testing using VIPcheck™ free of charge (see below).
Resistance testing will be performed using a combination of phenotypic as well as 
genotypic resistance tests. Phenotypic resistance testing means that the fungus is 
cultured in the presence and absence of triazole drugs to observe suppression of growth 
in the presence of triazole drugs. It is currently certainly not the standard of care diag-
nostic procedure in all Belgian centers. Centers where this is not a standard procedure 
will receive the necessary tools to implement phenotypic resistance testing with the 
use of the VIPcheck™. This test was developed and validated by Radboud UMC.6,14 The 
VIPcheck™ is a test consisting out of a 4-well plate in which three of the four wells con-
tain agar supplemented with an azole (voriconazole, itraconazole and posaconazole) 
and the fourth functions as a growth control. If an Aspergillus strain grows in a well with 
an azole, it is very likely that this strain is azole-resistant. This test will be performed 
locally at the sites where this is the standard of care and the presence of resistance will 
be confirmed with the European Committee on Antibiotic Susceptibility Testing (EUCAST) 
method at the reference mycology lab of the Netherlands or Belgium (Radboud UMC and 
UZ Gasthuisberg Leuven). Sites that are currently not using the VIPcheck but are willing 
to use it can contact the study team to get the test sent to them. Genotypic resistance 
testing means that a PCR test is used to document the absence or presence of certain 
mutations in the DNA of the fungus that are known to result in phenotypic resistance. 
For this purpose, 1.5 to 2ml of the BAL sample of each patient will be submitted to the 
central lab to test for the presence of with the commercially available AsperGenius®. 
This PCR allows for the simultaneous detection of Aspergillus species and identification 
of the most common mutations circulating in Belgium and the Netherlands (TR34/L98H 
or TR46/T289A/Y121F) in the A. fumigatus Cyp51A gen by using melting curve analysis.
With this state-of-the-art diagnostic approach, it is safe to start with azole mono-
therapy for the treatment of invasive aspergillosis and the treating physician will not be 
tempted to change therapy from azole monotherapy to combination therapy because 
of fear for resistance.
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5.4. escape medication (if applicable)
Not applicable
6. inVestiGational ProDUcts
See also 5.1 and the SPC for more details on anidulafungin, the IP used in this study. 
Here we describe the findings from non-clinical and clinical studies on combination 
therapy with a triazole and an echinocandin as combination therapy for the treatment 
of IA.
6.1. Summary of findings from non-clinical studies concerning triazoles 
and echinocandins as combination therapy
Findings from non-clinical studies concerning the investigational products show a posi-
tive effect of combination therapy in the treatment of IA. A study by Kirkpatrick et al.15 in 
which the efficacy of caspofungin and voriconazole combination therapy was evaluated 
in an immunocompromized guinea pig model of IA, showed a reduced mortality in the 
combination group compared to the single therapy dosage. In the combination therapy 
the colony counts were reduced compared to those obtained with either Amfo B alone 
or voriconazole alone. Only combination therapy resulted in more sterile cultures of 
organs 96 h after completion of therapy than those achieved with the other therapeutic 
regimens examined in these experiments. The authors concluded that the combination 
therapy has relevant clinical importance and the need for further clinical studies to 
investigate the use of combination therapy for invasive aspergillosis. In a neutropenic 
rabbit model of invasive pulmonary aspergillosis, the combination of voriconazole and 
anidulafungin was superior to single agent therapy with respect to mean pulmonary 
fungal burden and survival, among other measures.16
6.2. Summary of findings from clinical studies regarding triazoles and 
echinocandins as combination therapy.
A non-randomized observational study by Singh et al., 200617, in which the efficacy of 
combination of voriconazole and caspofungin as primary therapy for invasive asper-
gillosis in solid organ transplant recipients was assessed, showed that the survival at 
90 days was 67,5% (27/40) in the combination group compared to 51% (24/47) in the 
L-AmB group, a difference that was not statistically significant. In transplants recipients 
with renal failure and in those with A. fumigatus infection, combination therapy was 
independently associated with an improved 90-day survival in multivariate analysis. 
This study has important limitations as the control group did not receive triazole mono-
therapy but rather liposomal amphotericin-B as they were treated in the years 1999 
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and 2002 when voriconazole was not yet available. The only randomized clinical trial 
in which triazole monotherapy was compared with triazole-echinocandin combination 
therapy is the study by Marr et al., 2015, in which the efficacy of voriconazole with or 
without anidulafungin for the treatment of IA in haematology patients was assessed.2 
Patients were 16 years or older, had an underlying hematologic malignancy and/or had 
undergone a hematopoietic cell transplantation and were diagnosed with probable or 
proven IA according to the EORTC/MSG criteria. Patients received either voriconazole 
and a placebo or voriconazole in combination with anidulafungin. The primary end point 
was all-cause mortality at 6 weeks after inclusion and one of the secondary endpoints 
was the 12-week overall mortality. 459 patients were enrolled and were randomly as-
signed to one of the treatment arms. The miTT population included 277 patients who 
had confirmed proven or probable IA by the end of the first study week; 135 patients 
received combination treatment and 142 received monotherapy. The median duration 
of combination treatment was 14 days (range, 1 to 29); the median duration of vori-
conazole treatment was 42 days (range, 1 to 48 days). The mortality at 6 weeks in the 
miTT population was 19.5% (26 of 135) for combination treatment and 27,8% (39 of 142) 
for monotherapy (with a difference of -8.2%; 95% CI, -,19.0 to 1.5; 2-sided P= 0.087). 
The mortality at 12 weeks was 29.3% (39 of 135) for the combination treatment and 
39.4% (55 of 142) for monotherapy (difference -10.1%; P=0.077). A post-hoc analysis 
of mortality in the patients with confirmed diagnosis of probable IA that was based 
on radiographic findings and galactomannan antigen positivity in serum or BAL was 
performed. All-cause mortality was 15,7% (17 of 108) in the combination therapy group 
compared with 27,3% (30 of 110) in the monotherapy group (p=0.037). These results 
were clearly promising and we agree that in real-life a diagnosis of IA in hematology 
patients is indeed very often based on the combination of a positive galactomannan 
and pulmonary abnormalities. However, formal conclusions on the value of combination 
therapy cannot be based on a post-hoc analysis from a single clinical trial. The authors 
concluded that though results do not provide a conclusive evidence of superiority they 
add to the support of combination therapy for IA.
6.3. Summary of findings from clinical studies regarding triazole 
monotherapy
Voriconazole, available as an oral and IV formulation has been the first-line standard 
of care therapy for patients with invasive aspergillosis since 2003. Indeed, in a pivotal 
randomized clinical trial in which voriconazole was compared with IV amphotericin-B 
deoxycholate, the overall 12-week survival was significantly higher in patients treated 
with voriconazole (71% versus58%).1
Isavuconazole, available in capsule and IV formulation, is another triazole registered 
for the treatment of IA. In the large randomized SECURE trial, 527 patients with inva-
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sive mold infection were randomized to receive either IV isavuconazole followed by IV 
or oral (PO) isavuconazole versus IV voriconazole followed by IV or PO voriconazole. 
The majority of patients in both groups had underlying hematologic malignancy (82% in 
the isavuconazole group versus 86% in the voriconazole group). The primary endpoint 
was all-cause mortality at 6 weeks. At 6 weeks, 19% of patients in the isavuconazole 
group died compared to 20% in the voriconazole group, a difference that did not meet 
statistical significance. Drug-related adverse events were significantly higher in the 
voriconazole group compared to the isavuconazole group (60% versus 42%, p < 0.001), 
and permanent drug discontinuation was lower in the isavuconazole group compared to 
the voriconazole group (8% versus 14%).18
Posaconazole, available as tablets and IV formulation, is approved for the use as 
prophylaxis against invasive fungal infections in patients with acute myeloid leukemie 
and GVHD. It’s in vitro activitity against Aspergillus species is comparable to isavuco-
nazole. A phase III study in which posaconazole is compared with voriconazole is fully 
enrolled and results are expected in the near future. In patients who cannot tolerate 
voriconazole and/or isavuconazole, posaconazole is used off-label for the treatment of 
IA and this is allowed in this trial if the treating physicians things that posaconazole is 
the best treatment option available for the patient.
6.4. Summary of known and potential risks and benefits
Anidulafungin has an excellent safety profile with reduced toxicities, compared to other 
licensed antifungal agents. Adverse events that were observed in clinical trials are 
described in the SPC.
6.5. Description and justification of route of administration and dosage
Anidulafungin will be used at the licensed dose of a 200mg IV loading dose on day 1 and 
100mg QD IV thereafter. No dose adjustment is needed in patients with renal or hepatic 
insufficiency of any grade.
6.6. Dosages, dosage modifications and method of administration
Triazoles
All patients will receive triazole therapy as per standard of care and this will be initi-
ated by the treating physician before the patient is included in the study. Therefore, 
the triazoles (voriconazole or isavuconazole or posaconazole) are not considered study 
drugs.
Voriconazole or isavuconazole or posaconazole will be dosed according to the SPC and 
according to the route of administration (IV or orally) that is preferred by the treating 
physician. However, the dose may be changed based on therapeutic drug monitoring 
levels according to the local standard of care.
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Anidulafungin:
Anidulafungin (Ecalta) is available as an intravenous formulation only. It will be used at 
the licensed dose of a 200mg loading dose on day 1 and 100mg QD thereafter. No dose 
adjustment is needed in patients with renal or hepatic insufficiency of any grade.
6.7. Preparation and labeling of investigational medicinal Product
The investigational product will be labeled at the Erasmus MC trial pharmacy according 
to the relevant good manufacturing practice (GMP) guidelines and with the use of a 
study label compliant with the Annex 13 EU directive. The investigational products will 
be shipped to the study sites after labeling and resupplies can be ordered at Erasmus 
MC.
6.8. Drug accountability
The pharmacy at the study site will carry out the drug accountability. Batch numbers 
of medication administered to the patients will be recorded in the patient files and 
CRF. The central pharmacy at Erasmus MC or at the local site will be responsible for 
the destruction of medication that is returned pursuant to the ICH/GCP Guidelines, 
local regulations and the investigator’s institutional policies. Clinical supplies will 
be received by a designated person at the study site, handled and stored safely and 
properly, and kept in a secured location to which only the investigator, a pharmacist or 
its designated assistant have access. Clinical supplies are dispensed in accordance with 
the protocol. The investigator is responsible for keeping accurate records of the clinical 
supplies, the amount dispensed to the ward and returned to the pharmacy by the ward 
as well as the disposition at the end of the study. The investigator can delegate this 
task to the hospital pharmacist. A stock of at least 25 vials of 100mg should be in place 
at the site as long as the study is open for inclusion. If the stock falls below 25 vials, 
the investigator or the hospital pharmacist will order a new stock of 25 vials, using the 
order form that will be provided by the Erasmus MC trial pharmacy unit at the time of 
the first delivery. Ordering more vials is possible after sending a request to the study 
team (duet.study@erasmusmc.nl)
7. metHoDs
Primary hypothesis
For the treatment of IA, combination therapy of voriconazole or isavuconazole or 
posaconazole with anidulafungin will improve the overall survival compared with vori-
conazole or isavuconazole or posaconazole monotherapy.
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7.1. study parameters/endpoints
7.1.1. Main study endpoint
Overall survival 42 days after the start of antifungal therapy in the MITT population
7.1.2. Secondary study endpoints
1. Overall aspergillus attributable mortality 12 weeks after the start of antifungal 
therapy(*).
2. Overall survival 12 weeks after the start of antifungal therapy in the MITT popula-
tion
3. Overall survival 6 weeks after the start of therapy in the subgroup of patients in the 
MITT population with a positive serum galactomannan test at baseline.
4. Overall survival 6 weeks after the start of therapy in the subgroup of non-ICU pa-
tients who fulfill the EORTC/MSG probable or proven definition (MITT population).
5. Overall survival 6 weeks after the start of therapy in the subgroup of non-ICU pa-
tients with an underlying haematological disease (MITT population)
6. Overall survival 6 weeks after the start of therapy in the subgroup of non-ICU pa-
tients without an underlying haematological disease (MITT population)
7. Overall survival 6 weeks after the start of therapy in patients that started with 
triazole monotherapy and in which triazole resistance is detected during follow-up 
(MITT population)
8. Overall survival 6 weeks after the start of therapy in patients that started with 
triazole-anidulafungin combination therapy and in which triazole resistance is de-
tected during follow-up (MITT population)
9. In the subgroup of patients with a positive serum galactomannan; Kinetics of serum 
galactomannan levels with combination versus monotherapy
10. Outcome of patients in which resistance testing was unsuccessful
11. Time to hospital discharge (in the MITT subgroup of patients admitted to the hospital 
at baseline)
12. Cost-effectivity of azole-anidulafungin combination therapy
(*) Aspergillus attributable mortality is defined according to Vidal G et al. (with some 
modifications) as one of the following22:
When selecting one of the 4 options below, please consider the immediate cause of 
death as the disease process, injury, or complication immediately preceding death.
IA is considered the cause of death (=IA attributable mortality)
1. IA was considered the cause of death when the immediate cause of death was due 
to this infection. Examples are neurological complications of an aspergillus infection 
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that disseminated to the brain, lung bleeding or respiratory insufficiency in a patient 
with pulmonary aspergillosis or
2. IA was judged to have played a major role if death would not have occurred had the 
patient not had IA, even though another condition was present that also contributed 
to death. Examples are toxicity, interactions and other side effects of antifungal 
treatment that played a major role in the cause of death. Another example is a 
pseudomonas bacteremia in a patient with a cavitating pulmonary aspergillosis in 
which the lungs are considered the most likely source of the bacteremia. 
IA contributed to the death of the patient: Mortality is not considered attributable 
to IA but rather contributable if IA or treatment of IA was defined as playing a minor 
role but probably not essential in explaining the patient’s death but arguably did play 
some role in the event. An example is a patient an aspergillus infection as well as severe 
uncontrolled gastrointestinal GVHD at the time of death
ia did not contribute nor cause the death of the patient
Mortality was classified as not related to IA if there was a clear other cause of death
Unknown
If insufficient data were present about the circumstances of the death of the patient
7.1.3. Pragmatic study design
We have tried to design the study in such a way that the prompt inclusion of patients is 
facilitated as much as possible.
1. Registration trials of new antifungal drugs typically only include patients that fulfill 
the strict lung CT radiology criteria (e.g. halo sign) as described in appendix 1. 
However, in real-life as much as 50% of the patients treated for invasive aspergillosis 
do not have these typical abnormalities but are treated on the basis of the presence 
of a host factor, a positive mycological test and a (non-typical) pulmonary infiltrate. 
The outcome of these patients is similar to those with the typical pulmonary infil-
trate.12 Therefore, we consider the exclusion of these patients undesirable in the 
context of a pragmatic trial.
2. Typically, patients that have received antifungal therapy for more than 48-96 hours 
at the time of inclusion are excluded from registration trials. Again, this leads to 
many patients being excluded from study participation. To avoid this, we will allow 
that patients at high risk of IA (patents with AML or grade II or higher GVHD) are 
included at the time the triazole antifungal therapy is initiated by the treating 
physician even when the mycological criterium is not yet met. These patients will 
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be followed until day 7 and will leave the study if at that time the mycological tests 
have turned out to be negative.
3. While the previous randomized study on the use of combination antifungal therapy 
for IA only included patients with an underlying haematological disease, there is no 
reason to believe that the hypothesis of improved survival with combination therapy 
only applies to these patients. Therefore, our study population will not be limited to 
this subgroup of patients.
4. Our study design has overall mortality as the primary endpoint and no compulsory 
follow-up CT scans are required.
5. Given the 100% objective primary endpoint we have decided not to use a double-
blind design. This will make the study logistics and therefore the inclusion of patients 
more straightforward. By offering state-of-the-art triazole resistance testing to all 
patients, the presence of triazole resistance is made very unlikely and therefore 
the treating physician can be reassured that the treatment given to patients in the 
control arm is a fully active treatment.
7.1.4. Definitions of the patient populations
ITT: All patients randomized as registered in the IVRS
mitt: All patients randomized as registered in the IVRS, in whom the positive mycological 
test was available at the time of randomization or became available within 8 days after 
randomization will be included in the MITT population unless resistance to voriconazole 
was documented by culture or PCR (VIPcheck or Aspergenius, see below). Because 
Dutch guidelines currently recommend initiating combination antifungal therapy if the 
presence of an azole resistant A. fumigatus infection cannot be excluded by PCR or 
culture, Dutch patients in whom the resistance PCR or culture turns out unsuccessful 
will be excluded from the MITT population as well. The antifungal therapy given to 
these patients will be decided upon by their treating physician (see also flowdiagram) .
icU population: Patients already admitted to the ICU at the time of the start of triazole 
antifungal therapy
7.2. randomisation, blinding and treatment allocation
This is a phase 3 non-blinded non-placebo controlled pragmatic trial. Randomization 
will be stratified according to the following 3 risk groups: Acute myeloid leukemia, 
graft-versus host disease and other.
Randomization and concealed allocation will be performed and guaranteed via ran-
domization using blocks of different length and with the use of a randomization module 
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in the eCRF (Alea). Subjects will be randomized to a 1:1 allocation into 2 treatment 
group: monotherapy versus combination therapy.
7.3. study procedures
The study procedures involve a screening visit and follow-up up to week 24 for overall 
mortality. Taking the pragmatic design into account, this means that a formal hospital 
visit is not required for the primary endpoint evaluation after the patient is discharge 
from the hospital. However, investigators and patients will be encouraged to facilitate 
the collection of additional data as described in appendix 2 as much as possible to 
allow for the evaluation of several secondary endpoints in a large study population. 
Because these data are part of routine medical registration procedures (e.g. use of 
blood products, hospital days, ICU days, use of medication, blood test results) this will 
not obstruct the analysis of these secondary endpoints.
All patients will be receiving triazole therapy as prescribed by their treating physi-
cian at the time of screening for study participation. Monitoring for treatment related 
adverse events will be performed as per standard of care during triazole antifungal 
therapy and typically includes liver enzyme monitoring at least once a week during the 
first weeks of therapy. Given the overall very good safety profile of anidulafungin and 
the fact that it can only be administered intravenously at the hospital, no additional 
safety evaluations are needed.
7.4. Withdrawal of individual subjects
Subjects can leave the study at any time for any reason if they wish to do so without 
any consequences. The investigator can decide to withdraw a subject from the study 
for urgent medical reasons. Patients leaving the study will receive treatment as deemed 
appropriate by their treating physician
After randomization, the following patients will leave the interventional part of the 
study, but clinical data will continue to be collected:
1. Patients in whom none of the mycological criteria as described in appendix 1 have 
become positive within 8 days after randomization. This may be as soon as 48hrs 
after (e.g. if serum and BAL galactomannan testing and fungal culture result is final 
48hrs after randomization).
2. Patients in the Netherlands in whom the resistance tests were unsuccessful (asper-
gillus culture remained negative and aspergillus PCR demonstrated the presence of 
A. fumigatus but the resistance PCR is unsuccessful) will receive further treatment 
according to the choice of the treating physician because guidelines recommend to 
treat these patients with an azole in combination with a second antifungal drug. If 
the patient was randomized to the anidulafungin arm, the option will be given to 
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continue anidulafungin for up to 4 weeks, but these patients will be excluded from 
the MITT population (see 7.1.4) The 24-week outcome of these patients will be reg-
istered. In Belgium, currently no guidelines are in place recommending combination 
therapy for this patient group. Therefore, this does not apply to Belgian patients. 
Please note that patients in whom the Aspergenius PCR documents the presence 
of an aspergillus spp. other than fumigatus will remain in the study and will be 
included in the MITT population. This specific conclusion will be drawn when the 
aspergillus spp. PCR is positive with a CT value of 35 or lower but the aspergillus 
fumigatus PCR is negative as this demonstrates the presence of a non-fumigatus 
aspergillus infection.
7.5. replacement of individual subjects after withdrawal
As anidulafungin has limited side-effects, a low percentage of withdrawal can be ex-
pected, and patients withdrawn from the study will not be replaced.
7.6. follow-up of subjects withdrawn from treatment
Patients withdrawn from the study will be followed for overall mortality only
7.7. Premature termination of the study
One interim futility analysis will be performed at the time when the 6-week survival of 
50% of the planned sample size of 474 evaluable patients (=237) has become available. 
If this interim analysis shows that the conditional power after further enrolment of the 
remaining study population of observing the anticipated 33% reduction in the incidence 
of the primary endpoint in favor of combination therapy is <10%, the study team (the 
PI’s from Erasmus MC, UZ Leuven and Radboud UMC, the study statistician, a delegate 
from KCE and from ZONMW and a patient representative) will meet to decide upon fur-
ther enrollment. This decision will not only take the conditional power into account but 
also the recruitment speed as well as the relative decrease in mortality observed with 
the intervention under study (e.g. it may still be useful to continue the study if a 50% 
rather than a 30% decrease in overall mortality is observed when the conditional power 
to demonstrate a 30% is <10% as a result of a lower than expected overall absolute 
mortality in the control arm).
8. safetY rePortinG
background regarding the safety reporting paragraph of this study.
According to the current Dutch SWAB guideline, combination therapy consisting of an 
azole and an echinocandin (e.g. anidulafungin, the IMP in this study) is one of the 
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treatment options for patients with IA. Another treatment option recommended in this 
guideline is azole monotherapy. In Belgium, azole monotherapy is the current standard 
of care. Combination therapy with voriconazole and anidulafungin has been studied in 
a preceding phase III study. In this study, the number of AE and SAE in the combination 
therapy arm was comparable to the azole monotherapy arm. Therefore, in this study 2 
treatment options with a well-established safety profile will be compared.
Many if not the majority of the patients in this study will be receiving intensive 
chemotherapy or suffer from graft-versus-host-disease and its related AEs (e.g. anemia, 
leuco -or thrombocytopenia, diarrhea, mucositis, nausea, vomiting, alopecia, fever, 
bacteremia, fatigue, headache, bacterial and viral infections infection.
The study described in this protocol was designed as a pragmatic trial of which the 
goal is to compare two treatment options in a setting that simulates the treatment of 
IA in real-life as much as possible. This will the extrapolation of the study results as 
straightforward as possible.
For the reasons mentioned above, we think that registering all (S)AE will not only be 
very time consuming because the average number of AE per patient is expected to be 
very high but will not increase patient safety. We therefore will not register AE but only 
SAE with the limitations mentioned below.
8.1. Definitions
Serious adverse event (SAE)
A serious adverse event is defined as any untoward medical occurrence or effect that 
at any dose:
¨	 Results in death
¨	 Is a life-threatening event (i.e. the patient was at immediate risk of death at the 
time the reaction was observed)
¨	 Requires hospitalization or prolongation of an existing hospitalization
¨	 Results in significant or persistent disability or incapacity
¨	 Is a congenital anomaly or birth defect
¨	 Is an important medical event (i.e. important adverse events that are not immedi-
ately life threatening or do not result in death or hospitalization but may jeopardize 
the patient or may require intervention to prevent one of the above characteristics/
consequences, including suspected transmission of infectious agents by a medicinal 
product).
Suspected unexpected serious adverse reaction (SUSAR)
A suspected unexpected serious adverse reaction is defined as all suspected Adverse 
Reactions (AR) which occur in the trial and that are both unexpected and serious.
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Suspected adverse reactions are those AEs of which a reasonable causal relationship 
to any dose administered of the investigational medicinal product and the event is 
suspected. Unexpected adverse reactions are adverse reactions, of which the nature, 
or severity, is not consistent with the applicable product information (e.g. Investigator’s 
Brochure for an unapproved IMP or Summary of Product Characteristics (SPC) for an 
authorized medicinal product).
Overdose
This refers to the administration of a quantity of a medicinal product given per admin-
istration or cumulatively, which is above the maximum recommended dose according 
to the authorised product information. Clinical judgement should always be applied.
Misuse
This refers to situations where the medicinal product is intentionally and inappropri-
ately used not in accordance with the terms of the marketing authorisation.
Abuse
This corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by harmful physical or psychological effects.
Occupational exposure
This refers to the exposure to a medicinal product, as a result of one’s professional or 
non-professional occupation. It does not include the exposure to one of the ingredients 
during the manufacturing process before the release as finished product.
Medication error
This is an unintended failure in the drug treatment process that leads to or has the 
potential to lead to harm to the patient.
In accordance to section 10, subsection 1, of the WMO, the investigator will inform 
the subjects and the reviewing accredited METC/IRB if anything occurs, on the basis of 
which it appears that the disadvantages of participation may be significantly greater 
than was foreseen in the research proposal. The study will be suspended pending fur-
ther review by the accredited METC/IRB, except insofar as suspension would jeopardize 
the subjects’ health. The investigator will take care that all subjects are kept informed.
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8.2. adverse event
8.2.1. Reporting of adverse events
Adverse events that do not fulfill the definition of Serious adverse Event will not be 
reported.
8.3. serious adverse events
8.3.1. Reporting of serious adverse events
Serious Adverse Events (SAEs) will be reported from the first administration of treat-
ment according to protocol until day 14 days after the last dose of the IMP or until the 
start of subsequent systemic therapy for the disease under study, if earlier.
Serious adverse events (including death) occurring after day 42 days should also be 
reported if considered at least possibly related to the investigational medicinal product 
by the investigator.
SAEs must be reported to HOVON Data Center within 3 days after the event was 
known to the investigator, using the SAE report form provided. This initial report should 
contain a minimum amount of information regarding the event, associated treatment 
and patient identification, as described in the detail in the instructions for the SAE 
report form. Complete detailed information should be provided in a follow-up report 
within a further 7 business days, if necessary.
The following events do not require to be reported as a serious adverse event:
¨	 Relapse/Progression of the disease under study. However, death or complications 
as a result of disease progression should be reported as serious adverse events if 
occurring within 14 days after last dose of study drug.
¨	 Hospitalization for protocol therapy administration. Hospitalization or prolonged 
hospitalization for a complication of therapy administration will be reported as a 
serious adverse event.
¨	 Hospitalization for diagnostic investigations (e.g., scans, endoscopy, sampling for 
laboratory tests, bone marrow sampling) that are not related to an adverse event. 
Hospitalization or prolonged hospitalization for a complication of such procedures 
remains a reportable serious adverse event.
¨	 Prolonged hospitalization for technical, practical, or social reasons, in absence of an 
adverse event.
¨	 Hospitalization for a procedure that was planned prior to study participation (i.e. 
prior to registration or randomization). This should be recorded in the source docu-
ments. Prolonged hospitalization for a complication of such procedures remains a 
reportable serious adverse event.
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8.3.2. Causality assessment of serious adverse events
The investigator will decide whether the serious adverse event is related to trial medi-
cation, i.e. any of the products from the protocol treatment schedule. The decision will 
be recorded on the serious adverse event report. The assessment of causality is made 
by the investigator using the following:
causality term assessment criteria*
certain ¨	 	Event or laboratory test abnormality, with plausible time relationship to 
drug intake
¨	 	Cannot be explained by disease or other drugs
¨	 	Response to withdrawal plausible (pharmacologically, pathologically)
¨	 	Event definitive pharmacologically or phenomenologically (i.e. an 
objective and specific medical disorder or a recognised pharmacological 
phenomenon)
¨	 	Rechallenge satisfactory, if necessary
Probable /likely ¨	 	Event or laboratory test abnormality, with reasonable time relationship to 
drug intake
¨	 	Unlikely to be attributed to disease or other drugs
¨	 	Response to withdrawal clinically reasonable
¨	 	Rechallenge not required
Possible ¨	 	Event or laboratory test abnormality, with reasonable time relationship to 
drug intake
¨	 	Could also be explained by disease or other drugs
¨	 	Information on drug withdrawal may be lacking or unclear
Unlikely ¨	 	Event or laboratory test abnormality, with a time to drug intake that 
makes a relationship improbable (but not impossible)
¨	 	Disease or other drugs provide plausible explanations
Conditional / Unclassified ¨	 	Event or laboratory test abnormality
¨	 	More data for proper assessment needed, or
¨	 	Additional data under examination
Unassessable / Unclassifiable ¨	 	Report suggesting an adverse reaction
¨	 	Cannot be judged because information is insufficient or contradictory
¨	 	Data cannot be supplemented or verified
8.3.3. Follow up of serious adverse events
All serious adverse events will be followed clinically until they are resolved or until 
a stable situation has been reached. Depending on the event, follow up may require 
additional tests or medical procedures as indicated, and/or referral to the general 
physician or a medical specialist.
Follow up information on SAEs should be reported monthly until recovery or until a 
stable situation has been reached. The final outcome of the SAE should be reported on 
a final SAE report.
8.3.4. Processing of serious adverse event reports
HOVON Data Center will forward all SAE reports within 24 hours of receipt to the prin-
cipal investigator.
230 Chapter 11
The HDC safety desk will evaluate if the SAE qualifies as a suspected unexpected 
serious adverse reaction (SUSAR).
The SmPC will be used as a reference document for expectedness assessment.
Where reporting of SAEs to the ethics committee is required by national laws or 
regulations or by the procedures of the ethics committee, HOVON Data Center will 
report those SAEs by means of a six-monthly SAE line listing.
8.4. reporting suspected Unexpected serious adverse reactions
The HDC Safety Desk, on behalf of the sponsor, will ensure the reporting of any SUSARs 
to the ethics committees (EC), the competent authorities (CA) and the investigators 
in compliance with applicable laws and regulations, and in accordance with any trial 
specific agreements between the sponsor and a co-sponsor.
Expedited reporting of SUSARs will occur no later than 15 days after HOVON Data 
Center had first knowledge of the serious adverse event. For fatal or life-threatening 
cases this will be no later than 7 days for a preliminary report, with another 8 days for 
a complete report.
The manner of SUSAR reporting will be in compliance with the procedures of the 
ethics committees and health authorities involved.
8.5. reporting special situations
Overdose, abuse, misuse, medication error or occupational exposure are special report-
ing situations and must be reported to HOVON Data Center immediately.
Please inform HOVON Data Center of these events within 3 days hours after the event 
was known to the investigator by email (hdc@erasmusmc.nl). Note that these special 
reporting situations in and of themselves are not AEs. If a special reporting situation 
results in an SAE, an SAE form should be completed and sent to HOVON Data Center 
(see section 12.3.1).
8.6. annual safety report
The annual safety report will be combined with the annual progress report (see chapter 
12.4).
In addition to the expedited reporting of SUSARs, the sponsor will submit, once a 
year throughout the clinical trial, a safety report to the accredited METC, competent 
authority, and competent authorities of the concerned Member States.
This safety report consists of:
-	 a list of all suspected (unexpected or expected) serious adverse reactions, along 
with an aggregated summary table of all reported serious adverse reactions, ordered 
by organ system, per study;
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-	 a report concerning the safety of the subjects, consisting of a complete safety 
analysis and an evaluation of the balance between the efficacy and the harmfulness 
of the medicine under investigation.
8.7. follow-up of adverse events
All SAEs will be followed until they have abated, or until a stable situation has been 
reached. Depending on the event, follow up may require additional tests or medical 
procedures as indicated, and/or referral to the general physician or a medical special-
ist.
SAEs need to be reported from the first administration of treatment according to 
protocol until day 14 days after the last dose of the IMP or until the start of subsequent 
systemic therapy for the disease under study, if earlier.
8.8. Data safety monitoring
No data safety monitoring board (DSMB) will be implemented because the investiga-
tional product has been very well tolerated in the phase II and III studies and a previous 
fase III trial did not show any increase in AE or SAE in the anidulafungin voriconazole 
combination arm compared with the voriconazole monotherapy arm.
9. statistical analYsis
9.1. Primary endpoint analysis
The primary endpoint is defined as all-cause mortality at 42 days (6 weeks) after ran-
domization. The MITT population is considered the main analysis population.
The relation between randomly allocated treatment and the incidence of the primary 
endpoint in the MITT population will be described by
• the total number of endpoint events by allocated treatment;
 ·	 	a crude, unadjusted odds ratio. Logistic regression analysis will be conducted, 
with randomly allocated treatment as independent predictor variable and the 
incidence of the primary endpoint as dependent outcome variable;
 ·	 	an adjusted odds ratio. A multivariable logistic regression analysis will be applied. 
The effect of randomly allocated treatment will be adjusted for age, pulmonary 
or (also) extrapulmonary disease, ICU admission, baseline serum galactomannan 
status, post allogeneic stem cell transplantation status, and acute or chronic 
GVHD for which patients are receiving systemic immunosuppressive therapy.
The adjusted odds ratio will be considered the key primary endpoint analysis
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The same analysis will be performed for secondary endpoints 2 to 6. The listed sub-
populations will be analyzed using simple and multivariable logistic regression (the 
adjustment factors - as far as applicable - are listed above). Since these analyses will 
be considered exploratory only and these endpoints are defined as secondary endpoints, 
no correction for multiple testing will be performed.
9.2. secondary endpoints analyses
The 1st secondary endpoint is defined as attributable mortality at 84 days (12 weeks) 
follow-up, which will be analyzed in the main analysis population. For this analysis, 
non-attributable mortality will be considered competing risk for attributable mortality
For the analysis of secondary endpoints 2 to 6 see 9.1.
Secondary endpoints 7 and 8 will be analysis using descriptive statistics (6- and 
12-week mortality with 95% confidence intervals). If the number of patients in the 2 
subgroups described in endpoint 6 and 7 are sufficiently large (ä25) we will compare the 
6 mortality of both groups using the Fisher-Exact test.
Regarding endpoint 9, several studies have studied the impact of galactomannan 
kinetics on outcome in patients with IA. Studies have shown a reasonable correlation 
between galactomannan kinetics in the weeks following the initiation of therapy and 
outcome21. However, several questions remain; What is the optimal timing of the 
follow-up galactomannan measurement? Is the rate of decline more informative than a 
simpler binary outcome (decline/no decline or decline with 0.5 OD units)? The statisti-
cal analysis plan for this endpoint will be written when the study is completed, and 
the number of galactomannan positive patients and the number of follow-up plasma 
samples is known.
Secondary endpoints 10 will be analysis using descriptive statistics (6 and 12-week 
mortality with 95% confidence intervals).
The 11th secondary endpoint is defined as the total duration of the hospital stay. The 
relation between randomly allocated treatment and this secondary endpoint will be 
analyzed using a Mann-Whitney U test.
9.3. multiplicity
There is only 1 primary endpoint and no interim analysis for efficacy will be performed. 
Therefore, the primary endpoint will be tested at the α=0.05 level (two-sided test).
9.4. missing data
Patients that are lost to follow-up after the start of study drugs will be considered 
treatment failures in the mITT analysis.
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9.5. sample size calculation
In the pivotal trial on voriconazole and anidulafungin combination therapy the mortality 
in the voriconazole control group was 28% 6 weeks after the start of therapy.2 This study 
only included patients with an underlying haematological disease. Furthermore, in a 
large pragmatic trial with fewer exclusion criteria and in which a small number of ICU 
patients will be included as well, we expect a somewhat higher mortality of 35%, We 
consider a 33% lower overall mortality with combination therapy (=from 35% to 23,33%) 
compared to monotherapy of clinical importance. This leads to a sample size of 237 
evaluable patients per group (=included in the mITT population as defined above) to 
show superiority of combination therapy compared with monotherapy with an alfa of 
0.05 and a power of 80%. Follow-up for the primary endpoint is 6 weeks after the start 
of antifungal therapy.
9.6. responsibility for data analysis
The coordinating investigator will be responsible for analyzing the study data.
9.7. monitoring
This trial is part of the HOVON site evaluation visit program. Site evaluation visits will 
be performed for HOVON trials to review the quality of the site and not specifically the 
quality of a certain trial. It will enable HOVON to collect quality data and facilitate 
improvement of the participating sites. Data cleaning or monitoring of the performance 
of specific trials is not the goal of the site evaluation visits. Site evaluation visits will be 
performed according to the site evaluation visit plan.
The HOVON site evaluation visit plan applies to sites in the Netherlands and Belgium 
only. Monitoring of the quality of trial conduct in participating sites from other countries 
will be organized by the coordinating investigator or co-sponsor. The frequency and 
content of the site visits in other countries will be at least equal to the specifications 
of the site evaluation visit plan and are described in a monitoring plan provided by 
HOVON.
Direct access to source documentation (medical records) must be allowed for the 
purpose of verifying that the data recorded in the CRF are consistent with the original 
source data. The sponsor expects that during site visits the relevant investigational staff 
will be available, the source documentation will be available, and a suitable environ-
ment will be provided for review of study-related documents.
9.8. Interim efficacy analysis
An interim efficacy analysis will not be performed. One interim futility analysis will be 
performed after the inclusion of 50% of the planned sample (see 7.7).
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10. cost-effectiVeness analYsis
The cost-effectivity of combination therapy compared with triazole monotherapy will 
be analyzed only if a statistical difference (p0.05 or lower) is observed for the primary 
endpoint or for secondary endpoint 2. The full statistical analysis plan for endpoint 
12 is therefore not yet complete but will be developed after the analysis of these 
endpoints has been completed and in collaboration with prof. dr. C. Uyl-de Groot of 
the institute of Medical Technology Assessment in Rotterdam (iMTA). The analysis will 
estimate if combination therapy is cost saving and if this is not the case the cost per 
quality adjusted life year of combination therapy compared to monotherapy will be 
calculated. For this, not only quality of life data, the (time to) death but also detailed 
data on each of the following clinical parameters that are associated with substantial 
increase in costs will be collected; Duration of hospital stay and number of days admit-
ted to the intensive care unit, blood products and antifungal drugs administered as well 
as enteral or parenteral nutrition given between baseline and week 12 of follow-up. 
For the quality of life data collection, the EuroQOL EQ5D-5L questionnaire will be used 
(including the proxy or telephone version if needed, appendix 5). Because the majority 
of the patients with IA in our study will consist of patients treated for AML with intensive 
chemotherapy and of patients that received an allogeneic stem cell transplantation, 
previously published utility scores from these patient populations will be used to cal-
culate the cost per quality adjusted life years gained (QALY) with combination therapy 
compared with monotherapy.19 Apart from quality of life data, we will collect data on 
loss of income up to 24 weeks after inclusion to allow for an analysis of cost-effectivity 
from the society perspective. For this purpose, a set of dedicated questionnaires will 
be used (appendix 5).
The study population will consist of 3 major study populations: Patients receiving 
chemotherapy for AML, patients with graft-versus-host-disease and other patients. If a 
significant treatment effect of the intervention is observed in one of these subgroups, 
an exploratory cost-effectiveness analysis will be done for this subgroup.
11. etHical consiDerations
11.1. regulation statement
The study will be performed in accordance with the protocol, the guidelines of Good 
Clinical Practice/ICH, which underwrites the principles of the Declaration of Helsinki, 
as most recently revised by the 64th WMA General Assembly, Fortaleza, Brazil, October 
2013.
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11.2. ethical committee approval
The study protocol will be formally submitted to the ethical committee of the Erasmus 
MC. The study will start after approval from the ethical committee has been obtained. 
The nature of the study and an outline of those investigative procedures, which might 
be in excess of their usual care, will be explained to the patients. They will be required 
to give their written informed consent before entering the study.
11.3. recruitment and consent
Patients will be recruited at study sites in the Netherlands and Belgium. It is the respon-
sibility of the investigators or the co-investigators to obtain written informed consent 
from each subject participating in this study, after adequate explanation of the aims, 
methods, anticipated, and potential hazards of the study.
Besides the specific information regarding the study, the following standard items are 
covered in the patient information form (Dutch: patiënten informatie formulier):
·	 Patient’s right to withdraw from the clinical study anytime without giving reasons 
and without any consequences for further medical treatment.
·	 The information that all study findings will be stored in a computer database and 
handled confidentially
·	 Patient names will be kept separate from research data and patients will be identifi-
able by subject number only.
·	 Information about the possibility of inspection of relevant parts of the hospital 
records by regulatory authorities. Inspection will only take place if a confidentiality 
agreement has been signed.
·	 The existence of patient insurance policy in case the patient will be harmed by 
participating in the study (using the study drug)
·	 All novel clinically relevant information that will become available during the study 
and is possibly important for the patient will be communicated to him/her by one of 
the investigators.
The signature of an investigator or co-investigator on the form will attest that the 
information in the consent form was accurately explained and understood. Thereafter 
the patient will sign after a period of reflection. If new safety information results in 
significant changes in the risk/benefit assessment, the consent form will be reviewed 
and updated after approval by the ethical committee. Then, all subjects (including 
those already being treated) will be informed of the new information, will be given a 
copy of the revised form and will be asked to give their consent to continue the study.
236 Chapter 11
11.4. Benefits and risks assessment
Anidulafungin has been registered and used in the Netherlands for the treatment of 
invasive candida infections for >10 years and is considered a very safe drug. Also, the 
safety of the combination of anidulafungin and voriconazole that the patients in the 
intervention group will receive has previously been demonstrated in a large randomiza-
tion clinical trial.2 The risks are therefore considered very low.
If the improved mortality with combination therapy that was observed in the study 
by Marr K et al. is confirmed in our study, the patients in the study as well as future 
patients may potentially benefit from this combination treatment.
Hepatic metabolism of anidulafungin has not been observed and anidulafungin is not 
a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 (CYP450) iso-
enzymes. It is therefore very unlikely that anidulafungin will have significant drug-drug 
interactions with concomitant medication taken by the patient.
As a result of the underlying disease as well as the chemotherapy, serious adverse 
events are very frequently observed in this patient population (e.g. bleeding, life 
threatening infections, death due to progression of the underlying disease). The study 
will comprise of 4 study visits and as most patients will be hospitalized at the start of 
therapy few of these will be additional hospital visits on top of the standard of care.
11.5. compensation for injury
Liability insurance sponsor/investigator
The sponsor has a liability insurance in place for the Dutch study sites in accordance 
with article 7, subsection 6 of the WMO.
The Belgian coordinating party has a liability insurance in place for the Belgian sites 
in accordance with Belgian legislation.
insurance for study participants
The Erasmus MC WMO insurance applies for all patients included in one of the Dutch 
study sites. The certificate can be found in appendix 4a.
The UZ Gasthuisberg insurance (also called the “no-fault aansprakelijkheidsverzeker-
ing”) applies for all patients included in one of the Belgian study sites. The certificate 
can be found in appendix 4b.
11.6. incentives
No incentive will be given.
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12. aDministratiVe asPects, monitorinG anD PUblication
12.1. Handling and storage of data and documents
Data will be handled confidential and if possible, anonymously. Where it is necessary to 
be able to trace data to an individual subject, a subject identification code list will be 
used to link the data to the subject. The code will not be based on the patient initials 
and birthdate. The key to the code will be safeguarded by the investigator. as the data 
and human material will be kept for a longer period of time. The handling of personal 
data will comply with the Belgian and Dutch Personal Data Protection Act (in Dutch: De 
Wet Bescherming Persoonsgegevens, Wbp).
Case record form (CRF)
All data of patients, including results from standard procedures during treatment, 
collected during the study will be recorded in Case Record Forms. The CRF must be 
completed fully and legibly. Corrections of possibly erroneous entries must be carried 
out in such a manner that the initial entry is not rendered illegible. Corrections should 
be written alongside or above the pertinent place with the date and initials. Correction 
fluid must not be used.
The investigators are responsible for the quality of the data recorded in the Case 
Record Forms (CRF). Where the investigators have not been responsible for completing 
the CRF, an additional signature from the co-investigator overseeing the data entry of 
the study must be obtained.
In the event that the investigators need to deviate from the protocol, the nature 
of and reasons for protocol deviation must be recorded in the hospital patient record 
and in the CRF. In nearly all cases it is desirable that the patient continues the study 
to allow the most informative intention-to-treat analysis; This does not mean that the 
treatment to which the patient was randomized needs to be continued. As illustrated by 
the flow diagram of the study (figure 1) there can be good reasons to change antifungal 
therapy after randomization. However, also for patients that go off study for the 3 
reasons mentioned in figure 1, a limited number of data will be collected in the CRF 
(e.g. antifungal therapy, survival)
Privacy rules
Patients will be identified in the CRF by their identification code. The investigators will 
keep a patient identification log, including sufficient information to link the hospital 
record and CRFs.
The subjects will be informed that the data will be stored electronically, that local 
regulations for the handling of computerized data will be followed as described in 
the written patient information / consent form and that identification of individual 
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patient data will only be possible for the investigators. Furthermore, the subjects will 
be informed about the possibility of inspections of relevant parts of the hospital records 
by health authorities. These officials will be identified and have signed a confidenti-
ality agreement. The data are processed and stored using dedicated GCP compliant 
electronic CRF (ALEA). From this database the data will be transferred to a statistical 
program for further analysis. Only data, with coded patient identity will be transferred 
to the statistician for analysis.
Data processing
After a visual plausibility check the CRF data will be entered in the computer and 
processed using dedicated GCP compliant electronic CRF (ALEA). When all data have 
been approved by the local investigator, the database will be locked for that site and 
the data can be transferred from the database to a statistical data file, with conversion 
in uniform data and formation of a master file for further analysis. The data will also 
be approved by the investigator and locked after approval at the time when a patient 
moves from one hospital to another
Data achieving
Patient identification log, hospital records, informed consent forms, case record forms 
and databases must be kept for at least 15 years after completing the study. If the 
investigators move or retire, they must nominate someone in writing to be responsible 
for record keeping. Archived data may be held on microfiche or electronic record, 
provided that a backup exists, and a hard copy can be obtained from it if required.
12.2. monitoring and Quality assurance
Please refer to our monitoring plan.
12.3. amendments
Amendments are changes made to the research after a favorable opinion by the ac-
credited METC/IRB has been given. All amendments will be notified to the METC/IRB 
that gave a favorable opinion.
A ‘substantial amendment’ is defined as an amendment to the terms of the METC/IRB 
application, or to the protocol or any other supporting documentation, that is likely to 
affect to a significant degree:
- the safety or physical or mental integrity of the subjects of the trial;
- the scientific value of the trial;
- the conduct or management of the trial; or
- the quality or safety of any intervention used in the trial.
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All substantial amendments will be notified to the METC/IRB and to the competent 
authority.
Non-substantial amendments will not be notified to the accredited METC/IRB and 
the competent authority but will be recorded and filed by the sponsor. Examples of 
non-substantial amendments are typing errors and administrative changes like changes 
in names, telephone numbers and other contact details of involved persons mentioned 
in the submitted study documentation.
12.4. annual progress report
The sponsor/investigator will submit a summary of the progress of the trial to the 
accredited METC/IRB once a year. Information will be provided on the date of inclusion 
of the first subject, numbers of subjects included and numbers of subjects that have 
completed the trial, serious adverse events/ serious adverse reactions, other problems, 
and amendments.
12.5. end of study report
The sponsor will notify the accredited METC/IRB and the competent authority of the 
end of the study within a period of 90 days. The end of the study is defined as the last 
patient’s last visit.
In case the study is ended prematurely, the sponsor will notify the accredited METC/
IRB and the competent authority within 15 days, including the reasons for the prema-
ture termination.
Within one year after the end of the study, the investigator/sponsor will submit a final 
study report with the results of the study, including any publications/abstracts of the 
study, to the accredited METC/IRB and the Competent Authority.
12.6. Public disclosure and publication policy
The sponsor is free to publicly disclose and publish all research data. Please refer to 
the contract between de sponsor and the subsidizing party for arrangements made 
concerning public disclose and publication of research data.
13. strUctUreD risK analYsis
13.1. Potential issues of concern
a. Level of knowledge about mechanism of action
While voriconazole and other azoles inhibit fungal cell membrane synthesis, the echi-
nocandins block production of 1,3-beta-D glucan, a key component of fungal cell walls. 
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Combination therapy with voriconazole and an echinocandin is an intriguing possibility 
given the different mechanisms of action of these two agents.
b. Previous exposure of human beings with the test product(s) and/or products 
with a similar biological mechanism
See SPCs submitted with this protocol
c. Can the primary or secondary mechanism be induced in animals and/or in ex-
vivo human cell material?
The purpose of this study is showing efficacy of combination therapy in patients with 
IA. In a neutropenic rabbit model of invasive pulmonary aspergillosis, the combination 
of voriconazole and anidulafungin was superior to single agent therapy with respect to 
mean pulmonary fungal burden and survival, among other measures.16
d. Selectivity of the mechanism to target tissue in animals and/or human beings
Voriconazole has been shown to be more selective for fungal cytochrome P-450 enzymes 
than for various mammalian cytochrome P-450 enzyme systems. Anidulafungin inhibits 
the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of many 
filamentous fungi and yeast. Beta (1,3)-D-glucan is not present in mammalian cells.
e. Analysis of potential effect
The potential positive effects of combination therapy are described in 6.1 and 6.2
f. Pharmacokinetic considerations
Pharmacokinetics of voriconazole/isavuconazole/isavuconazole and anidulafungin are 
well known and described in the SPCs submitted with this protocol. There are no drug-
drug interactions between both drugs.
g. Study population
Immunocompromised patients with a suspected, probable or proven IA as well as ICU 
patients admitted with influenza diagnosed with IA according to the in -and exclusion 
criteria in the protocol
h. Interaction with other products
Voriconazole and isavuconazole or posaconazole have no significant drug-drug interac-
tions with anidulafungin. Anidulafungin is not metabolized by the liver and is not renally 
excreted. Hepatic metabolism of anidulafungin has not been observed and anidulafungin 
is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 (CYP450) 
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isoenzymes. It is unlikely that anidulafungin will have clinically relevant effects on the 
metabolism of drugs metabolized by CYP450 isoenzymes.
Anidulafungin undergoes slow chemical degradation at physiologic temperature and 
pH to a ring-opened peptide that lacks antifungal activity. The in vitro degradation 
half-life of anidulafungin under physiologic conditions is about 24 hours. In vivo, the 
ring-opened product is subsequently converted to peptidic degradants and eliminated.
i.Predictability of effect
There are no predictable side-effects of anidulafungin therapy. The effect of combina-
tion therapy on the survival in patients with IA is currently not predictable as it has been 
studied in only 1 randomized clinical trial and this trial was inconclusive.
j. Can effects be managed?
Not applicable
13.2. synthesis
In conclusion, we think that in this study the potential benefits outweight the risks 
as the drug that is being used is a registered drug that has been used extensively 
worldwide, has an overall good safety profile and has no drug-drug interactions.
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figure 1. flow diagram
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aPPenDix 1: moDifieD eortc/msG consensUs Definitions for 
DiaGnosis of ProVen, Probable, Possible or sUsPecteD 
inVasiVe asPerGillosis.
Proven invasive aspergillosis
Histopathologic, cytopathologic, or direct microscopic examination of a needle aspi-
ration or biopsy specimen showing hyphal forms with evidence of associated tissue 
damage (either microscopically or as an infiltrate or lesion by imaging) in combination 
with a positive aspergillus PCR on the sample
or
Recovery of a mould by culture from a sample obtained by a sterile procedure from a 
normally sterile and clinically or radiologically abnormal site consistent with an infec-
tious disease process, excluding BAL, cranial sinus cavity, and urine.
Probable invasive aspergillosis
Defined by at least:
·	 One host factor (See below)
 anD
·	 One clinical criterion (See below)
 anD
·	 One mycological criterion (See below)
Possible invasive aspergillosis
Defined by at least:
·	 One host factor (See below)
 anD
·	 One clinical criterion (See below)
suspected invasive pulmonary aspergillosis
Please note that the EORTC/MSG classification does not include suspected invasive 
pulmonary aspergillosis in its classification
Defined by at least:
·	 One host factor (See below)
 anD
·	 A pulmonary infiltrate other than a nodule, halo sign, cavity or air-crescent sign
 anD
·	 One mycological criterion (See below)
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Host factors
1. Recent history of neutropenia (<0.5 x 109/L (<500 neutrophils/mm3) for >10 days) 
temporally related to the onset of fungal disease or ongoing neutropenia; Patients 
with a newly diagnosed AML can be considered to be neutropenic for at least 10 days 
and therefore fulfill this criterium also at the time of AML diagnosis.
2. Receipt of an allogeneic stem cell transplant;
3. Prolonged use of corticosteroids (excluding patients with ABPA) at an average mini-
mum dose of 0.3 mg/kg/day prednisone equivalent for >3 weeks;
4. Treatment with other recognized T-cell immune suppressants such as ciclosporin, 
TNF-α blockers, specific monoclonal antibodies (such as alemtuzumab), or nucleo-
side analogues during the past 90 days;
5. Inherited severe immunodeficiency (eg, chronic granulomatous disease, severe 
combined immunodeficiency).
clinical criteria
Must be consistent with the microbiological findings, if any, and must be temporally 
related to current episode. Every reasonable attempt should be made to exclude an 
alternative etiology.
1. Lower respiratory tract fungal disease
The presence of one of the following three signs on CT:
·	 Dense, well-circumscribed lesion with or without a halo sign;
·	 Air crescent sign;
·	 Cavity.
·	 For patients with a serum galactomannan value of 0.5 or higher or for patients with 
a BAL galactomannan of 1.0 or higher, the presence of any pulmonary infiltrate is 
considered sufficient evidence of lower respiratory tract fungal disease
2. Tracheobronchitis:
Tracheobronchial ulceration, nodule, pseudomembrane, plaque or eschar seen on 
bronchoscopy.
3. Sinonasal infection
Imaging showing sinusitis PLUS at least one of the following:
·	 Acute localized pain (including pain radiating to the eye);
·	 Nasal ulcer with black eschar;
·	 Extension from the paranasal sinus across bony barriers, including into the orbit.
4. CNS infection
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At least one of the following:
·	 Focal lesions on imaging;
·	 Meningeal enhancement on MRI or CT.
mYcoloGical criteria
1. Cytology, direct microscopy or culture:
·	 Sputum, BAL and bronchial brush samples demonstrating the presence of fungal 
elements either by recovery by culture of Aspergillus spp. or detection by cytology 
or
·	 direct microscopy of hyphal forms in combination with a positive aspergillus PCR on 
sputum, BAL or bronchial brush
·	 Sinus aspirate: recovery by culture of Aspergillus spp. from aspirate or the detection 
of hyphal forms by cytology or microscopy in combination with a positive aspergillus 
PCR on the aspirate.
·	 Skin ulcers, draining soft tissue lesions or fissure for which both a positive micros-
copy (hyphae) and positive Aspergillus culture are required.
2. Detection of galactomannan antigen or DNA of aspergillus defined as one of the 
following:
·	 Galactomannan antigen EIA (Platelia):
 1. Serum sample positive for galactomannan (0.5 or higher);
 2. BAL sample positive for galactomannan (1.0 or higher).
·	 PCR:
 1.  Positive Aspergeniusä spp. PCR on BAL fluid (cycle threshold 38 or lower) in 
combination with a galactomannan BAL OD value of 0.5-0.9 is considered a posi-
tive mycological criterium in this study
 2.  Positive Aspergillus spp. PCR on sputum, BAL or bronchial brush sample in com-
bination with hyphal forms detected by cytology or direct microscopy
NOTE: Positive aspergillus PCR results alone will NOT be considered sufficient mycologi-
cal evidence of invasive fungal disease.
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aPPenDix 2: Patient Visit scHeDUle
Sc
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(D
1)
D2
-6
D3 D5 D7 D8
-D
28
D1
4
D2
8
D4
2
D8
4
D1
68
D8
-2
8
Eligibility check(#) x x (#)
Informed consent x
Study drug administration(^) x x x (x) x
Medical history x
Serum sampling(*) x x x x x x
Patiënt details x
Register use of any antifungals x x x x x x
Register use of TPV or EN after baseline visit x x
Register use of any blood products administered after 
baseline visit
x x
Register hospital and ICU days from baseline to week 24 x x
Quality of life questionnaire x x x x
Loss of income questionnaire x x x
Neutropenic status x x x x x x
Survival status x x x x x x
Please note that few exceptions notwithstanding, screening and baseline visit will be 
done on the same day.
Gray columns indicate the days that a hospital visit is required: Although the large 
majority of the patients will be in the hospital during the first week of therapy some 
patients will be outpatients. Patients who are outpatients and are included in the study 
are required to visit the outpatient clinic for study drug administration up until day 7.
Please note that, except for the screening and baseline visit, none of the other visits 
require an additional patient visit to the hospital as all these data can be collected from 
the patient files and by contacting the patient or the general practitioner or relatives 
of the patient.
(^) For the patients randomized in the combination therapy group. The minimum dura-
tion of study drug treatment is 7 days. After day 7 and up until day 28 the investigator 
decides if the treatment needs to be continued for a maximum of 28 days.
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(#) For ICU patients the SOFA score should be recalculated if >24hrs pass between screen-
ing and baseline and patient excluded if SOFA has increased to >11 points.
(*) This should only be done if the patient is still in the hospital or visiting the outpatient 
clinic at these study dates. Please note that the day 14 and day 28 sampling can be 
done between day 11 and 17 and day 25 and 31 respectively (so day 14±3days and day 
29±3days). The standard operating procedure regarding serum sampling and storage of 
serum by the lab is described in appendix 6 in more detail.
TPV= total parenteral nutrition. EN= enteral nutrition.
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General summary and discussion
“Trust me, I know what I’m doing” (Sledge Hammer)
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introDUction
An invasive fungal disease (IFD) is a life-threatening infection that is almost exclusively 
diagnosed in immunocompromised hosts. The most common invasive mould infection is 
caused by Aspergillus species and is called invasive aspergillosis (IA). Patients with acute 
myeloid leukaemia who are treated with intensive chemotherapy and haematopoietic 
stem cell transplant recipients are at highest risk for IA. Incidence rates of IA vary 
substantially and depend on host and environmental factors but also on the modali-
ties of allogeneic stem cell transplantation recipients as well as the use of antifungal 
prophylaxis. Without prophylaxis the incidence of IA in these populations can be as high 
as 10-20% [1-3]. IA does not only lead to a higher overall mortality and morbidity but 
also to substantially higher medical costs [4]. The case fatality rate of IA is estimated to 
lie between 20-38% at 6 to 12 weeks after diagnosis, although considerable variation in 
incidence rates has been reported between populations [5]. Therefore, optimizing the 
management of IA is key to reduce the burden of this devastating complication in the 
immunocompromised host.
For more than 15 years, voriconazole, a drug of the triazole class, has been the 
recommended treatment for this life-threatening infection after a pivotal randomized 
trial showed an improved survival with voriconazole compared with amphotericin B 
deoxycholate. Nevertheless, the overall 6-week mortality is still unacceptably high at 
25-30% even under treatment with voriconazole, combined with improved diagnostic 
tests [6]. A troublesome emerging problem in patients with IA is the increasing inci-
dence of infections with triazole-resistant A. fumigatus. Although limited in numbers, 
case series have demonstrated that the overall mortality of patients infected with 
triazole-resistant A. fumigatus is very high (50-88%) [7, 8]. This thesis focuses on risk 
factors for and the diagnosis of invasive aspergillosis. Additionally, the management of 
azole-resistant aspergillosis is addressed. Below, I discuss the main findings of this thesis 
and conclude with the future perspectives that I envision.
DiaGnosis of inVasiVe asPerGillosis: tHe matter of a Dream 
team
Consensus definitions
When a diagnosis of IA is made, the strength of the diagnosis is often reported according 
to the revised definitions of the European Organization for Research and Treatment of 
Cancer/Mycosis Study Group (EORTC/MSG) [9]. As such, IA is categorized into proven, 
probable and possible IFD. A proven diagnosis requires histopathologic evidence of 
fungal invasion or a positive culture from a sterile body site or fluid (e.g. pleural fluid 
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or CSF). A diagnosis of probable IA is based on the presence of a combination of host 
factors, clinical features and a positive mycology test. A diagnosis of possible IA is 
made in the presence of host factors and clinical features but in the absence of/or 
with negative mycological criteria [10]. To fulfil mycological criteria, a positive direct 
test or indirect test is required. Direct mycological tests are the detection of typi-
cal fungal elements (e.g. septate hyphae with a 45° angle) or a culture positive for 
Aspergillus species. Indirect tests involve the detection of fungal antigens or cell wall 
constituents such as galactomannan antigen (GM) or beta-D-glucan [11]. Despite the 
fact that polymerase chain reaction (PCR) for the detection of Aspergillus in human 
specimens had been described more than two decades ago, the technique was not 
included in the 2008 EORTC/MSG consensus definitions due to the lack of standardisa-
tion [12]. Therefore, in 2006 the European Aspergillus initiative was founded (EAPCRI) 
to support an international platform for international standardisation. This has led to 
the incorporation of PCR in the most recent 2019 EORTC/MSG consensus definitions for 
diagnosing IFD [13]. Systematic reviews have concluded that Aspergillus PCR methods 
on BAL and blood provide a robust diagnostic test for the diagnosis of IA. An important 
and crucial step towards standardisation involves the use of a commercially available 
PCR like the aforementioned AsperGenius© quantitative PCR (qPCR). Although the 
clinical usefulness of this PCR is likely given the results of a retrospective study, large 
prospective multicentre studies on the real-life added value of this test are lacking [8, 
14]. The Azole-Resistance Management study is such a study and is described later in 
this discussion and in chapter 9.
lateral flow Device:
Galactomannan antigen detection and detection of Aspergillus DNA are labour inten-
sive diagnostic tests with a turnaround time of at least 24 but typically 72 hours as 
they are mostly performed in batches in 96-well plates once or twice weekly. A timely 
diagnosis of IA is essential and improves clinical outcome, highlighting the need of a 
simple and rapid Aspergillus test that does not need to be performed in batches and 
that can be performed at any time of the day, also in small microbiology labs [15]. A 
newly CE-marked later flow device (LFD) might be the first of such tests. It consists 
of a self-contained immunochromatographic assay using a mouse monoclonal antibody 
(JF5) for the detection of an extracellular glycoprotein released by Aspergillus dur-
ing active growth [16]. We assessed the performance of this CE-approved LFD in a 
large multicenter retrospective study on a cohort of haematology patients from four 
large haematology centres in Belgium and The Netherlands [17]. These patients had 
undergone a diagnostic bronchoscopy with bronchoalveolar lavage fluid (BAL) sampling 
(chapter 7). The study included 247 patients of whom 79 had a proven or probable 
IA following the EORTC/MSG criteria [18]. In the primary analysis, only EORTC/MSG 
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proven cases were considered as true positives and patients with BAL samples that were 
culture and galactomannan negative, served as negative controls. The LFD showed a 
good diagnostic performance in this patient population known to be at high risk for IA. 
The sensitivity and specificity were 0.82 and 0.86 for visual readout and 0.82 and 0.96 
respectively when a digital reader was used for the readout [17]. The LFD also showed an 
excellent negative predictive value of 0.98. However, the results should be interpreted 
with caution as proven cases are relatively rare and as always, the predictive value may 
differ substantially in populations with a different prevalence of IA. The EORTC/MSG 
criteria were used as a diagnostic reference but these criteria are subject to misclas-
sification and incorporation bias (BAL galactomannan is one of the mycological criteria 
for probable disease). Therefore, the performance of LFD was also evaluated using the 
EORTC/MSG definitions with exclusion of galactomannan as mycological criterion. In 
this evaluation, LFD has similar sensitivity compared to galactomannan (0.76 versus 
0.85, p=0.18) but was less specific (0.86 versus 0.96, p=0.005). This device can be used 
to diagnose but most importantly to exclude the disease with a high negative predictive 
value. This test can help in reducing the time to diagnosis of IA but will not replace 
GM, PCR or B,D-Glucan. First, it cannot be seen as an actual point-of-care test because 
hemorrhagic or viscous samples still need pretreatment with heating and the use of an 
EDTA-containing buffer. Second, in patients with a high pre-test probability, its sensitiv-
ity is too low to be used as a single diagnostic test. Nevertheless, we believe that this 
test has considerable value in combination with other indirect tests. IA can be excluded 
with almost 100% certainty when a BAL sample from a patient with a high pre-test 
probability for IA is triple negative (GM, PCR and LFD). In patients with a low pre-test 
probability, the use of 1 or 2 tests may suffice to rule out the diagnosis. As suggested 
by the title of this paragraph, the diagnosis of invasive aspergillosis is mostly made 
by circumstantial evidence and by combining different diagnostic tests. Therefore, a 
dream team is needed for the diagnosis of invasive aspergillosis.
Further prospective validation of the test is needed before more definite conclusions 
can be drawn. Very recently a second point-of-care test, the Aspergillus galactomannan 
lateral flow assay (LFA), was developed and CE-marked. It detects galactomannan and 
needs significantly less hands-on time in the lab to get to a result compared with the 
Platelia galactomannan test [19]. In a recent comparative multicentre study by Mercier 
et al [20], this LFA showed to be more sensitive and equally specific when compared to 
the LFD. Differences in sensitivity might be explained by the use of different targeted 
monoclonal antibodies and differences in pre-treatment steps in the lab as well as 
sample volume. Although the LFA has a higher sensitivity, the LFD is easier to perform 
because no pre-treatment steps are needed if the samples are non-viscous and not 
contaminated with blood.
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aZole-resistant asPerGillosis: to WorrY or not to WorrY?
the azole resistance management study: past, present, future
IA is mostly, but not exclusively, caused by Aspergillus fumigatus. Azole-resistant A. 
fumigatus strains are an emerging global problem and significantly complicate the man-
agement of this infection [21]. Azole-resistance can develop in patients after prolonged 
treatment with azoles, primarily in patients with chronic pulmonary aspergillosis [22]. 
More importantly and more frequently, azole-resistance has an environmental origin 
and is the consequence of agricultural use of fungicides of the same azole drug class 
[22-24]. Therefore, the large majority of patients diagnosed with an azole-resistant 
Aspergillus infection have never received previous triazole therapy [25]. Azole-
resistance is mostly caused by mutations in the Cyp51A gene that encodes for the 
lanosterol 14α-demethylase, the target enzyme for azoles. Two mutation combinations 
in this Cyp51A gene, the TR34/L98H and the TR46/T289A/Y121F pattern, account for 
more than 80% of the mutations conferring resistance in the Netherlands [26, 27]. The 
prevalence of azole-resistance rates vary substantially between geographic regions 
and between hospitals [21]. From a global perspective it is very remarkable that the 
highest prevalence of triazole resistance has been and continues to be documented 
in the Netherlands. It increased from 0% before the year 2000 to 5.3% in 2009, and 
further increased to a problematic prevalence of 15% in 2018 [7, 28]. In 2011, triazole 
resistance was observed in 5% of IA cases in Belgium as well. In 2017, researchers from 
the Erasme hospital in Brussels for the first time reported a prevalence rather similar to 
the Netherlands of 13% [29, 30]. Recently, it became apparent that this is not a unique 
problem limited to one hospital. Indeed, in 2019 the University Hospitals of Leuven, 
in which the largest number of patients with acute leukaemia is treated annually, de-
scribed a prevalence of voriconazole resistance of 17% in their culture-positive IA cases 
at the department of haematology [31].
Detection of azole-resistant aspergillosis is challenging for several reasons. First, a 
positive fungal culture is required to allow for the use of conventional phenotypic resis-
tance testing methods but in the majority of IA cases cultures remain negative. Second, 
phenotypic susceptibility testing according to internationally agreed methods is almost 
exclusively done in mycology reference labs and is time-consuming. Recently, the clini-
cal usefulness and relevance of PCR-based testing for the presence of Cyp51A mutations 
was demonstrated in a study that used a now commercially available multiplex qPCR: 
i.e. the AsperGenius© qPCR [8, 14]. Besides detecting the presence of Aspergillus DNA, 
this qPCR allows for the detection of the two most frequent resistance-associated 
mutations (TR34/L98H and TR46/T289A/Y121F). Chong and colleagues evaluated the 
diagnostic performance of this qPCR in a retrospective study showing a sensitivity and 
specificity of 89% and 89%, respectively, as compared with galactomannan and culture 
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results, which were used as the gold standard. In addition, this study showed that 
response to voriconazole therapy was poor, when given to patients infected with an 
azole-resistant A. fumigatus strain [8].
To obtain a reliable picture of the fungal infection management landscape in the 
Netherlands and in particular in the context of increasing triazole-resistance, we per-
formed a survey questioning the prophylactic, diagnostic and therapeutic strategies 
regarding invasive fungal diseases in all academic Dutch haematology centres (chapter 
2) [32]. Fungal prophylaxis during neutropenia was directed against Candida and in most 
centres consisted of fluconazole orally sometimes combined with oral amphotericin B 
suspension. Mould-active prophylaxis was given to acute myeloid leukaemia patients 
during chemotherapy in only 2 of the 8 centres. All centres used triazole prophylaxis in 
a subset of patients with graft-versus-host-disease. This survey showed that a uniform 
approach towards the diagnosis and in particular the treatment of invasive fungal dis-
ease in the context of an azole-resistance prevalence above 10% was lacking.
The results of the survey were processed, discussed and resulted in a protocol for a 
prospective multicentre study on the management of invasive fungal disease in haema-
tology patients (The AZOle Resistance MANagement study (AzoRMan), NCT03121235). In 
this study, a standard diagnostic and therapeutic protocol for IA was agreed upon to be 
used as a guideline for patients with an underlying haematological disease who present 
with a new pulmonary infiltrate and for whom the treating physician decides to order 
a diagnostic bronchoscopy. The study aims to demonstrate that the use of resistance 
testing by real-time PCR on BAL fluid from haematology patients with suspected IA will 
lead to a more rational and evidence-based management and an improved outcome for 
patients infected with an azole-resistant A. fumigatus. The use of PCR-based resistance 
testing is faster than culture-based methods and is more sensitive. Therefore, an earlier 
switch to appropriate non-azole therapy as soon as resistance is detected has become 
possible, hence potentially improving outcome. In addition, the AzoRMan-study aims to 
monitor the prevalence of IA due to A. fumigatus strains carrying the TR34/L98H and 
TR46/T289A/Y121F resistance-associated mutations in the Netherlands, in particular in 
culture-negative patients. Indeed, previous studies have based prevalence estimates 
on culture-positive cases of IA only and this may lead to a biased overestimation of 
the prevalence. Furthermore, the resistance rates that are now mostly reported are 
the result of a national surveillance program in which all cultures that are sent for 
antifungal susceptibility testing to the lab are used as denominator and the number of 
resistant cultures as numerator. The clinical relevance of these cultures is not always 
apparent, as it is a mixture of patients colonized with Aspergillus species rather than 
infected. (e.g. patients with structurally destroyed lungs, chronic pulmonary aspergil-
losis) and patients with invasive disease (ICU patients, patients with a haematological 
malignancy, solid organ transplant recipients, etc.). The overall incidence of azole-
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resistance in the entire population of patients diagnosed with IA is therefore not entirely 
clear. This multicentre prospective study started in 2017 and is currently running in 11 
haematology centres in the Netherlands and Belgium. In chapter 9 preliminary results 
from the AzoRMan study are presented. To the best our knowledge, this is the largest 
prospective study evaluating the value of real-time PCR diagnosis of azole-resistance. 
As of December 2019, 212 patients have been included in the study. Galactomannan was 
positive (optical density of 1.0 or higher) on BAL fluid in 24% of the patients with avail-
able GM result. The AsperGenius® species and fumigatus PCR was positive in 40% and 
29% of the patients, respectively. These numbers show that the majority of the patients 
with a haematological disease that undergo BAL sampling to confirm or rule out an IA, 
do not have this infection. Remarkably, in patients with a negative galactomannan on 
BAL, the Aspergillus species PCR was successful in 28% of patients. This shows that the 
best way to diagnose IA lies in the combination of different diagnostic assays, otherwise 
cases would have been missed. Real-time daily use of this qPCR facilitates the clinician 
in managing patients that otherwise would have been classified as possible IA.
At a recent international consensus meeting it was concluded that in geographical 
regions with a prevalence of triazole resistance of at least 10%, a switch from triazole 
monotherapy to L-AmB, or triazole and echinocandin should be strongly considered. 
Furthermore, every patient is at risk for azole-resistant aspergillosis in these regions 
because it is not the use of triazoles as prophylaxis or treatment but the inhalation of 
conidia from environmental Aspergillus fumigatus that became resistant through the 
exposure to triazoles in agriculture [33].
In chapter 3, we showed that inappropriate treatment of azole-resistant aspergillosis 
is associated with an increased overall mortality. A prevalence of azole resistance above 
10% has been documented for several years in the Netherlands. Therefore, the Dutch 
guideline on the treatment of IA was changed in 2017. The guideline now recommends 
combination antifungal therapy (azole and echinocandin or azole and L-AmB) as one 
of the treatment options for patients suspected of having IA until resistance has been 
ruled out by culture or molecular diagnostic methods. In the 47 patients in whom the 
resistance PCR was successful in the AzoRMan-study, the prevalence of CYP51A gene 
mutations was 8.5%. Resistance seems lower than anticipated but data are too pre-
liminary for definite conclusions to be drawn. Yet, treating all patients with non-azole 
antifungals like liposomal-amphotericin B comes at a cost of significantly more toxic-
ity and higher costs. Furthermore, treatment duration often takes months. One may 
argue whether combination antifungal therapy is actually necessary with an observed 
resistance in fewer than 10% of patients. Furthermore, the vast majority of patients in 
the AzoRMan-study did not have IA. Starting combination antifungal therapy in all these 
patients would lead to an excessive use of non-azole antifungals. The AzoRMan study 
clearly supports another approach in this guideline. This approach consists of starting 
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azole-monotherapy while waiting for rapid antifungal resistance testing by PCR and 
culture, and streamlining therapy to the test results accordingly.
Resistance testing will not lead to an interpretable result in approximately 35-50% 
of the patients with IA (chapter 9). Indeed, fungal cultures remain negative in the 
majority of the patients with IA and PCR testing for Cyp51A resistance associated muta-
tions is not always successful either. For this subgroup of patients, the SWAB guideline 
recommends to switch from triazole monotherapy to combination therapy as soon as it 
becomes clear that no resistance results will become available. The latter recommen-
dation has been criticized when it relates to patients that are in good clinical condition, 
and have a lung-restricted, non-disseminated infection. Indeed, in my opinion, close 
monitoring for disease progression is a valid option because the poor outcome of azole-
resistant IA has not (yet) been convincingly demonstrated for culture-negative cases if 
close radiological and clinical surveillance is done.
In only 47 of the 195 patients with available AsperGenius® PCR results, the resistance 
PCR was successful. Therefore, the sample size of the study population needs to be 
increased substantially in order to answer the primary research question. There remain 
some other urgent but open questions that cannot be answered at this point of time, 
but that will hopefully be answered when the AzoRMan-study will be fully enrolled. In 
particular, what is the outcome of patients in which this qPCR is used to guide antifungal 
therapy? Does the immediate switch from a triazole to another antifungal drug as soon 
as resistance is documented by PCR reduces the overall mortality compared to the high 
mortality described above? How reliable is a negative resistance PCR result in culture 
negative but galactomannan positive patients?
treatment modalities of azole-resistant aspergillosis
In the AzoRMan-study treatment with liposomal-amphotericin B (L-AmB) is advised 
when azole resistance is documented. This is supported by the fact that A. fumigatus 
strains are susceptible to L-AmB and is also advised by guidelines [33-35]. If a treatment 
response is observed during therapy with daily L-AmB 3 mg/kg, the study suggests two 
possible strategies of which the first is a switch to oral posaconazole in patients in 
which the posaconazole MIC of the A. fumigatus strain is below 2 mg/L and as long 
as posaconazole serum target trough level of 3-4mg/L can be achieved and tolerated. 
Aspergillus species carrying resistance-associated mutations often have MICs lower than 
2 mg/L for posaconazole. In vitro and animal data suggest that they can be treated with 
posaconazole with therapeutic drug monitoring to ensure that high serum trough levels 
are obtained [36]. The efficacy of this strategy was demonstrated in a pharmacodynamic 
study in mice with azole-resistant IA. This study showed that posaconazole retains 
activity against an A. fumigatus strain with a posaconazole MIC of 0.5 mg/L as long 
as serum levels are sufficiently high. Human data on this strategy were only reported 
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anecdotally. Therefore, we describe in chapter 4 the experience with the use of oral 
high-dose posaconazole as a treatment strategy in patients from two university hospi-
tals in the Netherlands who were infected with moulds with a posaconazole MIC close 
to the clinical breakpoint. In the study, sixteen patients were intentionally treated with 
high-dose posaconazole. Grade 3-4 adverse events (AE) were observed in 6 patients and 
all of them were considered at least possibly related. Furthermore, we describe the 
adverse events observed in 25 patients with posaconazole concentrations at the higher 
end of the population distribution during treatment with the conventional licensed 
posaconazole dose. In this group of patients with spontaneously high posaconazole 
serum trough levels, grade 3-4 adverse events were observed in 5 of the 25 patients 
that were considered at least possibly related. The frequency of these side effects may 
be compared to intravenous treatment with L-AmB, which is associated with significant 
side effects as well. Therefore, we consider high-dose posaconazole a valid treatment 
option if strict monitoring for both exposure and adverse events (ECG for QTc time, 
electrolyte, liver enzyme and blood pressure monitoring) is possible.
The second strategy that we suggest in the AzoRMan-study is a step-down from daily 
L-AmB at 3 mg/kg to intermittent dosing of L-AmB 5 mg/kg three times a week. The 
long terminal half-life of L-AmB suggests that intermittent dosing could be effective, 
and can make outpatient antifungal therapy (OPAT) possible. L-AmB has a relatively 
short elimination half-life of 7 hours shortly after initiation of therapy, which increases 
to over 100 hours after prolonged use [37]. In chapter 5, we report our experience with 
the use of OPAT for IFD. All adult patients treated with L-AmB at a two- or three-times 
weekly administration frequency via the outpatient departments of four academic 
tertiary care centres in the Netherlands and Belgium in a time frame of 8 years were in-
cluded in a retrospective cohort study [38]. In total, 18 patients were included and in 10 
patients (66%) azole-resistant IA was the indication. The most frequently used regimen 
(67%) was 5 mg/kg 3 times weekly. In 94% of the patients a partial response to the daily 
treatment was confirmed by CT-scan before a switch from daily to intermittent dosing 
of L-AmB was made. An overall favourable outcome was achieved in 13 (72%) patients. 
The most important side effect was a decrease in renal function occurring in 10 (56%) 
cases. This was reversible in all and was treatment limiting in only one patient. 100-day 
mortality and 1-year mortality after initiation of OPAT were 0% and 6%, respectively. In 
a selected population like patients with azole-resistant IA, and after confirmation of 
initial response to treatment, our data support the use of outpatient antifungal therapy 
(OPAT) with L-AmB for treatment of IFD in a 3 times weekly dosing scheme. This treat-
ment regimen of OPAT allows for a significant reduction in hospitalization duration and 
will therefore improve the patient’s quality of life and the societal costs of treatment. 
A possible caveat of the favourable results that we observed for posaconazole and OPAT 
L-AmB might be patient selection. On the other hand, it illustrates that the decision 
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to choose one of these strategies that was made by clinician was done appropriately 
and probably in patients with a relatively favourable prognosis with regard to their 
IFD. Also, the heterogeneity of both the patient population and the different dosing 
regimens that were used for L-AmB makes it difficult to draw any definite conclusions 
about dosing, efficacy and tolerability. It is at the discretion of the physician to make a 
decision to apply these treatment options balancing the advantages of oral treatment 
and outpatient management versus the disadvantages described above. There are no 
validated other treatment options for azole-resistant aspergillosis as step-down therapy 
for daily L-AmB administration. Therefore, these case series are a welcome set of data 
to guide clinicians tackling these difficult-to-treat mould infections.
outcome of azole-resistant aspergillosis
Case series indicate that IA caused by azole-resistant Aspergillus is associated with very 
high mortality rates of 50-88% [7, 8]. Until now, case series have included very few pa-
tients and preclude a reliable estimation of the impact of azole-resistance on mortality. 
Therefore, together with colleagues from Radboud UMC and Leiden UMC we performed 
a 5-year retrospective cohort study in order to compare the mortality between patients 
diagnosed with a voriconazole-susceptible and a voriconazole-resistant IA from 2011 
to 2015. This study is described in chapter 3 [39]. The clinical files of patients from 
which an Aspergillus fumigatus was cultured were investigated to identify patients with 
proven, probable and putative IA using the relevant classification definitions known 
as the EORTC/MSG or AspICU criteria [9, 10]. 196 patients with IA were eventually 
identified of which more than half had a haematological malignancy as the underlying 
disease. 37 of them (19%) harboured a voriconazole-resistant Aspergillus fumigatus 
strain. Mortality was higher in patients infected with a resistant compared to those 
with a voriconazole-susceptible strain: It was 21% and 25% higher at day 42 and 90 
after the start of antifungal therapy, respectively. Patients that were not admitted 
to the ICU at the time of diagnosis had a 19% lower overall survival at day 42 when 
voriconazole-resistance was documented. In this study, antifungal therapy was consid-
ered appropriate if voriconazole was started in patients with voriconazole-susceptible 
disease and inappropriate in those with voriconazole-resistant IA. Thirty patients with 
voriconazole-resistant IA inappropriately received initial therapy with voriconazole at 
the time of first diagnosis of the IA. Therapy was switched to appropriate therapy (L-
AmB) at a median of 10 days which illustrates the limitations of culture based resistance 
testing. Inappropriate initial therapy corresponded with reduced survival at day 42 
compared with appropriate therapy (53 and 76%, respectively). One may argue that 
culture-positive IA cases have a higher fungal burden compared to culture-negative 
cases and will therefore have a higher mortality. Furthermore, resistance rates can be 
different in culture-negative cases with IA. However, in a single-centre study, resistance 
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prevalence was studied using culture-based strategy and using PCR. No difference was 
found in resistance prevalence using both strategies (11.7% versus 10.5%) [30].
societal shortcomings and new kids on the block
While for good reasons a lot of attention, time and money has gone and continues to go 
to antibiotic stewardship programs, the problem of azole-resistance received much less 
attention. Even in the Netherlands, the global hot-spot of azole-resistant A. fumiga-
tus, the national institute for public health and environment (RIVM) has not taken a 
nationwide initiative so far in order to map the epidemiology of azole-resistance in the 
Netherlands, let alone to tackle the source of the problem, in particular agricultural 
azole use. Outside the Netherlands, the problem is even worse as in many countries no 
data on the prevalence of azole-resistant Aspergillus are available. In the United States, 
the majority of the infectious diseases physicians are not familiar with the concept of 
azole-resistant aspergillosis and susceptibility testing is far from current practice [40]. 
As azole resistance is driven by agricultural use of fungicides, it is high time that strate-
gies are developed to at least stop but preferentially reverse the continuous increase 
in prevalence of azole resistance. While the Netherlands is in the position to take the 
initiative to reduce the agricultural use of antifungals that are also used for the treat-
ment of human disease, European cooperation is most probably needed. Meanwhile, 
new antifungal agents are being developed and studied in phase I and II clinical trials. 
However, these agents will not become available within the next several years, and 
will be extremely expensive. Furthermore, they may only offer a temporary solution 
without legislation regarding their non-use in agriculture. One of the compounds of 
which the clinical evaluation has been proceeding steadily is F901318 that was recently 
given the name olorofim. This synthetic small molecule inhibits dihydroorotate dehy-
drogenase (DHOH), which catalyses the conversion of dihydroorotate to orotate in the 
pyrimidine biosynthesis pathway [41]. Given its different mode of action from azoles, it 
is also active against azole-resistant Aspergillus species. It is currently being tested in 
a worldwide phase II trial [42, 43].
cns azole-resistant aspergillosis
The most devastating form of IA is observed when the infection disseminates to the 
brain. Brain infections with Aspergillus have an extremely high mortality and all 
but few survivors are left with at least some neurological deficit [44]. Although the 
chances of survival have improved since voriconazole became available, the increas-
ing prevalence of voriconazole resistance adversely impacts survival. Very few cases 
of central nervous system (CNS) aspergillosis caused by azole-resistant Aspergillus 
fumigatus have been reported, and most had a fatal outcome [33]. These patients were 
treated with combination antifungal therapy. Given the dismal prognosis of cerebral 
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infections with azole-resistant A. fumigatus and the lack of antifungals with activity 
against azole-resistant A. fumigatus that adequately penetrate the brain, off-label use 
and/or uncommon routes of administration of antifungal agents may improve outcome. 
However, as cerebral infections with azole-resistant Aspergillus fumigatus are rare, 
large prospective studies are very difficult to perform. In chapter 6, we describe our 
experience with the use of intraventricular liposomal-amphotericin B (L-AmB) on top 
of systemic antifungal therapy in 3 patients. The patients were treated with L-AmB 1 
mg given via a ventricular drain or reservoir on a weekly basis. Based on a theoretical 
total CSF volume of approximately 100-150 mL, the administration of 1 mg of L-AmB 
would result in a peak CSF concentration of L-AmB of 10 µg/mL. In a recent publication, 
the use of intrathecal or intraventricular L-AmB at a higher dose (10 mg daily for seven 
consecutive days) was shown to be well tolerated in 18 patients with cryptococcal 
meningitis [45]. A weekly administration of 1 mg L-AmB may not be optimal given this 
recent observation, and given the clearance of L-AmB is substantial because 500 mL 
of CSF is produced and reabsorbed each day. We therefore suggest that a higher dose 
as well as a more frequent administration should be strongly considered for future 
patients with azole-resistant cerebral IA. Measuring liquor levels of L-AmB may guide 
dosing. Therefore, a dose of 5 mg twice weekly may be suggested for these patients. 
Case series, as described in chapter 6 have several limitations. In particular, all 3 
patients received systemic treatment as well. In particular, the exact contribution of 
the intraventricular L-AmB administration is unclear. However, it is impossible that 
large prospective clinical studies will ever be performed. Therefore, treatment should 
be based on both preclinical data and thoroughly evaluated case reports.
mixed infections
Mixed infections with azole-susceptible and azole-resistant strains of A. fumigatus have 
occasionally been described [46]. Until now, these cases of mixed infections had been 
documented by the demonstration of two different A. fumigatus strains with two dif-
ferent antifungal susceptibility profiles with conventional culture based methods [46]. 
However, the majority of cases of IA lack a positive culture. In chapter 8, we describe 
three patients infected with an azole-susceptible and azole-resistant A. fumigatus and 
in whom, for the first time, a mixed infection was demonstrated by cyp51A PCR amplicon 
melting curve analysis using the AsperGenius© assay. In these patients, wild-type and 
mutant cyp51A DNA from A. fumigatus was detected. In one case the mixed infection 
could be documented by culture as well by showing growth of an azole-susceptible and 
azole-resistant strain. In the two other patients, the cultures remained negative. With-
out the application of a molecular assay (AsperGenius© PCR), these mixed infections 
would have been missed [47]. Different Aspergillus isolates can be present within the 
same host. One of the isolates can become dominant and disseminate causing disease. 
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This study demonstrates that even when an azole-susceptible strain is cultured, the 
patients can still harbour an azole-resistant A. fumigatus isolate. Therefore, in azole-
resistant endemic regions we advocate that at least five and preferably all colonies 
that are cultured on the agar plate are phenotypically tested for the presence of 
azole-resistance. Importantly, molecular assays should always be used in combination 
with conventional susceptibility testing as they can only detect the mutations that are 
included in the assay and new mutations or resistance mechanisms may occur.
inflUenZa-associateD asPerGillosis: a noVel anD letHal 
UnDerestimateD entitY
For almost a century, influenza has been known to set up for bacterial superinfections, 
but recently patients with severe influenza admitted to ICU were also reported to 
develop invasive pulmonary aspergillosis [48, 49]. As these reports were almost exclu-
sively single centre-based and limited to a single influenza season, several important 
questions regarding the epidemiology of influenza-associated invasive aspergillosis 
(IAA) remained unanswered. Therefore, we aimed to measure the incidence of invasive 
pulmonary aspergillosis over several seasons in patients with influenza pneumonia 
in the intensive care unit (ICU) and to assess whether influenza was an independent 
risk factor for invasive pulmonary aspergillosis. We performed a large retrospective 
multicentre cohort study of adult patients admitted to the ICU with severe influenza in-
fection and acute respiratory failure. Data were collected in 7 ICUs across Belgium and 
The Netherlands. All patients had a confirmed influenza infection based on a positive 
airway PCR test. The aforementioned EORTC/MSG criteria are used to classify patients 
with a fungal infection in an immunocompromised host but are not applicable to the 
intensive care setting. Therefore, an algorithm (AspICU) was described by Blot et al. 
to distinguish invasive pulmonary aspergillosis from Aspergillus colonisation in patients 
who are critically ill [10]. However, the entry criterion for this algorithm is a positive 
culture of Aspergillus species and cannot be applied to determine the incidence of 
Aspergillus infection in this cohort of severe influenza patients because the majority 
of cases are culture-negative. We applied a modified definition of invasive aspergillosis 
using the AspICU algorithm and this definition was based on the presence of clinical, 
radiological, and mycological criteria (see chapter 10.1 for the full definition) [50]. 
This definition did not require an EORTC/MSG-defined host factor because otherwise 
non-immunocompromised patients with severe influenza would never fulfil the defini-
tion. The influenza patient cohort consisted of 457 patients of which 25 patients with 
Aspergillus colonization of the airways were excluded. These 25 patients had a positive 
Aspergillus culture from a lower respiratory tract sample but had a negative or unavail-
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able BAL culture or galactomannan test and were excluded because it was impossible to 
determine if these patients were colonized or had invasive disease. 83 of the remaining 
432 patients (19%) fulfilled the modified IA definition. Mortality was higher in patients 
with influenza-associated aspergillosis when compared to patients without Aspergillus 
superinfection, 45% versus 20%, respectively. Remarkably, one out of three patients 
who were immunocompromised according to the EORTC/MSG criteria had an Aspergillus 
superinfection and 71% of them died within 90 days after ICU admission [9, 51]. Our 
results are in line with smaller retrospective studies that have reported similar rates of 
IAA superinfection [52, 53]. A recent study have reported lower rates of IAA [54]. These 
differences might be explained by different diagnostic strategies or tests that are used 
(e.g. the application of galactomannan testing on BAL fluid, local awareness of the 
problem of IAA, or differences in still to be elucidated geographical or host factors). 
Furthermore, our study was mostly conducted in tertiary referral centres that may have 
led to the inclusion of a sicker population with more severe respiratory failure that is 
necessarily captured by the APACHE II score at admission.
Besides a higher APACHE II score and male sex, the third independent risk factor for 
the occurrence of Aspergillus superinfection that we observed in patients admitted 
to the ICU with influenza was corticosteroid therapy in the 4 weeks preceding ICU 
admission. A recent Cochrane systematic review concluded that the administration of 
corticosteroids to patients with influenza admitted to the ICU is associated with higher 
mortality [55]. Our data are in agreement with this review and although a randomized 
study on the use of corticosteroids in patients with severe influenza is lacking, the avail-
able data seem to argue against its use. Another important observation was that the 
diagnosis of IA was made shortly after admission (median of 3 days). The data preceding 
our study suggested that almost all cases of IAA were diagnosed in patients infected 
with the pandemic influenza A H1N1. A recent single-centre case study reported that 
influenza B could trigger Aspergillus superinfection as well [56]. We observed that the 
incidence of IAA in patients admitted to the ICU with influenza B is comparable to 
patients admitted with influenza A (chapter 10.1) [50].
To determine whether invasive aspergillosis is independently associated with in-
fluenza, we included a control cohort of patients admitted to the ICU with severe 
community-acquired pneumonia (CAP) and respiratory insufficiency, similar to patients 
with influenza. We excluded immunocompromised patients from this analysis to focus 
on the risk of influenza and bacterial pneumonia per se as a risk factor. 45 patients 
(14%) of the 315 non-immunocompromised influenza cohort were diagnosed with As-
pergillus superinfection compared to 16 (or 5%) of the 315 CAP patients in the control 
cohort. We performed a binary logistic regression analysis to assess whether influenza 
was independently associated with IA in the pooled cohort of non-immunocompromised 
influenza-positive and influenza-negative patients. This analysis showed that influenza 
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infection was independently associated with the development of invasive aspergillosis. 
By choosing patients with severe community-acquired pneumonia as a comparative 
group, we can only conclude that the presence of influenza is a risk factor for invasive 
aspergillosis compared with this control group. We considered this control group the 
most appropriate because, just like patients with influenza, respiratory failure was the 
primary reason of the ICU admission.
Little is known about the pathophysiology of influenza-associated aspergillosis. Re-
spiratory epithelium damage and mucociliary clearance dysfunction might facilitate 
invasion of Aspergillus [57]. Another explanation might be that influenza induces 
immunoparesis and also induces cytokine release that negatively impacts the innate 
and adaptive immune response [57]. Another bold explanation for the increasing rates 
of IAA might be the use of oseltamivir, a neuraminidase blocker that is administered 
in patients with influenza. In vitro research has shown that neuraminidase activity is 
important for Aspergillus immune responses. Treatment with oseltamivir, thus block-
ing host neuraminidase activity, might therefore increase susceptibility for Aspergillus 
infection [58]. In our cohort, 90 patients did not receive a neuraminidase inhibitor 
and 13 (14.5%) patients had IAA in this cohort. 338 patients received a neuraminidase 
inhibitor and 70 patients had IAA in this cohort (21%). This trend towards an increased 
incidence was not statistically significant (p=0.18) and needs further study before any 
conclusions can be drawn.
We performed a mortality analysis on our influenza cohort of 432 patients admitted to 
the ICU with influenza to evaluate whether or not the higher mortality of patients with 
influenza-associated aspergillosis in the ICU can be attributed to the Aspergillus super-
infection in se or if it is just a marker of overall disease severity (see chapter 10.2) 
[59]. We therefore performed a cox regression analysis showing that the emergence of 
IAA was independently associated with 90-day mortality. Although we acknowledge that 
observational data can never prove a causal relationship, the association of IAA and 
mortality was independent of confounders like severity of illness and being immuno-
compromised at ICU admission. This finding again confirms the relevance of diagnosing 
IAA in the ICU. In accordance with recent literature, corticosteroids exposition before 
ICU admission significantly impacted mortality as well, and strongly suggests that cau-
tion is needed regarding the use of adjuvant corticosteroid therapy for patients with 
severe pneumonia during the influenza season.
Our study clearly shows that invasive aspergillosis is a frequent and lethal complica-
tion in patients admitted to the ICU with influenza pneumonia. A large part of our 
patients with IAA cannot be classified using the current diagnostic criteria (EORTC/MSG 
and AspICU) [9, 51] because influenza is not considered a host factor in these criteria. 
In December 2019 updated EORTC/MSG consensus definitions of invasive fungal diseases 
were published [13]. Unfortunately, patients admitted to the ICU with influenza were 
General summary and discussion 267
12
not included in the newly defined host factors. Therefore, it seems that the current 
definitions are already outdated in this regard. Application of these criteria would lead 
to missed diagnosis. Unfortunately, in Belgium the EORTC/MSG criteria are used for 
reimbursement of antifungal drugs, although these criteria were never meant to be 
used by a clinician, let alone to base reimbursement policies of drugs on. They were 
developed to design clinical trials uniformly. In addition, autopsy series have shown that 
strict interpretation of host criteria contributes to missed diagnosis of IA, in particular 
in the ICU [60]. Restricting reimbursement of antifungal drugs to EORTC/MSG defined 
cases of IA should therefore be abandoned.
initiateD stUDies anD fUtUre Directions
azole-echinocandin combination therapy for invasive aspergillosis
Azoles block the synthesis of ergosterol, a part of the fungal membrane while antifungals 
from the echinocandin class block the synthesis of Beta-D glucan, a component of the 
cell. Both drugs may work synergistically as suggested in vitro studies and neutropenic 
animal models [61, 62]. These observations led to the performance of a clinical trial 
comparing the efficacy of voriconazole with or without anidulafungin, an echinocandin, 
in a population with haematological malignancy [63]. In this trial, 6-week mortality 
was 30% lower in the group treated with combination antifungal therapy (19.3%) ver-
sus monotherapy (27.5%) but this was not statistically significant (p=0.09). However, 
a difference in overall mortality of 30% would already be very important. This study 
had a 70% power for an unrealistic overall mortality decrease of 65% rather than 30%. 
Therefore, no conclusions can be drawn and combination therapy has not been adopted 
by current guidelines so far. In a post-hoc analysis of the 222 patients with radiographic 
abnormalities and a positive galactomannan antigen test, a statistically significant dif-
ference in mortality was observed (p=0.037). A second clinical trial is therefore needed 
to confirm these promising findings. In 2019, dr. B. Rijnders, drs. A. Schauwvlieghe 
and Prof. dr. J. Maertens submitted a study proposal to the first grant call by BeNeFit 
(Belgium-Netherlands Funding of International Trials) and a grant was awarded to imple-
ment such a clinical trial in 25 haematology centres in the Netherlands and Belgium. 
BeNeFit is a new collaboration between Belgium (KCE) and the Netherlands (ZonMW) 
in order to support large pragmatic intervention trials. Given the evidence in favour 
of voriconazole-echinocandin combination therapy as well as the increasing incidence 
of voriconazole-resistant A. fumigatus in Belgium and the Netherlands, a large clinical 
study on the value of combination therapy is needed. Furthermore, this trial will allow 
for a reliable measurement of the incidence of azole-resistant IA in the Netherlands and 
Belgium continuing the main research aim of the AzoRMan-study (chapter 9).
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The study is designed as a large pragmatic clinical trial to facilitate enrolment as 
much as possible. In particular, we want to leave the choice of the triazole (voricon-
azole or isavuconazole or posaconazole IV or oral) to the treating physician. This will 
not only lead to less patients being excluded but also allow the clinician to switch from 
one drug to another (within the same class) in case of treatment limiting toxicity. With 
the unbiased endpoint of overall 6 weeks mortality, we consider a pragmatic approach 
that allows for easy recruitment of a sufficient number of patients more important than 
the use of one specific drug within a class or the use of a placebo. Combination therapy 
will be discontinued after 28 days in all patients in which triazole susceptibility was 
documented but when a treatment response is observed before day 28, the echinocan-
din can be discontinued as from day 7. Phenotypic real-time resistance testing will be 
performed on side using the VIPcheckä test while genotypic resistance testing will be 
done in reference labs in both countries with the use of the AsperGenius® PCR [8, 64].
Some patients will be excluded after randomization: patients in whom resistance 
is shown by PCR or culture, patients in the Netherlands in whom resistance cannot 
be excluded (culture and PCR not successful) and patients included at the time when 
the diagnosis of IA was possible but not probable or proven and in whom an upgrade 
to probable or proven IA is not achieved within 7 days after the start of antifungal 
therapy. These patients cannot be seen as collateral damage. Data will be collected of 
these patients and this study will give better insight in the outcome of patients with 
azole-resistant aspergillosis. In addition, information will be available on patients with 
documented azole-resistance IA when treatment is started with azole monotherapy 
or combination therapy. Patients that are excluded because resistance testing did not 
give a result, will deliver interesting information on the treatment of IA cases in which 
no information on azole-resistant aspergillosis is available. This DUET-trial will open in 
2020 and will enroll patients in 25 centres in Belgium and The Netherlands and contacts 
are being made with centres in Scandinavia as well to allow for swift recruitment. 
Expected accrual time is 3 to 4 years. This study elegantly continues the work presented 
in this thesis by (1) measuring the incidence of azole-resistance in the lowlands, (2) 
hopefully improving the outcome of patients with IA and influenza and (3) evaluating 
the effect of combination antifungal therapy on outcome of azole-susceptible IA.
azole-resistant Pcr optimalization study on serum study (arPos)
BAL sampling is invasive, costly, labour intensive and not always feasible in haematology 
patients. Therefore, the validation of the AsperGenius® assay to easily obtainable serum 
samples would be very advantageous. A small single centre study, showed that the As-
perGenius® assay can detect Aspergillus DNA and azole resistance on DNA isolated from 
serum samples [65, 66]. However, successful amplification of regions associated with 
azole resistance from serum samples was achieved in only 50% of the patients. There-
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fore, the diagnostic use of an azole resistance PCR shows promise but the sensitivity 
is clearly suboptimal when small serum volumes (0.5 or 1ml) are used. In 2008, Suarez 
et al. showed that DNA extraction from large serum volumes improved the diagnostic 
yield of a serum Aspergillus PCR [67]. DNA extraction is a critical process to the success 
of most PCR amplification systems [68]. Therefore, we think that the detection of As-
pergillus DNA and resistance associated mutations on serum could be further enhanced 
by extracting DNA from relatively large serum sample volumes (3 or even 10 ml) and by 
using greater DNA template volumes (>10 µl). In 2017, we started a prospective study 
collecting large serum and plasma samples of patients with haematological disease on 
the day the patient undergoes BAL sampling to exclude invasive fungal disease. This 
study will therefore prospectively examine the performance of DNA extraction and PCR 
from large volume serum and plasma samples of patients with haematological disease 
suspect of having (resistant) IA. The results of the PCR performed on serum/plasma 
will be compared with the results obtained on BAL samples. The objective of the study 
is to determine the best medium for Aspergillus DNA extraction, to determine the 
best serum/plasma volume to generate the most sensitive and specific Aspergillus PCR 
results and to compare different (commercially) available Aspergillus species PCR’s.
Upfront chest ct: a screening tool for ia in patients with acute leukaemia?
Diagnosis of IA is not only dependent on biomarkers but imaging is an essential part of 
the diagnostic steps towards a timely diagnosis of IA in patients with haematological 
malignancy. Recently, a prospective cohort study was published that evaluated the value 
of a baseline chest CT scan in high-risk haemato-oncological patients. In 107 patients 
with AML, a baseline CT scan was performed within days after the diagnosis of IA was 
established. In this cohort, 20 patients were diagnosed with proven or probable IA at 
any time during hospitalisation for induction chemotherapy. Remarkably, half of these 
cases were diagnosed at admission preceding the start of chemotherapy [69]. Another 
study by Ceesay and colleagues prospectively evaluated baseline chest CT among 198 
high-risk haemato-oncologic patients and found that a pathological baseline chest CT 
and EORTC/MSG-compatible CT findings was associated with a hazard ratio of 2.52 
(95% confidence interval [CI] 1.27–5.03) and 4.67 (95% CI 2.04–10.75), respectively, for 
subsequent diagnosis of IA. The median time to diagnosis of IA was 14 days. Yet, the 
studied patient population was heterogeneous, consisting mainly of heavily pre-treated 
patients [70]. The main concern of many clinicians for applying a baseline CT scan to all 
patients receiving induction chemotherapy is that non-clinically relevant findings will 
lead to a substantial amount of unneeded diagnostic testing. This was confirmed by a 
retrospective cohort study. This study reported that about two thirds of patients with 
AML had atypical lesions on baseline chest CT performed before or on the day of induc-
tion chemotherapy initiation [71]. This might lead to many unnecessary bronchoscopies 
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being performed in patients that already have much to endure at the time of AML 
diagnosis. At Ghent University Hospital baseline chest CT is already common practice 
since 2012 in newly diagnosed AML patients. We are performing a retrospective cohort 
study to evaluate the value of baseline chest CT at admission.
Db-msG: new consortium for future research
In 2017 the Dutch-Belgian mycoses study group (DB-MSG) was founded following the 
many multicentre projects that have been performed in the past (www.DBMSG.nl). 
This study group allows easy networking and enables a closer partnership between 
Belgian and Dutch academic centres in order to tackle invasive fungal disease together. 
A large volume of precious biological material of blood and BAL samples is and will be 
available with the past and future studies performed by the DB-MSG (AzoRMan, ARPOS, 
DUET study as well as the PosaFlu studies that are and will be performed) allowing the 
validation of existing and new biomarkers. A possible biomarker could be new cytokines 
like IL-6 and IL-8. A recent study has shown that elevated levels of IL-6 and an IL-8 
in blood and BAL fluid at the time of bronchoscopy and rising levels in blood 4 days 
following bronchoscopy were predictive for mortality in patient with haematological 
malignancy undergoing bronchoscopy for suspected IFD [72]. Cytokines are involved 
in the protective immunity against Aspergillus species and might facilitate treatment 
stratification and may function as surrogate markers for disease status in the future. 
Another marker that could be studied in this cohort is the use of mass spectrometry to 
measure panfungal serum disaccharide [73]. The prospective validation of the useful-
ness of new lateral flow devices is another study that should be performed, in particular 
in patients other than those with haematological disease.
Many centres apply antimould prophylaxis for AML patients and for patients receiv-
ing an allogeneic stem cell transplant. Several upcoming anti-leukemia drugs that 
specifically target pathogenic mutations will be combined with the classic intensive 
chemotherapy regimen (3+7) for the treatment of patients with AML. This will make 
the universal administration of azole prophylaxis to AML patients in many haematology 
units challenging. Indeed, due to the fact that most of these targeted therapies are 
metabolized by CYP enzymes, caution should be taken regarding azole induced CYP450 
enzyme inhibition. The opinions about the value of a good diagnostic-driven approach 
compared with the use of universal azole antimould prophylaxis differ substantially. 
However, the superiority of one of both strategies has never been demonstrated conclu-
sively. An ideal approach would be to have a more individualized approach by detecting 
patients with the highest risk for an IFD. A possible approach would be by the detection 
of single nucleotide polymorphisms (SNPs) that are associated with an increased risk to 
develop IFD. By the detection of a SNP, a possible selection could be made for patients 
that are at highest risk and in whom anti-mould prophylaxis can be expected to be most 
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valuable. A possible SNP, that could help to detect these patients, is pentraxin 3 (PTX3) 
deficiency. A randomized trial is needed to demonstrate that the detection of these 
risk-markers can benefit patients.
conclUsion
Several studies were performed to improve our knowledge on the incidence, mortality, 
risk factors and diagnosis of IA. In chapter 3, we demonstrate that culture-positive 
azole-resistant IA is associated with a higher overall mortality. In chapter 2, we described 
that in hospitals in the Netherlands in the context of an ever-increasing prevalence of 
azole-resistance the management of IA is diverse. With the AzoRMan-study, described in 
chapter 9, we implemented a uniform diagnostic-driven approach towards patients with 
a suspected IA. This study in 11 hospitals will not only result in a better overall picture 
of the prevalence of triazole resistance in this patient population but also demonstrate 
the exact value of PCR-based resistance testing on BAL fluid of haematology patients. 
Preliminary results from this study show that the majority of patients with haemato-
logical disease that undergo broncho-alveolar lavage sampling do not have invasive 
aspergillosis. In the patients in whom the resistance PCR was successful, the prevalence 
of Cyp51A gene mutations was 8.5%. The sample size has to be increased substantially 
to answer the primary research question because only in 25% of patients the resistance 
PCR led to an interpretable result. In chapter 4 and 5, we describe our experience with 
different step-down treatment options for patients infected with an azole-resistant 
A. fumigatus after initial induction therapy with daily liposomal-amphotericin B. We 
showed that posaconazole can be used while targeting higher than normal serum 
levels as long as appropriate safety measures are taken into account. Another valu-
able option is the use of intravenous L-AmB as outpatient antifungal therapy when 
administered three times weekly. In chapter 6, we describe our experience with the 
use of intraventricular L-AmB as a last resort therapy for patients with cerebral IA. In 
chapter 7, we demonstrated that a CE-marked lateral flow device that was developed 
to be used as a rapid diagnostic test for IA, performed well compared with the current 
gold-standard. In chapter 8, we showed that mixed infections with azole-susceptible 
and azole-resistant Aspergillus fumigatus can be diagnosed with the AsperGenius© PCR. 
Finally, in chapter 10, we demonstrated that in patients admitted for respiratory insuf-
ficiency, an infection with influenza is an important risk factor for the development 
of IA. We also showed that IAA was independently associated with a higher mortality. 
Several new studies are enrolling patients or will do so in the near future (ARPOS, DUET 
studies). We hope that they will improve the management and eventually outcome of 
patients with an invasive fungal infection.
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introDUctie
Jaarlijks sterven nagenoeg 1.5 miljoen mensen aan invasieve schimmelinfecties, ver-
oorzaakt door gisten of draadvormige schimmels. Een voorbeeld van een gist is candida. 
De belangrijkste vertegenwoordiger van de draadvormige schimmel is Aspergillus. Bij 
patiënten met een sterk verminderde afweer kan de Aspergillus schimmel een gevaar-
lijke invasieve infectie veroorzaken. We noemen deze ziekte invasieve aspergillose. Een 
verminderde afweer kan het gevolg zijn van het gebruik van afweer onderdrukkende 
medicijnen. Die medicijnen worden gebruikt om afstoting te voorkomen na stamcel- of 
orgaantransplantatie. Invasieve aspergillose kan ook optreden naar aanleiding van een 
tekort aan witte bloedcellen, zoals dat bijvoorbeeld veroorzaakt kan zijn door chemo-
therapie. Jammer genoeg zien we het aantal patiënten met invasieve aspergillose de 
laatste decennia sterk stijgen. Patiënten die langdurige immuunsysteem-onderdrukken-
de medicijnen nemen, leven dankzij de vooruitgang van de geneeskunde langer dan 
voorheen. Daardoor lopen ze ook meer risico om bepaalde “opportunistische” infecties 
op te lopen.
Er zijn verschillende soorten Aspergillus. Meestal wordt invasieve aspergillose ver-
oorzaakt door de Aspergillus fumigatus variant. Aspergillus fumigatus komt vaak voor 
in het milieu en verspreidt zich als “spore” door de lucht. Deze spore kan worden in-
geademd. Bij mensen met een goede afweer wordt deze schimmel snel opgeruimd. Bij 
sterk verminderde afweer kan de schimmel beginnen woekeren en schade berokkenen. 
Deze infectie begint dan ook meestal in de longen. Een schimmelinfectie in de longen 
veroorzaakt koorts, hoesten, pijn bij de ademhaling en kortademigheid. Soms is het 
moeilijk te bewijzen dat een patiënt een infectie met deze schimmel heeft opgelopen. 
Het stellen van de diagnose gebeurt aan de hand van specifieke criteria, opgesteld 
zijn door experten. Deze criteria worden de gereviseerde criteria van de European 
Organization for Research and Treatment of Cancer / Invasive Infectious Diseases Study 
Mycoses Group (EORTC/MSG)” genoemd. Een schimmelinfectie, of het vermoeden van 
een schimmelinfectie omschrijft men met de termen “proven” of bewezen, “probable” 
of waarschijnlijk en “possible” of mogelijk.
Men spreekt van een bewezen schimmelinfectie als er tekenen daarvan gevonden 
worden in een weefselbiopt (dit is een stukje weefselmateriaal van de patiënt, dat 
meestal na aanprikken of wegname van een verdacht letsel wordt verkregen) of als 
de schimmel kan gekweekt worden uit steriel bekomen lichaamsmateriaal. Het nemen 
van een biopt is vaak niet mogelijk omdat de patiënt te ziek is en de kans op mogelijke 
complicaties, zoals het prikken van een klaplong of het optreden van een ernstige 
nabloeding, te groot is. Daarom is de diagnose bijna altijd een waarschijnlijke of mo-
gelijke schimmelinfectie.
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Om die diagnose te stellen, moet aan drie voorwaarden zijn voldaan: ten eerste moet 
er sprake zijn van een vatbare patiënt ten gevolge van een onderdrukt immuunsysteem, 
zoals na een stamceltransplantatie of bij acute leukemie. Ten tweede moet voldaan 
zijn aan het klinisch criterium: beeldvorming, zoals CT-scan, moet het typisch teken 
van schimmelinfectie vertonen, met name een nodule (of knobbeltje) met daarrond 
een halo-teken. Ten derde moet er ook microbiologisch bewijs zijn: een positieve 
kweek met Aspergillus op een niet steriele manier bekomen, zoals door kweek op slijm, 
afkomstig van de bovenste of onderste luchtwegen. Helaas zijn de meeste invasieve 
aspergillosen zeer moeilijk te kweken en moet het bewijs vaak op een andere manier 
worden aangeleverd. Dit kan door diagnostische testen die indirect bewijs leveren 
voor de aanwezigheid van een schimmelinfectie of door het aantonen van antistoffen 
tegen een deel van de celmembraan van Aspergillus, zoals tegen het suikerbestand-
deel galactomannan, of tegen Bèta2-D-glucan. Vaak zijn patiënten niet in staat om het 
vereiste slijm op te hoesten, waardoor het nodige materiaal diep in de long dient te 
worden verzameld door middel van longspoeling, ook “broncho-alveolaire lavage” (BAL) 
genoemd. Een longspoeling gebeurt aan de hand van een bronchoscopie (endoscopie in 
de longen). Het longspoelvocht of “BAL-vocht” wordt verder onderzocht voor kweek 
en er wordt nagegaan of er schimmelmateriaal in het vocht kan worden gevonden. Dit 
schimmelmateriaal kan een deel van de celmembraan zijn of genetisch materiaal van 
de schimmel.
aZole-resistente asPerGillose
Invasieve aspergillose moet snel behandeld worden met een antischimmel medicijn. 
Er zijn vier klassen antischimmelmedicijnen: azoles, echinocandines, polyenen en 
fluorpyrimidines. Al meer dan 15 jaar bestaat de voorkeursbehandeling uit de klasse 
van de azoles: voriconazole of isavuconazole. Ondanks deze behandeling overlijden nog 
steeds 20 tot 30% van de patiënten binnen de 12 weken na de diagnose. Bovendien is er 
in Nederland, maar recenter ook in België, meer en meer sprake van resistentie tegen 
de antischimmelmedicijnen uit de klasse azoles zoals voriconazole. Daarmee wordt 
bedoeld dat de Aspergillus minder gevoelig of zelfs ongevoelig is voor de behandeling. 
Resistentie wordt soms vastgesteld bij patiënten die langdurig behandeld worden met 
antischimmelmedicijnen. Anderzijds wordt aangenomen dat het gebruik van antischim-
melmiddelen in de landbouw de belangrijkste oorzaak is van resistentie. De aangewende 
antischimmelmiddelen in de landbouw lijken zeer goed op de antischimmelmedicijnen 
die gebruikt worden om patiënten met invasieve aspergillose te behandelen. Schimmels 
wapenen zich door hun genetisch materiaal aan te passen, wat hen toelaat toch te 
groeien wanneer ze worden blootgesteld aan deze schimmelmedicijnen. Het inademen 
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van een spore van een azole-resistente schimmel kan leiden tot een azole-resistente 
invasieve schimmelinfectie.
Uit een aantal studies is gebleken dat patiënten, geïnfecteerd met azole-resistente 
aspergillose, in 50 tot 88% van de gevallen overlijden. Het aantal patiënten beschreven 
in deze studies is echter zeer beperkt, waardoor het moeilijk is om daaruit relevante 
conclusies te trekken. Om te onderzoeken of het vinden van een azole-resistente schim-
mel gepaard gaat met een hogere kans op overlijden, hebben we in hoofdstuk 3 twee 
groepen patiënten vergeleken met invasieve aspergillose en positieve kweek. Een lijst 
van patiënten werd bekomen uit 3 ziekenhuizen in Nederland. Deze patiënten werden 
behandeld tussen 2011 en 2015. De gegevens uit het medische dossier van deze patiën-
ten werden anoniem verwerkt en opgedeeld in twee groepen. De eerste groep bevat de 
patiënten met invasieve aspergillose gevoelig aan azolen. De tweede groep bestaat uit 
patiënten met azole-resistente invasieve aspergillose. In totaal werden gegevens van 
196 patiënten onderzocht waarvan 159 patiënten in groep 1 en 37 patiënten in groep 
2. Uit deze studie bleek dat, 3 maanden na het starten van antischimmelmedicijnen, 
62% van patiënten met azole-resistente invasieve aspergillose (groep 2) overleden 
waren. Dit percentage was veel hoger dan in de groep patiënten met azole-gevoelige 
aspergillose. In die groep was 3 maanden na het starten van de behandeling 37% van de 
patiënten niet meer in leven. Met andere woorden: de kans op overlijden is 25% hoger 
wanneer de verantwoordelijke aspergillus schimmel azole-resistent is. Dit is de grootste 
studie tot dusver die klaar en duidelijk aantoont dat, wanneer een patiënt geïnfecteerd 
is met een azole-resistente Aspergillus fumigatus, de prognose van de patiënt veel 
slechter is.
Jammer genoeg is resistentie van Aspergillus voor azole het hoogst in Nederland en 
blijkt dit nu ook in België toe te nemen. Recent werd in Nederland een nieuwe test 
ontwikkeld waarmee op een snellere manier zowel de aanwezigheid van Aspergillus als 
de gevoeligheid van deze schimmel voor de courant gebruikte “azole” antischimmel 
medicijnen (voriconazole, posaconazole, itraconazole) kan worden opgespoord in de 
vloeistof van het longonderzoek. Door deze test, kunnen we snel nagaan of er sprake is 
van een azole-resistente schimmel.
Om het probleem van azole-resistente aspergillose aan te pakken, hebben we in 
de zomer van 2016 een bijeenkomst georganiseerd met vertegenwoordiging uit alle 
universitaire centra in Nederland, waarbij een microbioloog, hematoloog en infecti-
oloog betrokken waren. Daarvoor hebben we als uitgangspunt naar elk centrum een 
enquête gestuurd met de bedoeling te inventariseren hoe invasieve aspergillose in het 
betrokken centrum wordt behandeld. De verschillen werden samengevat en er werd 
een gemeenschappelijk behandelplan afgesproken. De enquête is samengevat in hoofd-
stuk 2 en toonde aan dat er best wat verschillen zijn in de manier waarop invasieve 
aspergillose in de Nederlandse academische centra wordt behandeld. Het principe van 
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dit behandelplan proberen we in de volgende alinea kort samen te vatten zonder al te 
veel in detail te treden.
Bij vermoeden van invasieve schimmelinfectie bij patiënten met onderliggende 
bloedkanker, zoals leukemie, wordt een longspoeling of een broncho-aveolaire lavage 
(BAL) verricht in een poging microbiologisch bewijs te vinden voor invasieve schimmel-
infectie. Na de longspoeling wordt de behandeling gestart met een azole (voriconazole, 
posaconazole of isavuconazole). Het longspoelsel wordt ondertussen onderzocht op ge-
netisch materiaal van Aspergillus fumigatus. Als genetisch materiaal van de schimmel 
wordt gedetecteerd, wordt nagegaan of er bepaalde mutaties aanwezig zijn waarvan 
we weten dat ze gevonden worden bij azole-resistente Aspergillus schimmel. Als er 
resistentie wordt vastgesteld, hetzij door kweek, hetzij door deze genetische test op 
schimmel DNA, dan wordt de behandeling gewijzigd naar een ander schimmelmedicijn 
uit de klasse polyenen, met name liposomaal-amfotericine B. Volgens een internationaal 
expertenpanel kan je azole-resistente aspergillose enkel met dit medicijn behandelen.
Dit behandelplan wordt geëvalueerd in de Azole-Resistance MANagement Study 
(AzoRMan-study) in de hoop de overleving van patiënten met azole-resistente aspergil-
lose te verbeteren door azole-resistentie sneller vast te stellen en snel de correcte 
behandeling te starten. Deze studie laat ook toe in te schatten hoe vaak een patiënt 
geïnfecteerd is met een invasieve aspergillose die azole-resistent is. In december 2019, 
zijn er ruim 200 patiënten geïncludeerd in de studie. De tussentijdse resultaten zijn 
te lezen in hoofdstuk 9. Tot dusver is er bij minder dan de helft van de patiënten 
microbiologisch bewijs van invasieve aspergillose te vinden. Tot op heden zijn er bij 4 
patiënten (2%) tekenen van azole-resistente aspergillose gevonden. Dat betekent dat 
ongeveer 8.5% van alle patiënten met invasieve aspergillose geïnfecteerd is met een 
azole-resistente Aspergillus stam. De genetische test die resistentie opspoort, is helaas 
niet altijd succesvol. Het zal nog even duren tot deze studie klaar is en er definitieve 
conclusies kunnen getrokken worden.
Jammer genoeg kan liposomaal-amfotericine B enkel toegediend worden via infuus. 
Er is geen afdoende orale vorm (inname via de mond) voorhanden. Bovendien kan dit 
geneesmiddel gepaard gaan met soms ernstige bijwerkingen, zoals een allergische re-
actie, ernstige nierfunctiestoornissen en stoornissen van de zouten in het lichaam. Een 
behandeling moet in de regel verder gezet worden tot de patiënt geen longafwijkingen 
meer vertoont op beeldvorming en tot de patiënt geen immuunsysteem onderdruk-
kende medicatie meer neemt. Vaak duurt het maanden vooraleer een behandeling met 
antischimmelmedicijnen kan worden gestaakt, waardoor de patiënt langdurig in het 
ziekenhuis moet blijven. Dit niet alleen om het geneesmiddel toe te dienen, maar ook 
om mogelijke bijwerkingen tijdig op te sporen aan de hand van regelmatige bloed-
analyses ter controle van nierfunctie en zouten, en andere orgaansystemen. Als het 
laboratorium erin geslaagd is om de Aspergillus schimmel van de patiënt te kweken dan 
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kan de gevoeligheid van deze kweek voor verschillende antischimmelmedicijnen getest 
worden. Dit gebeurt in de regel door nationale schimmel referentie laboratoria. Daar 
wordt nagegaan met welke antischimmelmedicijnen de groei van Aspergillus kan worden 
gestopt. Soms is het zo dat een azole-resistente schimmel kan gedood worden met een 
antischimmelmedicijn, mits die in een hoge dosis wordt gegeven. Uit dierexperimenteel 
onderzoek is gebleken dat sommige invasieve azole-resistente aspergillosen behandeld 
kunnen worden met hogere dosissen van posaconazole, een antischimmelmedicijn uit 
de klasse van de azolen, dat ook onder de vorm van pillen kan ingenomen worden. Het 
Erasmus Medisch Centrum en Radboud UMC hebben ervaring met de behandeling van 
patiënten met een hogere dosis van posaconazole. Om deze ervaring te delen, hebben 
we in hoofdstuk 4 de gegevens gerapporteerd van 16 patiënten die behandeld zijn met 
hoge dosissen posaconazole en pluisden we de dossiers van deze patiënten uit om te 
kunnen inschatten hoeveel bijwerkingen deze behandeling heeft gehad. Bij 5 van de 
16 patiënten hebben we ernstige bijwerkingen gevonden die mogelijk verband hielden 
met het geven van posaconazole in hoge dosis. Deze konden in de regel goed worden 
opgevangen zonder het medicijn te moeten stoppen.
Sommige patiënten hebben hoge bloedspiegels, ook al slikken ze de gewone dosis. 
Daarom hebben we van 25 patiënten met spontaan hoge bloedspiegels bij normale 
dosering het medisch dossier doorgenomen, op zoek naar eventuele bijwerkingen ten 
gevolge van de verhoogde blootstelling aan dit middel. Bij vijf patiënten waren ernstige 
bijwerkingen te noteren en werd de dosis van dit geneesmiddel verminderd. Uit ons 
onderzoek blijkt dat patiënten op een veilige manier met dit geneesmiddel met een 
hoge dosis kunnen worden behandeld mits regelmatige controle van de bloedspiegels 
van het geneesmiddel en regelmatige bloedonderzoek om eventuele bijwerkingen snel 
te kunnen vaststellen. Uiteraard komen voor de behandeling met posaconazole enkel 
patiënten in aanmerking die een bewezen verbetering hebben gehad met liposomaal-
amfotericine B of patiënten die dit laatste geneesmiddel omwille van onaanvaardbare 
bijwerkingen hebben moeten staken. De bijwerkingen van posaconazole zijn aanvaard-
baar omdat de schimmelinfectie op zich een levensbedreigende infectie is en dus een 
goede behandeling vereist.
Zoals reeds aangehaald, vergt een invasieve aspergillose vaak een zeer langdurige 
behandeling. Azole-resistente invasieve aspergillose kan soms behandeld worden met 
hoge dosissen posaconazole onder de vorm van comprimés, althans nadat de infectie 
vooraf goed onder controle is gebracht met liposomaal-amfotericine B. Liposomaal-
amfotericine B kan ook, bij goede respons op een conventionele dagelijkse toediening, 
na verloop van tijd in plaats van dagelijks twee- of driemaal per week toegediend 
worden, waardoor de patiënt ook niet meer elke dag naar het ziekenhuis moet. 
Liposomaal-amfotericine B stapelt immers op in het lichaam als je het een aantal keer 
na elkaar hebt toegediend. In een paar centra, zoals LUMC en Erasmus MC, heeft men 
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enige ervaring met deze manier van behandelen. We hebben van 18 patiënten, die op 
deze manier behandeld zijn, de gegevens verzameld. We hebben onderzocht of er bij 
deze patiënten onverwachte bijwerkingen optreden en of de behandeling ook een goed 
therapeutisch effect heeft gehad. Dit hebben we samengevat in hoofdstuk 5. Uit ons 
onderzoek blijkt dat dit een veilige optie is, ook al moet men bedacht zijn op eventuele 
nierfunctiestoornissen. Zowel posaconazole in hoge dosis als liposomaal-amfotericine 
B in een frequentie van twee- tot driemaal per week, maken deel uit van het be-
handelprotocol dat nationaal is geïmplementeerd in alle Nederlandse academische 
ziekenhuizen. Deze behandelopties kunnen, zoals vermeld, enkel overwogen worden 
als de patiënt met azole-resistente aspergillose een goede verbetering heeft getoond 
met dagelijkse toediening van liposomaal-amfotericine B.
Invasieve aspergillose veroorzaakt niet alleen schimmelinfecties in de longen, maar 
kan ook leiden tot ernstige infecties op andere plaatsen in het lichaam, zoals in de 
hersenen. Een schimmelbol in de hersenen verstoort de werking van het hersenweefsel 
en kan ernstige symptomen veroorzaken zoals epilepsie en zenuwuitval. Ook dit wordt 
behandeld met azoles, maar als een patiënt geïnfecteerd is met een azole-resistente 
Aspergillus in de hersenen, dan is de behandeling veel complexer vermits liposomaal-
amfotericine B slecht in de hersenen doordringt. Deze gelukkig zeldzame complicatie 
is bijna altijd fataal. Onze ervaring, waarbij we 3 patiënten hebben behandeld met 
liposomaal-amfotericine B, toegediend in het hersenvocht en dit via een onderhuids 
reservoir dat rechtstreeks in verbinding staat met een hersenkamer of ventrikel in het 
brein, hebben we beschreven in hoofdstuk 6. Deze behandeling werd gestart omdat 
de algemene toestand van deze patiënten slechter werd niettegenstaande het toe-
dienen van antischimmelmedicijnen via de normale route. Bij deze patiënten werd de 
normale behandeling verdergezet en werd bijkomend liposomaal-amfotericine B in het 
hersenvocht toegediend. Met deze behandeling hebben de 3 patiënten het overleefd. 
Het is niet duidelijk of deze onconventionele behandeling er echt heeft toe geleid dat 
de toestand van deze patiënten is verbeterd, maar het is wel aannemelijk dat het ge-
holpen heeft. Omdat er tot dusver geen gegevens zijn gekend, hebben we, samen met 
collega’s van LUMC en Radboud UMC, onze ervaring als een mogelijke behandeloptie 
wanneer er geen andere behandelmogelijkheden meer zijn omschreven in hoofdstuk 6.
Sommige patiënten kunnen geïnfecteerd zijn met verschillende Aspergillus stammen. 
Een patiënt kan bijvoorbeeld tegelijkertijd geïnfecteerd zijn met een azole-gevoelige 
en een azole-resistente schimmel. Om dit aan te tonen, zouden verschillende kweken 
met Aspergillus uit de long moeten worden bekomen en zou de gevoeligheidsbepaling 
voor de verschillende kweken een resultaat moeten opleveren, waarbij de ene kweek 
gevoeligheid toont voor azoles, terwijl de andere resistentie toont. Om dit vast te 
stellen, moet er een kweek beschikbaar zijn, maar jammer genoeg is de kweek in de 
minderheid van de gevallen positief. In hoofdstuk 8 beschrijven we hoe je met een 
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test voor schimmel DNA kan aantonen dat een patiënt geïnfecteerd is door zowel een 
azole-gevoelige als een azole-resistente Aspergillus. Dit moet toelaten de patiënt van 
in het begin met het juiste antischimmelmedicijn te behandelen.
DiaGnose Van inVasieVe asPerGillose
We hebben hierboven al uitgebreid uitgelegd hoe de diagnose van invasieve aspergillose 
wordt gesteld. Om over een “mogelijke” invasieve aspergillose infectie te spreken, 
heb je indirect bewijs nodig van de aanwezigheid van invasieve aspergillose. Zo heb 
je testen die celwandbestanddelen aantonen of schimmel DNA detecteren. Deze on-
derzoeken vragen best wel wat werk en tijd in het laboratorium. Er is een nieuwe 
test ontwikkeld die snel kan worden uitgevoerd en heel snel resultaat geeft wanneer 
het wordt onderzocht op longvocht. Deze test heet in het Engels lateral flow device 
(LFD) en kan afgelezen worden net als een zwangerschapstest. Het detecteert de aan-
wezigheid van een eiwit dat Aspergillus vrijstelt als het actief groeit. In hoofdstuk 7 
hebben we deze LFD test uitgeprobeerd op restmateriaal van patiënten met en zonder 
invasieve aspergillose. Dit restmateriaal is longvocht of BAL vocht en wordt ingevroren 
aan -20°C, zodat nieuwe testen kunnen worden beoordeeld naar betrouwbaarheid. 
Zo hebben we deze test verricht op BAL vocht van 247 patiënten, waarvan 79 een 
zekere of mogelijke invasieve aspergillose hadden. Uit onze studie blijkt dat deze test 
goede resultaten oplevert. Zo geeft dit een positief resultaat bij 82% van de patiënten 
met invasieve aspergillose en een negatief resultaat in 86% van de patiënten die geen 
invasieve aspergillose hebben volgens de geldende definities. Als een digitaal toestel 
wordt gebruikt om het testresultaat te beoordelen, dan is een negatief resultaat van 
de test betrouwbaarder omdat de test dan negatief is in 96% van de patiënten die geen 
aspergillose blijken te hebben. Deze nieuwe test is een mooie aanvulling om snel de 
diagnose van invasieve aspergillose te stellen.
inflUenZa-GeassocieerDe inVasieVe asPerGillose
Jaarlijks worden meerdere patiënten met een ernstige longinfectie veroorzaakt door 
het influenzavirus (wetenschappelijk naam voor griepvirus) op de intensive care 
opgenomen. Het is al lang bekend dat een griepinfectie soms verwikkeld wordt door 
bacteriële infectie. In 2012 is er een studie verschenen aangaande 40 patiënten die 
met een longontsteking door griep werden opgenomen op de intensive care van het 
Universitaire Ziekenhuis van Leuven. Bij 9 van deze patiënten (23%) werd invasieve 
aspergillose gevonden. Dit is opmerkelijk vermits invasieve aspergillose, zoals reeds 
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aangehaald, bij patiënten voorkomt met een onderdrukt immuunsysteem. Om vast te 
stellen hoe vaak invasieve aspergillose als complicatie voorkomt bij patiënten, opge-
nomen op de intensive care met een longontsteking door griep, hebben we volgend 
onderzoek verricht: we hebben het dossier van een groot aantal patiënten onderzocht 
die met longontsteking door griep opgenomen waren op de intensive care afdelingen 
van zeven verschillende ziekenhuizen in België en Nederland. We hebben onderzocht 
hoeveel van deze patiënten invasieve aspergillose hebben ontwikkeld. Dit is beschreven 
in hoofdstuk 10.1. We hebben invasieve aspergillose vastgesteld bij 83 van de 432 on-
derzochte patiënten, wat 19% is, en dit bleek vaak voor te komen bij elk griepseizoen. 
Er zijn verschillende soorten griepvirus en er blijkt geen verband te zijn tussen het 
soort griepvirus en de kans om een bijkomende invasieve aspergillose te ontwikkelen. 
Deze complicatie doet zich ongeveer 2 dagen na het vaststellen van de infectie door 
griepvirus voor. Het is tot dusver onduidelijk waarom deze complicatie optreedt, maar 
mogelijk spelen er meerdere factoren mee. We vermoeden dat griep in ernstige vormen 
het immuunsysteem verzwakt en het longslijmvlies beschadigt, waardoor de schimmel 
makkelijker kan toeslaan. Maar het zou net zo goed kunnen dat bepaalde mensen ge-
netisch gevoeliger zijn voor schimmelinfecties. Dit moet in de toekomst verder worden 
onderzocht. In deze studie hebben we ook een groep van patiënten met een normaal 
immuunsysteem en grieplongontsteking opgenomen op de intensive care vergeleken 
met patiënten, ook met een normaal immuunsysteem, voor een gewone longontsteking 
opgenomen op de intensive care. In de groep met griepvirusinfectie kwam invasieve 
aspergillose in 15% voor terwijl deze bij andere patiënten, die wel een longontsteking 
hadden maar geen griep, maar in 5 % voorkomt. Uit deze cijfers concluderen wij dat 
griep de kans op een Aspergillus-infectie gevoelig verhoogt. In hoofdstuk 10.2 heb-
ben we onderzocht of invasieve aspergillose bij patiënten met griep op de intensive 
care aanleiding geeft tot een hogere mortaliteit. Bijna de helft van de patiënten met 
griep en invasieve aspergillose sterft, terwijl 20% van de patiënten met griep zonder 
Aspergillus infectie overlijden als gevolg van deze ernstige ziekte. Met deze studie 
kunnen we dus concluderen dat invasieve aspergillose een frequente complicatie is 
bij patiënten opgenomen met grieplongontsteking op de intensive care, die bovendien 
gepaard gaat met een hoge mortaliteit. Momenteel loopt er een studie waarbij een 
groep van patiënten met griep op de intensive care antischimmelmedicijn krijgt en een 
andere groep niet. De studie onderzoekt of het geven van antischimmelmedicijnen het 
optreden van invasieve aspergillose voorkomt.
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toeKomstiG onDerZoeK
Sinds 15 jaar is het antischimmelmedicijn voriconazole de voorkeursbehandeling voor 
invasieve aspergillose. Helaas is de mortaliteit van invasieve aspergillose, behandeld 
met voriconazole nog steeds 25 tot 30%, en dus veel te hoog. Het combineren van 2 
antischimmelmedicijnen zou mogelijk kunnen leiden tot een lagere sterfte. Tussen 2008 
en 2011 is er een klinische studie verricht om te onderzoeken of het toevoegen van 
een tweede antischimmelmedicijn aan voriconazole de mortaliteit kan verlagen. Dit 
bleek het geval, want met combinatietherapie van twee antischimmelmedicijnen was 
de sterfte 30% lager (19,3%) dan met voriconazole alleen (27,5%). Deze vermindering in 
mortaliteit van 30% was echter statistisch niet significant, waardoor combinatiethera-
pie in internationale richtlijnen (nog) geen plaats heeft. Een tweede studie is daarom 
nodig om deze bevinding te bevestigen. Bovendien is er een bijkomende reden om 
combinatietherapie in Nederland en België te bestuderen: resistentie voor schimmelm-
edicijnen wordt er in toenemende mate vastgesteld. Dit bemoeilijkt de behandeling 
van invasieve aspergillose in ernstige mate en gaat gepaard met een hogere sterfte. 
Zowel van de Belgische als van de Nederlandse overheid hebben we subsidie gekregen 
om een dergelijke studie uit te voeren. Deze studie zal van start gaan in 2020 en wordt 
beschreven in hoofdstuk 11.
conclUsie
In deze thesis hebben we gepoogd de kennis omtrent invasieve aspergillose te verbe-
teren met betrekking tot voorkomen, mortaliteit, risicofactoren en diagnose. We heb-
ben aangetoond dat azole-resistente invasieve aspergillose de mortaliteit aanzienlijk 
verhoogt (hoofdstuk 3). De aanpak van azole-resistente invasieve aspergillose is zeer 
divers in verschillende academische ziekenhuizen (hoofdstuk 2). We hebben voor de 
diagnose en behandeling van (azole-resistente) invasieve aspergillose een uniforme ma-
nier van aanpakken geïmplementeerd in alle Nederlandse academische ziekenhuizen en 
in een aantal Belgische academische ziekenhuizen. Deze Azole-Resitance Management 
Study (AzoRMan-studie) geeft niet alleen een goed idee van de prevalentie van azole-
resistentie, maar we hopen ook dat deze studie de mortaliteit van azole-resistente 
invasieve aspergillose vermindert. Tussentijdse resultaten van deze AzoRMan-studie 
zijn beschreven in hoofdstuk 9 en geven aan dat resistentie wordt gevonden in 8.5% 
van de patiënten. We beschrijven in hoofdstuk 4 en 5 verschillende behandelmoge-
lijkheden voor patiënten geïnfecteerd met azole-resistente invasieve aspergillose na 
een behandeling met liposomaal-amfotericine B. Posaconazole met hoge bloedspiegels 
of liposomaal-amfotericine B met dosering twee- of driemaal per week zijn een optie 
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wanneer bepaalde veiligheidsmaatregelen worden in acht genomen. In hoofdstuk 6, 
schrijven we onze ervaring neer met betrekking tot het toedienen van liposomaal-amfo-
tericine B in het hersenkamersysteem of rechtstreeks in het hersenvocht. In hoofdstuk 
7 hebben we aangetoond dat het lateral flow device (LFD) een mooie aanvulling is in het 
diagnostisch arsenaal voor invasieve aspergillose. In hoofdstuk 8, hebben we duidelijk 
gemaakt dat AsperGenius© PCR een infectie, veroorzaakt door zowel azole-gevoelige 
als azole-resistente Aspergillus kan detecteren. In hoofdstuk 10.1 stelden we vast dat 
een longontsteking veroorzaakt door het griepvirus op de intensive care kan verwikkeld 
worden door invasieve aspergillose en dit zowel bij patiënten met een normaal als bij 
patiënten met een onderdrukt immuunsysteem. We tonen aan in hoofdstuk 10.2 dat 
deze complicatie gepaard gaat met een sterk verhoogde kans op overlijden. Tot slot, 
stellen we in hoofdstuk 11 een nieuwe studie voor die zal starten in 2020 en waarbij 
het resultaat van de combinatie van twee antischimmelmedicijnen wordt vergeleken 
met de standaard behandeling van één antischimmelmedicijn. Met deze studie en 
een aantal actief lopende studies hopen we de uitkomst van patiënten met invasieve 
aspergillose te verbeteren.
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Belgian city. He graduated at the Jesuit College Sint-Barbara in 2005. With the convic-
tion he would like to become a medical doctor, he studied medicine at Ghent University 
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in London. Alexander graduated in 2012 with great distinction. Then, he started his 
Internal Medicine residency at AZ Sint-Jan Hospital in Bruges where he met his wife 
Judith with whom he is happily married since 2016. Not only Judith stole his heart 
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Diseases. The second year of his Internal Medicine rotation was performed in Maria Mid-
delares in Ghent. Following two years of Internal Medicine rotation, Alexander started 
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dr. F. Offner. During these years, he came in touch with dr. Bart Rijnders from Erasmus 
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Bart offered a PhD position on invasive fungal infections and after two years, Alexan-
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the supervision of Prof. Dr. J. Cornelissen and dr. P. te Boekhorst. In October 2019, 
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to continue research improving the care and outcome for patients with hematological 
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escalation of antibiotic therapy for febrile neutropenia in patients with longstanding 
neutropenia and on the diagnosis and management of invasive fungal infections.
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DanKWoorD
Het is zover, ik mag eindelijk aan mijn dankwoord beginnen. In oktober 2016 stak ik voor 
het eerst de Moerdijk over met de wispelturige Beneluxtrein om in een nu wijlen muffe 
Z-flat van het Erasmus MC zonder enige mogelijkheid tot temperatuurcontrole aan het 
werk te gaan. Een bokaal met een prachtig uitzicht op de Rotterdamse haven. Het was 
er lekker knus met mijn Z-flat kamergenoten Anne, Angelique en Lisanne. Tussen al 
het statistisch gesakker, herschrijven van artikels en beantwoorden van vele e-mails 
was het een verademing om af en toe een koffie te drinken of een wandeling in “Het 
Park” te maken. Ik ben mijn kamergenoten dan ook dankbaar om mij als zwervende 
Belg warm te hebben ontvangen en wegwijs te hebben gemaakt in de voor mij Nieuwe 
Wereld. Na de verhuis konden we genieten van een nieuw plekje op de 21ste etage met 
een nog mooier uitzicht.
Hoewel Nederlands en Vlaams als dezelfde taal worden beschouwd, leidde mijn 
verblijf in Rotterdam al snel tot een babylonische spraakverwarring. Het Vlaamse taal-
gebruik bleek niet altijd uitwisselbaar met dat van onze noorderburen. In mijn eerste 
week werd ik bij heel wat mensen op de kamer uitgenodigd. Als Vlaming voelt dit gek 
aan tenzij enige vrijblijvende promiscuïteit je niet vreemd is. Ook het medische jargon 
bleek jammer genoeg niet van hetzelfde laken een broek (in Rotterdam: van hetzelfde 
laken een pak). Toeren werd vervangen door visite lopen en de stap naar een gestruc-
tureerd overlegmodel was ook even wennen. Na enige acclimatisatie kon ik gelukkig 
al enkele dagdagelijkse begrippen zoals hemoculturen, staal, perifeer bloedbeeld en 
coprocultuur vertalen naar bloedkweken, monster, handdiffje en faeceskweek, respec-
tievelijk. Desondanks bleek communiceren in Nederland niet altijd een eitje. Graag zou 
ik dan ook mijn Nederlandse collega’s willen danken voor hun geduld in alle pogingen 
om mij te verstaan.
Beste Bart, het is dankzij jou dat mijn carrière een Nederlandse wending heeft gekend. 
Door het toeval kruisten onze wegen elkaar en mocht ik onder jouw deskundige bege-
leiding een promotietraject aanvatten. Net als jou werd ik omgedoopt tot Nederbelg 
met een Brompton. Ik heb onze samenwerking als ontzettend fijn en vlot ervaren. Ik 
ken niemand die jouw werkijver en efficiëntie kunnen navolgen. Een dag bestaat bij jou 
werkelijk uit 30 uur. Een multicenter studie lanceren in 5 dagen, 3 miljoen euro bin-
nenrijven voor een grote studie en oh ja, dan ook nog aan de lopende band publiceren 
en 5 doctorandi begeleiden: je doet het allemaal. Onder het motto ‘wie niet waagt, 
niet wint’ zijn we samen aan ons BeNeFit project begonnen, met een bijzonder mooi 
resultaat tot gevolg. Naast een fantastische mentor heb ik in jou ook een goede vriend 
gevonden. Ik kijk uit naar de vele grensoverschrijdende gezamenlijke projecten in de 
toekomst!
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Graag wil ik ook mijn opleider (Vlaams: stagemeester), dr. Peter te Boekhorst bedan-
ken, en bij uitbreiding de hele Rotterdamse staf. Ik heb erg veel van jullie manier van 
geneeskunde doen geleerd! Mijn bijzondere dank gaat ook naar dr. Van Zaanen en dr. Li-
bourel, Henk en Ward, voor de warme ontvangst in het Sint-Franciscus Gasthuis en voor 
de zelfstandigheid die ik van jullie kreeg. Dank je Pim en Elly, mijn poli-supervisoren 
(geen gerichte Vlaamse vertaling voorhanden), voor de kennis die ik van jullie kon op-
doen! Dank je aan de mede-fellows: Jurjen en Jurriaan voor de fijne overlegmomenten.
Beste professor Cornellissen en professor Verbon, beste Jan en Annelies, dank om mijn 
promotoren te zijn. Bijna 4 jaar heb ik in het Erasmus MC gewerkt. Ik heb het als zeer 
verrijkend ervaren en zal uit Rotterdam een grote rugzak kennis en ervaring meenemen 
voor mijn latere carrière als hematoloog/onderzoeker. Dank je Annelies om bij onze 
overlegmomenten het overzicht te houden en Jan voor je stimulerende interventies 
en steun zodat ik aan EHA’s Clinical Research Training in Hematology kon deelnemen.
Beste Gentse collega’s, ik ben erg blij dat ik ben opgeleid in mijn geboortestad. We 
hebben een leuke, gezellige dienst en ik ben verheugd jullie collega te worden. Beste 
professor Offner, beste Fritz, dank dat je mijn atypisch opleidingstraject met Neder-
landse escapades altijd hebt ondersteund. Beste professor Kerre, beste Tessa, dank dat 
je deel wil uitmaken van mijn leescommissie. Beste Ciel, we hebben in het begin van 
onze opleiding heel wat avondlijke uren doorgebracht en gestreden voor onze patiën-
ten. Je bent een heel goede vriendin geworden waarop ik altijd kan rekenen!
Beste Leuvense collega’s, ik ben erg blij dat ik bij jullie zeven maanden heb mogen 
doorbrengen. Het was tijdens de vreemde COVID-19 periode dat ik te gast was. Beste 
professor Vandenberghe, beste Peter, dank om mij hartelijk te ontvangen. Beste profes-
sor Maertens, beste Johan, het was fijn je droge humor te leren kennen en ik kijk uit 
naar een verdere productieve samenwerking. Toine, we hebben samen heel wat pro-
jecten tot een goed einde gebracht en nog vele projecten lopende. Ik hoop dat we ons 
inzicht en onze kennis in het domein van infectieziekten bij onze fragiele hematologie 
patiënten samen, als joint venture, verder kunnen uitdiepen.
Beste Rosanne, dank voor al je inbreng bij het schrijven van het CIA artikel. Je bent 
nu al een bijna volleerde onderzoeker onder de vleugels van Bart. Beste Albert, het 
vele werk waar we mee gestart zijn wordt door jou verder gezet. Ik wens je hier veel 
succes mee.
Beste leden van de leescommissie, hartelijk dank voor de snelle beoordeling van mijn 
proefschrift. Ook wil ik de leden van de grote commissie bedanken voor jullie deelname 
aan de oppositie.
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Beste Pieter, bro, wat ben ik blij dat mijn Rotterdams avontuur onze band weer nieuw 
leven heeft ingeblazen. Beiden trekvogels, kruisten onze wegen bij toeval in Rotterdam. 
We verkenden culinair Rotterdam minstens wekelijks en ’s avonds kon ik in jouw flat op 
mijn matras in de gang blijven overnachten. Je bent een goede en dierbare vriend. Met 
je heldere en positieve blik help je me te zien wat belangrijk is.
Olivia, dank om mijn vaste treinbuddy te zijn. Het was een eer vaak de grens met jou 
over te steken.
Beste Olivier, zonder mijn getuige en kameraad had ik nooit de stappen gezet naar een 
buitenlandse avontuur. Dank om er altijd te zijn voor een goede babbel en een Gulden 
Draak in de Aba-Jour.
Mama, papa, Pieter-Paul, Leen, Ann-Sofie, Marthe, Emiel en Gust, ook wel de clan 
Schauwvlieghe. We zijn een hechte familie en delen lief en leed. Het is altijd fijn om 
een verlengde van mijn thuis te vinden in Antwerpen, Maastricht, Gent of aan zee. 
Mama, je bent mijn steun en toeverlaat. Je staat altijd paraat om het minste euvel vlot 
van de baan te helpen. Geen telefoontje is je te veel. Je springt altijd direct op elk 
uur van de dag om ons bij te staan. Pieter-Paul, de tennis op vrijdagavond met daarna 
zalig gerstenat is een instituut geworden. Op de vraag wat ik eerst wil/wou hervatten 
na de lockdown zal het wel dit sportief vrijdags evenement zijn. Papa, dank je voor 
je luisterbereidheid en interesse in mijn projecten! Je bent altijd paraat om te helpen 
zoals het nalezen van mijn Nederlandse samenvatting! Lieve moetie, je bent er al een 
tijdje niet meer. Ik mis onze vele gezellige momenten en babbels. Je bent voor mij een 
groot voorbeeld en ik weet dat je erg trots moet zijn dat ik nu dit doctoraat tot een 
goed einde heb gebracht zoals opa! Plus est en vous, ik hoop dat mijn kinderen dit ook 
trachten na te streven!
Linda, Esther en Jacques, ik ben erg blij in een warme schoonfamilie thuis te zijn. 
Lieve Linda, geen afstand is jou te ver, geen moeite te groot. Je ovenschotels hebben 
al menig stad in Vlaanderen bereikt. Dank je om ons te helpen en zo betrokken te 
zijn. Esther, La Esterella, dank om een toffe meter voor Oscar te zijn en ons te hulp te 
schieten waar je kan. Jacques, onze sportieve uitjes zijn super ontspannend en dank 
om als eindredacteur te dienen voor mijn nederlandstalige teksten!
Lieve Judith, mijn darling. Mijn Nederlands avontuur heeft ook heel wat van jou 
gevraagd. Het was het begin van een nomadenbestaan waarbij we op vele plaatsen 
gewoond hebben langs de sporen van de Beneluxtrein. Eerst woonden we in Mechelen 
waarbij je dagelijks naar Leuven moest pendelen. De twee volgende jaren woonden we 
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in Antwerpen, van waaruit jij ook gedurende een jaar de grens overstak naar Breda, 
waar je het na een zekere gewenningsperiode best naar je zin had. Het mooiste moest 
toen nog komen en vol verlangen keken we ernaar uit. Op 24 mei 2019 was hij daar: 
onze lieve vriend Oscar. Werken is een ding, maar jij en Oscar zijn mijn alles. Elke dag 
ben ik erg dankbaar voor het lieve gezinnetje waarin ik thuiskom. Zonder jullie was 
deze promotie nooit een succes geweest.
Dit proefschrift is het slotakkoord geworden van een mooie periode in Rotterdam 
waar ik ook mijn opleiding heb voltooid. Met gemengde gevoelens van trots, weemoed, 
voldoening en opluchting zet ik een punt achter dit hoofdstuk.
Het ga jullie allemaal goed,
Zon op al jullie wegen,
Alexander
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